<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="./PMC2259160/results/search/disease/results.xml">
   <result pre="The role of wildlife in our understanding of highly pathogenic" exact="avian influenza." post="Cook Robert A. [], ppub: 2005-10 78 5 343"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC3427559/results/search/disease/results.xml">
   <result pre="infect humans. The first of these to be discovered was" exact="yellow fever" post="virus in 1901, and three to four new species"/>
   <result pre="the first ‘filterable agent’ to be discovered in humans was" exact="yellow fever" post="virus in 1901 [ 1]. New species of human"/>
   <result pre="human pathogen. As experiences with HIV-1 and new variants of" exact="influenza" post="A (and also with novel animal pathogens such as"/>
   <result pre="itself is an imprecise designation, especially for viruses such as" exact="influenza" post="A where different serotypes can have very different epidemiologies"/>
   <result pre="the ICTV (notably for the human papillomaviruses and the vesicular" exact="stomatitis" post="viruses). The year of discovery was taken to be"/>
   <result pre="as ‘specialist’ human pathogens [ 27]). Some of these (e.g." exact="hepatitis" post="B) may have co-evolved with humans over very long"/>
   <result pre="a simian immunodeficiency virus found in chimpanzees); HIV-2 (sooty mangabeys);" exact="severe acute respiratory syndrome" post="virus (SARS; horseshoe bats); hepatitis B, human T-lymphotropic virus"/>
   <result pre="(sooty mangabeys); severe acute respiratory syndrome virus (SARS; horseshoe bats);" exact="hepatitis" post="B, human T-lymphotropic virus (HTLV)-1 and -2, dengue and"/>
   <result pre="hepatitis B, human T-lymphotropic virus (HTLV)-1 and -2, dengue and" exact="yellow fever" post="(all primates); human coronavirus OC43, measles, mumps and smallpox"/>
   <result pre="dengue and yellow fever (all primates); human coronavirus OC43, measles," exact="mumps" post="and smallpox (all livestock); and influenza A (wildfowl). However,"/>
   <result pre="yellow fever (all primates); human coronavirus OC43, measles, mumps and" exact="smallpox" post="(all livestock); and influenza A (wildfowl). However, we do"/>
   <result pre="human coronavirus OC43, measles, mumps and smallpox (all livestock); and" exact="influenza" post="A (wildfowl). However, we do not know the origins"/>
   <result pre="the past hundred years alone (HIV-1, SARS, plus variants of" exact="influenza" post="A) and many more in the past few millennia"/>
   <result pre="populations [ 26]. An illustrative case study is bovine spongiform" exact="encephalopathy" post="(BSE). After BSE's emergence in the 1980s, well before"/>
   <result pre="This was in marked contrast to a much more familiar" exact="prion disease," post="scrapie, which was naturally restricted to sheep and goats."/>
   <result pre="unknown reovirus of bat origin is associated with an acute" exact="respiratory disease" post="in humans . Proc. Natl Acad. Sci. USA 104,"/>
   <result pre="a highly divergent astrovirus isolated from a child with acute" exact="diarrhea" post=". Virol. J. 5, 117 10.1186/1743-422X-5-117 ( doi:10.1186/1743-422X-5-117) 18854035"/>
   <result pre="novel picornavirus related to cosaviruses in a child with acute" exact="diarrhea" post=". Virol. J. 5, 159– 164 10.1186/1743-422X-5-159 ( doi:10.1186/1743-422X-5-159)"/>
   <result pre="novel astrovirus (astrovirus VA1) associated with an outbreak of acute" exact="gastroenteritis" post=". J. Virol. 83, 10 836– 10 839 10.1128/JVI.00998-09"/>
   <result pre="11352066 28 Simmonds P. 2001 Reconstructing the origins of human" exact="hepatitis" post="viruses. Phil. Trans. R. Soc. Lond. B 356, 1013–"/>
   <result pre="E. 2010 Host phylogeny constrains cross-species emergence and establishment of" exact="rabies" post="virus in bats . Science 329, 676– 679 10.1126/science.1188836"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC3544629/results/search/disease/results.xml">
   <result pre="concern. A number of viruses including respiratory syncytial virus (RSV)," exact="influenza" post="viruses, parainfluenza viruses, rhinovirus, and adenovirus are responsible for"/>
   <result pre="early and late-preterm infants and those with bronchopulmonary dysplasia and" exact="congenital heart disease" post="[ 3, 5]. In Canada, the annual cost of"/>
   <result pre="and late-preterm infants and those with bronchopulmonary dysplasia and congenital" exact="heart disease" post="[ 3, 5]. In Canada, the annual cost of"/>
   <result pre="tract infections ICD-10 Code Description J10.1 Influenza due to other" exact="influenza" post="virus with J10.81 Influenza gastroenteritis J10.89 Influenza due to"/>
   <result pre="J10.1 Influenza due to other influenza virus with J10.81 Influenza" exact="gastroenteritis" post="J10.89 Influenza due to other influenza virus with J12.0"/>
   <result pre="virus with J10.81 Influenza gastroenteritis J10.89 Influenza due to other" exact="influenza" post="virus with J12.0 Adenoviral pneumonia J12.1 Respiratory syncytial virus"/>
   <result pre="J10.89 Influenza due to other influenza virus with J12.0 Adenoviral" exact="pneumonia" post="J12.1 Respiratory syncytial virus pneumonia J12.2 Parainfluenza virus pneumonia"/>
   <result pre="influenza virus with J12.0 Adenoviral pneumonia J12.1 Respiratory syncytial virus" exact="pneumonia" post="J12.2 Parainfluenza virus pneumonia J12.3 Pneumonia due to SARS-associated"/>
   <result pre="Adenoviral pneumonia J12.1 Respiratory syncytial virus pneumonia J12.2 Parainfluenza virus" exact="pneumonia" post="J12.3 Pneumonia due to SARS-associated coronavirus J12.8 Other viral"/>
   <result pre="virus pneumonia J12.3 Pneumonia due to SARS-associated coronavirus J12.8 Other" exact="viral pneumonia" post="J12.81 Pneumonia due to SARS-associated coronavirus J12.89 Other viral"/>
   <result pre="pneumonia J12.3 Pneumonia due to SARS-associated coronavirus J12.8 Other viral" exact="pneumonia" post="J12.81 Pneumonia due to SARS-associated coronavirus J12.89 Other viral"/>
   <result pre="viral pneumonia J12.81 Pneumonia due to SARS-associated coronavirus J12.89 Other" exact="viral pneumonia" post="J12.9 Viral pneumonia, unspecified J13.0 Pneumonia due to Streptococcus"/>
   <result pre="pneumonia J12.81 Pneumonia due to SARS-associated coronavirus J12.89 Other viral" exact="pneumonia" post="J12.9 Viral pneumonia, unspecified J13.0 Pneumonia due to Streptococcus"/>
   <result pre="pneumoniae J15.8 Pneumonia due to other specified bacteria J15.9 Unspecified" exact="bacterial pneumonia" post="J16.0 Chlamydial pneumonia J16.8 Pneumonia due to other specified"/>
   <result pre="J15.8 Pneumonia due to other specified bacteria J15.9 Unspecified bacterial" exact="pneumonia" post="J16.0 Chlamydial pneumonia J16.8 Pneumonia due to other specified"/>
   <result pre="to other specified bacteria J15.9 Unspecified bacterial pneumonia J16.0 Chlamydial" exact="pneumonia" post="J16.8 Pneumonia due to other specified infectious organisms J17.0"/>
   <result pre="J20.9 Acute bronchitis, unspecified J18.9 Pneumonia, unspecified organism J21.0 Acute" exact="bronchiolitis" post="due to respiratory syncytial virus J21.1 Acute bronchiolitis due"/>
   <result pre="J21.0 Acute bronchiolitis due to respiratory syncytial virus J21.1 Acute" exact="bronchiolitis" post="due to human metapneumovirus J21.8 Acute bronchiolitis due to"/>
   <result pre="virus J21.1 Acute bronchiolitis due to human metapneumovirus J21.8 Acute" exact="bronchiolitis" post="due to other specified organisms J21.9 Acute bronchiolitis, unspecified"/>
   <result pre="High-risk infants were defined according to the ICD-10 codes for" exact="congenital heart disease," post="bronchopulmonary dysplasia, congenital lung disease, and preterm birth defined"/>
   <result pre="infants were defined according to the ICD-10 codes for congenital" exact="heart disease," post="bronchopulmonary dysplasia, congenital lung disease, and preterm birth defined"/>
   <result pre="the ICD-10 codes for congenital heart disease, bronchopulmonary dysplasia, congenital" exact="lung disease," post="and preterm birth defined as &amp;lt;37 weeks completed gestation"/>
   <result pre="the effects of non-pharmacological interventions on hospitalizations for severe viral" exact="respiratory disease." post="Based on this review, the most reasonable and appropriate"/>
   <result pre="listed LRTI as the primary diagnosis (1215/4588; 26.5%) with acute" exact="bronchiolitis" post="due to RSV (ICD-10 code J21.0; 1198/4588; 26.1 %);"/>
   <result pre="18.6%); bronchopneumonia, unspecified organism (ICD-10 code J18.0; 354/4588; 7.7%); and" exact="viral pneumonia" post="unspecified (ICD-10 code J12.9; 138/4588; 3%) also among the"/>
   <result pre="bronchopneumonia, unspecified organism (ICD-10 code J18.0; 354/4588; 7.7%); and viral" exact="pneumonia" post="unspecified (ICD-10 code J12.9; 138/4588; 3%) also among the"/>
   <result pre="&amp;lt;19 years of age. Most RSV-associated hospitalizations were for acute" exact="bronchiolitis" post="due to RSV accounting for 1198 (86%) RSV-associated hospitalizations,"/>
   <result pre="RSV accounting for 1198 (86%) RSV-associated hospitalizations, followed by RSV" exact="pneumonia" post="(ICD-10 code J12.1; 115 cases; 8.5%), and acute bronchitis"/>
   <result pre="&amp;lt;1 year of age. Most RSV-associated hospitalizations were for acute" exact="bronchiolitis" post="due to RSV accounting for 961 (92.2%) RSV-associated hospitalizations,"/>
   <result pre="RSV accounting for 961 (92.2%) RSV-associated hospitalizations, followed by RSV" exact="pneumonia" post="(52 cases; 5%), and acute bronchitis due to RSV"/>
   <result pre="and acute bronchitis due to RSV (29 cases; 2.8%). Acute" exact="bronchiolitis" post="due to RSV was the most frequently listed LRTI"/>
   <result pre="organism (194/2165; 9%); bronchopneumonia, unspecified organism (102/2165; 4.7%); and acute" exact="bronchiolitis" post="due to other specified organisms (ICD-10 code J21.8; 51/2165;"/>
   <result pre="pediatric LRTIs and LRTIs specifically due to RSV, respectively. Acute" exact="bronchiolitis" post="due to RSV was the most frequently listed LRTI"/>
   <result pre="to 11.8 days for pediatric patients with diagnoses such as" exact="congenital heart disease," post="chronic lung disease, immunodeficiency, or multiple congenital anomalies, ["/>
   <result pre="11.8 days for pediatric patients with diagnoses such as congenital" exact="heart disease," post="chronic lung disease, immunodeficiency, or multiple congenital anomalies, ["/>
   <result pre="pediatric patients with diagnoses such as congenital heart disease, chronic" exact="lung disease," post="immunodeficiency, or multiple congenital anomalies, [ 19] and up"/>
   <result pre="strategies to infectious diseases was illustrated during the 2009 H1N1" exact="influenza" post="pandemic. Public opinion polls demonstrated that 59–67% Americans adopted"/>
   <result pre="evaluate the impact of health prevention strategies in decreasing severe" exact="respiratory disease" post="as the effectiveness of such measures may only be"/>
   <result pre="JC Smith B Wang EE Increasing incidence of hospitalization for" exact="bronchiolitis" post="among Canadian children, 1980–2000 J Infect Dis 2003 188"/>
   <result pre="14639549 Schanzer DL Langley JM Tam TW Hospitalization attributable to" exact="influenza" post="and other viral respiratory illnesses in Canadian children Pediatr"/>
   <result pre="Care Trials Group H1N1 Collaborative Critically ill patients with 2009" exact="influenza" post="A (H1N1) infection in Canada JAMA 2009 302 17"/>
   <result pre="MM Lubell K The public’s response to the 2009 H1N1" exact="influenza" post="pandemic N Engl J Med 2010 362 22 e65"/>
   <result pre="Russell FM Buttery J Vaccine development for capsulate bacteria causing" exact="pneumonia" post="Curr Opinion Pul Med 2003 9 227 232 10.1097/00063198-200305000-00012"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC3702433/results/search/disease/results.xml">
   <result pre=": Research Article The incidence and aetiology of hospitalised community-acquired" exact="pneumonia" post="among Vietnamese adults: a prospective surveillance in Central Vietnam"/>
   <result pre="http://www.biomedcentral.com/1471-2334/13/296 Abstract Background Lower respiratory tract infection (LRTI) including Community-acquired" exact="pneumonia" post="(CAP) is a common infectious disease that is associated"/>
   <result pre="tract infection (LRTI) including Community-acquired pneumonia (CAP) is a common" exact="infectious disease" post="that is associated with significant morbidity and mortality. The"/>
   <result pre="incidence, aetiological pathogens, clinical pictures and risk factors of community-acquired" exact="pneumonia" post="(CAP) in the Vietnamese adult population. Methods A prospective"/>
   <result pre="for viral PCR, 73 (21%) were positive for respiratory viruses;" exact="influenza" post="A (n = 32, 9%) was the most common. Conclusions The"/>
   <result pre="attributed to the young age of our study population. Community-acquired" exact="pneumonia" post="Aetiology Incidence Ageing Southeast Asia Vietnam Viral pneumonia Nasopharyngeal"/>
   <result pre="population. Community-acquired pneumonia Aetiology Incidence Ageing Southeast Asia Vietnam Viral" exact="pneumonia" post="Nasopharyngeal swab Multiplex PCR Background Community-acquired pneumonia (CAP) is"/>
   <result pre="Asia Vietnam Viral pneumonia Nasopharyngeal swab Multiplex PCR Background Community-acquired" exact="pneumonia" post="(CAP) is a major cause of morbidity and mortality"/>
   <result pre="[ 1, 2]. Worldwide, lower respiratory tract infections (LRTIs) including" exact="pneumonia" post="are the third highest cause of death in adults,"/>
   <result pre="adults, and 1.8 million people aged ≥15 years die from" exact="pneumonia" post="every year [ 3]. Studies have shown that the"/>
   <result pre="antimicrobial therapy and vaccination (e.g., 23-valent pneumococcal polysaccharide vaccine and" exact="influenza" post="vaccine) programmes recommended in Western countries may not be"/>
   <result pre="Nha Trang City [ 16]. Patient enrolment All physicians and" exact="infectious disease" post="specialists screened adult patients hospitalised with acute LRTI. Our"/>
   <result pre="extraction kit and tested for 13 previously described respiratory viruses:" exact="influenza" post="A/B (FLUA, FLUB), respiratory syncytial virus (RSV), Human adenovirus"/>
   <result pre="1–4, and Human coronavirus OC43/229E (HCoV) [ 16]. Definitions of" exact="pneumonia" post="Patients were classified into either CAP or non-pneumonic lower"/>
   <result pre="adult chest X-ray, the World Health Organization’s guideline for childhood" exact="pneumonia" post="were modified to standardize the interpretation algorithm [ 20]."/>
   <result pre="discharge and address codes. The cases of hospitalised ICD-10 coded" exact="pneumonia" post="were defined by ICD-10 codes J10–J18 (ICD-10 coded pneumonia)."/>
   <result pre="C d denote the number of cases with ICD-10 coded" exact="pneumonia" post="in the hospital database. Amongst C d there were"/>
   <result pre="proportion was the same for the rest of ICD-10 coded" exact="pneumonia" post="cases and calculated the total number of cases with"/>
   <result pre="own district level hospitals for mild symptoms. Definition of 2009pH1N1" exact="influenza" post="season During the study period, 2009pH1N1 influenza outbreak occurred"/>
   <result pre="Definition of 2009pH1N1 influenza season During the study period, 2009pH1N1" exact="influenza" post="outbreak occurred from Sep until Dec 2009. No cases"/>
   <result pre="occurred from Sep until Dec 2009. No cases with 2009pH1N1" exact="influenza" post="infection were detected from Jan 2010 until the end"/>
   <result pre="this area [ 16, 22]. Incidence of CAP in 2009pH1N1" exact="influenza" post="season was defined as cases detected from Sep to"/>
   <result pre="0.004   HIV infection 4 (2) 3 (2) 0.6   History of" exact="tuberculosis" post="(%) 13 (7) 3 (2) 0.006   Asthma (%) 11"/>
   <result pre="for numerical variables. † Underlying conditions include malnutrition, chronic diarrhoea," exact="heart disease," post="chronic lung disease, neuro-nervous disease, renal disease, thalassemia, liver"/>
   <result pre="† Underlying conditions include malnutrition, chronic diarrhoea, heart disease, chronic" exact="lung disease," post="neuro-nervous disease, renal disease, thalassemia, liver disease, chronic heart"/>
   <result pre="heart disease, chronic lung disease, neuro-nervous disease, renal disease, thalassemia," exact="liver disease," post="chronic heart failure, cerebrovascular disease, active tuberculosis, and COPD."/>
   <result pre="patients and two NPLRTI patients were transferred to a local" exact="tuberculosis" post="hospital. Malnutrition was observed more in deceased patients than"/>
   <result pre="however, taking antibiotics did not affect the risk of developing" exact="pneumonia" post="in both age groups in the multivariate logistic regression"/>
   <result pre="regression analysis (P = 0.9). Incidence of CAP The number of ICD-10-coded" exact="pneumonia" post="cases as identified from the hospital admission database was"/>
   <result pre="cases estimated using ICD-10 coded hospital database. † Radiological confirmed" exact="pneumonia" post="enrolled in our active surveillance. ‡ Per 1,000 person"/>
   <result pre="years. § Confidence interval. Figure 2 The incidence of hospitalised" exact="pneumonia" post="per 1, 000 persons by age group and gender."/>
   <result pre="    M. catarrhalis 5(2) 3(2) 2(1) 4(2) 1(1)     H." exact="influenza" post="10(3) 5(4) 5(3) 8(4) 2(3)     S. aureus 11(4)"/>
   <result pre="    P. aeruginosa 4(1) 4(3) 0 1(0) 3(4)     K." exact="pneumonia" post="5(2) 3(2) 2(1) 3(1) 2(3) Bacterial PCR No. tested"/>
   <result pre="61 (45) 71 (47) 104 (46) 28 (45)     H." exact="influenza" post="79 (28) 37 (27) 42 (28) 63 (28) 16"/>
   <result pre="37 (27) 42 (28) 63 (28) 16 (26)     S." exact="pneumonia" post="65 (23) 31 (23) 34 (23) 51 (23) 14"/>
   <result pre="years old were presented right (B). Impact of the 2009" exact="influenza" post="pandemic In Vietnam, the first case of pandemic influenza"/>
   <result pre="2009 influenza pandemic In Vietnam, the first case of pandemic" exact="influenza" post="A (H1N1) 2009 was reported on May 31, 2009"/>
   <result pre="0.57 – 0.88 vs. 0.63, 0.53 – 0.74) despite the" exact="influenza" post="pandemic (Figure 4). Figure 4 The monthly incidence of"/>
   <result pre="and young adult 15– 64 years and number of 2009pH1N1" exact="influenza" post="infections. The 2009pH1N1 season was defined between September 2009"/>
   <result pre="fact, lower than that of similar studies with chest X-ray-confirmed" exact="pneumonia" post="in the Western world, such as studies in the"/>
   <result pre="26]. Several factors explain this difference. First, the definition of" exact="pneumonia" post="varies by study [ 25]. Certain studies used chest"/>
   <result pre="[ 25]. Certain studies used chest X-ray findings to determine" exact="pneumonia" post="[ 4, 6, 26], whereas others used clinically defined"/>
   <result pre="sites [ 24, 25]. In our study, we carefully defined" exact="pneumonia" post="using stringent criteria based on chest X-ray findings; with"/>
   <result pre="5 years old with a very high incidence rate of" exact="pneumonia" post="[ 12]. Aetiology of CAP H. influenzae and S."/>
   <result pre="12, 32- 34]. Recent evidence indicates that HRV can cause" exact="pneumonia" post="in very young children and in severely immunocompromised patients,"/>
   <result pre="in severely immunocompromised patients, but the role of HRV in" exact="pneumonia" post="among immunocompetent adults remains controversial [ 32, 34]. Although"/>
   <result pre="cases suggests the involvement of HRV as a cause of" exact="pneumonia" post="[ 34]. RSV is also not uncommon in the"/>
   <result pre="as Falsey reported that RSV infection accounted for 11% of" exact="pneumonia" post="among elderly and at-risk adults in the winter season"/>
   <result pre="not changed much (0.81/1,000 population-year, 95%CI 0.71-0.91). The aetiology of" exact="pneumonia" post="amongst patients with HIV/AIDS may differ, but because of"/>
   <result pre="was not enrolled. This situation was mainly due to certain" exact="pneumonia" post="patients who were un-diagnosed on admission, and this tendency"/>
   <result pre="could not review chest X-rays amongst retrospectively identified ICD-10 coded" exact="pneumonia" post="cases, because their chest X-rays were kept by patients,"/>
   <result pre="in the hospital. The difficulty still remains in distinguishing nosocomial" exact="pneumonia" post="from CAP in ICD-10 coded pneumonia cases. However, the"/>
   <result pre="remains in distinguishing nosocomial pneumonia from CAP in ICD-10 coded" exact="pneumonia" post="cases. However, the length of hospital stay amongst patients"/>
   <result pre="However, the length of hospital stay amongst patients with nosocomial" exact="pneumonia" post="is expected to be longer than those with CAP"/>
   <result pre="our study groups indicates that the majority of ICD-10 coded" exact="pneumonia" post="cases were not nosocomial pneumonia. Another limitation comes from"/>
   <result pre="5). Early intervention, such as vaccination against S. pneumoniae and" exact="influenza" post="for the adult population, is warranted to address this"/>
   <result pre="Woodhead MA BTS guidelines for the management of community acquired" exact="pneumonia" post="in adults: update 2009 Thorax 2009 64 Suppl 3"/>
   <result pre="America/American Thoracic Society consensus guidelines on the management of community-acquired" exact="pneumonia" post="in adults Clin Infect Dis 2007 44 Suppl 2"/>
   <result pre="P Niklasson B Bartolomé M Balanzó X Epidemiology of community-acquired" exact="pneumonia" post="in adults: a population-based study Eur Respir J 2000"/>
   <result pre="Baggett HC Chunsuttiwat S Incidence, seasonality and mortality associated with" exact="influenza" post="pneumonia in Thailand: 2005–2008 PLoS One 2009 4 e7776"/>
   <result pre="HC Chunsuttiwat S Incidence, seasonality and mortality associated with influenza" exact="pneumonia" post="in Thailand: 2005–2008 PLoS One 2009 4 e7776 10.1371/journal.pone.0007776"/>
   <result pre="of age and gender on the population-based incidence of community-acquired" exact="pneumonia" post="caused by different microbial pathogens J Infect 2006 53"/>
   <result pre="publications/4_Population-Projections.pdf 22617687 Brown JS Geography and the aetiology of community-acquired" exact="pneumonia" post="Respirology 2009 14 1068 1071 19909456 Maxmen A On"/>
   <result pre="Thamlikitkul V Hsueh P-R Clinical and economic burden of community-acquired" exact="pneumonia" post="amongst adults in the Asia-Pacific region Int J Antimicrob"/>
   <result pre="Dowell SF Incidence of respiratory pathogens in persons hospitalized with" exact="pneumonia" post="in two provinces in Thailand Epidemiol Infect 2010 138"/>
   <result pre="E Chang LF Reyburn SW Diagnosis and treatment of community-acquired" exact="pneumonia" post="Am Fam Physician 2006 73 442 450 16477891 Johansson"/>
   <result pre="quantitative PCR for detection of lower respiratory tract infection and" exact="meningitis" post="caused by Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis"/>
   <result pre="nasopharyngeal load of Streptococcus pneumoniae, viral coinfection, and radiologically confirmed" exact="pneumonia" post="in Vietnamese children Pediatr Infect Dis J 2011 30"/>
   <result pre="paired sputum and transtracheal aspirates in the initial management of" exact="pneumonia" post="Chest 1985 87 631 635 10.1378/chest.87.5.631 3921315 Cherian T"/>
   <result pre="Standardized interpretation of paediatric chest radiographs for the diagnosis of" exact="pneumonia" post="in epidemiological studies Bull World Health Organ 2005 83"/>
   <result pre="2005 83 353 359 15976876 Lim WS Defining community acquired" exact="pneumonia" post="severity on presentation to hospital: an international derivation and"/>
   <result pre="NT Chau NVV Farrar J Van Doorn HR Early pandemic" exact="influenza" post="(2009 H1N1) in Ho Chi Minh City, Vietnam: a"/>
   <result pre="Santosham M O’Brien KL Measuring the incidence of adult community-acquired" exact="pneumonia" post="in a Native American community Epidemiol Infect 2010 138"/>
   <result pre="T Approaches to estimate the population-based incidence of community acquired" exact="pneumonia" post="J Infect 2007 55 233 239 10.1016/j.jinf.2007.04.355 17599417 Jokinen"/>
   <result pre="S Rönnberg PR Seppä A Soimakallio S Incidence of community-acquired" exact="pneumonia" post="in the population of four municipalities in eastern Finland"/>
   <result pre="Serra-Prat M Balanzó X Differences in the etiology of community-acquired" exact="pneumonia" post="according to site of care: a population-based study Respir"/>
   <result pre="55 169 178 10.1016/j.diagmicrobio.2006.01.007 16626914 Falsey AR Walsh EE Viral" exact="pneumonia" post="in older adults Clin Infect Dis 2006 42 518"/>
   <result pre="Shtainberg R Lieberman D Respiratory viruses in adults with community-acquired" exact="pneumonia" post="Chest 2010 138 811 816 10.1378/chest.09-2717 20363845 Ruuskanen O"/>
   <result pre="20363845 Ruuskanen O Lahti E Jennings LC Murdoch DR Viral" exact="pneumonia" post="Lancet 2011 377 1264 1275 10.1016/S0140-6736(10)61459-6 21435708 Papadopoulos NG"/>
   <result pre="Poll T Lutter R Juffermans NP Schultz MJ Bench-to-bedside review:" exact="bacterial pneumonia" post="with influenza - pathogenesis and clinical implications Crit Care"/>
   <result pre="T Lutter R Juffermans NP Schultz MJ Bench-to-bedside review: bacterial" exact="pneumonia" post="with influenza - pathogenesis and clinical implications Crit Care"/>
   <result pre="R Juffermans NP Schultz MJ Bench-to-bedside review: bacterial pneumonia with" exact="influenza" post="- pathogenesis and clinical implications Crit Care 2010 14"/>
   <result pre="long-term outcomes of ICU-treated severe community- and hospital-acquired, and ventilator-associated" exact="pneumonia" post="patients Acta Anaesthesiol Scand 2011 55 1254 1260 10.1111/j.1399-6576.2011.02535.x"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC3787546/results/search/disease/results.xml">
   <result pre="3787546 doi: 10.3389/fmicb.2013.00293 : Microbiology: Review Article Virus-induced exacerbations in" exact="asthma" post="and COPD Kurai Daisuke * Saraya Takeshi * Ishii"/>
   <result pre="characterized by chronic airway inflammation and/or airflow limitation due to" exact="pulmonary emphysema." post="Chronic bronchitis, pulmonary emphysema, and bronchial asthma may all"/>
   <result pre="inflammation and/or airflow limitation due to pulmonary emphysema. Chronic bronchitis," exact="pulmonary emphysema," post="and bronchial asthma may all be associated with airflow"/>
   <result pre="due to pulmonary emphysema. Chronic bronchitis, pulmonary emphysema, and bronchial" exact="asthma" post="may all be associated with airflow limitation; therefore, exacerbation"/>
   <result pre="may all be associated with airflow limitation; therefore, exacerbation of" exact="asthma" post="may be associated with the pathophysiology of COPD. Furthermore,"/>
   <result pre="associated with a wide variety of respiratory viruses. COPD and" exact="asthma" post="have different underlying pathophysiological processes and thus require individual"/>
   <result pre="increased mortality. Similar pathogens, including human rhinovirus, respiratory syncytial virus," exact="influenza" post="virus, parainfluenza virus, and coronavirus, are also frequently detected"/>
   <result pre="virus, and coronavirus, are also frequently detected during exacerbation of" exact="asthma" post="and/or COPD. Immune response to respiratory viral infections, which"/>
   <result pre="and differences of clinical features in patients with COPD and/or" exact="asthma" post="associated with respiratory viral infections, especially in the exacerbative"/>
   <result pre="to summarize current knowledge concerning exacerbation of both COPD and" exact="asthma" post="by focusing on the clinical significance of associated respiratory"/>
   <result pre="focusing on the clinical significance of associated respiratory virus infections." exact="asthma" post="COPD respiratory virus exacerbation overlap syndrome human rhinovirus respiratory"/>
   <result pre="virus fig-count: table-count: equation-count: ref-count: page-count: word-count: INTRODUCTION Asthma and" exact="chronic obstructive pulmonary disease" post="(COPD) are very common inflammatory diseases of the airways."/>
   <result pre="of the airways. The World Health Organization (WHO) estimates that" exact="asthma" post="accounts for 1 in every 250 deaths worldwide ("/>
   <result pre="every 250 deaths worldwide ( O’Sullivan, 2005). The prevalence of" exact="asthma" post="in developed countries is approximately 10% in adults and"/>
   <result pre="in the world by 2020 (Global initiative for chronic obstructive" exact="lung disease" post="[GOLD], 2013 1 ). Acute deterioration of symptoms and"/>
   <result pre="deterioration of symptoms and lung function, which often results in" exact="respiratory failure," post="is a so-called &quot;exacerbation,&quot; and it is an important"/>
   <result pre="adults and a major cause of exacerbations in patients with" exact="asthma" post="( Figure 1 ) and/or COPD ( Figure 2"/>
   <result pre="Figure 2 ). FIGURE 1 Human respiratory pathogens associated with" exact="asthma" post="exacerbations. Pathogens are divided into three categories as bacteria,"/>
   <result pre="review aims to summarize the clinical aspects of exacerbations in" exact="asthma" post="and COPD from the perspective of the definition of"/>
   <result pre="of airflow limitation is incomplete in COPD, while that in" exact="asthma" post="can be complete. Airway inflammation in asthma is characterized"/>
   <result pre="while that in asthma can be complete. Airway inflammation in" exact="asthma" post="is characterized by allergic phenotypes, such as dense infiltration"/>
   <result pre="such as smoking. With respect to the site of inflammation," exact="asthma" post="involves predominantly larger airways, while in COPD, inflammation affects"/>
   <result pre="bronchial biopsied specimens as well as eosinophils in severe refractory" exact="asthma" post="( Wenzel et al., 1999). DIFFERENCES AND SIMILARITIES BETWEEN"/>
   <result pre="DIFFERENCES AND SIMILARITIES BETWEEN ASTHMA AND COPD As described above," exact="asthma" post="is typically characterized by chronic allergic inflammatory airway inflammation"/>
   <result pre="airflow limitation that is usually progressive and ultimately results in" exact="respiratory failure." post="Therefore, it is not difficult to differentiate clinically between"/>
   <result pre="between the two disorders. However, determining whether a patient has" exact="asthma" post="or an exacerbation of COPD is often difficult, because"/>
   <result pre="auscultation, special maneuvers, and vital signs. Table 1 Differences between" exact="asthma" post="and COPD. Asthma COPD Age at onset At any"/>
   <result pre="sound of an expiratory wheeze is identical in asthma, COPD," exact="congestive heart failure," post="and pneumonia, and it cannot be used to distinguish"/>
   <result pre="with no consensus about it. There are many similarities in" exact="asthma" post="and COPD ( Bleecker, 2004), and previous studies suggested"/>
   <result pre="and COPD ( Bleecker, 2004), and previous studies suggested that" exact="asthma" post="may be a risk factor for the development of"/>
   <result pre="COPD ( Silva et al., 2004), while the coexistence of" exact="asthma" post="and COPD, so-called &quot;overlap syndrome,&quot; has recently been attracting"/>
   <result pre="et al., 2011). Furthermore, previous reports noted that exacerbations of" exact="asthma" post="or COPD are associated with accelerated loss of lung"/>
   <result pre="is crucial to recognize and understand the clinical features of" exact="asthma" post="and COPD patients, not only in the stable phase,"/>
   <result pre="viral infections. Johnston and Sears (2006) reported that exacerbations of" exact="asthma" post="and COPD appear to have a seasonal predilection in"/>
   <result pre="healthy participants (8.5%) were similar. The term virus-induced exacerbation of" exact="asthma" post="is not uncommon, but only a small number of"/>
   <result pre="condition in adult asthmatic patients. FIGURE 3 Multidisciplinary assessment for" exact="asthma" post="exacerbation. PCR, polymerase-chain reaction; RT-PCR, real-time PCR; BALF, bronchoalveolar"/>
   <result pre="SABA, short-acting β-agonist inhalers; GINA, Global Initiative for Asthma; ABPA," exact="allergic bronchopulmonary aspergillosis;" post="EPR, expert panel report. Definitions of acute exacerbation of"/>
   <result pre="aspergillosis; EPR, expert panel report. Definitions of acute exacerbation of" exact="asthma" post="The diagnosis of asthma is usually defined based on"/>
   <result pre="report. Definitions of acute exacerbation of asthma The diagnosis of" exact="asthma" post="is usually defined based on history and variability of"/>
   <result pre="therapy or spontaneously. There is no clear consensus definition for" exact="asthma" post="exacerbation; clinical trials usually define a severe exacerbation as"/>
   <result pre="to the latest NIH National Asthma Education and Prevention Guidelines," exact="asthma" post="exacerbations are acute or subacute episodes of progressively worsening"/>
   <result pre="asthma exacerbations are acute or subacute episodes of progressively worsening" exact="shortness" post="of breath, cough, wheezing, and chest tightness, or some"/>
   <result pre="American Thoracic Society and European Respiratory Society has recently defined" exact="asthma" post="exacerbations as events characterized by a change from the"/>
   <result pre="due to being outside the patient’s usual range of day-to-day" exact="asthma" post="variation. Mild exacerbations are not defined because such events"/>
   <result pre="defined because such events can be indistinguishable from loss of" exact="asthma" post="control ( Reddel et al., 2009; Figure 3 )."/>
   <result pre="female than in male patients, and the higher prevalence of" exact="asthma" post="in adult women contrasts with the higher prevalence of"/>
   <result pre="asthma in adult women contrasts with the higher prevalence of" exact="asthma" post="in male children ( Bjornson and Mitchell, 2000). Between"/>
   <result pre="Bjornson and Mitchell, 2000). Between 14 and 45% of acute" exact="asthma" post="exacerbations in children is thought to be related to"/>
   <result pre="is less clear, previous reports showed that RTIs associated with" exact="asthma" post="exacerbation in adults ranged from 10–21% ( Teichtahl et"/>
   <result pre="suggest that viral infections are involved in about 50% of" exact="asthma" post="exacerbations among adults and in probably substantially more childhood"/>
   <result pre="asthma exacerbations among adults and in probably substantially more childhood" exact="asthma" post="exacerbations. Another report also showed that the virus most"/>
   <result pre="report also showed that the virus most commonly implicated in" exact="asthma" post="exacerbations appears to be HRV ( Murray et al.,"/>
   <result pre="other respiratory tract viruses, such as respiratory syncytial virus (RSV)," exact="influenza" post="viruses, coronaviruses, human metapneumoviruses (HMPVs), parainfluenza viruses (PIVs), adenoviruses"/>
   <result pre="(AdVs), and bocaviruses, have all been detected in subjects with" exact="asthma" post="exacerbations ( Jackson and Johnston, 2010). In adults requiring"/>
   <result pre="2010). In adults requiring hospital admission for an acute severe" exact="asthma" post="exacerbation in a 1-year period, virus was identified in"/>
   <result pre="was identified in 29% of the subjects, with HRV and" exact="influenza" post="A the most commonly identified infectious agents ( Teichtahl"/>
   <result pre="that nasopharyngeal secretions and induced sputum during acute exacerbations of" exact="asthma" post="in adult patients were equal, while Falsey et al."/>
   <result pre="largely cell-associated ( Murray et al., 2004). Causes of acute" exact="asthma" post="exacerbations Eczema and a family history of asthma are"/>
   <result pre="of acute asthma exacerbations Eczema and a family history of" exact="asthma" post="are the dominant non-infectious risk factors for pediatric asthma,"/>
   <result pre="of adult-onset disease are less well defined. The causes for" exact="asthma" post="exacerbation have been described and categorized. Of note, clinicians"/>
   <result pre="should recognize the seasonal trends for exacerbations of wheezing or" exact="asthma" post="in adults, which occur 1–2 weeks later than in"/>
   <result pre="1 ). Viruses . The most important viruses relevant to" exact="asthma" post="development are RSV and HRV. Jackson et al. (2008)"/>
   <result pre="a large, high-risk cohort, children had an increased risk of" exact="asthma" post="at 6 years of age if they wheezed in"/>
   <result pre="1995). The exact mechanisms by which respiratory viral infection causes" exact="asthma" post="exacerbation remains to be determined, but the respiratory viruses"/>
   <result pre="role of severe RSV infection as a risk factor for" exact="asthma" post="in adulthood is less certain, but it is still"/>
   <result pre="young children and accounts for ~70% of severe infantile viral" exact="bronchiolitis" post="and/or pneumonia cases, most of whom have wheezing, and"/>
   <result pre="and accounts for ~70% of severe infantile viral bronchiolitis and/or" exact="pneumonia" post="cases, most of whom have wheezing, and it is"/>
   <result pre="Furthermore, this study showed the strongest evidence that human RSV-mediated" exact="bronchiolitis" post="has long-term effects using palivizumab (a humanized monoclonal antibody"/>
   <result pre="the most common pathogens, whereas in older children, rhinovirus and" exact="influenza" post="A virus are more prevalent ( Beasley et al.,"/>
   <result pre="Beasley et al., 1988). Even in elderly persons, RSV causes" exact="pneumonia" post="( Falsey et al., 2006), exacerbations of COPD, and"/>
   <result pre="infection with HRV as a predominant respiratory pathogen associated with" exact="asthma" post="later in life ( Kusel et al., 2007). HRV"/>
   <result pre="is the most important virus type associated with exacerbations of" exact="asthma" post="leading to hospital admission in both adults and children"/>
   <result pre="and AdV were most commonly identified in near-fatal asthma, whereas" exact="influenza" post="virus predominated in COPD. Corne et al. (2002) found"/>
   <result pre="children. AdVs are associated with up to 7% of virus-related" exact="asthma" post="exacerbations ( McErlean et al., 2010), and they cause"/>
   <result pre="variety of clinical syndromes, such as diarrhea, keratoconjunctivitis, and hemorrhagic" exact="cystitis" post="( Brodzinski and Ruddy, 2009). It has been demonstrated"/>
   <result pre="It has been demonstrated that 94% of children with refractory" exact="asthma" post="has detectable AdV antigens, compared with 0% of controls"/>
   <result pre="noted, PIV is one of the most common pathogens for" exact="asthma" post="exacerbation in children under 5 years. In adults with"/>
   <result pre="department ( Atmar et al., 1998). Other viruses . Most" exact="asthma" post="studies describe relatively low levels of influenza viruses in"/>
   <result pre="viruses . Most asthma studies describe relatively low levels of" exact="influenza" post="viruses in asthmatic patients with exacerbations, approximately 1–9% of"/>
   <result pre="in asthmatic patients with exacerbations, approximately 1–9% of all virus-related" exact="asthma" post="exacerbations. Several studies indicated that human bocaviruses ( Gendrel"/>
   <result pre="are found more frequently in the airways of patients with" exact="asthma" post="than in healthy patients ( Nisar et al., 2007),"/>
   <result pre="been shown to increase mucus secretion, which is recognized in" exact="asthma" post="or COPD by characteristic goblet cell hyperplasia or enhanced"/>
   <result pre="al., 2007; Kraft et al., 2008). Fungus . Allergic bronchopulmonary" exact="aspergillosis" post="(ABPA) is a unique form of asthma caused by"/>
   <result pre=". Allergic bronchopulmonary aspergillosis (ABPA) is a unique form of" exact="asthma" post="caused by colonization of the LRT ( Vlahakis and"/>
   <result pre="mold Aspergillus spp., by which colonization leads to allergic and/or" exact="asthma" post="symptoms ( Edwards et al., 2012). Other factors ."/>
   <result pre="et al., 2012). Other factors . The diverse etiologies for" exact="asthma" post="exacerbation are well known, including viruses, allergens (dust mite,"/>
   <result pre="pollutants. Physicians should be aware of these risk factors for" exact="asthma" post="exacerbation ( Dougherty and Fahy, 2009). Mechanisms of viral-induced"/>
   <result pre="asthma exacerbation ( Dougherty and Fahy, 2009). Mechanisms of viral-induced" exact="asthma" post="exacerbations Respiratory virus infection affects the pathogenesis of asthma."/>
   <result pre="these patients remain unknown. Virus-associated clinical symptoms and exacerbations of" exact="asthma" post="In general, upper respiratory tract (URT) symptoms include rhinorrhea,"/>
   <result pre="fever, while LRT symptoms include symptoms such as wheeze, cough," exact="shortness" post="of breath, and chest tightness ( Corne et al.,"/>
   <result pre="pathogens were implicated in almost half of the most severe" exact="asthma" post="exacerbations with a &amp;gt; 50 L/min mean decrease in"/>
   <result pre="found that URT infections were strongly associated with exacerbations of" exact="asthma" post="leading to hospital admission, in both adults and children"/>
   <result pre="Johnston et al., 1996), and they may have contributed to" exact="asthma" post="mortality, especially in the setting of hospital admission. Specific"/>
   <result pre="admission. Specific anti-viral therapies have not been established except for" exact="influenza" post="viral infection, which have been recommended for persons with"/>
   <result pre="influenza viral infection, which have been recommended for persons with" exact="asthma" post="or COPD. Furthermore, regarding preventive therapy for RSV, palivizumab"/>
   <result pre="it might be appropriate for infants and young children with" exact="congenital heart disease," post="bronchopulmonary dysplasia, and prematurity before 35 weeks of gestation"/>
   <result pre="might be appropriate for infants and young children with congenital" exact="heart disease," post="bronchopulmonary dysplasia, and prematurity before 35 weeks of gestation"/>
   <result pre="or steroids with or without admission. Diseases such as pneumonia," exact="congestive heart failure," post="and pulmonary embolism that mimic and/or aggravate exacerbations were"/>
   <result pre="without admission. Diseases such as pneumonia, congestive heart failure, and" exact="pulmonary embolism" post="that mimic and/or aggravate exacerbations were generally excluded from"/>
   <result pre="fall and winter in the same fashion as in adult" exact="asthma" post="( Johnston and Sears, 2006). CAUSES OF EXACERBATIONS It"/>
   <result pre="Moraxella catarrhalis, and P. aeruginosa) and respiratory viruses (HRV, RSV," exact="influenza" post="virus, HMPV, coronavirus, and AdVs) were recognized during exacerbations."/>
   <result pre="with exacerbation of COPD. Viruses such as HRV, RSV, and" exact="influenza" post="virus have a higher prevalence in patients with exacerbations"/>
   <result pre="viruses associated with exacerbations were HRV (3.1–26.6%), RSV (0.7–40.5%), and" exact="influenza" post="virus (2.0–22.4%; Seemungal et al., 2001; Rohde et al.,"/>
   <result pre="viruses detected during exacerbations of COPD were HRV, RSV, and" exact="influenza" post="virus, similar to those of asthma ( Tan et"/>
   <result pre="were HRV, RSV, and influenza virus, similar to those of" exact="asthma" post="( Tan et al., 2003). Other viruses, such as"/>
   <result pre="a key pro-allergic cytokine that has recently been linked to" exact="asthma" post="( Redhu and Gounni, 2012). In addition, genome-wide association"/>
   <result pre="TSLP gene were associated with various allergic diseases, including bronchial" exact="asthma" post="( Hirota et al., 2011; Ober and Yao, 2011)."/>
   <result pre="diseases ( Harper et al., 2009). A meta-analysis showed that" exact="influenza" post="vaccination prevented exacerbations in COPD patients ( Poole et"/>
   <result pre="disease ( Kaiser et al., 2003). Thus, treatment to prevent" exact="influenza" post="has been recommended for COPD patients ( Harper et"/>
   <result pre="prescribed, because specific anti-viral therapies do not exist, except for" exact="influenza" post="virus and RSV. Treatment for influenza appears appropriate in"/>
   <result pre="not exist, except for influenza virus and RSV. Treatment for" exact="influenza" post="appears appropriate in patients with COPD ( Harper et"/>
   <result pre="SUMMARY AT A GLANCE The associations between virus infections and" exact="asthma" post="and/or COPD were reviewed, and the significance of viral"/>
   <result pre="HRV and RSV are major causes of exacerbations both in" exact="asthma" post="and COPD patients. (2) The frequency of viral detection"/>
   <result pre="COPD patients. (2) The frequency of viral detection in both" exact="asthma" post="and COPD patients appears to be similar to that"/>
   <result pre="subjects, but the effect on their clinical course is different;" exact="asthma" post="and COPD patients tend to have more severe or"/>
   <result pre="function, and mortality may be increased. (3) Since discrimination between" exact="asthma" post="and COPD is difficult, especially during exacerbations, whenever clinicians"/>
   <result pre="is required for diagnosis. (4) The clinical findings of both" exact="asthma" post="and COPD, so-called &quot;overlap syndrome,&quot; are commonly recognized in"/>
   <result pre="Granulocyte inflammatory markers and airway infection during acute exacerbation of" exact="chronic obstructive pulmonary disease." post="Am. J. Respir. Crit. Care Med. 163 349– 355"/>
   <result pre="21680942 Barnes P. J. ( 2008). The cytokine network in" exact="asthma" post="and chronic obstructive pulmonary disease. J. Clin. Invest. 118"/>
   <result pre="P. J. ( 2008). The cytokine network in asthma and" exact="chronic obstructive pulmonary disease." post="J. Clin. Invest. 118 3546– 3556 10.1172/JCI36130 18982161 Beasley"/>
   <result pre="M. ( 1988). Viral respiratory tract infection and exacerbations of" exact="asthma" post="in adult patients. Thorax 43 679– 683 10.1136/thx.43.9.679 3194873"/>
   <result pre="B. Heilbronner C. et al. ( 2004). Mycoplasma pneumoniae and" exact="asthma" post="in children. Clin. Infect. Dis 38 1341– 1346 10.1086/392498"/>
   <result pre="Halkjaer L. B. Bonnelykke K. et al. ( 2007). Childhood" exact="asthma" post="after bacterial colonization of the airway in neonates. N."/>
   <result pre="Bjornson C. L. Mitchell I. ( 2000). Gender differences in" exact="asthma" post="in childhood and adolescence. J. Gend. Specif. Med. 3"/>
   <result pre="12149525 Bleecker E. R. ( 2004). Similarities and differences in" exact="asthma" post="and COPD. The Dutch hypothesis. Chest 126 93S– 95S"/>
   <result pre="2012). Viral stimuli trigger exaggerated thymic stromal lymphopoietin expression by" exact="chronic obstructive pulmonary disease" post="epithelium: role of endosomal TLR3 and cytosolic RIG-I-like helicases."/>
   <result pre="al. ( 2007). Salmeterol and fluticasone propionate and survival in" exact="chronic obstructive pulmonary disease." post="N. Engl. J. Med. 356 775– 789 10.1056/NEJMoa063070 17314337"/>
   <result pre="Ward M. E. ( 1998). Chronic Chlamydia pneumoniae infection and" exact="asthma" post="exacerbations in children. Eur. Respir. J. 11 345– 349"/>
   <result pre="et al. ( 2012). Viral epidemiology of acute exacerbations of" exact="chronic obstructive pulmonary disease." post="Pulm. Pharmacol. Ther. 25 12– 18 10.1016/j.pupt.2011.08.004 21983132 Donaldson"/>
   <result pre="2002). Relationship between exacerbation frequency and lung function decline in" exact="chronic obstructive pulmonary disease." post="Thorax 57 847– 852 10.1136/thorax.57.10.847 12324669 Dougherty R. H."/>
   <result pre="( 2006). Detection of respiratory syncytial virus in adults with" exact="chronic obstructive pulmonary disease." post="Am. J. Respir. Crit. Care Med. 173 639– 643"/>
   <result pre="( 2000). Respiratory viral infections in adults with and without" exact="chronic obstructive pulmonary disease." post="Am. J. Respir. Crit. Care Med. 162 167– 173"/>
   <result pre="Gravenstein S. Hayden F. G. et al. ( 2009). Seasonal" exact="influenza" post="in adults and children–diagnosis, treatment, chemoprophylaxis, and institutional outbreak"/>
   <result pre="et al. ( 1979). The etiologic and epidemiologic spectrum of" exact="bronchiolitis" post="in pediatric practice. J. Pediatr. 95 183– 190 10.1016/S0022-3476(79)80647-2"/>
   <result pre="Genome-wide association study identifies three new susceptibility loci for adult" exact="asthma" post="in the Japanese population. Nat. Genet. 43 893– 896"/>
   <result pre="et al. ( 2004). The nature of small-airway obstruction in" exact="chronic obstructive pulmonary disease." post="N. Engl. J. Med. 350 2645– 2653 10.1056/NEJMoa032158 15215480"/>
   <result pre="Tal-Singer R. et al. ( 2010). Susceptibility to exacerbation in" exact="chronic obstructive pulmonary disease." post="N. Engl. J. Med. 363 1128– 1138 10.1056/NEJMoa0909883 20843247"/>
   <result pre="al. ( 2008). Wheezing rhinovirus illnesses in early life predict" exact="asthma" post="development in high-risk children. Am. J. Respir. Crit. Care"/>
   <result pre="Community study of role of viral infections in exacerbations of" exact="asthma" post="in 9-11 year old children. BMJ 310 1225– 1229"/>
   <result pre="D. Kim H. Mcivor R. A. ( 2009). Diagnosis of" exact="asthma" post="in adults. CMAJ 181 E210– E220 10.1503/cmaj.080006 19770241 Keatings"/>
   <result pre="and tumor necrosis factor-alpha in induced sputum from patients with" exact="chronic obstructive pulmonary disease" post="or asthma. Am. J. Respir. Crit. Care Med. 153"/>
   <result pre="Beck E. Vandewalker M. et al. ( 2012). Tiotropium in" exact="asthma" post="poorly controlled with standard combination therapy. N. Engl. J."/>
   <result pre="900– 908 10.1378/chest.07-0530 17573516 Kraft M. ( 2006). Asthma and" exact="chronic obstructive pulmonary disease" post="exhibit common origins in any country! Am. J. Respir."/>
   <result pre="induces degradation of antimicrobial peptides and secondary bacterial infection in" exact="chronic obstructive pulmonary disease." post="Am. J. Respir. Crit. Care Med. 186 1117– 1124"/>
   <result pre="( 2011). Experimental rhinovirus infection as a human model of" exact="chronic obstructive pulmonary disease" post="exacerbation. Am. J. Respir. Crit. Care Med. 183 734–"/>
   <result pre="al. ( 2008). Rhinovirus-induced lower respiratory illness is increased in" exact="asthma" post="and related to virus load and Th1/2 cytokine and"/>
   <result pre="S. Simpson A. Custovic A. ( 2004). Allergens, viruses, and" exact="asthma" post="exacerbations. Proc. Am. Thorac. Soc. 1 99– 104 10.1513/pats.2306027"/>
   <result pre="B. Mullooly J. P. Hak E. ( 2007). Effectiveness of" exact="influenza" post="vaccine in the community-dwelling elderly. N. Engl. J. Med."/>
   <result pre="Ireland D. C. ( 1993). Respiratory viruses and exacerbations of" exact="asthma" post="in adults. BMJ 307 982– 986 10.1136/bmj.307.6910.982 8241910 Nisar"/>
   <result pre="Ober C. Yao T. C. ( 2011). The genetics of" exact="asthma" post="and allergic disease: a 21st century perspective. Immunol. Rev."/>
   <result pre="E. et al. ( 2010). Weekly monitoring of children with" exact="asthma" post="for infections and illness during common cold seasons. J."/>
   <result pre="monitoring of children with asthma for infections and illness during" exact="common cold" post="seasons. J. Allergy Clin. Immunol. 125 1001– 1006 e1."/>
   <result pre="Identification of human metapneumovirus and Chlamydophila pneumoniae in children with" exact="asthma" post="and wheeze in Singapore. Singapore Med. J. 48 291–"/>
   <result pre="G. et al. ( 2006). Infections and airway inflammation in" exact="chronic obstructive pulmonary disease" post="severe exacerbations. Am. J. Respir. Crit. Care Med. 173"/>
   <result pre="Cates C. J. ( 2000). Influenza vaccine for patients with" exact="chronic obstructive pulmonary disease." post="Cochrane Database Syst. Rev. CD002733 10.1002/14651858.CD002733 Rakes G. P."/>
   <result pre="( 2009). An official American Thoracic Society/European Respiratory Society statement:" exact="asthma" post="control and exacerbations: standardizing endpoints for clinical asthma trials"/>
   <result pre="Society statement: asthma control and exacerbations: standardizing endpoints for clinical" exact="asthma" post="trials and clinical practice. Am. J. Respir. Crit. Care"/>
   <result pre="S. ( 2012). Function and mechanisms of TSLP/TSLPR complex in" exact="asthma" post="and COPD. Clin. Exp. Allergy 42 994– 1005 10.1111/j.1365-2222.2011.03919.x"/>
   <result pre="A. et al. ( 2003). Respiratory viruses in exacerbations of" exact="chronic obstructive pulmonary disease" post="requiring hospitalisation: a case-control study. Thorax 58 37– 42"/>
   <result pre="Ruggieri M. P. Roggeri A. et al. ( 1994). Airway" exact="eosinophilia" post="in chronic bronchitis during exacerbations. Am. J. Respir. Crit."/>
   <result pre="viruses, symptoms, and inflammatory markers in acute exacerbations and stable" exact="chronic obstructive pulmonary disease." post="Am. J. Respir. Crit. Care Med. 164 1618– 1623"/>
   <result pre="Effect of exacerbation on quality of life in patients with" exact="chronic obstructive pulmonary disease." post="Am. J. Respir. Crit. Care Med. 157 1418– 1422"/>
   <result pre="F. ( 2002). New strains of bacteria and exacerbations of" exact="chronic obstructive pulmonary disease." post="N. Engl. J. Med. 347 465– 471 10.1056/NEJMoa012561 12181400"/>
   <result pre="F. ( 2008). Infection in the pathogenesis and course of" exact="chronic obstructive pulmonary disease." post="N. Engl. J. Med. 359 2355– 2365 10.1056/NEJMra0800353 19038881"/>
   <result pre="65 10.1378/chest.126.1.59 15249443 Tan W. C. ( 2005). Viruses in" exact="asthma" post="exacerbations. Curr. Opin. Pulm. Med. 11 21– 26 15591884"/>
   <result pre="patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or" exact="chronic obstructive pulmonary disease." post="Am. J. Med. 115 272– 277 10.1016/S0002-9343(03)00353-X 12967691 Tashkin"/>
   <result pre="et al. ( 2008). A 4-year trial of tiotropium in" exact="chronic obstructive pulmonary disease." post="N. Engl. J. Med. 359 1543– 1554 10.1056/NEJMoa0805800 18836213"/>
   <result pre="9315789 Tokuda Y. Miyagi S. ( 2007). Physical diagnosis of" exact="chronic obstructive pulmonary disease." post="Intern. Med. 46 1885– 1891 10.2169/internalmedicine.46.0455 18057759 Vallet C."/>
   <result pre="et al. ( 2009). Human bocavirus: a cause of severe" exact="asthma" post="exacerbation in children. J. Pediatr. 155 286– 288 10.1016/j.jpeds.2009.01.069"/>
   <result pre="E. Aksamit T. R. ( 2001). Diagnosis and treatment of" exact="allergic bronchopulmonary aspergillosis." post="Mayo Clin. Proc. 76 930– 938 10.1016/S0025-6196(11)62114-9 11560305 Vogelmeier"/>
   <result pre="Ansari Z. Stockley R. A. ( 2008). The prevention of" exact="chronic obstructive pulmonary disease" post="exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J."/>
   <result pre="Gibbs R. L. et al. ( 1999). Evidence that severe" exact="asthma" post="can be divided patholo{-}gically into two inflammatory subtypes with"/>
   <result pre="syncytial virus, airway inflammation, and FEV1 decline in patients with" exact="chronic obstructive pulmonary disease." post="Am. J. Respir. Crit. Care Med. 173 871– 876"/>
   <result pre="2005). Human metapneumovirus infection plays an etiologic role in acute" exact="asthma" post="exacerbations requiring hospitalization in adults. J. Infect. Dis. 192"/>
   <result pre="10.1186/1710-1492-4-3-111 20525132 Xepapadaki P. Papadopoulos N. G. ( 2010). Childhood" exact="asthma" post="and infection: virus-induced exacerbations as determinants and modifiers. Eur."/>
   <result pre="2012). Reduced rhinovirus-specific antibodies are associated with acute exacerbations of" exact="chronic obstructive pulmonary disease" post="requiring hospitalisation. BMC Pulm. Med. 12: 37 10.1186/1471-2466-12-37% Abbreviations"/>
   <result pre="requiring hospitalisation. BMC Pulm. Med. 12: 37 10.1186/1471-2466-12-37% Abbreviations ABPA" exact="allergic bronchopulmonary aspergillosis" post="AdVs adenoviruses BAL bronchoalveolar lavage COPD chronic obstructive lung"/>
   <result pre="BMC Pulm. Med. 12: 37 10.1186/1471-2466-12-37% Abbreviations ABPA allergic bronchopulmonary" exact="aspergillosis" post="AdVs adenoviruses BAL bronchoalveolar lavage COPD chronic obstructive lung"/>
   <result pre="bronchopulmonary aspergillosis AdVs adenoviruses BAL bronchoalveolar lavage COPD chronic obstructive" exact="lung disease" post="CRP C-reactive protein FEV 1.0 forced expiratory volume in"/>
   <result pre="volume in 1 second GOLD Global initiative for chronic obstructive" exact="lung disease" post="HMPV human metapneumovirus HRV human rhinovirus ICS inhaled corticosteroid"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC4142007/results/search/disease/results.xml">
   <result pre="Safety; http://www.aabb.org/resources/bct/eid/Pages/default.aspx) published a Supplement to Transfusion that reviewed emerging" exact="infectious disease" post="(EID) agents that pose a real or theoretical threat"/>
   <result pre="prion, dengue viruses and the obligate red-cell parasite that causes" exact="babesiosis" post="( B. microti and related Babesia). Although the focus"/>
   <result pre="of Q fever, dengue viruses, HAV, HEV, Japanese encephalitis-JE complex," exact="tick-borne encephalitis" post="viruses-TBEV, and human parvovirus B19). Also, tables were released"/>
   <result pre="Q fever, dengue viruses, HAV, HEV, Japanese encephalitis-JE complex, tick-borne" exact="encephalitis" post="viruses-TBEV, and human parvovirus B19). Also, tables were released"/>
   <result pre="epidemiology transfusion transmissible infections Introduction The recognition of newly described" exact="infectious disease" post="agents will continue to place demands on the collectors"/>
   <result pre="newly described Middle East respiratory syndrome coronavirus (MERS-CoV), dengue viruses," exact="chikungunya" post="virus and hepatitis E virus (HEV). Defining emerging infectious"/>
   <result pre="East respiratory syndrome coronavirus (MERS-CoV), dengue viruses, chikungunya virus and" exact="hepatitis" post="E virus (HEV). Defining emerging infectious disease (EID) agents"/>
   <result pre="viruses, chikungunya virus and hepatitis E virus (HEV). Defining emerging" exact="infectious disease" post="(EID) agents and their risk to transfusion safety In"/>
   <result pre="prion, dengue viruses and the obligate red-cell parasite that causes" exact="babesiosis" post="( B. microti and related Babesia). Although the focus"/>
   <result pre="with priority given to West Nile virus, dengue viruses, Leishmania," exact="chikungunya" post="virus, the agents of malaria and Lyme disease, and"/>
   <result pre="Nile virus, dengue viruses, Leishmania, chikungunya virus, the agents of" exact="malaria" post="and Lyme disease, and tick-borne encephalitis virus [ 5];"/>
   <result pre="chikungunya virus, the agents of malaria and Lyme disease, and" exact="tick-borne encephalitis" post="virus [ 5]; of note, several of these agents,"/>
   <result pre="virus, the agents of malaria and Lyme disease, and tick-borne" exact="encephalitis" post="virus [ 5]; of note, several of these agents,"/>
   <result pre="publication of the Supplement, six new Fact Sheets were released:" exact="yellow fever" post="viruses including vaccine breakthrough infections, miscellaneous arboviruses, XMRV including"/>
   <result pre="of published literature, human parvoviruses other than B19, and bocaviruses," exact="measles" post="due to localized US outbreaks, MERS-CoV. Also, 14 existing"/>
   <result pre="the Netherlands, increasing numbers precipitated by high-intensity pig farming, Japanese" exact="encephalitis" post="(JE) complex, tick-borne encephalitis viruses (TBEV), dengue viruses with"/>
   <result pre="numbers precipitated by high-intensity pig farming, Japanese encephalitis (JE) complex," exact="tick-borne encephalitis" post="viruses (TBEV), dengue viruses with three transfusion-transmission clusters, one"/>
   <result pre="precipitated by high-intensity pig farming, Japanese encephalitis (JE) complex, tick-borne" exact="encephalitis" post="viruses (TBEV), dengue viruses with three transfusion-transmission clusters, one"/>
   <result pre="in Hong Kong, Singapore and Puerto Rico, human parvovirus B19," exact="hepatitis" post="A virus (HAV) due to a large multi-state outbreak"/>
   <result pre="or existing threats to blood safety include MERS-CoV, dengue viruses," exact="chikungunya" post="virus and HEV; each will be briefly reviewed. MERS-CoV"/>
   <result pre="in Saudi Arabia [ 6]. It is related to the" exact="severe acute respiratory syndrome" post="coronavirus (SARS) that from 2002 to 2003 resulted in"/>
   <result pre="with severe disease of the lower respiratory tract resulting in" exact="pneumonia" post="and multi-organ failure; the most susceptible to clinical disease"/>
   <result pre="been reported in 96% of clinical cases including diabetes, hypertension," exact="heart disease" post="and kidney disease. It is unclear whether persons with"/>
   <result pre="the family Flaviviridae along with related viruses: West Nile virus," exact="yellow fever" post="virus and over 65 other related viruses. Arboviruses also"/>
   <result pre="other viral families ( Bunyaviridae and Togaviridae including the alphavirus," exact="chikungunya" post="described below). Dengue viruses are the most important of"/>
   <result pre="(i.e. mosquito versus transfusion) [ 16]. Chikungunya virus Another flavivirus," exact="chikungunya" post="virus, is endemic in many of the same tropical"/>
   <result pre="with more severe body aches, especially joint pains and crippling" exact="arthritis" post="than that of dengue. The name ‘chikungunya’ refers to"/>
   <result pre="risk was estimated to be higher than the risk from" exact="hepatitis" post="B virus transfusion transmission, the implementation for platelets of"/>
   <result pre="transfusion transmission, the implementation for platelets of pathogen inactivation and" exact="chikungunya" post="virus RNA nucleic acid testing, and for continental France,"/>
   <result pre="severe disease [ 21]. Subsequently, a case-control study during a" exact="chikungunya" post="outbreak in Thailand in 2009 investigated the development of"/>
   <result pre="E virus is globally the most common cause of acute" exact="hepatitis" post="with an estimated 20 million incident infections per year,"/>
   <result pre="transplant (SOT) recipients leading to chronic infection (&amp;gt;60%), and to" exact="cirrhosis" post="and severe liver disease in 14% of those who"/>
   <result pre="leading to chronic infection (&amp;gt;60%), and to cirrhosis and severe" exact="liver disease" post="in 14% of those who become chronically infected ["/>
   <result pre="were positive; of those, 11 of 12 HEV-RNA-positive patients developed" exact="cirrhosis" post="[ 24]. Antibody prevalence in blood donors varies greatly"/>
   <result pre="1 Stramer SL Hollinger FB Katz LM et al. Emerging" exact="infectious disease" post="agents and their potential threat to transfusion safety Transfusion"/>
   <result pre="al. Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi Arabia N Engl J Med 2012 367"/>
   <result pre="C Bernillon P Quatresous I et al. Estimated risk of" exact="chikungunya" post="viremic blood donations during an epidemic on Reunion Island"/>
   <result pre="I Iteman I Michault A et al. Genome microevolution of" exact="chikungunya" post="viruses causing the Indian Ocean outbreak PLoS Med 2006"/>
   <result pre="20 Liumbruno GM Calteri D Petropulacos K et al. The" exact="chikungunya" post="epidemic in Italy and its repercussion on the blood"/>
   <result pre="Kemapunmanus M et al. Viremic profiles in asymptomatic and symptomatic" exact="chikungunya" post="fever: a blood transfusion threat? Transfusion 2013 53 2567"/>
   <result pre="Garrouste C Haagsma EB et al. Factors associated with chronic" exact="hepatitis" post="in patients with hepatitis E virus infection who have"/>
   <result pre="et al. Factors associated with chronic hepatitis in patients with" exact="hepatitis" post="E virus infection who have received solid organ transplants"/>
   <result pre="25 Slot E Hogema BM Riezebos-Brillman A et al. Silent" exact="hepatitis" post="E infection in Dutch blood donors, 2011-2012 Euro Surveill"/>
   <result pre="C Wang R Schecherly C et al. An assessment of" exact="hepatitis" post="E virus in US blood donors and recipients: no"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC4589665/results/search/disease/results.xml">
   <result pre="and nature of contact between animal and human populations. The" exact="influenza" post="A viruses are probably the most notorious viruses which"/>
   <result pre="F. Senne D. A. et al. . ( 1998). Human" exact="influenza" post="A H5N1 virus related to a highly pathogenic avian"/>
   <result pre="Human influenza A H5N1 virus related to a highly pathogenic" exact="avian influenza" post="virus. Lancet 351, 472– 477. 10.1016/S0140-6736(97)11212-0 9482438 Coffey L."/>
   <result pre="influenza A H5N1 virus related to a highly pathogenic avian" exact="influenza" post="virus. Lancet 351, 472– 477. 10.1016/S0140-6736(97)11212-0 9482438 Coffey L."/>
   <result pre="A. M. ( 2014). Role of receptor binding specificity in" exact="influenza" post="A virus transmission and pathogenesis. EMBO J. 33, 823–"/>
   <result pre="15958664 Koopmans M. ( 2013). The expanding list of zoonotic" exact="influenza" post="viruses. Lancet. Respir. Med. 1, 756– 757. 10.1016/S2213-2600(13)70233-9 24461744"/>
   <result pre="2014). Ball python nidovirus: a candidate etiologic agent for severe" exact="respiratory disease" post="in Python regius . MBio 5, e01484– e01414. 10.1128/mBio.01484-14"/>
   <result pre="E. ( 2010). Human picobirnaviruses identified by molecular screening of" exact="diarrhea" post="samples. J. Clin. Microbiol. 48, 1787– 1794. 10.1128/JCM.02452-09 20335418"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC5309255/results/search/disease/results.xml">
   <result pre="of clinicians, and limited surveillance efforts. Classical food- and waterborne" exact="viral disease" post="outbreaks are mainly caused by caliciviruses, but the source"/>
   <result pre="difficult to discriminate from human-to-human transmission. Atypical food- and waterborne" exact="viral disease" post="can be caused by viruses such as hepatitis A"/>
   <result pre="waterborne viral disease can be caused by viruses such as" exact="hepatitis" post="A and hepatitis E. In addition, a source of"/>
   <result pre="can be caused by viruses such as hepatitis A and" exact="hepatitis" post="E. In addition, a source of novel emerging viruses"/>
   <result pre="by the fecal-oral route. Particularly caliciviruses (norovirus, sapovirus) can cause" exact="diarrhea" post="and vomiting and less commonly astroviruses, rotaviruses, and adenoviruses"/>
   <result pre="2010). Other viruses cause symptoms resulting from extra-intestinal spread, like" exact="hepatitis" post="A (HAV), and hepatitis E (HEV). High levels of"/>
   <result pre="symptoms resulting from extra-intestinal spread, like hepatitis A (HAV), and" exact="hepatitis" post="E (HEV). High levels of viral shedding through stool"/>
   <result pre="there is limited coverage in surveillance of food- and waterborne" exact="viral disease," post="hampering detecting and tracing ( Ahmed et al., 2014;"/>
   <result pre="humans. Classic clinical symptoms of foodborne disease vary, ranging from" exact="diarrhea" post="and vomiting to abdominal cramps and general malaise, which"/>
   <result pre="captures the tip of the iceberg of food- and waterborne" exact="viral disease" post="cases. FIGURE 1 Schematic representation of the phenomenon known"/>
   <result pre="means that outbreaks often are merely registered. Of the 941" exact="viral disease" post="outbreaks reported as foodborne in the joint ECDC-EFSA surveillance"/>
   <result pre="et al., 2014). To be able to recognize food- waterborne" exact="viral disease" post="outbreaks and stop underestimation of its disease burden there"/>
   <result pre="and Waterborne Diseases Although the list of viruses causing acute" exact="gastroenteritis" post="is long, norovirus ranks among the top causes of"/>
   <result pre="used with some success to quantify the contribution of foodborne" exact="viral disease" post="stemming from environmentally contaminated food (e.g., associated with shellfish;"/>
   <result pre="environmental samples in the same area. However, food associated acute" exact="gastroenteritis" post="is not limited to norovirus infections. In a large"/>
   <result pre="norovirus infections. In a large retrospective study of oyster-related acute" exact="gastroenteritis" post="outbreaks in Osaka City in Japan 30.7% of the"/>
   <result pre="2016). Recent reports have shown potential in metagenomic detection of" exact="hepatitis" post="C, chikungunya, Ebola and Zika virus in hospital settings"/>
   <result pre="miss-annotations and incomplete reference databases. One example is &quot;non-A, non-B" exact="hepatitis" post="virus&quot;, a sequence present in the NCBI GenBank, which"/>
   <result pre="realistic insight in the global burden of food- and waterborne" exact="viral disease," post="and to make informed decisions on how to reduce"/>
   <result pre="et al. ( 2016). Key role of sequencing to trace" exact="hepatitis" post="a viruses circulating in Italy during a large multi-country"/>
   <result pre="Bartelds A. I. et al. ( 2001). A comparison of" exact="gastroenteritis" post="in a general practice-based study and a community-based study."/>
   <result pre="E. Ostanello F. Ruggeri F. M. ( 2015). Detection of" exact="hepatitis" post="E virus in pork liver sausages. Int. J. Food"/>
   <result pre="Severi E. ( 2014). Three simultaneous, food-borne, multi-country outbreaks of" exact="hepatitis" post="A virus infection reported in EPIS-FWD in 2013: What"/>
   <result pre="2016). High proportion of asymptomatic infections in an outbreak of" exact="hepatitis" post="E associated with a spit-roasted piglet, France, 2013. Clin."/>
   <result pre="L. Bhatt S. et al. ( 2013). Global mapping of" exact="infectious disease." post="Philos. Trans. R. Soc. Lond. B Biol. Sci. 368:"/>
   <result pre="Detection of pathogenic viruses in sewage provided early warnings of" exact="hepatitis" post="A virus and norovirus outbreaks. Appl. Environ. Microbiol. 80"/>
   <result pre="Detection and genetic characterization of human enteric viruses in oyster-associated" exact="gastroenteritis" post="outbreaks between 2001 and 2012 in Osaka City, Japan."/>
   <result pre="monitoring of municipal wastewater by pyrosequencing and virological surveillance of" exact="gastroenteritis" post="cases. Water Res. 92 244– 253. 10.1016/j.watres.2015.10.024 26874777 La"/>
   <result pre="Bruni R. Taffon S. et al. ( 2014). Surveillance of" exact="hepatitis" post="A virus in urban sewages and comparison with cases"/>
   <result pre="E. ( 2010). Transmission routes and risk factors for autochthonous" exact="hepatitis" post="E virus infection in Europe: a systematic review. Epidemiol."/>
   <result pre="Groeger J. Wiersma S. T. ( 2012). Global epidemiology of" exact="hepatitis" post="B virus infection: new estimates of age-specific HBsAg seroprevalence"/>
   <result pre="2015). Epidemiologic Association between FUT2 secretor status and severe rotavirus" exact="gastroenteritis" post="in children in the United States. JAMA Pediatr. 169"/>
   <result pre="Steenbergen J. E. et al. ( 2014). Underdiagnosis of foodborne" exact="hepatitis" post="A, the Netherlands, 2008–2010. Emerg. Infect. Dis. 20 596–"/>
   <result pre="L. et al. ( 2015). Large and prolonged food-borne multistate" exact="hepatitis" post="A outbreak in Europe associated with consumption offrozen berries,"/>
   <result pre="N. Takahashi K. Mishiro S. ( 2003). Zoonotic transmission of" exact="hepatitis" post="E virus from deer to human beings. Lancet 362"/>
   <result pre="Abreu-Silva J. Rodrigues A. et al. ( 2016). Prevalence of" exact="hepatitis" post="E virus antibodies in workers occupationally exposed to swine"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC5325067/results/search/disease/results.xml">
   <result pre="In terms of relative distribution, overt abundance, and resulting progeny," exact="rabies" post="virus is the most successful lyssavirus species today, but"/>
   <result pre="unknown reasons. All mammals are believed to be susceptible to" exact="rabies" post="virus infection. Besides reservoirs among the Chiroptera, meso-carnivores also"/>
   <result pre="true eradication. Despite having the highest case fatality of any" exact="infectious disease" post="and a burden in excess of or comparative to"/>
   <result pre="burden in excess of or comparative to other major zoonoses," exact="rabies" post="remains neglected. Once illness appears, no treatment is proven"/>
   <result pre="thousands succumb annually, primarily children in developing countries, where canine" exact="rabies" post="is enzootic. Rather than culling animal populations, one of"/>
   <result pre="to achieve success in disease control, prevention, and elimination. lyssaviruses" exact="rabies" post="rabies vaccine zoonoses Funding The author(s) declared that no"/>
   <result pre="achieve success in disease control, prevention, and elimination. lyssaviruses rabies" exact="rabies" post="vaccine zoonoses Funding The author(s) declared that no grants"/>
   <result pre="nightmarish myth, or literary allegory but rather a significant viral" exact="encephalitis" post="with the highest case fatality of any conventional infectious"/>
   <result pre="viral encephalitis with the highest case fatality of any conventional" exact="infectious disease." post="Who else, besides those afflicted and affected, should care"/>
   <result pre="Who else, besides those afflicted and affected, should care about" exact="rabies" post="today? Legions—including the true animal lover, anthropologist, administrator, caver,"/>
   <result pre="period. Among warm-blooded vertebrates, birds are susceptible to infection, but" exact="rabies" post="predominates naturally among various mammalian populations. Within the Mammalia,"/>
   <result pre="article, more than 1,300 people will have been exposed to" exact="rabies" post="virus (RABV). Annually, tens of thousands of persons will"/>
   <result pre="of associated health parameters of two vector-borne diseases and human" exact="rabies" post="transmitted by dogs a . Yellow fever Japanese encephalitis"/>
   <result pre="human rabies transmitted by dogs a . Yellow fever Japanese" exact="encephalitis" post="Rabies Disease Mild to acute viral hemorrhagic syndrome Mild"/>
   <result pre="Mild to acute viral hemorrhagic syndrome Mild to severe viral" exact="encephalitis" post="Acute progressive viral encephalitis Etiology Flavivirus Flavivirus Lyssavirus Distribution"/>
   <result pre="hemorrhagic syndrome Mild to severe viral encephalitis Acute progressive viral" exact="encephalitis" post="Etiology Flavivirus Flavivirus Lyssavirus Distribution Endemic in tropics of"/>
   <result pre="eliminated in nature. Vaccination protects humans at risk, but Japanese" exact="encephalitis" post="is not a candidate for elimination. Human rabies can"/>
   <result pre="but Japanese encephalitis is not a candidate for elimination. Human" exact="rabies" post="can be prevented by vaccination and canine rabies can"/>
   <result pre="elimination. Human rabies can be prevented by vaccination and canine" exact="rabies" post="can be eliminated by mass dog vaccination. Global Alliance"/>
   <result pre="good, at what level should one come to terms with" exact="rabies" post="in the 21st century? Management, control, prevention, elimination, eradication,"/>
   <result pre="lexicon of disease deliberations but are not synonymous terms. Unlike" exact="smallpox" post="or rinderpest, rabies is not a candidate for actual"/>
   <result pre="deliberations but are not synonymous terms. Unlike smallpox or rinderpest," exact="rabies" post="is not a candidate for actual eradication today, given"/>
   <result pre="today, given the extent of host breadth and diversity. However," exact="rabies" post="has at least three major attributes in common with"/>
   <result pre="practices. Somewhat paradoxically, based upon a century of experience, modern" exact="rabies" post="management accomplishes, in a truly One Health capacity, what"/>
   <result pre="phylogenetically related viruses (all of which cause the acute progressive" exact="encephalomyelitis" post="known as rabies) belong to the genus Lyssavirus, within"/>
   <result pre="bat virus; LLEBV, Lleida bat lyssavirus; MOKV, Mokola virus; RABV," exact="rabies" post="virus; RABV(IA), rabies virus, &quot;indigenous American&quot; lineage; RABV(C), rabies"/>
   <result pre="Lleida bat lyssavirus; MOKV, Mokola virus; RABV, rabies virus; RABV(IA)," exact="rabies" post="virus, &quot;indigenous American&quot; lineage; RABV(C), rabies virus, &quot;carnivore&quot; strain"/>
   <result pre="RABV, rabies virus; RABV(IA), rabies virus, &quot;indigenous American&quot; lineage; RABV(C)," exact="rabies" post="virus, &quot;carnivore&quot; strain (further shifted to other host mammals);"/>
   <result pre="of laboratory-based surveillance systems In an applied One Health context," exact="rabies" post="diagnosis is the only routine procedure applied to a"/>
   <result pre="there has been increasing augmentation by molecular methods for routine" exact="rabies" post="diagnosis 10, 36, 37 . Yet despite the innumerable"/>
   <result pre="rabies diagnosis 10, 36, 37 . Yet despite the innumerable" exact="rabies" post="cases that occur in wildlife, domestic animals, and humans"/>
   <result pre="in children because of confusion with other diseases, such as" exact="cerebral malaria" post="38 . Conversely, in some situations, a history of"/>
   <result pre="children because of confusion with other diseases, such as cerebral" exact="malaria" post="38 . Conversely, in some situations, a history of"/>
   <result pre="patient does not realize that exposure has occurred, such that" exact="rabies" post="does not enter the original differential diagnosis of encephalitis"/>
   <result pre="that rabies does not enter the original differential diagnosis of" exact="encephalitis" post="39 . The relationship between exposure and illness may"/>
   <result pre="opportunity is gone, and the child dies 41 . If" exact="rabies" post="is not suspected in an infected donor, organs may"/>
   <result pre="of viral quasispecies Next-generation sequencing 104 Prophylaxis concerns Often forgotten," exact="rabies" post="qualifies as a vaccine-preventable disease. Effective rabies biologics have"/>
   <result pre="concerns Often forgotten, rabies qualifies as a vaccine-preventable disease. Effective" exact="rabies" post="biologics have been available for over a century 45"/>
   <result pre="application of post-exposure prophylaxis (PEP)—consisting of wound care, infiltration of" exact="rabies" post="immune globulin (RIG), and administration of modern rabies vaccines—virtually"/>
   <result pre="infiltration of rabies immune globulin (RIG), and administration of modern" exact="rabies" post="vaccines—virtually ensures survival 48 . Nevertheless, the majority of"/>
   <result pre="to one week or less? What is the role for" exact="rabies" post="pre-exposure vaccine inclusion into childhood schedules? When will GAVI"/>
   <result pre="vaccine inclusion into childhood schedules? When will GAVI add human" exact="rabies" post="vaccine to its portfolio? Will monoclonal antibodies help to"/>
   <result pre="the appropriate use of existing products and protocols to prevent" exact="rabies" post="now ( Table 3). Table 3. Risk assessment to"/>
   <result pre="3). Table 3. Risk assessment to maximize the utility of" exact="rabies" post="prophylaxis after human exposure 10, 48, 75 . Category"/>
   <result pre="Health Does the animal show compatible clinical signs with an" exact="encephalitis" post="or other behavioral abnormalities suggestive of rabies? In general,"/>
   <result pre="to excrete virus. Epidemiological status What is the occurrence of" exact="rabies" post="in the area? Unless an epizootic or enzootic status"/>
   <result pre="the area? Unless an epizootic or enzootic status is apparent," exact="rabies" post="is less frequent in areas without cases for several"/>
   <result pre="discontinued). Vaccination status Is the animal up to date on" exact="rabies" post="vaccination? Vaccine failures are possible, but rare, with modern"/>
   <result pre="Is the brain available for a timely examination? If no" exact="rabies" post="virus antigens are detected by a qualified laboratory using"/>
   <result pre="drive virus deeper in tissues. Biologics Are modern vaccines and" exact="rabies" post="immune globulin (RIG) available? If the diagnosis is positive"/>
   <result pre="the diagnosis is positive or (under the worst conditions when" exact="rabies" post="is strongly suspected) if an unprovoked bite is from"/>
   <result pre="immune-suppressed patient, such as someone with AIDS, passive immunization with" exact="rabies" post="immune globulin (RIG) becomes an even more critical part"/>
   <result pre="wound&quot;? Today, as in the past, a diagnosis of a" exact="rabies" post="case is, in a statistical sense (&amp;gt;99.9%), synonymous with"/>
   <result pre="presents a huge dilemma to the clinician faced with a" exact="rabies" post="patient, with few options 59 . For a veterinarian,"/>
   <result pre="history of vaccination) and the occasional spontaneous &quot;survivor&quot; during animal" exact="rabies" post="studies suggested that clinical rabies may not always end"/>
   <result pre="occasional spontaneous &quot;survivor&quot; during animal rabies studies suggested that clinical" exact="rabies" post="may not always end in death, prompting the administration"/>
   <result pre="Who can witness the face of pathos in a Manila" exact="rabies" post="ward and not be sensitized ( http://www.aljazeera.com/programmes/lifelines/2013/09/rabies-lifelines-isolation-patient-2013923164345829402.html)? Who can"/>
   <result pre="http://www.aljazeera.com/programmes/lifelines/2013/09/rabies-lifelines-isolation-patient-2013923164345829402.html)? Who can listen to the heart-breaking personal impact of" exact="rabies" post="on a family and not feel moved ( https://www.youtube.com/watch?v=u8o1tOuyghk)?"/>
   <result pre="toward consideration of potential treatment administered to the patient with" exact="rabies" post="62 . Asklepios is but one example of such"/>
   <result pre="in veterinary or human medicine, a more complete approach to" exact="rabies" post="treatment should be taken, combining insights on rabies pathobiology"/>
   <result pre="approach to rabies treatment should be taken, combining insights on" exact="rabies" post="pathobiology gleaned from both experimental animal research and individual"/>
   <result pre="may offer future hope to a more prescriptive treatment of" exact="rabies" post="( Table 4). Table 4. Consideration for a strategic"/>
   <result pre="rabies. Proposed need Suggested consideration References Management of the dying" exact="rabies" post="patient? Responsible palliative care, toward death with dignity 105"/>
   <result pre="toward death with dignity 105 Intensive care of acute progressive" exact="rabies" post="encephalitis? Ventilation, sedation, cardiac monitoring, body temperature regulation, parenteral"/>
   <result pre="Concerns over vaccine needs to achieve global human and dog" exact="rabies" post="elimination—by 2030 Throughout the late-20th and early-21st centuries, target"/>
   <result pre="and early-21st centuries, target dates for the elimination of human-dog-mediated" exact="rabies" post="were set by the WHO, the Pan American Health"/>
   <result pre="May 2013 69 . The main components of this human" exact="rabies" post="elimination program are control, prevention, and eventual elimination of"/>
   <result pre="rabies elimination program are control, prevention, and eventual elimination of" exact="rabies" post="in dogs by mass immunization. Successive annual vaccination campaigns,"/>
   <result pre="to achieve these goals is of upmost importance. Understandably, dog" exact="rabies" post="vaccine production and access have not received the same"/>
   <result pre="and access have not received the same attention as human" exact="rabies" post="biologics, even though the latter are still in somewhat"/>
   <result pre="use of canine vaccines in dog rabies-enzootic countries. To prevent" exact="rabies" post="in humans, manufacturers from the Northern Hemisphere and an"/>
   <result pre="India) produce enough vaccine annually to deliver approximately 28 million" exact="rabies" post="PEP courses in dog rabies-enzootic countries of Africa, Asia,"/>
   <result pre="and the Eastern Mediterranean region, preventing nearly 98% of human" exact="rabies" post="deaths. Unfortunately, easier access to rabies vaccine, particularly in"/>
   <result pre="nearly 98% of human rabies deaths. Unfortunately, easier access to" exact="rabies" post="vaccine, particularly in urban centers of Africa and Asia,"/>
   <result pre="are not uncommon in Europe and North America, where human" exact="rabies" post="caused by dogs has been eliminated. A canine rabies"/>
   <result pre="human rabies caused by dogs has been eliminated. A canine" exact="rabies" post="vaccine bank was established in 2012 by the World"/>
   <result pre="the WHO has expressed an intention of constructing a human" exact="rabies" post="vaccine stockpile to rapidly provide quality-ensured vaccines upon request"/>
   <result pre="rapidly provide quality-ensured vaccines upon request 73 . Globally, human" exact="rabies" post="vaccine quantities produced seem close to adequate, but at"/>
   <result pre="&quot;bite treatment centers&quot; to needed communities; providing free or low-cost" exact="rabies" post="biologics; and applying economical and easier-to-use PEP regimens to"/>
   <result pre="held at the WHO in 2015 on human and dog" exact="rabies" post="vaccines and RIG. Objectives were to discuss forecasting needs,"/>
   <result pre="regional level 74 . During this meeting, manufacturers of canine" exact="rabies" post="vaccines stated that production capacity shortages were not an"/>
   <result pre="maximum capacity is about 150 million doses 75 . This" exact="rabies" post="vaccine production is meant to satisfy the most profitable"/>
   <result pre="The vaccine requirements of Latin American countries, where dog-mediated human" exact="rabies" post="has almost been eliminated (mostly through dog rabies immunization),"/>
   <result pre="dog-mediated human rabies has almost been eliminated (mostly through dog" exact="rabies" post="immunization), are estimated at about 42 million doses annually"/>
   <result pre="(2020–2029) terms to achieve the goal of human and dog" exact="rabies" post="elimination. As a given, these vaccines should comply with"/>
   <result pre="needs over time, we used a conservative 10-year country-based dog" exact="rabies" post="elimination model divided into a 5-year attack phase, a"/>
   <result pre="or maintenance phases than others. Ten years of sustained dog" exact="rabies" post="immunization activities were considered long enough to bring human"/>
   <result pre="rabies immunization activities were considered long enough to bring human" exact="rabies" post="cases down toward zero in most places, if carried"/>
   <result pre="from 2023 to 2024, as the target date for human" exact="rabies" post="elimination here is 2020. Many countries in the above"/>
   <result pre="regions which carry a large part of the global human" exact="rabies" post="burden have committed themselves to achieve the goal of"/>
   <result pre="burden have committed themselves to achieve the goal of human" exact="rabies" post="elimination by 2020 and already scaled-up their dog and"/>
   <result pre="elimination by 2020 and already scaled-up their dog and human" exact="rabies" post="control activities (e.g Philippines, Sri Lanka, Thailand, Vietnam and"/>
   <result pre="from 2028 to 2029, as the target date for human" exact="rabies" post="elimination here is 2030. The African region particularly sub-Saharan"/>
   <result pre="as the number of countries with experience of large-scale dog" exact="rabies" post="immunization campaigns is comparatively small. Table 7. Estimated dog"/>
   <result pre="dog vaccine requirements in 2014–2030 to achieve human and dog" exact="rabies" post="elimination target dates in World Health Organization regions. Program"/>
   <result pre="populations, were excluded from this computation. In India, a special" exact="rabies" post="control program targets major cities 88 . In large"/>
   <result pre="targets major cities 88 . In large Chinese cities, dog" exact="rabies" post="prevalence is lower, but dog ownership laws (though somewhat"/>
   <result pre="mass dog vaccination, to achieve the concomitant goal of human" exact="rabies" post="elimination by 2030, international organizations must also support RIG"/>
   <result pre="addition of new vaccines to the WHO list of pre-qualified" exact="rabies" post="vaccines, and invest in production of new, safer, and"/>
   <result pre="PEP, which contribute to creating shortages in areas where these" exact="rabies" post="biologics are truly needed ( Table 8). Table 8."/>
   <result pre="Asia; WHO, World Health Organization; WP, West Pacific. Concerning dog" exact="rabies" post="vaccines, their sustained availability at the ground level has"/>
   <result pre="been shown to be essential to the initiation of dog" exact="rabies" post="control activities 85 . Essential steps to effectively increase"/>
   <result pre="control activities 85 . Essential steps to effectively increase veterinary" exact="rabies" post="vaccine production to achieve human-dog-mediated rabies elimination by 2030"/>
   <result pre="to effectively increase veterinary rabies vaccine production to achieve human-dog-mediated" exact="rabies" post="elimination by 2030 must be seriously considered by international"/>
   <result pre="transfer to Africa and Asia and redirecting some existing human" exact="rabies" post="vaccine manufacturing capacities toward canine vaccine production, as proposed"/>
   <result pre="joint Rockefeller/WHO initiative 91 . Similarly, GAVI support of human" exact="rabies" post="vaccines might allow those eligible governments to use any"/>
   <result pre="is predicted to have major cost-effective outcomes for the human" exact="rabies" post="burden, even in some of the most severely affected"/>
   <result pre="specific etiological names responsible for this disease, the moniker for" exact="rabies" post="will remain. Theories on lyssavirus and host co-evolution will"/>
   <result pre="PEP failures. Eventual application of the growing knowledge base on" exact="rabies" post="pathogenetic mechanisms, pronounced intensive clinical skills in managing encephalitis,"/>
   <result pre="of biologics and anti-viral drugs will gradually result in additional" exact="rabies" post="survivors in human and veterinary medicine without losing the"/>
   <result pre="risk, new champions, and dedicated sponsorships without vaccination fatigue), human" exact="rabies" post="mediated by dogs should be eliminated in Latin America"/>
   <result pre="Holmes EC : The evolutionary history and dynamics of bat" exact="rabies" post="virus. Infect Genet Evol. 2006; 6( 6): 464– 73."/>
   <result pre="al. : A reassessment of the evolutionary timescale of bat" exact="rabies" post="viruses based upon glycoprotein gene sequences. Virus Genes. 2013;"/>
   <result pre="al. : Variable evolutionary routes to host establishment across repeated" exact="rabies" post="virus host shifts among bats. Proc Natl Acad Sci"/>
   <result pre="al. : Host phylogeny constrains cross-species emergence and establishment of" exact="rabies" post="virus in bats. Science. 2010; 329( 5992): 676– 9."/>
   <result pre="et al. : Molecular inferences suggest multiple host shifts of" exact="rabies" post="viruses from bats to mesocarnivores in Arizona during 2001–2009."/>
   <result pre="Hughes GJ Orciari LA Rupprecht CE : Evolutionary timescale of" exact="rabies" post="virus adaptation to North American bats inferred from the"/>
   <result pre="Mousse D et al. : Spatial and temporal dynamics of" exact="rabies" post="virus variants in big brown bat populations across Canada:"/>
   <result pre="Ade C et al. : Monoclonal antibodies for characterization of" exact="rabies" post="virus isolated from non-hematophagous bats in Brazil. J Infect"/>
   <result pre="Diagnostic Tests and Vaccines for Terrestrial Animals 2016, chapter 2.1.17" exact="rabies" post=". (accessed 10/26/2016). Reference Source 38 Mallewa M Vallely"/>
   <result pre="Giesen A Gniel D Malerczyk C : 30 Years of" exact="rabies" post="vaccination with Rabipur: a summary of clinical data and"/>
   <result pre="Minutello M et al. : A serum-free, purified vero cell" exact="rabies" post="vaccine is safe and as immunogenic as the reference"/>
   <result pre="Madhusudana SN Gaunta PL et al. : Local infiltration of" exact="rabies" post="immunoglobulins without systemic intramuscular administration: An alternative cost effective"/>
   <result pre="to assess post-exposure prophylaxis by a new purified vero cell" exact="rabies" post="vaccine (Rabivax-S) administered by intramuscular and intradermal routes. Vaccine."/>
   <result pre="et al. : Development of broad-spectrum human monoclonal antibodies for" exact="rabies" post="post-exposure prophylaxis. EMBO Mol Med. 2016; 8( 4): 407–"/>
   <result pre="Madhusudana SN Ashwin BY Sudarshan S : Feasibility of reducing" exact="rabies" post="immunoglobulin dosage for passive immunization against rabies: results of"/>
   <result pre="vaccination at a virus-inoculated site as an alternative option to" exact="rabies" post="immunoglobulin. Arch Virol. 2016; 161( 9): 2537– 41. 10.1007/s00705-016-2916-6"/>
   <result pre="et al. : Zagreb regimen, an abbreviated intramuscular schedule for" exact="rabies" post="vaccination. Clin Vaccine Immunol. 2015; 22( 1): 1– 5."/>
   <result pre="Two decades of pharmacovigilance and clinical experience with highly purified" exact="rabies" post="immunoglobulin F(ab') 2 fragments. Expert Rev Vaccines. 2016; 1–"/>
   <result pre="Wilde H Lumlertdacha B Meslin FX et al. : Worldwide" exact="rabies" post="deaths prevention--A focus on the current inadequacies in postexposure"/>
   <result pre="Y Zhang S Li L et al. : Ineffectiveness of" exact="rabies" post="vaccination alone for post-exposure protection against rabies infection in"/>
   <result pre=": Ineffectiveness of rabies vaccination alone for post-exposure protection against" exact="rabies" post="infection in animal models. Antiviral Res. 2016; 135: 56–"/>
   <result pre="27737787 59 Warrell MJ : The dilemma of managing human" exact="rabies" post="encephalitis. Trop Med Int Health. 2016; 21( 4): 456–"/>
   <result pre="KS Hoffman GM et al. : Survival after treatment of" exact="rabies" post="with induction of coma. N Engl J Med. 2005;"/>
   <result pre="65 collab: Pan American Health Organization: Elimination of dog-transmitted human" exact="rabies" post="is by 2015 within reach. PAHO, 2013; (accessed 09/27/2016)."/>
   <result pre="72 collab: OIE: Regional Vaccine Bank for Asia provides 50,000" exact="rabies" post="vaccine doses to Lao PDR. OIE Press releases, 28"/>
   <result pre="10.2471/BLT.16.183012 27708465 74 collab: World Health Organization: Human and dog" exact="rabies" post="vaccines and immunoglobulins report of a WHO/OIE meeting. Geneva"/>
   <result pre="2015. WHO/HTM/NTD/NZD/2015.11. Reference Source 75 collab: CDC: Compendium of animal" exact="rabies" post="prevention and control. NASPHV Recommendations and Report, MMWR. 2011;"/>
   <result pre="A Adé MP et al. : Current status of human" exact="rabies" post="transmitted by dogs in Latin America. Cad Saude Publica."/>
   <result pre="in a range of rural and urban settings. In Canines" exact="rabies" post="blueprint (accessed 10/06/2016). Reference Source 80 Knobel DL Cleaveland"/>
   <result pre="S Coleman PG et al. : Re-evaluating the burden of" exact="rabies" post="in Africa and Asia. Bull World Health Organ. 2005;"/>
   <result pre="Mahendra BJ et al. : Assessing the burden of human" exact="rabies" post="in India: results of a national multi-center epidemiological survey."/>
   <result pre="Bögel K Meslin FX : Economics of human and canine" exact="rabies" post="elimination: guidelines for programme orientation. Bull World Health Organ."/>
   <result pre="91. 2118428 83 collab: FAO: Developing a stepwise approach for" exact="rabies" post="prevention and control. FAO/GARC workshop FAO Animal Production and"/>
   <result pre="Source 84 collab: Partners For Rabies Prevention: Blueprint for dog" exact="rabies" post="control. (accessed 10/06/2016). Reference Source 85 collab: World Health"/>
   <result pre="group of the Gates Foundation/WHO project for human and dog" exact="rabies" post="elimination in low-income countries . 19–21 October 2011, PieterMartizburg,"/>
   <result pre="Penny MA et al. : Transmission dynamics and economics of" exact="rabies" post="control in dogs and humans in an African city."/>
   <result pre="Educate, vaccinate, eliminate: Achieving zero human deaths from dog- transmitted" exact="rabies" post="by 2030 . Joint Statement World Health Organization (WHO),"/>
   <result pre=": Development of a mouse monoclonal antibody cocktail for post-exposure" exact="rabies" post="prophylaxis in humans. PLoS Negl Trop Dis. 2009; 3("/>
   <result pre=". Presented at the occasion of the inauguration of VECOL" exact="rabies" post="vaccine production unit, Bogota, Columbia 1/25/ 2002; (accessed 1/23/2017)."/>
   <result pre="Pandey A et al. : One Health approach to cost-effective" exact="rabies" post="control in India. Proc Natl Acad Sci U S"/>
   <result pre="22365905 94 Mani RS Anand AM Madhusudana SN : Human" exact="rabies" post="in India: an audit from a rabies diagnostic laboratory."/>
   <result pre="SN : Human rabies in India: an audit from a" exact="rabies" post="diagnostic laboratory. Trop Med Int Health. 2016; 21( 4):"/>
   <result pre="a direct rapid immunohistochemical test (dRIT) for rapid diagnosis of" exact="rabies" post="in animals and humans. Virol Sin. 2012; 27( 5):"/>
   <result pre="ZM Paciencia ML et al. : Laboratory diagnosis of equine" exact="rabies" post="and its implications for human postexposure prophylaxis. J Virol"/>
   <result pre="A et al. : First international collaborative study to evaluate" exact="rabies" post="antibody detection method for use in monitoring the effectiveness"/>
   <result pre="Horton DL et al. : Elucidating the phylodynamics of endemic" exact="rabies" post="virus in eastern Africa using whole-genome sequencing. Virus Evol."/>
   <result pre="H Lao V et al. : Ultra-deep sequencing of intra-host" exact="rabies" post="virus populations during cross-species transmission. PLoS Negl Trop Dis."/>
   <result pre="Y Mahendra BJ et al. : Caring for patients with" exact="rabies" post="in developing countries - the neglected importance of palliative"/>
   <result pre="Diagnosis, management and post-mortem findings of a human case of" exact="rabies" post="imported into the United Kingdom from India: a case"/>
   <result pre="Ertl HC et al. : Protection of non-human primates against" exact="rabies" post="with an adenovirus recombinant vaccine. Virology. 2014; 450–451: 243–"/>
   <result pre="for intravenously administered virus neutralizing antibodies to clear an established" exact="rabies" post="virus infection from the brain and prevent the development"/>
   <result pre="virus infection from the brain and prevent the development of" exact="rabies" post="in mice. Antiviral Res. 2014; 110: 132– 41. 10.1016/j.antiviral.2014.07.013"/>
   <result pre="CW Fu ZF : CXCL10 and blood-brain barrier modulation in" exact="rabies" post="virus infection. Oncotarget. 2016; 7( 10): 10694– 5. 10.18632/oncotarget.7428"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC5327784/results/search/disease/results.xml">
   <result pre="deepened by the continued emergence of new, unrecognized, and old" exact="infectious disease" post="epidemics of global impact. Over the past three and"/>
   <result pre="infectious diseases and highlights the scope, dynamics, and advances in" exact="infectious disease" post="management with particular focus on WHO top priority emerging"/>
   <result pre="of the host's organs and/or systems is referred to as" exact="infectious disease" post="[ 1– 3]. Infectious diseases are generally caused by"/>
   <result pre="infectious diseases occur over time. Prior to causing an epidemic," exact="infectious disease" post="agents go through various stages of adaptation to access"/>
   <result pre="Thus, human, microbial, and environmental factors constitute major causes of" exact="infectious disease" post="emergence and the virulence or pathogenic potential depends on"/>
   <result pre="of the EID threat, having caused about two-thirds of the" exact="infectious disease" post="burden and usually characterized by very high epidemics. Examples"/>
   <result pre="(1348–1350) killed 30%–60% of Europe's population. In the 18th century," exact="smallpox" post="killed an estimated 400,000 Europeans each year and rapidly"/>
   <result pre="eradication in the late 1970s [ 33– 35]. Like smallpox," exact="measles" post="has been a scourge for centuries, afflicting millions of"/>
   <result pre="the years. In 1989–91, there were 55,000 cases in a" exact="measles" post="outbreak in the US, which led to 11,000 hospitalizations"/>
   <result pre="which led to 11,000 hospitalizations and 123 deaths. In 2000" exact="measles" post="was declared eradicated in the US; however, it continues"/>
   <result pre="Even with the availability of a safe and cost-effective vaccine," exact="measles" post="remains one of the leading causes of death among"/>
   <result pre="WHO, diarrhoeal disease), while, in older children, pneumonia, diarrhoea, and" exact="malaria" post="represent the leading causes of death due to infectious"/>
   <result pre="of death due to infectious disorders. Influenza is another major" exact="infectious disease" post="the world has witnessed. No other infectious disease has"/>
   <result pre="another major infectious disease the world has witnessed. No other" exact="infectious disease" post="has ever claimed as many lives as the 1918-1919"/>
   <result pre="killed as many as 40 million people worldwide. The 1918-1919" exact="influenza" post="pandemic killed more people than the World War I"/>
   <result pre="of neglected infectious diseases can also be cited, for example," exact="malaria" post="and diarrhoeal diseases, which alone cause about three million"/>
   <result pre="diseases that worsen the plight of people living with an" exact="infectious disease" post="[ 46, 47]. Some infectious diseases such as leprosy"/>
   <result pre="infectious disease [ 46, 47]. Some infectious diseases such as" exact="leprosy" post="bring shame on those affected and make them shunned"/>
   <result pre="worth. Furthermore, loss of capacity to work due to an" exact="infectious disease" post="further increases poverty in adults, which consequently may affect"/>
   <result pre="in Lassa fever, Hantavirus Pulmonary Syndrome, and the Nipah virus" exact="encephalitis" post="( Table 2), whose viral pathogens have been found"/>
   <result pre="rodent species [ 55]. The emergence and transmission of an" exact="infectious disease" post="pathogen in humans, as exemplified in Table 1, primarily"/>
   <result pre="In most cases, a combination of risk factors accounts for" exact="infectious disease" post="emergence and/or outbreak of epidemic such as the 2014"/>
   <result pre="exemplifies the complex and interrelated nature of factors involved in" exact="infectious disease" post="emergence. 6. Current Top Priority Infectious Diseases As part"/>
   <result pre="by WHO [ 68]. Diseases such as HIV/AIDS, tuberculosis, malaria," exact="avian influenza," post="and dengue, which also have epidemic potential, were not"/>
   <result pre="[ 70, 71]. A reasonable public health response towards addressing" exact="infectious disease" post="problem in general therefore aims at addressing the fundamental"/>
   <result pre="need to galvanize investment to enhance preparation and response to" exact="infectious disease" post="threats. Recognizing the existence of many tropical, poverty-related diseases,"/>
   <result pre="and foundations with vigorous research and financial commitments towards addressing" exact="infectious disease" post="threats [ 76, 77]. Apparently, NTDs were not listed"/>
   <result pre="a long-term commitment [ 83, 84]. The ultimate goal of" exact="infectious disease" post="control, however, is to achieve total eradication. With smallpox"/>
   <result pre="infectious disease control, however, is to achieve total eradication. With" exact="smallpox" post="having been eradicated, and a great wealth of lessons"/>
   <result pre="genome sequencing technology in the nineteenth century has tremendously revolutionized" exact="infectious disease" post="research, especially pathogenesis, diagnosis, and treatment and hence optimum"/>
   <result pre="successful vaccine design and drug development against most of the" exact="infectious disease" post="pathogens. A better understanding of known pathogens and discovery"/>
   <result pre="genomic and proteomic studies. Elucidation of the pathogenesis of the" exact="malaria" post="parasite Plasmodium falciparum and individual's susceptibility or resistance to"/>
   <result pre="malaria parasite Plasmodium falciparum and individual's susceptibility or resistance to" exact="malaria" post="contributed to the development of malaria vaccine (Mosquirix, the"/>
   <result pre="susceptibility or resistance to malaria contributed to the development of" exact="malaria" post="vaccine (Mosquirix, the first against a parasitic infection in"/>
   <result pre="agents like cancer-causing human papilloma virus, meningitis-causing pneumococci, and Haemophilus" exact="influenza" post="type B; the recent Ebola vaccine represents landmark breakthroughs"/>
   <result pre="reverse transcriptase inhibitor d, Abacavir (ABC), is associated with drug" exact="hypersensitivity" post="reactions. This drug may lead to high rates of"/>
   <result pre="have been achieved in the global sociopolitical front in addressing" exact="infectious disease" post="problems. Since the dawn of this century concerted efforts"/>
   <result pre="globally by global organizations, governments, foundations, and partner bodies towards" exact="infectious disease" post="control. The United Nation's decision to &quot;combat HIV/AIDS, malaria,"/>
   <result pre="In real terms, the outcome of advances in response to" exact="infectious disease" post="threats reflects in marked progress in infectious disease control"/>
   <result pre="response to infectious disease threats reflects in marked progress in" exact="infectious disease" post="control and human health protection. The discovery of vaccine"/>
   <result pre="towards eradication include polio, diphtheria, whooping cough, measles, neonatal tetanus," exact="hepatitis" post="B, and tuberculosis. Others are Rubella, Dracunculiasis (Guinea worm),"/>
   <result pre="B, and tuberculosis. Others are Rubella, Dracunculiasis (Guinea worm), Lymphatic" exact="filariasis" post="(elephantiasis), onchocerciasis (river blindness), and Mumps [ 37, 51,"/>
   <result pre="tuberculosis. Others are Rubella, Dracunculiasis (Guinea worm), Lymphatic filariasis (elephantiasis)," exact="onchocerciasis" post="(river blindness), and Mumps [ 37, 51, 102]. WHO"/>
   <result pre="Mumps [ 37, 51, 102]. WHO has planned to eliminate" exact="measles" post="by the year 2020. Polio is currently seen in"/>
   <result pre="Guinea worm disease could be the second human disease after" exact="smallpox" post="to be eradicated. 9. The Challenge and the Way"/>
   <result pre="and the Way Forward The persistent and unpredictable nature of" exact="infectious disease" post="emergence represents a continual challenge. Despite significant advances, especially"/>
   <result pre="Human, social, political, environmental, technological, microbial, and ecological factors impacting" exact="infectious disease" post="upsurge continue to increase [ 104]. Successful approaches to"/>
   <result pre="be favoured by changing host and environmental conditions. This enhances" exact="infectious disease" post="emergence and reemergence, often causing new pandemics. Influenza viruses"/>
   <result pre="depicts the complex nature of factors that may lead to" exact="infectious disease" post="emergence and the enormity of the infectious disease challenge."/>
   <result pre="lead to infectious disease emergence and the enormity of the" exact="infectious disease" post="challenge. There is therefore no promise that advances in"/>
   <result pre="disease challenge. There is therefore no promise that advances in" exact="infectious disease" post="detection and control strategies can successfully stop new diseases"/>
   <result pre="challenges. Besides, the fact that so far only one human" exact="infectious disease" post="(smallpox) has been successfully eradicated and there are many"/>
   <result pre="treatment of AIDS [ 110]. 9.3. Surveillance This nature of" exact="infectious disease" post="challenge calls for constant surveillance and timely intervention. There"/>
   <result pre="international cooperation; effective local, regional, and global networks for strong" exact="infectious disease" post="surveillance and research collaboration to enable sharing of biological"/>
   <result pre="neglected infectious diseases are a real public health threat, and" exact="infectious disease" post="outbreaks can have serious social, political, and economic effects."/>
   <result pre="human interactions with animals have been found to contribute to" exact="infectious disease" post="emergence and transmission. Aggressive research is warranted to unravel"/>
   <result pre="poverty reduction are very vital for addressing emerging and neglected" exact="infectious disease" post="threats. Competing Interests The author declares that there is"/>
   <result pre="Press, 2001 15 collab: World Health Organization WHO | Global" exact="infectious disease" post="surveillance http://www.who.int/mediacentre/factsheets/fs200/en/ 16 Cohen F. L. Larson E. Emerging"/>
   <result pre="Cotter P. A. Kumamoto C. A. Microbial pathogenesis: mechanisms of" exact="infectious disease" post="Cell Host and Microbe 2007 2 4 214 219"/>
   <result pre="Santa Barbara, Calif, USA ABC-CLIO 34 Native Americans and the" exact="smallpox" post="epidemic-archiving early America http://www.varsitytutors.com/earlyamerica/early-america-review/volume-11/native-americans-smallpox 35 collab: World Health Organization"/>
   <result pre="W. A. Hinman A. R. Papania M. J. Evolution of" exact="measles" post="elimination strategies in the United States Journal of Infectious"/>
   <result pre="S17 S22 10.1086/377694 15106084 37 Baker J. P. The first" exact="measles" post="vaccine Pediatrics 2011 128 3 435 437 10.1542/peds.2011-1430 21873696"/>
   <result pre="38 collab: World Health Organization WHO—Measles http://www.who.int/mediacentre/factsheets/fs286/en/ 39 The 1918" exact="influenza" post="pandemic https://virus.stanford.edu/uda/ 40 collab: World Health Organization WHO—HIV/AIDS http://www.who.int/mediacentre/factsheets/fs360/en/"/>
   <result pre="J. F. Pathogenic responses among young adults during the 1918" exact="influenza" post="pandemic Emerging Infectious Diseases 2012 18 2 201 207"/>
   <result pre="Lindgren E. Balkanyi L. et al. Determinants and drivers of" exact="infectious disease" post="threat events in Europe Emerging Infectious Diseases 2016 22"/>
   <result pre="S2 10.1186/1471-2458-11-s2-s2 71 collab: World Health Organization WPRO—Responding to emerging" exact="infectious disease" post="threats http://www.wpro.who.int/mediacentre/releases/2013/20131024apsed/en/ 72 Wiysonge C. S. Waggie Z. Hawkridge"/>
   <result pre="Tropical Diseases 2012 Thomson Reuters Table 1 Some past emerging" exact="infectious disease" post="epidemics and probable factors for outbreak. Year Emerging disease"/>
   <result pre="to ticks of sheep and small wild animals 1996 Haemorrhagic" exact="colitis" post="Escherichia coli O157:H7 Ingestion of contaminated food, undercooked beef,"/>
   <result pre="of infectious aerosolized rodent faces and urine 1997 Highly pathogenic" exact="avian influenza" post="(HPAI) H5N1 virus Animal-animal influenza virus gene reassortment; emergence"/>
   <result pre="infectious aerosolized rodent faces and urine 1997 Highly pathogenic avian" exact="influenza" post="(HPAI) H5N1 virus Animal-animal influenza virus gene reassortment; emergence"/>
   <result pre="urine 1997 Highly pathogenic avian influenza (HPAI) H5N1 virus Animal-animal" exact="influenza" post="virus gene reassortment; emergence of H5N1 avian influenza, extensive"/>
   <result pre="H5N1 virus Animal-animal influenza virus gene reassortment; emergence of H5N1" exact="avian influenza," post="extensive chicken farming 1889, 1890, 1918, 1957 Pandemic Influenza"/>
   <result pre="extensive chicken farming 1889, 1890, 1918, 1957 Pandemic Influenza Paramyxovirus" exact="influenza" post="A Animal-human virus reassortment and antigenic shift 1969 Lassa"/>
   <result pre="Ranges from no symptoms to death. Generally fever, cough, and" exact="shortness" post="of breath; pneumonia, gastrointestinal problems, and respiratory failure About"/>
   <result pre="fever, cough, and shortness of breath; pneumonia, gastrointestinal problems, and" exact="respiratory failure" post="About 80% of infections are asymptomatic. Symptoms are variable:"/>
   <result pre="brain inflammation leading to coma Humans: include fever, muscle/joint pain;" exact="eye disease," post="meningoencephalitis, and haemorrhagic fever Animals: mortality and abortion Pathogenesis"/>
   <result pre="with benznidazole and nifurtimox Vector (triatomine bug) control Dengue and" exact="chikungunya" post="Dengue virus sp.: DENV 1, DENV 2, DENV 3"/>
   <result pre="anthelminthic medicines Reduce infection risk; control associated morbidity Human African" exact="trypanosomiasis" post="(sleeping sickness) Trypanosoma parasite sp. T. brucei gambiense (98%)"/>
   <result pre="&amp;amp; clofazimine) Early diagnosis and treatment to avert disability Lymphatic" exact="filariasis" post="(elephantiasis) Filarioidea nematodes: Wuchereria bancrofti, Brugia malayi, and B."/>
   <result pre="citrate Morbidity management; mass drug administration Onchocerciasis (river blindness) Onchocerca" exact="volvulus" post="(parasite) Bite of blackfly ( Simulium damnosum sp. mainly)"/>
   <result pre="and Mebendazole Deworming people at risk, improved sanitation, education Taeniasis/" exact="cysticercosis" post="Taenia (tapeworm) parasites T. solium (pork tapeworm)T. saginata (beef"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC5435908/results/search/disease/results.xml">
   <result pre="we have selected single stranded negative- and positive-sense RNA viruses," exact="influenza" post="virus, and rhinovirus, respectively, which annually cause respiratory illnesses"/>
   <result pre="cellular proteins and expression of housekeeping genes. The titers of" exact="influenza" post="A (H1N1pdm) virus and human rhinovirus serotype 1A were"/>
   <result pre="were reduced by 40% and 65%, respectively. A preincubation of" exact="influenza" post="virus with binase before infection significantly reduced viral titer"/>
   <result pre="reduced viral titer after single-cycle replication of the virus. Using" exact="influenza" post="A virus mini genome system we showed that binase"/>
   <result pre="stranded RNA viruses, such as negative-sense Ebola, Marburg, Lassa, and" exact="influenza" post="and positive-sense human immunodeficiency viruses, are very important human"/>
   <result pre="RNA viruses like Ebola, corona, Zika, and different strains of" exact="influenza" post="A viruses. Among RNA viruses, the respiratory viruses are"/>
   <result pre="and cause annually worldwide epidemics and occasional pandemic outbreaks. The" exact="influenza" post="A virus even without a pandemic outbreak kills up"/>
   <result pre="human rhinoviruses (HRV) which are the major cause of the" exact="common cold." post="HRV infections are suffered by everyone. Recent reports suggest"/>
   <result pre="inactivated or attenuated antigenic material of viruses helps to prevent" exact="influenza" post="illness or to reduce its impact in individuals. There"/>
   <result pre="its impact in individuals. There is no permanent vaccination against" exact="influenza" post="virus and each year countries lose a large amount"/>
   <result pre="types of medicinal products for the prevention and treatment of" exact="influenza" post="infections. Currently, there is no vaccine against HRV ["/>
   <result pre="that quickly normalized the state and decreased the symptoms of" exact="meningitis" post="and cerebrospinal pleocytosis in patients with tick borne encephalitis"/>
   <result pre="of meningitis and cerebrospinal pleocytosis in patients with tick borne" exact="encephalitis" post="[ 6]. Shortcoming of mammalian RNases is their affinity"/>
   <result pre="We have demonstrated that binase reduced the titer of pandemic" exact="influenza" post="A/Hamburg/4/2009 (H1N1pdm), reovirus serotype 1 (Reo 1-Lang), herpes virus"/>
   <result pre="(MDBK) epithelial cells, human fetal lung fibroblast (MRC5) cells, and" exact="hepatocellular carcinoma" post="(Huh7) cells, respectively [ 9– 11]. Influenza viruses contain"/>
   <result pre="at 37°C in a 5% CO 2 atmosphere. The pandemic" exact="influenza" post="A/Hamburg/04/09 (H1N1pdm) and human rhinovirus serotype 1A (HRV1A) were"/>
   <result pre="3′- and 5′-noncoding region of the NS RNA segment of" exact="influenza" post="A/WSN/33 virus [ 2] placed between a truncated human"/>
   <result pre="between a truncated human RNA polymerase I promotor (POLI) and" exact="hepatitis" post="delta virus ribozyme (R). The expressed subunits of the"/>
   <result pre="of the viral polymerases and nucleoprotein replicated and transcribed the" exact="influenza" post="virus-like RNA expressed by pPOLI-GFP-RT into mRNA. To perform"/>
   <result pre="ATA AC-3′) were used to identify the binase effect on" exact="influenza" post="A viral RNA using real-time RT-PCR. 2.13. RNA Extraction"/>
   <result pre="(binase-treated) samples data. The ΔCt value of the calibrator from" exact="influenza" post="virus-infected and binase nontreated cells (Ct target (Ct value"/>
   <result pre="in A549 cells)) and ΔCt value of the test from" exact="influenza" post="virus-infected and binase-treated cells (Ct target − Ct reference)"/>
   <result pre="a P value of &amp;lt;0.05. 2.17. Biosafety All experiments involving" exact="influenza" post="A (H1N1pdm) and rhinovirus serotype 1A (HRV1A) were performed"/>
   <result pre="ribonuclease binase on infectious titer of negative-sense single stranded RNA" exact="influenza" post="A (H1N1pdm) virus after its single-cycle replication in A549"/>
   <result pre="and NP genes of H1N1pdm viral RNP complex and an" exact="influenza" post="virus-like RNA encoding a GFP reporter protein (see Sections"/>
   <result pre="scheme reflecting different possible mechanisms of a binase effect on" exact="influenza" post="A viral functional ribonucleoprotein (RNP) complex gene expression using"/>
   <result pre="complex, which is essential for the replication and transcription of" exact="influenza" post="virus RNA. Novel small molecule compounds which inhibited the"/>
   <result pre="viral replication and include inhibitors of human immunodeficiency virus (HIV)," exact="hepatitis" post="C virus (HCV), severe acute respiratory syndrome coronavirus (SARS"/>
   <result pre="inhibitors of human immunodeficiency virus (HIV), hepatitis C virus (HCV)," exact="severe acute respiratory syndrome" post="coronavirus (SARS CoV), and influenza A virus [ 20]."/>
   <result pre="virus (HCV), severe acute respiratory syndrome coronavirus (SARS CoV), and" exact="influenza" post="A virus [ 20]. Highly conserved noncoding RNA (ncRNA)"/>
   <result pre="viruses can be targeted by binase. The +ssRNA transcript of" exact="influenza" post="virus is used as mRNA for the synthesis of"/>
   <result pre="does not need to be transported into the nucleus; the" exact="influenza" post="+ssRNA is also located in the cytoplasm. Cytoplasmic allocation"/>
   <result pre="Palese P. Garcia-Sastre A. A plasmid-based reverse genetics system for" exact="influenza" post="A virus Journal of Virology 1996 70 6 4188"/>
   <result pre="P. Canter V. M. Salganik R. I. Ribonuclease treatment of" exact="tick-borne encephalitis" post="Archives of Neurology 1976 33 9 598 603 10.1001/archneur.1976.00500090004002"/>
   <result pre="Canter V. M. Salganik R. I. Ribonuclease treatment of tick-borne" exact="encephalitis" post="Archives of Neurology 1976 33 9 598 603 10.1001/archneur.1976.00500090004002"/>
   <result pre="Ilinskaya O. N. Antiviral activity of binase against the pandemic" exact="influenza" post="A (H1N1) virus Acta Naturae 2013 5 19 44"/>
   <result pre="J. Pleschka S. Improved dual promotor-driven reverse genetics system for" exact="influenza" post="viruses Journal of Virological Methods 2013 193 2 603"/>
   <result pre="Neumann G. Watanabe T. Ito H. et al. Generation of" exact="influenza" post="A viruses entirely from cloned cDNAs Proceedings of the"/>
   <result pre="RNA polymerase I-polymerase II transcription system for the generation of" exact="influenza" post="A virus from eight plasmids Journal of General Virology"/>
   <result pre="19 Faburay B. Richt J. A. Short interfering RNA inhibits" exact="rift valley fever" post="virus replication and degradation of protein kinase R in"/>
   <result pre="Screening for novel small molecule inhibitors targeting the assembling of" exact="influenza" post="virus polymerase complex by a BiLC-based reporter system Journal"/>
   <result pre="formation monitored by GFP fluorescence in the cells using the" exact="influenza" post="A virus mini genome system. For the in vitro"/>
   <result pre="3′- and 5′-noncoding region of the NS RNA segment of" exact="influenza" post="A/WSN/33 virus [ 2] placed between a truncated human"/>
   <result pre="between a truncated human RNA polymerase I promotor (POLI) and" exact="hepatitis" post="delta virus ribozyme (R). The expressed subunits of the"/>
   <result pre="of the viral polymerases and nucleoprotein replicate and transcribe the" exact="influenza" post="virus-like RNA expressed by pPOLI-GFP-RT into GFP mRNA, resulting"/>
   <result pre="and (D) inhibitory effect of binase on the expression of" exact="influenza" post="A virus mini genome system in cytoplasm and nucleus,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC5493079/results/search/disease/results.xml">
   <result pre="dysfunction is associated with leukopenia: A possible mechanism for sepsis-induced" exact="leukopenia" post="R. Riff, O. Naamani, A. Douvdevani P005 - Analysis"/>
   <result pre="response in septic patients secondary to community and hospital acquired" exact="pneumonia" post="N. K. Sharma, A. K. Tashima, M. K. Brunialti,"/>
   <result pre="M. Williams, J. Russell P053 - Assessment of coagulopathy in" exact="cancer" post="patients with severe sepsis or septic shock. A case-control"/>
   <result pre="S. Arama P054 - Thromboelastometry in critically ill patients with" exact="disseminated intravascular coagulation" post="M. Müller, M. Straat, S. S. Zeerleder, N. P."/>
   <result pre="D. Tomescu, Z. Ghiorghiu, R. Macovei P065 - Predicting bacteremic" exact="urinary tract infection" post="in community setting: A prospective observational study S. Nimitvilai,"/>
   <result pre="Lostarakos, B. Carr P068 - Improved detection of spontaneous bacterial" exact="peritonitis" post="by uritop + tm strip test and inoculation of blood culture"/>
   <result pre="Maaoui, A. Ezzamouri, M. Salem P069 - Increased risk of" exact="cellulitis" post="in patients with congestive heart failure: a population based"/>
   <result pre="based cohort study J. Chen P070 - Outcomes of severe" exact="cellulitis" post="and necrotizing fasciitis in the critically ill D. R."/>
   <result pre="study J. Chen P070 - Outcomes of severe cellulitis and" exact="necrotizing fasciitis" post="in the critically ill D. R. Cranendonk, L. A."/>
   <result pre="J. Chen P070 - Outcomes of severe cellulitis and necrotizing" exact="fasciitis" post="in the critically ill D. R. Cranendonk, L. A."/>
   <result pre="B. Civantos, J. C. Figueira, J. López P080 - Mediterranean" exact="spotted fever" post="in an infectious diseases intensive care unit A. Silva-Pinto,"/>
   <result pre="- ‘BUNS’: An investigation protocol improves the ICU management of" exact="pneumonia" post="R. Sharvill, J. Astin P087 - Pneumonia in patients"/>
   <result pre="J. Patel, C. Kruger P089 - Incidence of community acquired" exact="pneumonia" post="with viral infection in mechanically ventilated patients in the"/>
   <result pre="V. Avramidis P093 - A comparison of two ventilator associated" exact="pneumonia" post="surveillance techniques T. H. Craven, G. Wojcik, K. Kefala,"/>
   <result pre="ultrasound before and after fiberbronchoscopy - modifications may improve ventilator-associated" exact="pneumonia" post="diagnosis S. Mongodi, B. Bouhemad, A. Orlando, A. Stella,"/>
   <result pre="- Comparing the accuracy of predictors of mortality in ventilator-associated" exact="pneumonia" post="M. Haliloglu, B. Bilgili, U. Kasapoglu, I. Sayan, M."/>
   <result pre="a series of interventions on the rate of ventilator associated" exact="pneumonia" post="in a large teaching hospital H. E. Ellis, K."/>
   <result pre="Jafri P099 - Short-term inhaled colistin adjunctive therapy for ventilator-associated" exact="pneumonia" post="Y. Nassar, M. S. Ayad P100 - Effect of"/>
   <result pre="Bilgili, M. Haliloglu, F. Gul, I. Cinel P102 - Nosocomial" exact="pneumonia" post="- emphasis on inhaled tobramycin A. Kuzovlev, A. Shabanov,"/>
   <result pre="nebulized amikacin/fosfomycin and systemic meropenem on severe amikacin-resistant meropenem-susceptible P.aeruginosa" exact="pneumonia" post="G. Li Bassi, E. Aguilera, C. Chiurazzi, C. Travierso,"/>
   <result pre="and activated prothrombin complex concentrate in a model of severe" exact="thrombocytopenia" post="I. Budnik, B. Shenkman P126 - Assessment of point-of-care"/>
   <result pre="transfusion thresholds on mortality and cardiovascular events in patients with" exact="cardiovascular disease" post="(non-cardiac surgery): a systematic review and meta-analysis A. Docherty,"/>
   <result pre="- Impact of simple clinical practice guidelines for reducing post-operative" exact="atrial fibrillation" post="after cardiac surgery. A. Omar, M. Allam, O. Bilala,"/>
   <result pre="Suhodolo, V. Kiselev, Y. Svirko, Y. Podoksenov P143 - New-onset" exact="atrial fibrillation" post="in intensive care: incidence, management and outcome S. A."/>
   <result pre="One single spot measurement of the sublingual microcirculation during acute" exact="pulmonary hypertension" post="in a pig model of shock M. S. Tovar"/>
   <result pre="abnormal central venous pressure waveform morphology during an episode of" exact="pulmonary hypertension" post="in a porcine shock model M. S. Tovar Doncel,"/>
   <result pre="- Left ventricular outflow tract velocity time integral correlates with" exact="stroke" post="volume index in mechanically ventilated patients Ó. Martínez González,"/>
   <result pre="fluids and outcomes in emergency department patients hospitalized with community-acquired" exact="pneumonia" post="P. Hou, W. Z. Linde-Zwirble, I. D. Douglas, N."/>
   <result pre="in MUDPILES – a rare cause of high anion gap" exact="metabolic acidosis" post="(HAGMA) C. P. Lee, X. L. Lin, C. Choong"/>
   <result pre="Elsayed, N. Ward, A. Tridente, A. Raithatha P187 - Severe" exact="hypophosphatemia" post="during citrate-anticoagulated CRRT A. Steuber, C. Pelletier, S. Schroeder,"/>
   <result pre="to dose consistency across two different gas flow rates using" exact="cystic fibrosis" post="and normal adult breathing profiles during nasal high flow"/>
   <result pre="- Psv-niv versus cpap in the treatment of acute cardiogenic" exact="pulmonary edema" post="A. Pagano, F. Numis, G. Vison, L. Saldamarco, T."/>
   <result pre="noninvasive ventilation success and ICU outcome in patients with hypercapnic" exact="respiratory failure" post="N. Boyacý, Z. Isýkdogan, Ö. Özdedeoglu, Z. Güllü, M."/>
   <result pre="- Outcome of patients admitted to the intensive care with" exact="pulmonary fibrosis" post="F. Asota, K. O’Rourke, S. Ranjan, P. Morgan P260"/>
   <result pre="and analgesia practice in extra-corporeal membrane oxygenation (ECMO)-treated patients with" exact="acute respiratory distress syndrome" post="(ARDS): a retrospective study J. W. DeBacker, E. Tamberg,"/>
   <result pre="months post extra corporeal membrane oxygenation (ECMO) for severe acute" exact="respiratory failure" post="in adult survivors C. Sampson, S. Harris-Fox P265 -"/>
   <result pre="L. Lagunes, J. Rello P267 - New molecular biomarkers of" exact="acute respiratory distress syndrome" post="in abdominal sepsis A. K. Kuzovlev, V. Moroz, A."/>
   <result pre="Volta P270 - Epidemiological and clinical profile of patients with" exact="acute respiratory distress syndrome" post="in the surgical intensive care unit surgical, hospital JRA,"/>
   <result pre="S. Squire, M. Boichat P274 - Epidemiological study of severe" exact="acute pancreatitis" post="in Japan, comparison of the etiology and the patient"/>
   <result pre="Squire, M. Boichat P274 - Epidemiological study of severe acute" exact="pancreatitis" post="in Japan, comparison of the etiology and the patient"/>
   <result pre="for liver injury and may lead to intestinal failure associated" exact="liver disease" post="in critical illness N. Lefel, F. Schaap, D. Bergmans,"/>
   <result pre="Poll P280 - Bowel care on the intensive care unit:" exact="constipation" post="guideline compliance and complications K. Tizard, C. Lister, L."/>
   <result pre="meta-analysis P. Langlois, W. Manzanares P293 - Can 5-hydroxytriptophan prevent" exact="post-traumatic stress disorder" post="in critically ill patients? R. Tincu, C. Cobilinschi, D."/>
   <result pre="a population-based cohort study Y. Su P297 - Incidence of" exact="hypoglycemia" post="in an intensive care unit depending on insulin protocol"/>
   <result pre="glucose variability, especially in moderately to severely ill patients with" exact="glucose intolerance." post="M. Hoshino, Y. Haraguchi, S. Kajiwara, T. Mitsuhashi, T."/>
   <result pre="C. Magalhaes, P. Casteloes, A. Marinho P301 - Impact of" exact="hyperglycemia" post="duration on the day of operation on short-term outcome"/>
   <result pre="Koutsogiannidis, M. Moschopoulou, G. Drossos P302 - Lactate levels in" exact="diabetic ketoacidosis" post="patients at ICU admissions G. Taskin, M. Çakir, AK"/>
   <result pre="Özer, L. Yamanel P303 - Intensive care implications of merging" exact="heart attack" post="centre units in London J. M. Wong, C. Fitton,"/>
   <result pre="primary percutaneous coronary intervention (PPCI) following out of the hospital" exact="cardiac arrest" post="K. Hoyland, D. Pandit P313 Prognostic indicators and outcome"/>
   <result pre="Cerebral oxygen saturation during resuscitation in a porcine model of" exact="cardiac arrest" post="E. Oloktsidou, K. Kotzampassi, B. Fyntanidou, S. Patsatzakis, L."/>
   <result pre="Rootselaar, J. Horn P317 Prognostic value of neuron-specific enolase after" exact="cardiac arrest" post="F. Ragusa, A. Marudi , S. Baroni, A. Gaspari,"/>
   <result pre="findings and serum neuron specific enolase with outcome of post" exact="cardiac arrest" post="patients A. Taha, T. Abdullah, S. Abdel Monem P319"/>
   <result pre="Monem P319 Introduction of a targeted temperature management strategy following" exact="cardiac arrest" post="in a district general hospital intensive care unit. S."/>
   <result pre="P322 Adherence to targeted temperature management after out of hospital" exact="cardiac arrest" post="B. Avard, R. Burns P323 Implementation of a therapeutic"/>
   <result pre="of a therapeutic hypothermia protocol for comatose survivors of out-of-hospital" exact="cardiac arrest." post="A. Patarchi, T. Spina P324 Factors associated with ventilator"/>
   <result pre="Factors associated with ventilator weaning after targeted temperature management for" exact="cardiac arrest" post="patients in japan H. Tanaka, N. Otani, S. Ode,"/>
   <result pre="P326 Monitoring of cTroponin I in patients with acute ischemic" exact="stroke" post="- predictor of inhospital mortality S. Dakova, Z. Ramsheva,"/>
   <result pre="post conditioning in the hippocampus of a gerbil model of" exact="transient cerebral ischemia" post="J. Cho, J. B. Moon, C. W. Park, T."/>
   <result pre=". Esen P331 Benefits of L-carnitine in valproic acid induced" exact="encephalopathy" post="R. Tincu, C. Cobilinschi, D. Tomescu, Z. Ghiorghiu, R."/>
   <result pre="open-ended 14-gauge catheter through the chest wall causes a significant" exact="pneumothorax" post="in a self-ventilating swine model M. Q Russell, K."/>
   <result pre="C. Skourtis P378 - Ketamine for analgosedation in severe hypoxic" exact="respiratory failure" post="S. D. Lee, K. Williams, I. D. Weltes P379"/>
   <result pre="J. Shak, C. Senver, R. Howard-Griffin P385 - Effect of" exact="obesity" post="on mortality in surgical critically ill patients. P. Wacharasint,"/>
   <result pre="score (news) reliably improves adverse clinical outcome prediction in community-acquired" exact="pneumonia" post="- results from a 6 year follow-up D. Sbiti-Rohr,"/>
   <result pre="- Comparison of mortality prediction scoring systems in patients with" exact="cirrhosis" post="admitted to general intensive care unit M. Cooper, K."/>
   <result pre="P398 - Organizational factors, outcomes and resource use in 9,946" exact="cancer" post="patients admitted to 70 ICUs M Soares, U. V."/>
   <result pre="haematological malignancies admitted to an intensive care unit of a" exact="cancer" post="center D. Mota, B. Loureiro, J. Dias, O. Afonso,"/>
   <result pre="(dols): audit of compliance in a of a 16-bed specialist" exact="cancer" post="critical care unit. C. Stone, T. Wigmore P443 -"/>
   <result pre="49 required admission to intensive care unit. Sixty-four patients developed" exact="viral pneumonia" post="and 26 acute respiratory distress syndrome. No differences in"/>
   <result pre="required admission to intensive care unit. Sixty-four patients developed viral" exact="pneumonia" post="and 26 acute respiratory distress syndrome. No differences in"/>
   <result pre="intensive care unit. Sixty-four patients developed viral pneumonia and 26" exact="acute respiratory distress syndrome." post="No differences in the serum levels of IgG, IgA,"/>
   <result pre="1. Gordon C. et al. Association between severe pandemic 2009" exact="influenza" post="A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency."/>
   <result pre="severe cases than in mild cases of pandemic H1N1 2009" exact="influenza" post="is associated with cytokine dysregulation. Clin Vaccine Immunol 2011;"/>
   <result pre="dysfunction is associated with leukopenia: A possible mechanism for sepsis-induced" exact="leukopenia" post="R. Riff 1, O. Naamani 1, A. Douvdevani 2"/>
   <result pre="receptor (A1R, Gi receptor) dominates the pro-inflammatory phase of bacterial" exact="peritonitis" post="and that activation of this receptor by a specific"/>
   <result pre="Conclusions: The similarities in the phenotype induced by sepsis and" exact="suppression" post="of A1R support our hypothesis that dysfunction/down-regulation of the"/>
   <result pre="onset of sepsis changes the effect of adenosine towards Gs-A2AR/A2BR-mediated" exact="leukopenia" post="and immune paralysis. Suppression of IL-15 might be a"/>
   <result pre="of IL-15 might be a part of the mechanism of" exact="leukopenia" post="observed in CLP-treated mice and A1R-/- mice. P005 Analysis"/>
   <result pre="spectral imaging (HSI) is available for analysis including diagnosis of" exact="malaria" post="infected cells and distinction of the cells to produce"/>
   <result pre="surgery. Methods: Forty eight patients who underwent elective surgery for" exact="gastrointestinal cancer" post="were enrolled in this study. Blood samples were taken"/>
   <result pre="Methods: Forty eight patients who underwent elective surgery for gastrointestinal" exact="cancer" post="were enrolled in this study. Blood samples were taken"/>
   <result pre="were also strong predictors for adverse outcome defined as death," exact="pulmonary embolism" post="and major adverse cardiac and cerebrovascular events. Conclusions: In"/>
   <result pre="response in septic patients secondary to community and hospital acquired" exact="pneumonia" post="NK Sharma 1, AK Tashima 1, MK Brunialti 1,"/>
   <result pre="and known as pneumonia. On the basis of infection site," exact="pneumonia" post="can be categorised as community acquired pneumonia (CAP) and"/>
   <result pre="of infection site, pneumonia can be categorised as community acquired" exact="pneumonia" post="(CAP) and hospital acquired pneumonia (HAP). To understand the"/>
   <result pre="be categorised as community acquired pneumonia (CAP) and hospital acquired" exact="pneumonia" post="(HAP). To understand the response of body under CAP"/>
   <result pre="shock). This can range from an increased thrombotic risk to" exact="disseminated intravascular coagulation" post="(DIC) contributing to increased morbidity and mortality. Previous studies"/>
   <result pre="a key role in the accumulation of microthrombi leading to" exact="disseminated intravascular coagulation" post="(DIC). The aim of this study was to assess"/>
   <result pre="Δ T-max of 3.2 °C (p &amp;lt; 0.001). The gel showed significant" exact="suppression" post="in cutaneous temperature by 2.6 °C, from 39.5 ± 0.11 °C"/>
   <result pre="had a lower body mass index and increased incidence of" exact="cardiovascular disease." post="Levels of pro- and anti-inflammatory cytokines were not different"/>
   <result pre="However, there was more shock, need for vasopressors, renal failure," exact="respiratory failure" post="and neurological alterations in the BC positive group. The"/>
   <result pre="lactates levels (3,9vs3,6; p = 0,39) NV group had greater incidence of" exact="thrombocytopenia" post="(105vs207, p = 0,03). Conclusions: We didn’t find any statistically significant"/>
   <result pre="significantly different in the two groups. The greater incidence of" exact="thrombocytopenia" post="(p = 0.03) observed in NV group is in line with"/>
   <result pre="and platelets which may even lead to the development of" exact="disseminated intravascular coagulation" post="(DIC). In the present study we investigated the usefulness"/>
   <result pre="increasing mortality in a monotonic, increasing fashion whereas only severe" exact="thrombocytopenia" post="(platelets (&amp;lt;80,000) was associated with significantly increased mortality. Conclusions:"/>
   <result pre="and organ dysfunction in sepsis. P053 Assessment of coagulopathy in" exact="cancer" post="patients with severe sepsis or septic shock. A case-control"/>
   <result pre="Davila&quot;, Bucharest, Romania Introduction: Hypercoagulability has been described both in" exact="cancer" post="patients and also in sepsis, leading to microcirculatory failure"/>
   <result pre="aim of this pilot study was to compare hemostasis in" exact="cancer" post="patients in the early stage of severe sepsis/septic shock"/>
   <result pre="patients in the early stage of severe sepsis/septic shock to" exact="cancer" post="patients without sepsis Methods: Adult patients operated for solid"/>
   <result pre="the control group (CG). Exclusion criteria were: liver diseases, chronic" exact="kidney failure," post="hematologic diseases, pregnancy, chronic anticoagulant/antiplatelet therapy and blood derivates"/>
   <result pre="compared to patients with APACHE &amp;lt; 25. Conclusions: Our study showed that" exact="cancer" post="patients with severe sepsis/septic shock had similar hypercoagulability after"/>
   <result pre="similar hypercoagulability after a delayed clot initiation as compared to" exact="cancer" post="patients without sepsis, despite thrombocytopenia and prolonged SCTs. These"/>
   <result pre="clot initiation as compared to cancer patients without sepsis, despite" exact="thrombocytopenia" post="and prolonged SCTs. These abnormalities were only detected by"/>
   <result pre="Thrombosis and Haemostasis,1,551–558,2003. P054 Thromboelastometry in critically ill patients with" exact="disseminated intravascular coagulation" post="M. Müller, M. Straat, S. S. Zeerleder, N. P."/>
   <result pre="1- Tamayo E, Álvarez FJ, Martínez-Rafael B, et al. Ventilator-associated" exact="pneumonia" post="is an important risk factor for mortality after major"/>
   <result pre="were the most uropathogenic bacteria. We observed significant association between" exact="urinary tract infection" post="caused by Escherichia coli and female gender (p &amp;lt; 0.05). Conclusions:"/>
   <result pre="lower in noble metal alloy-coated catheter group. P065 Predicting bacteremic" exact="urinary tract infection" post="in community setting: A prospective observational study S. Nimitvilai,"/>
   <result pre="frequent or urgent urination, flank pain or costovertebral tenderness) and" exact="pyuria" post="(defined by a presence of [&amp;gt;=] 5 WBC per"/>
   <result pre="[SD] age, 54.0 [12.6] vs 42.3 [16.9] years, p 0.004)," exact="diabetes mellitus" post="(40 % vs 16 %, p 0.04), chill (100"/>
   <result pre="acquired UTI. References 1. Prevalence and predictive features of bacteremic" exact="urinary tract infection" post="in emergency department patients. Eur J Clin Microbiol Infect"/>
   <result pre="P = 0.016), resistance to cefalosporins (n = 57, 86.4 %, OR = 2.367, P = 0.04), and" exact="alcohol abuse" post="(n = 9, 81.8 %, OR = 3.926, P = 0.05). Conclusions: Acinetobacter spp. monobacteremia"/>
   <result pre="extremely high overall mortality rate. Mortality was associated with elderly," exact="alcohol abuse," post="multi-drug-resistant strain and resistance to cefalosporins also mechanical ventilation."/>
   <result pre="Observed mortality 20% 16.6% P068 Improved detection of spontaneous bacterial" exact="peritonitis" post="by uritop + tm strip test and inoculation of blood culture"/>
   <result pre="Charles-Nicolle, Bab Saadoun, Tunisia Introduction: The diagnosis of spontaneous bacterial" exact="peritonitis" post="(SBP) is usually investigated by cytobacteriologic analysis.we purpose to"/>
   <result pre="identification of bacteria. Methods: Our study included 44 patients with" exact="cirrhosis" post="and tense ascites. Immediately, after paracentesis a urine test"/>
   <result pre="SBP and ameliorate consequently the prognosis. P069 Increased risk of" exact="cellulitis" post="in patients with congestive heart failure: a population based"/>
   <result pre="Chiayi County, Taiwan Introduction: Although it is well known that" exact="lymphedema" post="of limbs is associated with higher possibility of developing"/>
   <result pre="associated with higher possibility of developing cellulitis, the relation between" exact="congestive heart failure" post="and cellulitis has never been established. We investigated the"/>
   <result pre="of developing cellulitis, the relation between congestive heart failure and" exact="cellulitis" post="has never been established. We investigated the risks of"/>
   <result pre="cellulitis has never been established. We investigated the risks of" exact="cellulitis" post="in patients hospitalized with congestive heart failure in Taiwan"/>
   <result pre="We investigated the risks of cellulitis in patients hospitalized with" exact="congestive heart failure" post="in Taiwan to evaluate whether the risk is higher"/>
   <result pre="models were applied to compare the hazards between patients with" exact="congestive heart failure" post="and the unexposed group after controlling for selected covariates."/>
   <result pre="for selected covariates. Results: We identified 4,842 patients hospitalized with" exact="congestive heart failure" post="and 748,701 patients without congestive heart failure. After controlling"/>
   <result pre="patients hospitalized with congestive heart failure and 748,701 patients without" exact="congestive heart failure." post="After controlling for age, gender, urbanization level, socioeconomic status,"/>
   <result pre="urbanization level, socioeconomic status, diabetes, hypertension, hyperlipidemia, malignancies, liver cirrhosis," exact="atrial fibrillation," post="smoking, obesity, peripheral artery disease and Charlson Comorbidity Index"/>
   <result pre="diabetes, hypertension, hyperlipidemia, malignancies, liver cirrhosis, atrial fibrillation, smoking, obesity," exact="peripheral artery disease" post="and Charlson Comorbidity Index score, the adjusted hazard ratio"/>
   <result pre="was 1.65 (95 % confidence interval, 1.49¡X1.82) in patients with" exact="congestive heart failure." post="Conclusions: Congestive heart failure may be associated with increased"/>
   <result pre="associated with increased risk of cellulitis. P070 Outcomes of severe" exact="cellulitis" post="and necrotizing fasciitis in the critically ill D. R."/>
   <result pre="increased risk of cellulitis. P070 Outcomes of severe cellulitis and" exact="necrotizing fasciitis" post="in the critically ill D. R. Cranendonk 1, L."/>
   <result pre="risk of cellulitis. P070 Outcomes of severe cellulitis and necrotizing" exact="fasciitis" post="in the critically ill D. R. Cranendonk 1, L."/>
   <result pre="infection in intensive care units (ICU’s). However, in contrast to" exact="necrotizing fasciitis" post="(NF), limited clinical data is available for severe cellulitis"/>
   <result pre="in intensive care units (ICU’s). However, in contrast to necrotizing" exact="fasciitis" post="(NF), limited clinical data is available for severe cellulitis"/>
   <result pre="necrotizing fasciitis (NF), limited clinical data is available for severe" exact="cellulitis" post="in the critically ill. The objective of this study"/>
   <result pre="admission were excluded. Using set criteria, sepsis admissions attributed to" exact="cellulitis" post="or soft tissue infections were retrospectively recategorized by an"/>
   <result pre="(i.e. ICU necessitating) cellulitis, or another primary diagnosis but where" exact="cellulitis" post="was present as a comorbidity. Results: Among 2562 ICU"/>
   <result pre="diagnosed as a comorbidity in another 25 patients. Comparing severe" exact="cellulitis" post="to NF, there were no differences in age, BMI,"/>
   <result pre="of hospital stay prior to ICU admission. Patients with severe" exact="cellulitis" post="had lower rates of shock (30 % vs 61"/>
   <result pre="p = 0.01). With causative agents identified in 78 % of severe" exact="cellulitis" post="patients, S. aureus was the dominant organism (present in"/>
   <result pre="(61.3 %). Length of ICU stay was shorter for severe" exact="cellulitis" post="patients (3 [2-5] vs 5 [3-11] days, p = 0.01). Hospital-"/>
   <result pre="vs 22.6 %, p = 0.54 respectively). Conclusions: Although patients with severe" exact="cellulitis" post="were less critically ill on ICU admission, when compared"/>
   <result pre="critically ill on ICU admission, when compared to patients with" exact="necrotizing fasciitis" post="their mortality rates appear similar. This study is limited"/>
   <result pre="ill on ICU admission, when compared to patients with necrotizing" exact="fasciitis" post="their mortality rates appear similar. This study is limited"/>
   <result pre="C. botulinum species produce seven serologically distinct toxins, A-G. Human" exact="botulism" post="is primarily caused by toxin types A, B or"/>
   <result pre="toxin types A, B or E. In Europe, most wound" exact="botulism" post="is now associated with injectable drug use. Symptoms are"/>
   <result pre="drug use. Symptoms are of descending paralysis, bulbar palsies and" exact="respiratory failure." post="Methods: This is a review of the clinical, microbiological"/>
   <result pre="clinical, microbiological and public health aspects of an outbreak of" exact="botulism" post="in Scotland from December 2014 to June 2015. Data"/>
   <result pre="interview and clinical data collation. Results: 47 cases of wound" exact="botulism" post="were reported: 23 probable, 17 confirmed, 5 discounted and"/>
   <result pre="to contaminated heroin, or cutting agent. There were four deaths," exact="botulism" post="contributing to two. Police Scotland was closely involved in"/>
   <result pre="of muscle popping. Conclusions: This is the largest outbreak of" exact="botulism" post="among PWIDs in Europe. Prompt identification of cases and"/>
   <result pre="risk factors for acquiring MDR infection in ICU. Ventilator associated" exact="pneumonia" post="was the most frequent acquired infection as well in"/>
   <result pre="an effective fighting technique against carbapenemases producing bacteria. P080 Mediterranean" exact="spotted fever" post="in an infectious diseases intensive care unit A. Silva-Pinto,"/>
   <result pre="Fever (MSF) is considered a benign disease characterized by fever," exact="rash" post="and eschar. However, in some cases it can have"/>
   <result pre="in some cases it can have severe forms with purpuric" exact="rash" post="and multiorganic failure. The objective of this study is"/>
   <result pre="had comorbidities. At admission, the most common analytic abnormalities were" exact="thrombocytopenia" post="(93 %), transaminases elevation (90 %), elevation of the"/>
   <result pre="impairment (90 %), renal failure (70 %), pneumonitis (57 %)," exact="respiratory failure" post="(53 %) and gastrointestinal bleeding (13 %). Four patients"/>
   <result pre="admission for a median stay of 28 days: 7 developed" exact="acute respiratory distress syndrome," post="4 were treated with proning, 4 needed continuous renal"/>
   <result pre="university hospital general intensive care unit with radiographically confirmed severe" exact="pneumonia" post="underwent bronchoscopy and lavage, with the samples being analysed"/>
   <result pre="P086 ‘BUNS’: An investigation protocol improves the ICU management of" exact="pneumonia" post="R. Sharvill, J. Astin Royal United Hospital, Bath, UK"/>
   <result pre="mortality. Prompt investigation facilitates tailored antimicrobial strategy, guides management, and" exact="aids" post="prognostication. The British Thoracic Society (BTS)[1] suggest specific tests"/>
   <result pre="undertaken or delayed in our ICU, and introduced a computerised" exact="pneumonia" post="screen, ‘BUNS’, (Blood cultures and viral serology/Urinary antigens/Nasal +/-"/>
   <result pre="this condition. Methods: All patients with a primary diagnosis of" exact="pneumonia" post="admitted to a UK district hospital ICU over a"/>
   <result pre="to the BTS guideline [1]. We subsequently implemented the ‘BUNS" exact="pneumonia" post="screen’ within our electronic investigation system. A single click"/>
   <result pre="study over the past 20 years has focused specifically on" exact="pneumonia" post="following secondary peritonitis. Our objective is to determine epidemiological"/>
   <result pre="objective is to determine epidemiological features and in-hospital mortality of" exact="pneumonia" post="in this kind of patients. Methods: Prospective observational study"/>
   <result pre="with mortality and development of pneumonia. Results: The incidence of" exact="pneumonia" post="following secondary peritonitis was 9.6 %. Risk factors associated"/>
   <result pre="development of pneumonia. Results: The incidence of pneumonia following secondary" exact="peritonitis" post="was 9.6 %. Risk factors associated with the development"/>
   <result pre="was 9.6 %. Risk factors associated with the development of" exact="pneumonia" post="were hospital-acquired peritonitis, &amp;gt;48 h of mechanical ventilation, and"/>
   <result pre="h of mechanical ventilation, and SOFA score. The onset of" exact="pneumonia" post="was late in majority of patients (about 16.8 days"/>
   <result pre="peritonitis. The 90-day in-hospital mortality rate was 47.5 % of" exact="pneumonia" post="patients. Independent factors associated with 30–90-day in-hospital mortality were"/>
   <result pre="pneumonia patients. Independent factors associated with 30–90-day in-hospital mortality were" exact="pneumonia" post="and SOFA score Conclusions: Pneumonia in patients who had"/>
   <result pre="a secondary peritonitis, increases the 90-day mortality. The onset of" exact="pneumonia" post="following secondary peritonitis usually is late (16.8 days) and"/>
   <result pre="increases the 90-day mortality. The onset of pneumonia following secondary" exact="peritonitis" post="usually is late (16.8 days) and with etiological microorganisms"/>
   <result pre="and with etiological microorganisms different than those responsable for secondary" exact="peritonitis" post="References 1. Jang JY, Lee SH, Shim H, et"/>
   <result pre="L, et al. The attributable morbidity and mortality of ventilator-associated" exact="pneumonia" post="in the critically ill patient. Am J Respir Crit"/>
   <result pre="severity and aid in the clinical management of community acquired" exact="pneumonia" post="(CAP) [1]. Recent literature however demonstrates that its use"/>
   <result pre="J Tuberc Lung Dis (2011) P089 Incidence of community acquired" exact="pneumonia" post="with viral infection in mechanically ventilated patients in the"/>
   <result pre="Jancik Hennepin County Medical Center, Minneapolis, USA Introduction: Community acquired" exact="pneumonia" post="(CAP) guidelines acknowledge respiratory viruses as a cause for"/>
   <result pre="mortality was 25 %. Mortality occurred in a patient with" exact="influenza" post="A and in a patient with rhinovirus. Both had"/>
   <result pre="aureus virulence. The use of MEDI4893 to prevent S aureus" exact="pneumonia" post="offers a novel paradigm for managing specific high-risk patients."/>
   <result pre="aureus, but have not been diagnosed with new onset of" exact="pneumonia" post="prior to randomization. Results: N/A Conclusions: The SAATELLITE study"/>
   <result pre="an innovative pre-emptive therapy approach to prevent S aureus nosocomial" exact="pneumonia" post="in MV patients, by utilizing the novel monoclonal antibody"/>
   <result pre="trauma (73.8 %) and chest trauma (76.19 %). Ventilatory acquired" exact="pneumonia" post="was the most common NI (73.8 %). The most"/>
   <result pre="-0.32 0.96 0.210 P093 A comparison of two ventilator associated" exact="pneumonia" post="surveillance techniques T. H. Craven 1, G. Wojcik 1,"/>
   <result pre="Glasgow, UK; 3Western General Hospital, Edinburgh, UK Introduction: Ventilator associated" exact="pneumonia" post="(VAP) rates are a key quality metric and the"/>
   <result pre="ultrasound before and after fiberbronchoscopy - modifications may improve ventilator-associated" exact="pneumonia" post="diagnosis S. Mongodi 1, B. Bouhemad 2, A. Orlando"/>
   <result pre="P095 Comparing the accuracy of predictors of mortality in ventilator-associated" exact="pneumonia" post="M. Haliloglu, B. Bilgili, U. Kasapoglu, I. Sayan, M."/>
   <result pre="University Pendik Teaching and Research Hospital, Istanbul, Turkey Introduction: Ventilator-associated" exact="pneumonia" post="(VAP) remains an important cause of morbidity and mortality"/>
   <result pre="a series of interventions on the rate of ventilator associated" exact="pneumonia" post="in a large teaching hospital H. E. Ellis, K."/>
   <result pre="Teaching Hospital NHS Foundation Trust, Sheffield, UK Introductions: Ventilator associated" exact="pneumonia" post="(VAP) has a reported incidence of between 9 –"/>
   <result pre="aeruginosa, but have not been diagnosed with new onset of" exact="pneumonia" post="prior to randomization. Conclusions: The EVADE study represents an"/>
   <result pre="an innovative pre-emptive therapy approach to prevent P aeruginosa nosocomial" exact="pneumonia" post="in MV patients by utilizing the novel mAb, MEDI3902,"/>
   <result pre="high-risk patients. P099 Short-term inhaled colistin adjunctive therapy for ventilator-associated" exact="pneumonia" post="Y. Nassar, M. S. Ayad Cairo University, Giza, Egypt"/>
   <result pre="Nassar, M. S. Ayad Cairo University, Giza, Egypt Introductions: Ventilator-associated" exact="pneumonia" post="(VAP) is an important cause of prolonged intensive-care stay"/>
   <result pre="Endotracheal (ETT) aspirates after &amp;gt; = 48 hrs of mechanical ventilation and" exact="pneumonia" post="clinical criteria: radiological infiltrates, fever, leucocutosis or leucopenia, purulent"/>
   <result pre="University hospital Center of La Rabta, Tunis, Tunisia Introductions: Ventilator-associated" exact="pneumonia" post="(VAP) due to multidrug-resistant (MDR), gram-negative bacteria (GNB) is"/>
   <result pre="cohort study. Critical care (London, England) 2013, 17(4):R174. P102 Nosocomial" exact="pneumonia" post="- emphasis on inhaled tobramycin A. Kuzovlev 1, A."/>
   <result pre="as a significant treatment modality in ICU patients with nosocomial" exact="pneumonia" post="(NP). The aim of this study was to investigate"/>
   <result pre="primary reason for ICU stay - intraabdominal infections (80 %)," exact="mediastinitis" post="(13 %), other (9 %)). Diagnosis of NP was"/>
   <result pre="specially formulated Amikacin Inhalation Solution (AIS) in development for Gram-negative" exact="pneumonia" post="in intubated &amp;amp; mechanically ventilated patients (Fig. 18). This"/>
   <result pre="nebulized amikacin/fosfomycin and systemic meropenem on severe amikacin-resistant meropenem-susceptible P.aeruginosa" exact="pneumonia" post="G. Li Bassi, E. Aguilera, C. Chiurazzi, C. Travierso,"/>
   <result pre="Kg) were anesthetized and on MV for 78 hours. Multi-lobar" exact="pneumonia" post="was developed by P. aeruginosa (1), resistant to amikacin"/>
   <result pre="location was unspecified in most cases (79 %). Symptoms included" exact="encephalopathy" post="(75 %), myoclonus (41 %), seizures (11 %), and"/>
   <result pre="an electrical instability could be detected during repolarisation shortly before" exact="cardiac arrest," post="not recordable with a conventional ECG [2]. Therefore we"/>
   <result pre="had empyema and 1 (20 %) in vancomycin group had" exact="chronic obstructive pulmonary disease" post="(COPD). Treatment failure in vancomycin group was 5/50 (10"/>
   <result pre="had combination of over-dosing and under-dosing. Septic patients with chronic" exact="cardiovascular disease" post="(p = 0.035) and chronic renal failure (p = 0.021) were more likely"/>
   <result pre="(p = 0.021) were more likely to have antibiotic dosing errors. However," exact="respiratory failure," post="liver failure, immunodeficiency state and diabetes mellitus were not"/>
   <result pre="dosing errors. However, respiratory failure, liver failure, immunodeficiency state and" exact="diabetes mellitus" post="were not clearly associated with dposing errors. Vancomycin was"/>
   <result pre="La Rabta. , Tunis, Tunisia Introductions: The management of invasive" exact="candidiasis" post="(IC) remains a major challenge. Delayed antifungal therapy is"/>
   <result pre="Corporation, Doha, Qatar Introductions: Neurocysticercosis (NCC) is the most common" exact="parasitic disease" post="of the central nervous system. Every newly diagnosed patient"/>
   <result pre="and activated prothrombin complex concentrate in a model of severe" exact="thrombocytopenia" post="I Budnik 1, B Shenkman 2 1Sechenov First Moscow"/>
   <result pre="Russia; 2Sheba Medical Center, Tel-Hashomer, Israel Introductions: Bleedings in severe" exact="thrombocytopenia" post="(TCP) vary from mild to severe and may be"/>
   <result pre="and two patients showed mild thrombocytopenia. All patients with severe" exact="thrombocytopenia" post="and 73 of 122 patients with moderate thrombocytopenia had"/>
   <result pre="with severe thrombocytopenia and 73 of 122 patients with moderate" exact="thrombocytopenia" post="had a DIC score of ≥2. Conclusions: DIC, although"/>
   <result pre="in critically ill patients. In patients with moderate or severe" exact="thrombocytopenia" post="a truncated DIC score should be calculated. If the"/>
   <result pre="Optimal hemoglobulin during CPB has not been defined. Severe hemodilutional" exact="anemia" post="(Hb &amp;lt; 7 g/dl) has statistical significant correlation with increase of"/>
   <result pre="and 109 girls) were recorded. There were 53 children with" exact="respiratory failure," post="39 children with pathology of the nervous system, 31"/>
   <result pre="reasons for admission in the pediatric intensive care unit were" exact="respiratory failure" post="and pathology of the nervous system. These critically ill"/>
   <result pre="system. These critically ill children presented in many occasions with" exact="anemia" post="and thrombocytopenia, hemodynamic instability, clotting and bleeding disorders (while"/>
   <result pre="transfusion thresholds on mortality and cardiovascular events in patients with" exact="cardiovascular disease" post="(non-cardiac surgery): a systematic review and meta-analysis A. Docherty"/>
   <result pre="of hospital patients with anaemia. Uncertainty exists for patients with" exact="cardiovascular disease," post="in whom the heart may be more susceptible to"/>
   <result pre="restrictive vs liberal transfusion threshold and that included patients with" exact="cardiovascular disease." post="A comprehensive search of databases (including CENTRAL, MEDLINE and"/>
   <result pre="is associated with higher rates of ACS in patients with" exact="cardiovascular disease." post="This supports the uncertainty highlighted in current guidelines, and"/>
   <result pre="P137 Impact of simple clinical practice guidelines for reducing post-operative" exact="atrial fibrillation" post="after cardiac surgery A. Omar , M. Allam, O."/>
   <result pre="Doha, Qatar Introductions: In view the adverse consequence of post-operative" exact="atrial fibrillation" post="(POAF) encompassing hemodynamic deterioration, thromboembolic hazards beside the intolerable"/>
   <result pre="cardiac surgery: does rophylactic therapy decrease adverse outcomes associated with" exact="atrial fibrillation." post="J Intensive Care Med. 2009; 24(1), 18-25 2) Tapio"/>
   <result pre="H, Jari H, Kimmo M &amp;amp; Juha H. Prevention of" exact="atrial fibrillation" post="after cardiac surgery. Scandin Cardiovasc J. 2007; 41(2), 72-78."/>
   <result pre="has no protective impact on postoperative LCOS, septicemia, stroke, AKI," exact="atrial fibrillation," post="sternal infections and mortality. There is a tendency for"/>
   <result pre="heart failure 17.9 % vs 4.9 % (p = .000); and post-operative" exact="atrial fibrillation," post="12.4 % vs 2.9 % (p = 0.005). Lengths of ventilation,"/>
   <result pre="0.86 (0.67 – 1.02) 1.37 (1.10 – 1.66) P143 New-onset" exact="atrial fibrillation" post="in intensive care: incidence, management and outcome S. A."/>
   <result pre="with new-onset AF frequently had evidence of sepsis (81 %)," exact="respiratory failure" post="(62 %), circulatory shock (38 %) and acute kidney"/>
   <result pre="One single spot measurement of the sublingual microcirculation during acute" exact="pulmonary hypertension" post="in a pig model of shock M. S. Tovar"/>
   <result pre="Valladolid, Spain; 2Erasmus MC, Rotterdam, Netherlands Introductions: The effect of" exact="pulmonary hypertension" post="in the sublingual microcirculation (mci) remains unclear. We described"/>
   <result pre="of shock the effects of the hemodynamic changes during acute" exact="pulmonary hypertension" post="in conjunction with sublingual mci alterations measured with the"/>
   <result pre="Cytocam-IDF imaging fixed on a metal arm support. Results: Acute" exact="pulmonary hypertension" post="was characterized by an increase in the mPAP, followed"/>
   <result pre="was observed. Conclusions: Abnormalities in the sublingual mci during severe" exact="pulmonary hypertension" post="were mainly associated with decrease perfusion pressure due to"/>
   <result pre="abnormal central venous pressure waveform morphology during an episode of" exact="pulmonary hypertension" post="in a porcine shock model M. S. Tovar Doncel"/>
   <result pre="information. We described CVP tracings recorded during an episode of" exact="pulmonary hypertension" post="in a porcine model of shock, aiming to characterize"/>
   <result pre="rate, and systolic/diastolic arterial pulmonary pressures. Results: The episode of" exact="pulmonary hypertension" post="lasted for 3-5 min with spontaneous recovery. The CVP"/>
   <result pre="components of the tracing recorded during the entire episode of" exact="pulmonary hypertension." post="A simultaneous ECG is shown to demonstrate the timing"/>
   <result pre="Conclusions: The abnormal CVP waveform morphology during an episode of" exact="pulmonary hypertension" post="shows a series of waves that can provide invaluable"/>
   <result pre="absence of formation on ultrasound technique. Coagulation abnormalities (64 %)," exact="obesity" post="(54 %) and anatomical difficulties (52 %) were the"/>
   <result pre="thermodilutions. The TTE CO (COTTE) was derived from the Doppler" exact="stroke" post="volume, the E/A ratio from the transvalvular mitral flow"/>
   <result pre="SS. Reference 1. V. De Castro et al. Comparison of" exact="stroke" post="volume and stroke volume respiratory variation measured by the"/>
   <result pre="V. De Castro et al. Comparison of stroke volume and" exact="stroke" post="volume respiratory variation measured by the axillary artery pulse-contour"/>
   <result pre="echocardiography examinations of critically ill patients performed between 2013-2014. The" exact="stroke" post="volume (SV) was calculated using left ventricular outflow tract"/>
   <result pre="and flow velocity time integral (DT) and was compared to" exact="stroke" post="volume estimated from the difference between the end diastolic"/>
   <result pre="measured by Simpson biplane method (S2D). We excluded patients with" exact="atrial fibrillation" post="and any significant valvulopathy. Low end diastolic value (EDV)"/>
   <result pre="We evaluated 147 exams. Twenty patients were excluded because of" exact="atrial fibrillation" post="and 41 because of a significant valvulopathy. A total"/>
   <result pre="because of a significant valvulopathy. A total 86 pairs of" exact="stroke" post="volumes measured by the two methods were evaluated. The"/>
   <result pre="r^2 = 0.25 and p &amp;lt; 0.01 by regression analysis. The mean bias of" exact="stroke" post="volume measured with DT over that estimated with S2D"/>
   <result pre="% ± 33 vs 20 % ± 31 p &amp;lt; 0.01). Conclusions: A significant overestimation of" exact="stroke" post="volume measured with Doppler ultrasound by transthoracic echocardiography compared"/>
   <result pre="P157 Left ventricular outflow tract velocity time integral correlates with" exact="stroke" post="volume index in mechanically ventilated patients Ó. Martínez González"/>
   <result pre="observers. We hypothesize that LVOT-VTI is an accurate estimation of" exact="stroke" post="volume index (SVI). The objective of the study was"/>
   <result pre="calculate SVI (r = 0,470, p = 0,004). Correlation was acceptable for patients on" exact="atrial fibrillation" post="(r = 0,619, p &amp;lt; 0,001). Conclusions: LVOT-VTI could be useful as a"/>
   <result pre="based on results from hemodynamic measurements, defined as cardiac output," exact="stroke" post="volume, stroke volume variation, oxygen delivery, central venous oxygenation"/>
   <result pre="results from hemodynamic measurements, defined as cardiac output, stroke volume," exact="stroke" post="volume variation, oxygen delivery, central venous oxygenation (ScvO2) or"/>
   <result pre="pressure (MAP), central venous pressure (CVP), cardiac output (CO) and" exact="stroke" post="volume (SV) were recorded at baseline and immediately after"/>
   <result pre="fluids and outcomes in emergency department patients hospitalized with community-acquired" exact="pneumonia" post="P. Hou 1, W. Z. Linde-Zwirble 2, I. D."/>
   <result pre="Emergency department (ED) patients admitted to the hospital with community-acquired" exact="pneumonia" post="(CAP) may be at particular risk for volume overload"/>
   <result pre="ventilator free days (VFD). Methods: CAP was defined as a" exact="bacterial pneumonia" post="diagnosis present on admission in ED patients receiving chest"/>
   <result pre="free days (VFD). Methods: CAP was defined as a bacterial" exact="pneumonia" post="diagnosis present on admission in ED patients receiving chest"/>
   <result pre="sepsis was thought to have started as an inadequately treated" exact="urinary tract infection." post="The patient was initially treated aggressively with hypotonic saline"/>
   <result pre="follows: 4 (28.6 %) patients HHS, 1 (7.1 %) patient" exact="diabetic ketoacidosis," post="1 (7.1 %) patient lithium-induced diabetes insipidus and 8"/>
   <result pre="(7.1 %) patient diabetic ketoacidosis, 1 (7.1 %) patient lithium-induced" exact="diabetes insipidus" post="and 8 (57.1 %) patients with dehydration secondary to"/>
   <result pre="significantly higher risk of mortality in patients who developed mixed" exact="metabolic acidosis" post="plus respiratory acidosis on their admission day (OR = 3.45, p-value &amp;lt; 0.001)."/>
   <result pre="day (OR = 3.45, p-value &amp;lt; 0.001). Multiple logistic regression analysis demonstrated that mixed" exact="metabolic acidosis" post="plus respiratory acidosis (OR = 3.91, 95 % CI = 1.37-10.21, p-value = 0.003) and"/>
   <result pre="The results show that in critically ill patients initial mixed" exact="metabolic acidosis" post="plus respiratory acidosis, hyponatremia and hyperkalemia are significant predictors"/>
   <result pre="in MUDPILES – a rare cause of high anion gap" exact="metabolic acidosis" post="(HAGMA) C. P. Lee 1, X. L. Lin 2,"/>
   <result pre="overdose. Methods: A 41 year old male was intubated for" exact="status epilepticus." post="He had a medical history of pulmonary tuberculosis (pTB)"/>
   <result pre="intubated for status epilepticus. He had a medical history of" exact="pulmonary tuberculosis" post="(pTB) and had been treated with a course of"/>
   <result pre="for status epilepticus. He had a medical history of pulmonary" exact="tuberculosis" post="(pTB) and had been treated with a course of"/>
   <result pre="inclusion, 13 patients were excluded because of a history of" exact="chronic kidney disease," post="5 patients were excluded because no creatinine at CRRT"/>
   <result pre="admission weight ( HR 1.036, p = 0.016) ICU admission because of" exact="respiratory failure" post="(HR 9.275, p = 0.29) and creatinine at CRRT initiation (HR"/>
   <result pre="M et al. Am J Clin Oncol. 1982;6:649-655 P187 Severe" exact="hypophosphatemia" post="during citrate-anticoagulated CRRT A. Steuber 1, C. Pelletier 1,"/>
   <result pre="running times and effective dialysis doses. Thus, the risk of" exact="hypophosphatemia" post="(hypoPO4) is high and PO4 substitution is required. We"/>
   <result pre="Despite rigorous efforts to maintain normal PO4-levels via PO4-infusion, severe" exact="hypophosphatemia" post="occured in 66 % of all pts. In contrast,"/>
   <result pre="only in septic multiorgan failure as well as in severe" exact="pancreatitis" post="and other critical ill patients and is well tolerated"/>
   <result pre="shock or severe SIRS. The focus was abdominal (28.6 %)," exact="pneumonia" post="(50 %) and pancreatitis (14.3 %). Aim of our"/>
   <result pre="The focus was abdominal (28.6 %), pneumonia (50 %) and" exact="pancreatitis" post="(14.3 %). Aim of our case study was to"/>
   <result pre="Hetz H, et al. Septic shock secondary to ß-hemolytic streptococcus-induced" exact="necrotizing fasciitis" post="treated with a novel cytokine adsorption therapy. Int J"/>
   <result pre="H, et al. Septic shock secondary to ß-hemolytic streptococcus-induced necrotizing" exact="fasciitis" post="treated with a novel cytokine adsorption therapy. Int J"/>
   <result pre="with 6 (12 %) either on chronic dialysis or with" exact="chronic kidney disease." post="At follow-up, 32 % (17 patients) had renal injury."/>
   <result pre="all these equations have been validated in patients with stable" exact="chronic kidney disease." post="Most Dutch hospital laboratories, ours included, still report MDRD-eGFR"/>
   <result pre="higher in the AKI group. The AKI group with post-operative" exact="atrial fibrillation" post="29.8 % vs 10.5 % (p = 0.001). AKI group had"/>
   <result pre="7,9 %, failed intubations from 19 % to 0,3 %," exact="mediastinitis" post="from 27 % to 2,6 %, deaths from 32,4"/>
   <result pre="flow oxygen (NHFO) is an attractive therapy for acute hypoxemic" exact="respiratory failure" post="(AHRF), with reported comfort, and theoretical wash-out of CO2"/>
   <result pre="use of NHFO rather than conventional therapy for acute hypoxemic" exact="respiratory failure" post="in adults, and further study of patients at risk"/>
   <result pre="ICU Respiratory failure 40/106 44/94 p = 0.19 Lemiale 2015 ICU Immunocompromise/" exact="respiratory failure" post="5/52 4/48 p = 0.82 P221 Setting optimal flow rate during"/>
   <result pre="respiratory support that might impact major clinical outcomes of acute" exact="respiratory failure" post="patients [1]. We present preliminary data from a clinical"/>
   <result pre="We performed a prospective randomized cross-over study on 4 acute" exact="respiratory failure" post="patients admitted to the ICU with PaO[sub]2[/sub]/FiO[sub]2[/sub] &amp;lt; =300 mmHg. FiO[sub]2[/sub]"/>
   <result pre="to dose consistency across two different gas flow rates using" exact="cystic fibrosis" post="and normal adult breathing profiles during nasal high flow"/>
   <result pre="across two different gas flow rates during simulated normal and" exact="cystic fibrosis" post="(CF) breathing. Salbutamol was used as a tracer aerosol."/>
   <result pre="center between 1999 and 2013. Only patients requiring tracheostomy for" exact="respiratory failure" post="of varying etiology and difficult weaning were included. Patients"/>
   <result pre="in patients with a high Charlson Comorbidity Index (p = 0.02) or" exact="chronic kidney disease" post="(p &amp;lt; 0.001). QoL was assessed in 21 ventilated and 22"/>
   <result pre="(due to head injury, ischemic and hemorrhagic events), 14 %" exact="chronic obstructive pulmonary disease," post="8 % severe miopathy, 6 % postanoxic encephalopathy, 2"/>
   <result pre="% postanoxic encephalopathy, 2 % Guillain Barre and 2 %" exact="amyotrophic lateral sclerosis." post="10 % of the patients with a high length"/>
   <result pre="children received a special critical care under the Protocol of" exact="pneumonia" post="prophylaxis associated with artificial ventilation: gentle suctioning of secretions"/>
   <result pre="P233 Psv-niv versus cpap in the treatment of acute cardiogenic" exact="pulmonary edema" post="A. Pagano 1, F. Numis 2, G. Visone 3,"/>
   <result pre="Hospital, Naples, Italy; 3Cardarelli Hospital, Naples, Italy Introductions: Acute cardiogenic" exact="pulmonary edema" post="(ACPE) is a common cause of acute respiratory failure."/>
   <result pre="cardiogenic pulmonary edema (ACPE) is a common cause of acute" exact="respiratory failure." post="Non invasive continuous airway positive pressure (CPAP) has been"/>
   <result pre="bilevel positive airway pressure by face mask in acute cardiogenic" exact="pulmonary edema." post="Crit Care Med 2004; 12 2407-2415 2 Scot. Two-Hour"/>
   <result pre="as a first line therapy for immunocompromised patients with acute" exact="respiratory failure," post="although it may not be appropriate for every patient."/>
   <result pre="haematologic malignancy admitted to Mount Sinai Hospital ICU for acute" exact="respiratory failure" post="between January 1, 2010 and May 31, 2015, and"/>
   <result pre="27.6 ± 4.6) with haematologic malignancy were treated with NIV for acute" exact="respiratory failure." post="76 % of patients had acute leukaemia, 10 %"/>
   <result pre="10 % had lymphoma, and 14 % had chronic leukaemia," exact="multiple myeloma" post="or myelodysplastic syndrome. Aetiology of respiratory failure was multifactorial"/>
   <result pre="lymphoma, and 14 % had chronic leukaemia, multiple myeloma or" exact="myelodysplastic syndrome." post="Aetiology of respiratory failure was multifactorial in 39 %"/>
   <result pre="had chronic leukaemia, multiple myeloma or myelodysplastic syndrome. Aetiology of" exact="respiratory failure" post="was multifactorial in 39 % patients, with features of"/>
   <result pre="failure was multifactorial in 39 % patients, with features of" exact="pneumonia" post="in 77 % patients, severe sepsis or septic shock"/>
   <result pre="Conclusions: Two thirds of patients with haematologic malignancy and acute" exact="respiratory failure" post="required ETI following NIV failure and had a high"/>
   <result pre="scientific evidence in acutely decompensated chronic pulmonary disease and acute" exact="pulmonary edema." post="NIV has been also successful in immunosuppressed patients with"/>
   <result pre="The use of NIV remains controversial in pneumonia, tuberculosis, flu," exact="acute respiratory distress syndrome" post="(ARDS)… The aim of this study is to analyse"/>
   <result pre="excluded patients who need NIV with chronic pulmonary disease, acute" exact="pulmonary edema" post="or during weaning of mechanic ventilation. The patients were"/>
   <result pre="their comorbidities. The most frequent reason to perform NIV was" exact="bacterial pneumonia" post="(44 %) followed by pneumocystosis (30 %), ARDS (16"/>
   <result pre="comorbidities. The most frequent reason to perform NIV was bacterial" exact="pneumonia" post="(44 %) followed by pneumocystosis (30 %), ARDS (16"/>
   <result pre="to perform NIV was bacterial pneumonia (44 %) followed by" exact="pneumocystosis" post="(30 %), ARDS (16 %), flu (6 %) and"/>
   <result pre="pneumocystosis (30 %), ARDS (16 %), flu (6 %) and" exact="tuberculosis" post="(2 %). Median time of NIV was 3,5 days."/>
   <result pre="noninvasive ventilation success and ICU outcome in patients with hypercapnic" exact="respiratory failure" post="N. Boyacý, Z. Isýkdogan, Ö. Özdedeoglu, Z. Güllü, M."/>
   <result pre="is interact with the noninvasive ventilation (NIV) therapy in hypercapnic" exact="respiratory failure." post="Because of the frequent diuretic and steroid usage lots"/>
   <result pre="reason of NIV failure has not been investigated in hypercapnic" exact="respiratory failure" post="yet. The aim of this study is to assess"/>
   <result pre="and intensive care unit (ICU) outcome in patients with hypercapnic" exact="respiratory failure" post="and receiving NIV therapy. Methods: Data of 206 patients"/>
   <result pre="receiving NIV therapy. Methods: Data of 206 patients with hypercapnic" exact="respiratory failure" post="and treated with NIV screened retrospectively. Patients who received"/>
   <result pre="seen as high as 30 % in patients with hypercapnic" exact="respiratory failure" post="and requiring NIV and may cause to increase in"/>
   <result pre="Minnesota, Minneapolis, USA Introduction: Optimizing positive end-expiratory pressure (PEEP) in" exact="acute respiratory distress syndrome" post="(ARDS) patients to attain lung recruitment while avoiding over-distension"/>
   <result pre="robustness. Methods: In 8 intubated patients, with hypoxemic or hypercapnic" exact="respiratory failure," post="we measured EIT signals at 50 images per second"/>
   <result pre="Germany; 2Swisstom, Chur, Switzerland Introduction: Obstructive airway diseases such as" exact="asthma" post="or COPD are increasing in numbers and frequently lead"/>
   <result pre="opening. Methods: In 12 intubated patients with hypoxemic and/or hypercapnic" exact="respiratory failure" post="we performed EIT and pneumatic volume measurements (Swisstom BB2,"/>
   <result pre="P259 Outcome of patients admitted to the intensive care with" exact="pulmonary fibrosis" post="F. Asota, K. O’Rourke, S. Ranjan, P. Morgan East"/>
   <result pre="the outcomes of patients admitted to the intensive care with" exact="pulmonary fibrosis." post="Numerous studies have demonstrated a poor outcome with patients"/>
   <result pre="with patients admitted to the intensive care unit (ICU) with" exact="pulmonary fibrosis" post="[1-2]. Methods: A computerised hospital database was used to"/>
   <result pre="patients admitted to the ICU at East Surrey Hospital with" exact="pulmonary fibrosis" post="between 2003-2015. Data was analysed using Microsoft Excel 2007"/>
   <result pre="criteria. A control group of patients without a diagnosis of" exact="pulmonary fibrosis" post="was used for comparison (7954). Results showed 54 %"/>
   <result pre="for comparison (7954). Results showed 54 % of patients with" exact="pulmonary fibrosis" post="died before discharge from the unit compared to 18.8"/>
   <result pre="group p = 0.0001 (Table 34). Similarly, 63.3 % of patients with" exact="pulmonary fibrosis" post="died before hospital discharge compared to 26.3 % of"/>
   <result pre="care unit is almost 30 % higher for patients with" exact="pulmonary fibrosis." post="From the data presented above, it may be prudent"/>
   <result pre="above, it may be prudent to consider that patients with" exact="pulmonary fibrosis" post="presenting with no reversible causes of acute respiratory failure"/>
   <result pre="with pulmonary fibrosis presenting with no reversible causes of acute" exact="respiratory failure" post="may be less likely to benefit from admission to"/>
   <result pre="of patients admitted to the ICU for acute exacerbation of" exact="idiopathic pulmonary fibrosis." post="Can Respir J 2004;11: 117-122 2. Bilvet S, Philit"/>
   <result pre="patients admitted to the ICU for acute exacerbation of idiopathic" exact="pulmonary fibrosis." post="Can Respir J 2004;11: 117-122 2. Bilvet S, Philit"/>
   <result pre="2. Bilvet S, Philit F, Sab JM.Outcome of patients with" exact="idiopathic pulmonary fibrosis" post="admitted to ICU for respiratory failure. Chest 2001;120:209-212. Table"/>
   <result pre="Bilvet S, Philit F, Sab JM.Outcome of patients with idiopathic" exact="pulmonary fibrosis" post="admitted to ICU for respiratory failure. Chest 2001;120:209-212. Table"/>
   <result pre="of patients with idiopathic pulmonary fibrosis admitted to ICU for" exact="respiratory failure." post="Chest 2001;120:209-212. Table 34 (Abstract P259). Discharges from unit"/>
   <result pre="and analgesia practice in extra-corporeal membrane oxygenation (ECMO)-treated patients with" exact="acute respiratory distress syndrome" post="(ARDS): a retrospective study J. W. DeBacker 1, E."/>
   <result pre="is a well-established life-saving measure in patients with severe acute" exact="respiratory failure" post="refractory to conventional therapies. There are currently no accepted"/>
   <result pre="months post extra corporeal membrane oxygenation (ECMO) for severe acute" exact="respiratory failure" post="in adult survivors C. Sampson, S. Harris-Fox Glenfield Hospital,"/>
   <result pre="6 months post ECMO. ECMO is used in severe acute" exact="respiratory failure" post="refractory to conventional management. Support entails gas exchange through"/>
   <result pre="USA Introduction: Low tidal volume ventilation improves outcomes in the" exact="acute respiratory distress syndrome," post="but may impair carbon dioxide (CO[sub]2[/sub]) clearance. Extracorporeal carbon"/>
   <result pre="22 ICU mortality, no. 9 P267 New molecular biomarkers of" exact="acute respiratory distress syndrome" post="in abdominal sepsis A. K. Kuzovlev 1, V. Moroz"/>
   <result pre="respiratory distress syndrome (ARDS) is a common complication of nosocomial" exact="pneumonia" post="(NP) in patients with abdominal sepsis. The aim of"/>
   <result pre="Methods: The observational study in ICU ventilated septic patients with" exact="peritonitis" post="(76 %) and pancreonecrosis (24 %) was performed in"/>
   <result pre="of Patras, Rio, Achaia, Greece Introduction: Acute Lung Injury and" exact="acute respiratory distress syndrome" post="(ALI/ARDS) is characterized by tight junction’s (TJ’s) barrier disruption"/>
   <result pre="P269). ᅟ P270 Epidemiological and clinical profile of patients with" exact="acute respiratory distress syndrome" post="in the surgical intensive care unit surgical, hospital JRA,"/>
   <result pre="had a history of ethyl and smoking, 8 % had" exact="asthma" post="and 30 % had no particular experience. In 69"/>
   <result pre="improve the ARDS mortality rate. References Younsuck Koh. Update in" exact="acute respiratory distress syndrome." post="Koh Journal of Intensive Care 2014,2:2 Eric Kipnis.SDRA Aspects"/>
   <result pre="a safe and successful switchover. P274 Epidemiological study of severe" exact="acute pancreatitis" post="in Japan ; comparison of the etiology and the"/>
   <result pre="safe and successful switchover. P274 Epidemiological study of severe acute" exact="pancreatitis" post="in Japan ; comparison of the etiology and the"/>
   <result pre="Tokyo, Japan; 2JSEPTIC Clinical Trial Group, Tokyo, Japan Introduction: Acute" exact="pancreatitis" post="is known to have a variety of causes, but"/>
   <result pre="and severity for each cause remains unknown. Epidemiological studies of" exact="acute pancreatitis" post="have been reported in China and Europe, but these"/>
   <result pre="severity for each cause remains unknown. Epidemiological studies of acute" exact="pancreatitis" post="have been reported in China and Europe, but these"/>
   <result pre="study was a retrospective study. We studied cases of severe" exact="acute pancreatitis" post="in 20 Japanese facilities from January 2009 to December"/>
   <result pre="was a retrospective study. We studied cases of severe acute" exact="pancreatitis" post="in 20 Japanese facilities from January 2009 to December"/>
   <result pre="factors using statistical techniques. Results: The total cases of severe" exact="acute pancreatitis" post="(n = 1159) were divided into gallstone cases (n = 456), alcoholic cases"/>
   <result pre="using statistical techniques. Results: The total cases of severe acute" exact="pancreatitis" post="(n = 1159) were divided into gallstone cases (n = 456), alcoholic cases"/>
   <result pre="total cases of severe acute pancreatitis (n = 1159) were divided into" exact="gallstone" post="cases (n = 456), alcoholic cases (n = 456), idiopathic cases (n = 240), and"/>
   <result pre="in outcome may differ according to the cause of severe" exact="acute pancreatitis." post="There might be a need to examine tailor-made treatments"/>
   <result pre="might be a need to examine tailor-made treatments for severe" exact="acute pancreatitis" post="according to cause. P275 Extracorporeal liver support therapy. Experience"/>
   <result pre="be a need to examine tailor-made treatments for severe acute" exact="pancreatitis" post="according to cause. P275 Extracorporeal liver support therapy. Experience"/>
   <result pre="included in the study (ACLF = 118, ALF = 102). The main aetiology of" exact="cirrhosis" post="in ACLF group was alcohol (91.5 %). The leading"/>
   <result pre="The leading causes of ALF were paracetamol overdose (48 %)," exact="alcoholic hepatitis" post="(31.4 %) and viral hepatitis (11.8 %). ACLF patients"/>
   <result pre="leading causes of ALF were paracetamol overdose (48 %), alcoholic" exact="hepatitis" post="(31.4 %) and viral hepatitis (11.8 %). ACLF patients"/>
   <result pre="were paracetamol overdose (48 %), alcoholic hepatitis (31.4 %) and" exact="viral hepatitis" post="(11.8 %). ACLF patients were significantly more likely to"/>
   <result pre="paracetamol overdose (48 %), alcoholic hepatitis (31.4 %) and viral" exact="hepatitis" post="(11.8 %). ACLF patients were significantly more likely to"/>
   <result pre="known that the risk of hemorrhage in patients with chronic" exact="liver disease" post="is higher compared with general population. However, the evidences"/>
   <result pre="higher compared with general population. However, the evidences between chronic" exact="liver disease" post="and coronary artery disease are inconclusive. We investigated the"/>
   <result pre="the diagnosis of coronary artery disease in patients with chronic" exact="liver disease" post="in Taiwan to evaluate if there is a higher"/>
   <result pre="diagnosed with coronary artery disease. We further identified patients with" exact="liver disease" post="and compared their risk of coronary artery disease with"/>
   <result pre="the general population. Results: We identified 28,511 patients with chronic" exact="liver disease" post="and 728,285 patients without. After controlling for age, gender,"/>
   <result pre="urbanization level, socioeconomic status, diabetes, hypertension, hyperlipidemia, malignancies, heart failure," exact="atrial fibrillation," post="smoking, obesity, peripheral artery disease and Charlson Comorbidity Index"/>
   <result pre="diabetes, hypertension, hyperlipidemia, malignancies, heart failure, atrial fibrillation, smoking, obesity," exact="peripheral artery disease" post="and Charlson Comorbidity Index score, the adjusted hazard ratio"/>
   <result pre="0.74 (95 % confidence interval, 0.65¡X0.84) in patients with chronic" exact="liver disease." post="In subgroup analyses of cirrhotic patients with severe complications,"/>
   <result pre="(hazard ratio, 0.30; 95 % confidence interval, 0.04¡X2.14) Conclusions: Chronic" exact="liver disease" post="may be associated with decreased risk of coronary artery"/>
   <result pre="for liver injury and may lead to intestinal failure associated" exact="liver disease" post="in critical illness N. Lefel, F. Schaap, D. Bergmans,"/>
   <result pre="Van de Poll MUMC, Maastricht, Netherlands Introduction: We hypothesize that" exact="diarrhea" post="can lead to intestinal failure associated liver disease (IFALD)"/>
   <result pre="We hypothesize that diarrhea can lead to intestinal failure associated" exact="liver disease" post="(IFALD) in critical illness. Risk factors for liver injury"/>
   <result pre="cycle also may be an important cause. Diarrhea induces nutrient" exact="malabsorption" post="but may also impair reabsorption of bile acids and"/>
   <result pre="disturbance of the gut-liver axis. Along this line of reasoning" exact="diarrhea" post="may be a hitherto unidentified risk factor for liver"/>
   <result pre="other clinical and biochemical parameters were recorded on the day" exact="diarrhea" post="(&amp;gt;250 ml/day) developed (median at the 2d day of"/>
   <result pre="of ICU admission) and 2 days thereafter. In patients without" exact="diarrhea" post="data were recorded at the day of ICU admission"/>
   <result pre="levels above reference values) on admission or at the moment" exact="diarrhea" post="occurred were excluded. 79 patients remained for analysis (19"/>
   <result pre="Results: In patients who developed liver injury the incidence of" exact="diarrhea" post="(58 %) was higher than in control patients (22"/>
   <result pre="(22 %) p = 0.003, X2-test. Multivariate logistic regression analysis showed that" exact="diarrhea" post="is an independent risk factor for the development of"/>
   <result pre="the hypothesis that disturbance of the liver-gut axis due to" exact="diarrhea" post="and bile salt malabsorption in ICU patients should be"/>
   <result pre="of the liver-gut axis due to diarrhea and bile salt" exact="malabsorption" post="in ICU patients should be regarded as a manifestation"/>
   <result pre="manifestation of intestinal failure, potentially leading to intestinal failure associated" exact="liver disease." post="Future research should be aimed at unraveling mechanisms of"/>
   <result pre="mechanisms of IFALD in ICU patients and at interventions limiting" exact="malabsorption" post="or its consequences for intestinal-hepatic bile salt signaling. P280"/>
   <result pre="salt signaling. P280 Bowel care on the intensive care unit:" exact="constipation" post="guideline compliance and complications K. Tizard, C. Lister, L."/>
   <result pre="ICU patients over a two-months to establish the incidence of" exact="constipation" post="as well as adherence to bowel care guideline. Patients"/>
   <result pre="the 37 patients included, 43 % suffered a period of" exact="constipation" post="during their ICU stay. Treatment for patients who had"/>
   <result pre="initiated in only 44 % of patients. Treatment strategies for" exact="constipation" post="varied and were partially or fully compliant with guidelines"/>
   <result pre="compared with non-constipated patients (35 %). Conclusions: The incidence of" exact="constipation" post="on our unit is decreasing, however it remains a"/>
   <result pre="Y, Abubaker J, Ahmed R. Prophylactic use of laxative for" exact="constipation" post="in critically ill patients. Ann Thorac Med. 2010 Oct-Dec;"/>
   <result pre="have assessed the effect of perioperative n-3 PUFA preventing postoperative" exact="atrial fibrillation" post="(POAF), although their efficacy still remains controversial. Therefore, we"/>
   <result pre="(Abstract P292). Atrial Fibrillation: subgroup analysis P293 Can 5-hydroxytriptophan prevent" exact="post-traumatic stress disorder" post="in critically ill patients? R. Tincu 1, C. Cobilinschi"/>
   <result pre="was the primary outcome; secondary outcomes were overall mortality, ventilator-associated" exact="pneumonia" post="(VAP), diarrhea, ICU length of stay (LOS), and hospital"/>
   <result pre="Foundation, Chiayi County, Taiwan Introduction The relationship between diabetes and" exact="pancreatic cancer" post="has been discussed. However, the effects of diabetes with"/>
   <result pre="Chiayi County, Taiwan Introduction The relationship between diabetes and pancreatic" exact="cancer" post="has been discussed. However, the effects of diabetes with"/>
   <result pre="discussed. However, the effects of diabetes with poor control on" exact="pancreatic cancer" post="have never been evaluated. We address the strength of"/>
   <result pre="However, the effects of diabetes with poor control on pancreatic" exact="cancer" post="have never been evaluated. We address the strength of"/>
   <result pre="address the strength of association for relationship between diabetes and" exact="pancreatic cancer." post="Methods The data from 1,000,000 National Health Insurance beneficiaries"/>
   <result pre="1 January 2005 to 31 December 2012 to evaluate if" exact="pancreatic cancer" post="was diagnosed. Cox regression models were applied to compare"/>
   <result pre="January 2005 to 31 December 2012 to evaluate if pancreatic" exact="cancer" post="was diagnosed. Cox regression models were applied to compare"/>
   <result pre="status, liver cirrhosis, hypertension, coronary artery disease, hyperlipidemia, malignancy, smoking," exact="chronic obstructive pulmonary disease," post="obesity, history of alcohol intoxication, chronic renal insufficiency, biliary"/>
   <result pre="pulmonary disease, obesity, history of alcohol intoxication, chronic renal insufficiency," exact="biliary tract disease," post="chronic pancreatitis and Charlson Comorbidity Index score, the adjusted"/>
   <result pre="of alcohol intoxication, chronic renal insufficiency, biliary tract disease, chronic" exact="pancreatitis" post="and Charlson Comorbidity Index score, the adjusted hazard ratio"/>
   <result pre="and Charlson Comorbidity Index score, the adjusted hazard ratio of" exact="pancreatic cancer" post="was 2.48 (95 % confidence interval, 1.84¡X3.34) in patients"/>
   <result pre="Charlson Comorbidity Index score, the adjusted hazard ratio of pancreatic" exact="cancer" post="was 2.48 (95 % confidence interval, 1.84¡X3.34) in patients"/>
   <result pre="with history of hyperglycemic crisis episodes, the hazard ratio of" exact="pancreatic cancer" post="was significant higher. (hazard ratio, 3.60; 95 % confidence"/>
   <result pre="history of hyperglycemic crisis episodes, the hazard ratio of pancreatic" exact="cancer" post="was significant higher. (hazard ratio, 3.60; 95 % confidence"/>
   <result pre="cohort study provided evidence for the relationship between diabetes and" exact="pancreatic cancer." post="Moreover, diabetes with hyperglycemic crisis episodes is associated with"/>
   <result pre="with hyperglycemic crisis episodes is associated with higher risk of" exact="pancreatic cancer." post="P297 Incidence of hypoglycemia in an intensive care unit"/>
   <result pre="associated with higher risk of pancreatic cancer. P297 Incidence of" exact="hypoglycemia" post="in an intensive care unit depending on insulin protocol"/>
   <result pre="control in an intensive care unit and the incidence of" exact="hypoglycemia" post="depending on insulin protocol. Methods Single-center prospective observational study."/>
   <result pre="glucose value of 70 mg/dL or less was considered moderate" exact="hypoglycemia" post="and 40 mg/dL or less as severe hypoglycemia. SPSS"/>
   <result pre="patients (16,04 %) had at least 1 episode of moderate" exact="hypoglycemia" post="and 7 patients (6,6 %) had severe hypoglycemia. In"/>
   <result pre="40 mg/dL. Depending on insulin protocol, the incidence of moderate" exact="hypoglycemia" post="was 2,88 % in DP, 0,98 % in NDP"/>
   <result pre="in NDP and 0,96 % in IP; and in severe" exact="hypoglycemia" post="was 0,89 % in DP, 0,25 % in NDP"/>
   <result pre="0,21 % in IP. Conclusions As usually the incidence of" exact="hypoglycemia" post="was higher in the diabetic population. With the new"/>
   <result pre="target for glycemic control in intensive therapy, the incidence of" exact="hypoglycemia" post="is now very low in this group. In contrast"/>
   <result pre="glucose variability, especially in moderately to severely ill patients with" exact="glucose intolerance." post="M. Hoshino 1, Y. Haraguchi 2, S. Kajiwara 1,"/>
   <result pre="fully performed. Methods One hundred and forty nine patients with" exact="glucose intolerance" post="were analyzed during 1 week after ICU admission. Studied"/>
   <result pre="0.45, 0.54, 0.62 and 0.70, respectively. Conclusions 1)BG control to" exact="hyperglycemia" post="is one of the measures which bring the reduction"/>
   <result pre="glucose during RI more than 22.525 mg/dl. Only a mild" exact="hypoglycemia" post="event was observed with spontaneously resolved. Otherwise among 8"/>
   <result pre="among 8 participants in failure subgroup, half of them developed" exact="hyperglycemia" post="at 8th hour. This research also found that median"/>
   <result pre="ill patients in Portuguese ICUs and evaluate the incidence of" exact="hyperglycemia" post="and hypoglycemia. Methods Prospective observational study conducted in eleven"/>
   <result pre="Conclusions Using a target glucose level of 180 mg/DL, uncontrolled" exact="hyperglycemia" post="was avoided over 72 %, with fewer hypoglycemic episodes."/>
   <result pre="be diabetic patients should have different targets. P301 Impact of" exact="hyperglycemia" post="duration on the day of operation on short-term outcome"/>
   <result pre="Greece Introduction Aim of this study was to investigate whether" exact="hyperglycemia" post="duration (hours/24 hour cycle) intraoperative and on first ICU"/>
   <result pre="of hyperglycemia. We investigated the possible relationship between duration of" exact="hyperglycemia" post="and the following postoperative complications: Deep sternal wound infection,"/>
   <result pre="need of IV diuretics and RRT requirement. In our study," exact="hyperglycemia" post="has no impact on postoperative sternal wound infections. Table"/>
   <result pre="4 616 (p = 0.03) (p = 0.00) (p = 0.01) (p = 1) P302 Lactate levels in" exact="diabetic ketoacidosis" post="patients at ICU admissions G. Taskin 1, M. Çakir"/>
   <result pre="a life-threatening acute complication of diabetes that presents with high-anion-gap" exact="metabolic acidosis," post="hyperglycemia and ketonemia (1). The aim of this study"/>
   <result pre="acute complication of diabetes that presents with high-anion-gap metabolic acidosis," exact="hyperglycemia" post="and ketonemia (1). The aim of this study is"/>
   <result pre="Cocchi MN, Salciccioli JD, et al. Prevalence and significance of" exact="lactic acidosis" post="in diabetic ketoacidosis. J Crit Care. 2012 April ;"/>
   <result pre="JD, et al. Prevalence and significance of lactic acidosis in" exact="diabetic ketoacidosis." post="J Crit Care. 2012 April ; 27(2): 132–137. P303"/>
   <result pre="April ; 27(2): 132–137. P303 Intensive care implications of merging" exact="heart attack" post="centre units in London J. M. Wong, C. Fitton,"/>
   <result pre="significance. Results The underlying diseases were as follows: sepsis (5)," exact="acute respiratory distress syndrome" post="(3), lethal arrhythmia (2), ileus (1), suffocation (1), amyotrophic"/>
   <result pre="sepsis (5), acute respiratory distress syndrome (3), lethal arrhythmia (2)," exact="ileus" post="(1), suffocation (1), amyotrophic lateral sclerosis (1), sudden unexpected"/>
   <result pre="distress syndrome (3), lethal arrhythmia (2), ileus (1), suffocation (1)," exact="amyotrophic lateral sclerosis" post="(1), sudden unexpected death in epilepsy (1), unknown (4)."/>
   <result pre="suffocation (1), amyotrophic lateral sclerosis (1), sudden unexpected death in" exact="epilepsy" post="(1), unknown (4). The SOFA scores of the FP-group"/>
   <result pre="non-trained students were assessed using a serious game reproducing real-life" exact="cardiac arrest" post="situation (3D real-time simulation software, Stayingalive®, ILUMENS-Dassault system). Primary"/>
   <result pre="time spent to complete the serious game (from onset of" exact="cardiac arrest" post="to shock delivery and recovery). Secondary outcomes included knowledge"/>
   <result pre="of Medical Biostatistics, University of Liège, Belgium Introduction Pediatric out-of-hospital" exact="cardiac arrest" post="(OHCA) is a devastating event with low survival rates,"/>
   <result pre="References 1. Atkins DL et al. Improving outcomes from out-of-hospital" exact="cardiac arrest" post="in young children and adolescents. Pediatr Cardiol. 2012; 33(3):"/>
   <result pre="Germany Introduction Dantrolene is a therapeutic drug for patients with" exact="malignant hyperthermia." post="Interestingly, dantrolene has antiarrhythmic characteristics and might be an"/>
   <result pre="for dantrolene versus amiodarone in a pig model of sustained" exact="cardiac arrest" post="(8 min) under VF. Methods Ventricular fibrillation was induced"/>
   <result pre="Oslo University Hospital, Oslo, Norway Introduction Kidney disease after out-of-hospital" exact="cardiac arrest" post="(OHCA) is previously incompletely described. We examined the occurrence"/>
   <result pre="(OHCA) is previously incompletely described. We examined the occurrence of" exact="chronic kidney disease" post="(CKD) and acute kidney injury (AKI) in OHCA patients,"/>
   <result pre="primary percutaneous coronary intervention (PPCI) following out of the hospital" exact="cardiac arrest" post="K. Hoyland, D. Pandit William Harvey Hospital, Ashford, UK"/>
   <result pre="early PCI improves outcome for non STEMI out of hospital" exact="cardiac arrest" post="(OHCA) patients with suspected cardiac cause [1,2]. Adoption of"/>
   <result pre="2013. Criteria for inclusion of this study were a witnessed" exact="cardiac arrest," post="age greater than 17 years, presumed cardiac origin of"/>
   <result pre="Cerebral oxygen saturation during resuscitation in a porcine model of" exact="cardiac arrest" post="E. Oloktsidou, K. Kotzampassi, B. Fyntanidou, S. Patsatzakis, L."/>
   <result pre="and evaluate NIRS during CPR in a porcine model of" exact="cardiac arrest" post="(CA). Methods 24 pigs under general anesthesia and mechanical"/>
   <result pre="between arterial blood pressure and rSO2 in patients with out-of-hospital" exact="cardiac arrest" post="(OHCA). Methods This study was a prospective observational study"/>
   <result pre="use EEG reactivity as a marker for poor outcome after" exact="cardiac arrest" post="[1]. However, there is no clearly defined protocol how"/>
   <result pre="which stimulus type most effectively evokes a cortical response in" exact="cardiac arrest" post="patients. Methods Prospective cohort study in patients monitored with"/>
   <result pre="Prospective cohort study in patients monitored with continuous EEG after" exact="cardiac arrest" post="in two Dutch ICUs. Twice a day a very"/>
   <result pre="to most effectively evoke a cortical response in patients after" exact="cardiac arrest." post="We suggest integrating this stimulus in the standard set"/>
   <result pre="Med. 2014; 40(12):1816–1831. P317 Prognostic value of neuron-specific enolase after" exact="cardiac arrest" post="F. Ragusa 1, A. Marudi 2, S. Baroni 2,"/>
   <result pre="established as a highly specific predictor of poor outcome after" exact="cardiac arrest" post="but no clear cut-off has been identified. Methods We"/>
   <result pre="cut-off has been identified. Methods We prospectively included all out-of-hospital" exact="cardiac arrest" post="patients admitted in our intensive care unit (ICU) from"/>
   <result pre="Recent guideline suggest to sample NSE at 72 hours after" exact="cardiac arrest." post="Results 132 patients were admitted from 2011 to 2014."/>
   <result pre="NSE serum concentration was sampled at the 3rd days after" exact="cardiac arrest." post="In the first group NSE value was 22.3 mcg/l."/>
   <result pre="NSE could be an important biomarker of poor outcome after" exact="cardiac arrest." post="Further investigation is necessary to clarify timing for sample"/>
   <result pre="findings and serum neuron specific enolase with outcome of post" exact="cardiac arrest" post="patients A. Taha, T. Abdullah, S. Abdel Monem Faculty"/>
   <result pre="Monem Faculty of Medicine Alexandria University, Alexandria, Egypt Introduction Anoxic–ischemic" exact="encephalopathy" post="after cardiac arrest is a common cause of coma"/>
   <result pre="of Medicine Alexandria University, Alexandria, Egypt Introduction Anoxic–ischemic encephalopathy after" exact="cardiac arrest" post="is a common cause of coma requiring intensive care"/>
   <result pre="correlate with poor prognosis. Neuron specific enolase (NSE) released after" exact="cardiac arrest" post="is regarded as a severity indicator of postanoxic neuronal"/>
   <result pre="and outcome scales. Methods 34 Egyptian patients after resuscitation from" exact="cardiac arrest" post="were subjected to, EEG, NSE measurement, and Glasgow outcome"/>
   <result pre="about 30 minutes and repeated on the seventh days after" exact="cardiac arrest." post="EEG classification on days 1 and 7 post-arrest according"/>
   <result pre="will be sampled at both day 1 and 3 after" exact="cardiac arrest." post="Serum concentrations of NSE will be measured using ELISA"/>
   <result pre="&amp;lt;0.001 P319 Introduction of a targeted temperature management strategy following" exact="cardiac arrest" post="in a district general hospital intensive care unit S."/>
   <result pre="unit (ICU) introducing a targeted temperature management (TTM) strategy following" exact="cardiac arrest" post="based on the TTM trial investigation protocol [1], including"/>
   <result pre="[1], including pre- and post-intervention data. Our unit averages 4" exact="cardiac arrest" post="cases a month; at this low frequency, and given"/>
   <result pre="most patients who die during their hospital stay after out-of-hospital" exact="cardiac arrest" post="(OHCA) decease due to post-anoxic neurological injury. Near infrared"/>
   <result pre="and neurological outcomes of therapeutic hypothermia in comatose survivors from" exact="cardiac arrest" post=": 8-year single center experience J. Cholkraisuwat, N. Kongpolprom"/>
   <result pre="neurological outcome and survival in comatose patients with ROSC after" exact="cardiac arrest" post="[1]. Our institute has developed hypothermia protocol and used"/>
   <result pre="P322 Adherence to targeted temperature management after out of hospital" exact="cardiac arrest" post="B. Avard 1, R. Burns 2 1The Canberra Hospital,"/>
   <result pre="Canberra, Australia Introduction Targeted temperature management after out of hospital" exact="cardiac arrest" post="remains a recommended therapeutic approach by the Australian Resuscitation"/>
   <result pre="after return of spontaneous circulation (ROSC) from out of hospital" exact="cardiac arrest," post="collecting data from our electronic medical records system ‘Metavision’"/>
   <result pre="Targeted temperature management at 33 °C versus 36 °C after" exact="cardiac arrest." post="N Engl J Med. 2013; 369(23): 2197-2206. Wise MP,"/>
   <result pre="of a therapeutic hypothermia protocol for comatose survivors of out-of-hospital" exact="cardiac arrest" post="A. Patarchi, T. Spina &quot;Spirito Santo&quot; Hospital, Pescara, Italy"/>
   <result pre="therapeutic hypothermia (MTH) improves neurological outcome and survival after out-of-hospital" exact="cardiac arrest" post="(OOH-CA) from TV/FV [1]. However, this technique is not"/>
   <result pre="320′, bradycardia was common in this phase (6/6), as were" exact="hypokalemia" post="(4/6) and metabolic acidosis (4/6). Mean active rewarming time"/>
   <result pre="common in this phase (6/6), as were hypokalemia (4/6) and" exact="metabolic acidosis" post="(4/6). Mean active rewarming time was 375′. Mild hyperkalemia"/>
   <result pre="of mild therapeutic hypothermia on good neurological recovery after out-of-hospital" exact="cardiac arrest" post="according to location of return of spontaneous circulation: a"/>
   <result pre="Factors associated with ventilator weaning after targeted temperature management for" exact="cardiac arrest" post="patients in japan H. Tanaka, N. Otani, S. Ode,"/>
   <result pre="Lukes International Hospital, Akashi-Chou Chuo-Ku, Japan Introduction Out of hospital" exact="cardiac arrest" post="(OHCA) patients treated with targeted temperature management (TTM) may"/>
   <result pre="S. Prediction protocol for neurological outcome for survivors of out-of-hospital" exact="cardiac arrest" post="treated with targeted temperature management. Resuscitation. 2012; 83(6): 734-739."/>
   <result pre="P326 Monitoring of cTroponin I in patients with acute ischemic" exact="stroke" post="- predictor of inhospital mortality S. Dakova, Z. Ramsheva,"/>
   <result pre="investigate if elevated levels of serum cTnI in acute Ischemic" exact="stroke" post="patients are able to predict higher inhospital mortality. Methods"/>
   <result pre="post conditioning in the hippocampus of a gerbil model of" exact="transient cerebral ischemia" post="J. Cho, J. B. Moon, C. W. Park, T."/>
   <result pre="ischemia neuronal death in the hippocampus following 5 min of" exact="transient cerebral ischemia" post="in gerbils. Methods Animals were randomly assigned to sham-,"/>
   <result pre="prevent hippocampal CA1 pyramidal neurons from neuronal death induced by" exact="transient cerebral ischemia." post="P329 Brain death and admission diagnosis in neurologic intensive"/>
   <result pre="coma for 91(19.6 %), brain trauma for 71(15.3 %), ischemic" exact="stroke" post="for 46 (9.9 %), brain cancers for 9 (1.9"/>
   <result pre="hyperintensity (leukoencephalopathy), three patients showed ischemic lesions and posterior reversible" exact="encephalopathy" post="syndrome findings were evident in three patients. Unexpected findings"/>
   <result pre="poor outcome. P331 Benefits of L-carnitine in valproic acid induced" exact="encephalopathy" post="R. Tincu 1, C. Cobilinschi 1, D. Tomescu 2,"/>
   <result pre="decrease in ammoniac plasma levels, therefore reducing systemic toxicity and" exact="encephalopathy" post="risk. Further controlled, extented trials are required to better"/>
   <result pre="as a predictor of outcome in comatose patients with post-anoxic" exact="encephalopathy" post="[1,2]. However, visual analysis of EEG reactivity has a"/>
   <result pre="testing. References 1. Rossetti, A. O. et al. Prognostication after" exact="cardiac arrest" post="and hypothermia: a prospective study. Annals of Neurology. 2010;"/>
   <result pre="Prognostic value of continuous EEG monitoring during therapeutic hypothermia after" exact="cardiac arrest." post="Critical Care. 2010; 14(5): R173. 3. Westhall, E, et"/>
   <result pre="E, et al. Interrater variability of EEG interpretation in comatose" exact="cardiac arrest" post="patients. Clinical Neurophysiology. 2015; 126(12): 2397-2404. 4. Hermans, MC,"/>
   <result pre="(on either imaging or lumbar puncture) due to a ruptured" exact="cerebral aneurysm" post="(as demonstrated on angiography, neuro-imaging or autopsy). Data Collection:"/>
   <result pre="% of patients), and mostly reserved for patients with significant" exact="anemia" post="(Hb &amp;lt;80 g/L). P337 Aneurysmal subarachnoid hemorrhage and anemia:"/>
   <result pre="Hospital Research Institute, Ottawa, Canada Introduction Little is published about" exact="anemia" post="in aneurysmal subarachnoid hemorrhage (aSAH). We aimed to describe"/>
   <result pre="in Canadian hospitals, and the prevalence and incidence of moderate" exact="anemia" post="(hemoglobin &amp;lt;100 g/L) in preparation for a transfusion trial."/>
   <result pre="(on either imaging or lumbar puncture) due to a ruptured" exact="cerebral aneurysm" post="(as demonstrated on any of angiography, neuro-imaging or autopsy)."/>
   <result pre="by endovascular coiling, and 39.7 % by surgical clipping). Moderate" exact="anemia" post="was prevalent in 29 patients (5.5 %) at admission"/>
   <result pre="g/L, respectively. Within the first 21 days of admission, moderate" exact="anemia" post="occurred in 273 (51.8 %) of patients by median"/>
   <result pre="discharged from hospital with moderate to severe disability. Conclusions Moderate" exact="anemia" post="(hemoglobin &amp;lt;100 g/L) is common in patients admitted with"/>
   <result pre="to ICU and 32 to IMCU. Main diagnoses were supratentorial" exact="meningioma" post="(n = 27) and glioma (n = 20), infratentorial tumor (n = 21) and transsphenoidal"/>
   <result pre="32 to IMCU. Main diagnoses were supratentorial meningioma (n = 27) and" exact="glioma" post="(n = 20), infratentorial tumor (n = 21) and transsphenoidal resection of pituitary"/>
   <result pre="the Transplant Center after transplantation of organs donated by 14" exact="stroke" post="patients with a diagnosis of brain death in our"/>
   <result pre="neurocritical care unit (subarachnoid haemorrhage 7, intracerebral haemorrhage 4, ischemic" exact="stroke" post="3). Overall 29 organs (27 kidneys, 2 livers) were"/>
   <result pre="bioimpedance measurement of healthy and ischaemic rat brain: implications for" exact="stroke" post="imaging using electrical impedance tomography. Physiol. Meas. 36 (2015)"/>
   <result pre="have repeatedly been demonstrated to be poor at identifying structural" exact="heart disease" post="[3]. Syncopal events in such context are associated with"/>
   <result pre="open-ended 14-gauge catheter through the chest wall causes a significant" exact="pneumothorax" post="in a self-ventilating swine model MQ Russell 1, KJ"/>
   <result pre="ultrasound (US) guided study aimed to determine the rate of" exact="pneumothorax" post="progression after 14-gauge (G) cannula insertion in a self-ventilating"/>
   <result pre="in a self-ventilating swine model. Standard treatment of suspected tension" exact="pneumothorax" post="includes emergent insertion of a large bore catheter into"/>
   <result pre="the development of pneumothorax. Lung-point shift was used to track" exact="pneumothorax" post="expansion within pre-mapped numeric chest wall segments. In the"/>
   <result pre="Insertion of an uncapped 14G cannula resulted in a significant" exact="pneumothorax" post="developing in &amp;lt;2 minutes. Each insertion (n = 3) resulted in"/>
   <result pre="replacement of caps and monitoring over 5 mins, no subsequent" exact="pneumothorax" post="or physiological distress were observed, suggesting that the expanding"/>
   <result pre="pneumothorax or physiological distress were observed, suggesting that the expanding" exact="pneumothorax" post="resulted from air entrained via the open ended catheter."/>
   <result pre="had nausea and vomiting (12 %); the same patient had" exact="ptosis" post="and sweating with neck rigidity and back pain (12"/>
   <result pre="no improvement in their symptoms. In addition, all patients received" exact="tetanus" post="toxoid vaccine. Four of the patients required admission (50"/>
   <result pre="objective of the present survey was to identify the ventilator-associated" exact="pneumonia" post="(VAP) risk and prognostic factors among poisoned patients, who"/>
   <result pre="tracheal intubation and mechanical ventilation, with subsequent ICU admission. Severe" exact="hypokalemia" post="was documented (minimum K+ 1.2 mmol/L), complicated by frequent"/>
   <result pre="of serum K+. Clinical improvement ensued with the correction of" exact="hypokalemia" post="and restored muscular function, allowing spontaneous ventilation and extubation"/>
   <result pre="VA, Happ MB. Clinicians’ evaluation and management of mental health," exact="substance abuse," post="and chronic pain conditions in the intensive care unit."/>
   <result pre="has positive effects both on HR and on sepsis induced" exact="pulmonary hypertension." post="The decrease of mSAP was similar in all study"/>
   <result pre="comparison between groups P378 Ketamine for analgosedation in severe hypoxic" exact="respiratory failure" post="S. D. Lee 1, K. Williams 1, I. D."/>
   <result pre="suggests that ketamine may be beneficial for analgosedation in acute" exact="respiratory failure" post="due to bronchospasmolytic and immunomodulatory effects. However, limited data"/>
   <result pre="period we retrospectively identified patients who received ketamine for hypoxic" exact="respiratory failure" post="after admission to critical care. Ketamine dose, mean arterial"/>
   <result pre="the first 5 days of ketamine treatment. Complications (delirium, arrhythmias," exact="malabsorption" post="of feed) were documented. Chest X-ray findings were documented"/>
   <result pre="% died while on Intensive Care. The underlying diagnosis of" exact="respiratory failure" post="included COPD in 14 and severe asthma in 13"/>
   <result pre="diagnosis of respiratory failure included COPD in 14 and severe" exact="asthma" post="in 13 patients. The mean length of stay in"/>
   <result pre="tachycardia. Conclusions Ketamine is safe for analgosedation in severe hypoxic" exact="respiratory failure" post="caused by COPD or asthma. Chest infection was a"/>
   <result pre="at any point, new acute kidney injury (AKI), lactate &amp;gt; =4 or" exact="metabolic acidosis" post="on blood gas analysis and need for high flow"/>
   <result pre="for high flow oxygen at transfer (chi-squared = 19.394, p &amp;lt; 0.00001), detection of" exact="metabolic acidosis" post="on blood gas analysis (chi-squared = 4.764, p = 0.030) and new AKI"/>
   <result pre="this ongoing study. Conclusions: NEWS &amp;gt; =5, new AKI, elevated respiratory rate," exact="metabolic acidosis" post="and a high inspired oxygen fraction requirement are significant"/>
   <result pre="consistent assessment of suitability for ward-based care. P385 Effect of" exact="obesity" post="on mortality in surgical critically ill patients P. Wacharasint"/>
   <result pre="of chronic diseases including diabetes, cardiovascular diseases and cancer. While" exact="obesity" post="itself is a chronic inflammatory condition, previous studies showed"/>
   <result pre="with normal BMI [1]. In surgical critically ill patients whether" exact="obesity" post="confers a &quot;protective&quot; effect is not clearly defined. We"/>
   <result pre="(BMI &amp;lt;18.5), normal BMI (BMI 18.5-24.9), overweight (BMI 25-29.9), and" exact="obesity" post="(BMI &amp;gt;30). Primary outcome was 28-day mortality, and secondary"/>
   <result pre="score (news) reliably improves adverse clinical outcome prediction in community-acquired" exact="pneumonia" post="- results from a 6 year follow-up D. Sbiti-Rohr,"/>
   <result pre="Schuetz Kantonsspital Aarau, Aarau, Switzerland Introduction: Clinical scores such as" exact="pneumonia" post="severity index (PSI) and CURB-65 are recommended for risk"/>
   <result pre="(PSI) and CURB-65 are recommended for risk assessment in community-acquired" exact="pneumonia" post="(CAP). We investigated the prognostic potential of the National"/>
   <result pre="P388 Comparison of mortality prediction scoring systems in patients with" exact="cirrhosis" post="admitted to general intensive care unit M. Cooper 1,"/>
   <result pre="2University of Liverpool, Liverpool, UK Introduction: Mortality of patients with" exact="cirrhosis" post="admitted to the intensive care unit (ICU) has been"/>
   <result pre="with established prediction models. Methods: Data on patients with confirmed" exact="cirrhosis" post="admitted to a general ICU at a major university"/>
   <result pre="years, 66.9 % male). ICU mortality was 54.2 %. Alcoholic" exact="liver disease" post="was the main aetiological factor present in 91.5 %"/>
   <result pre="median 40) were recorded. The main reasons for admission were" exact="respiratory failure" post="(26 %), postoperative care (15.7 %), seisures (11.5 %),"/>
   <result pre="a significantly higher risk of mortality in patients who developed" exact="metabolic acidosis" post="plus hyperlactatemia (OR = 2,98, p-value 0.01). Multiple logistic regression analysis"/>
   <result pre="(OR = 2,98, p-value 0.01). Multiple logistic regression analysis demonstrated that mixed" exact="metabolic acidosis" post="plus respiratory acidosis (OR = 3.19, 95 % CI = 1.48-9.32, p-value = 0.001) and"/>
   <result pre="Conclusions: The results show that in critically septic patients initial" exact="metabolic acidosis" post="and hyperlactatemia are significant predictors of mortality, reinforcing the"/>
   <result pre="mortality. P398 Organizational factors, outcomes and resource use in 9,946" exact="cancer" post="patients admitted to 70 ICUs M Soares 1, U."/>
   <result pre="of organizational factors on the outcomes and resource use in" exact="cancer" post="patients admitted to a large sample of Brazilian ICUs."/>
   <result pre="sample of Brazilian ICUs. Methods: Retrospective cohort study of 9,946" exact="cancer" post="patients (solid = 8,956; hematological = 990) (surgical = 4,929; medical = 5,017) admitted to 70 ICUs"/>
   <result pre="70 ICUs (51 located in general hospitals and 19 in" exact="cancer" post="centers) during 2013. We retrieved clinical and outcome data"/>
   <result pre="located in private hospitals (n = 66, 94 %). Median number of" exact="cancer" post="patients per center was 110 (IQR 58-154), corresponding to"/>
   <result pre="Adjusting for relevant patients’ characteristics (age, MV use, admission diagnosis," exact="cancer" post="type, performance status, comorbidities, neutropenia), the presence of clinical"/>
   <result pre="use (both low SMR and SRU). Admission to ICUs in" exact="cancer" post="centers compared to general hospitals and annual case-volume had"/>
   <result pre="targets to improve mortality and resource use in critically ill" exact="cancer" post="patients. References Funded by IDOR, CNPq and FAPERJ. Endorsed"/>
   <result pre="Cariacica, Brazil Introduction: Cancer has grown steadily in ICU. The" exact="cancer" post="patients are gradually improving the treatment of the underlying"/>
   <result pre="to improve the knowledge of the main clinical outcomes of" exact="cancer" post="patients in the ICU of a large private hospital."/>
   <result pre="a large private hospital. Can we break the paradigm that" exact="cancer" post="patients may have a non-significantly different evolution of a"/>
   <result pre="may have a non-significantly different evolution of a patient without" exact="cancer" post="admitted to the ICU? Methods: We evaluated 2341 patients"/>
   <result pre="there were differences for in-hospital mortality, was more significant for" exact="cancer" post="patients. Conclusions: Oncology patients have the same outcome as"/>
   <result pre="diagnosis of haematological malignancy, were excluded. Demographics, functional status, current" exact="cancer" post="treatment, interventions received, and palliative care team involvement were"/>
   <result pre="accurate prognostic information in the context of critically unwell palliative" exact="cancer" post="patients. Overall ICU mortality was lower than those documented"/>
   <result pre="haematological malignancies admitted to an intensive care unit of a" exact="cancer" post="center D. Mota 1, B. Loureiro 2, J. Dias"/>
   <result pre="patients with FN admitted to an ICU in a comprehensive" exact="cancer" post="center between January, 2011 and December, 2014. Baseline clinical"/>
   <result pre="University for Health Sciences , Riyadh, Saudi Arabia Introduction: Acute" exact="respiratory failure" post="may complicate the course of patients with hematological malignancies"/>
   <result pre="the ICU and 123 (64.7 %) required intubation for acute" exact="respiratory failure." post="These patients had mean age = 56.9 ± 19.6 years and APACHE II"/>
   <result pre="has not been previously well researched. During acute critical illness," exact="alopecia" post="is of minimal concern to an ICU team, as"/>
   <result pre="the primary aim. In the recovery phase of illness however" exact="alopecia" post="can prove distressing. (1) The aim of this study"/>
   <result pre="study was to investigate the incidence and nature of patient-reported" exact="alopecia" post="in a cohort of critical illness survivors. Methods: This"/>
   <result pre="(%) and medians (IQR). Comparisons between patients with and without" exact="alopecia" post="were made using Fisher’s Exact test and Mann Whitney"/>
   <result pre="significant differences were found between the patients with and without" exact="alopecia" post="in the demographic variables. Conclusions: Limited research exists examining"/>
   <result pre="Limited research exists examining the incidence and nature of patient-reported" exact="alopecia" post="in adult survivors of critical illness. The type, amount"/>
   <result pre="warranted. References 1) Bernstein, G.M., Crollick, J.S., Hassett, J.M. Post-febrile" exact="telogen effluvium" post="in critically ill patients. Crit Care Med 1988;16:98–99. 2)"/>
   <result pre="CST due to the severity of their physical debilitation. Anxiety," exact="post-traumatic stress disorder" post="and depression are common psychological problems post discharge (4),"/>
   <result pre="set metrics and there was a reduction in the actual" exact="cardiac arrest" post="rate as against the forecast cardiac arrest rate based"/>
   <result pre="in the actual cardiac arrest rate as against the forecast" exact="cardiac arrest" post="rate based on local historical NCAA data (P &amp;lt; 0.021). There"/>
   <result pre="(dols): audit of compliance in a of a 16-bed specialist" exact="cancer" post="critical care unit. C. Stone, T. Wigmore Royal Marsden"/>
   <result pre="Cerebrovascular disease, Dementia/cognitive impairment, Long term institutionalised mental health, Chronic" exact="liver disease," post="Solid tumours, Hospital stay &amp;gt;5days before critical care review,"/>
   <result pre="most frequent admission diagnosis of LSC limited patients was acute" exact="respiratory failure" post="(51,8% of patients). Non Invasive Ventilation (NIV) use was"/>
   <result pre="elevated SOFA score -OR 1,36 (1.03 - 1.8)- and hypoxemic" exact="respiratory failure" post="–OR 24,8 (3.52 – 175.3). Withdrawal of LSC was"/>
   <result pre="associated with age, acute and preexisting organ failures, and hypoxemic" exact="respiratory failure." post="Life support withdrawal includes NIV terminal weaning and palliative"/>
   <result pre="or initiate cardiopulmonary resuscitation (CPR) in the event of a" exact="cardiac arrest." post="Methods: our critical care nurses suffer when they think"/>
   <result pre="followed withdrawal or withholding of care.11(18% of the dead)had spontaneous" exact="cardiac arrest" post="or `Brain Dead.all patients who had limitation of therapy"/>
   <result pre="disease were excluded as potential kidney donors and patients with" exact="lung disease" post="as potential lung donors. Within the Eurotransplant region, 75"/>
   <result pre="of children with a relative in our ICU. Methods: Practical" exact="aids" post="were developed for our caregivers. An information leaflet was"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC5605151/results/search/disease/results.xml">
   <result pre="Objectives: Here, we evaluate the ability of CPC to disrupt" exact="influenza" post="viruses in vitro and in vivo. Methods: The virucidal"/>
   <result pre="CPC was evaluated against susceptible and oseltamivir- resistant strains of" exact="influenza" post="viruses. The effective virucidal concentration (EC) of CPC was"/>
   <result pre="was evaluated using transmission electron microscopy (TEM). The ability of" exact="influenza" post="virus to develop resistance was evaluated after multiple passaging"/>
   <result pre="the efficacy of CPC in formulation to prevent and treat" exact="influenza" post="infection was evaluated using the PR8 murine influenza model."/>
   <result pre="and treat influenza infection was evaluated using the PR8 murine" exact="influenza" post="model. Results: The virucidal effect of CPC occurred within"/>
   <result pre="ranging between 5 to 20 μg/mL, for most strains of" exact="influenza" post="tested regardless of type and resistance to oseltamivir. Examinations"/>
   <result pre="CPC possesses virucidal activity against susceptible and resistant strains of" exact="influenza" post="virus by targeting and disrupting the viral envelope. Substantial"/>
   <result pre="substantial morbidity and mortality worldwide [ 1 – 5]. Globally," exact="influenza" post="is estimated to adversely affect up to 5% to"/>
   <result pre="20% to 30% of children each year [ 6]. Annual" exact="influenza" post="epidemics in the United States result in nearly 600,000"/>
   <result pre="visits [ 7]; in addition, the total economic burden of" exact="influenza" post="exceeds $80 billion. Current prevention strategies for influenza are"/>
   <result pre="burden of influenza exceeds $80 billion. Current prevention strategies for" exact="influenza" post="are dependent on the use of anti-influenza medications and"/>
   <result pre="are approved in the United States to prevent and treat" exact="influenza" post="[ 8, 9]. However, the use of antiviral medications"/>
   <result pre="14 – 16]. While the most effective way to prevent" exact="influenza" post="disease and its severe outcomes is by vaccination, current"/>
   <result pre="the development of effective novel strategies to prevent and treat" exact="influenza" post="disease is a significant unmet need. Cetylpyridinium chloride (CPC)"/>
   <result pre="viruses. Here, we evaluated CPC efficacy against the prototypical respiratory" exact="influenza" post="virus demonstrating: (1) direct virucidal activity against influenza, (2)"/>
   <result pre="activity following exposure, (3) viral ultrastructure disruption, (4) absence of" exact="influenza" post="resistance following prolonged exposure, and (5) prevention and treatment"/>
   <result pre="resistance following prolonged exposure, and (5) prevention and treatment of" exact="influenza" post="infection in a murine model. MATERIALS AND METHODS Viral"/>
   <result pre="AND METHODS Viral Strains: Influenza strains were obtained from national" exact="influenza" post="repositories: influenza A/Victoria/3/1975 (H3N2), A/Virginia/1/2009 (H1N1), B/Lee/40, oseltamivir-resistant A/"/>
   <result pre="Viral Strains: Influenza strains were obtained from national influenza repositories:" exact="influenza" post="A/Victoria/3/1975 (H3N2), A/Virginia/1/2009 (H1N1), B/Lee/40, oseltamivir-resistant A/ California/08/2009 (H1N1)pdm09"/>
   <result pre="VR-1535, IRR# FR-202, IRR# FR-486), and a clinical strain of" exact="influenza" post="A (H1N1pdm09) virus which was propagated from a patient"/>
   <result pre="50, Prism; v6.0 software). Influenza Cell Culture: Growth of the" exact="influenza" post="virus was performed as previously described [ 31]. Briefly,"/>
   <result pre="MDCK were grown to 90% confluence followed by inoculation with" exact="influenza" post="virus at a multiplicity of infection (MOI) of 0.1"/>
   <result pre="microscopy (TEM): Influenza virus (B/Lee/40) was chosen as a prototypical" exact="influenza" post="virus and was treated with 50 μg/mL CPC for"/>
   <result pre="(LD 50, 8.0 x 10 3 pfu/mouse) with the mouse-adapted" exact="influenza" post="strain A/Puerto Rico/8/1934 H1N1 (PR8, ATCC). Viral stocks were"/>
   <result pre="assessment of therapeutic efficacy of ARMS-I, mice were challenged with" exact="influenza" post="virus as above, and then treated with ARMS-I (10"/>
   <result pre="the percentage effective concentration of CPC (EC 50) against all" exact="influenza" post="viruses ranged between 5 μg/mL and 12.5 μg/mL ("/>
   <result pre="(H1N1:12.5 ± 5.6 μg/mL, H3N2: 10 ± 5.0 μg/mL), whereas" exact="influenza" post="B was significantly more susceptible to the disrupting effects"/>
   <result pre="virucidal concentration (EC 50) and therapeutic index of CPC against" exact="influenza" post="viruses. Virus (ATCC Strain Number) EC 50 (Range) Therapeutic"/>
   <result pre="we observed that CPC conferred a 2 log reduction in" exact="influenza" post="virus by TCID 50 (EC 2log) at ≤20 μg/mL"/>
   <result pre="50 (EC 2log) at ≤20 μg/mL (EC 2log) for all" exact="influenza" post="strains tested. Again, influenza B appeared more susceptible to"/>
   <result pre="≤20 μg/mL (EC 2log) for all influenza strains tested. Again," exact="influenza" post="B appeared more susceptible to CPC than influenza A"/>
   <result pre="tested. Again, influenza B appeared more susceptible to CPC than" exact="influenza" post="A (4 μg/mL vs 20 μg/mL respectively). To assess"/>
   <result pre="assess if the susceptibility to CPC is different in oseltamivir-resistant" exact="influenza" post="strains, we compared the virucidal activity of CPC against"/>
   <result pre="showed that CPC was effective against both susceptible and resistant" exact="influenza" post="strains. Table 1 shows the EC 50 for resistant"/>
   <result pre="influenza strains. Table 1 shows the EC 50 for resistant" exact="influenza" post="A and B viruses were both 8 μg/mL, while"/>
   <result pre="(within minutes of exposure) antiviral activity against susceptible and resistant" exact="influenza" post="virus. Figure 2. Semi-logarithmic time-kill curves of influenza exposed"/>
   <result pre="and resistant influenza virus. Figure 2. Semi-logarithmic time-kill curves of" exact="influenza" post="exposed to EC50 concentrations of CPC at increasing exposure"/>
   <result pre="except for FluB. Isolate 40 is a clinical strain of" exact="influenza" post="A (H1N1pdm09) virus propagated from a patient sample. B)"/>
   <result pre="= 3 experimental replicates. Mechanism of action of CPC against" exact="influenza" post="virus involves rapid disruption of the viral envelope The"/>
   <result pre="the viral envelope The mechanism of action of CPC against" exact="influenza" post="virus was evaluated using time-course and TEM analyses. First,"/>
   <result pre="influenza virus was evaluated using time-course and TEM analyses. First," exact="influenza" post="virus was exposed to CPC for increasing periods of"/>
   <result pre="the remaining intact virus was titered by HA. Exposure of" exact="influenza" post="virus to CPC for more than 5 minutes caused"/>
   <result pre="CPC for 90 minutes led to a 90% decrease in" exact="influenza" post="titer ( Figure 2A). Second, TEM analyses showed that"/>
   <result pre="TEM analyses showed that while the viral envelope of untreated" exact="influenza" post="viruses was intact, exposure to CPC led to disruption"/>
   <result pre="disrupts the integrity of the viral envelope and morphology of" exact="influenza" post="virus. (A) Untreated influenza virus, (B, C) influenza virus"/>
   <result pre="the viral envelope and morphology of influenza virus. (A) Untreated" exact="influenza" post="virus, (B, C) influenza virus treated with 50 μg/mL"/>
   <result pre="morphology of influenza virus. (A) Untreated influenza virus, (B, C)" exact="influenza" post="virus treated with 50 μg/mL CPC for 5 minutes."/>
   <result pre="(9/200) were disrupted. To further confirm that CPC disrupts the" exact="influenza" post="virus envelope, we used ELISA to monitor the release"/>
   <result pre="μg/mL. Taken together, these results demonstrate that CPC acts against" exact="influenza" post="virus by rapid disruption of the viral envelope. Figure"/>
   <result pre="= 8 experimental replicates, shown as mean ± SD. Mean" exact="influenza" post="nucleoprotein levels in the presence of CPC were compared"/>
   <result pre="to CPC does not induce the development of resistance in" exact="influenza" post="virus To evaluate the potential of CPC to induce"/>
   <result pre="To evaluate the potential of CPC to induce drug resistance," exact="influenza" post="virus was exposed to sub-inhibitory concentrations of CPC, and"/>
   <result pre="exposure was determined ( Figure 5). Figure 5. Exposure of" exact="influenza" post="to 3 sub-inhibitory concentrations of CPC for 10 passages"/>
   <result pre="Ten passages, with 3–4 days exposure per passage, of each" exact="influenza" post="strain were performed for all concentrations of CPC. The"/>
   <result pre="change in EC 50) was seen in any strain of" exact="influenza" post="at any tested concentration of CPC, n = 3"/>
   <result pre="This definition is more stringent than that used for other" exact="influenza" post="medications [ 35]. No increase in EC 50 was"/>
   <result pre="CPC for 10 passages that was not significant. Of note," exact="influenza" post="B susceptibility to CPC continued to be comparable to"/>
   <result pre="susceptibility to CPC continued to be comparable to that of" exact="influenza" post="A. These results suggested that CPC has a low"/>
   <result pre="suggested that CPC has a low potential to select for" exact="influenza" post="virus resistance consistent with its mechanism of action. Orally"/>
   <result pre="Orally applied CPC formulation exhibits prophylactic and therapeutic efficacy against" exact="influenza" post="infection in a murine model The clinical formulation of"/>
   <result pre="tested whether ARMS-1 conferred protection from the widely used mouse-adapted" exact="influenza" post="H1N1 strain PR8 [ 36] in both prophylactic and"/>
   <result pre="PR8 [ 36] in both prophylactic and therapeutic models of" exact="influenza" post="infection. Evaluation of the prophylactic efficacy of ARMS-I showed"/>
   <result pre="We found that CPC is active against susceptible and oseltamivir-resistant" exact="influenza" post="strains. CPC disrupted influenza particles rapidly, within minutes of"/>
   <result pre="is active against susceptible and oseltamivir-resistant influenza strains. CPC disrupted" exact="influenza" post="particles rapidly, within minutes of exposure, analogous to CPC's"/>
   <result pre="directly disrupt the membranes and subsequently inhibit infection of pathogenic" exact="influenza" post="viruses. Lastly, we found that the clinical formulation of"/>
   <result pre="Here we demonstrate that the EC 50 of CPC against" exact="influenza" post="viruses is within a clinically meaningful range. All influenza"/>
   <result pre="against influenza viruses is within a clinically meaningful range. All" exact="influenza" post="strains had CPC-associated EC 50 and EC 2log well"/>
   <result pre="MDCK cells consistent with a clinically viable therapeutic index. Interestingly," exact="influenza" post="B had lower EC 50 and EC 2log compared"/>
   <result pre="B had lower EC 50 and EC 2log compared to" exact="influenza" post="A suggesting that this strain is more susceptible to"/>
   <result pre="of CPC. The reasons for this remain unclear as both" exact="influenza" post="A and B derive their envelope from the host"/>
   <result pre="lipid species of the viral envelope revealed subtle differences between" exact="influenza" post="A and B strains [ 39]. As these bilayers"/>
   <result pre="protective signal [ 34]. The virucidal kinetics of CPC against" exact="influenza" post="viruses sensitive or resistant to oseltamivir were similar to"/>
   <result pre="disrupts the viral envelope. Although these experiments were performed using" exact="influenza" post="B as a prototype virus, we expect the results"/>
   <result pre="prototype virus, we expect the results to be similar with" exact="influenza" post="A. This observation is in agreement with the known"/>
   <result pre="common annual epidemic of these viral pathogens in addition to" exact="influenza" post="highlight the unmet need for broad anti-virals. The potential"/>
   <result pre="binding to the microbial lipid bilayer, and CPC acts against" exact="influenza" post="by disrupting the lipid envelope, which is analogous to"/>
   <result pre="unlikely to be influenced by mutation. We have shown that" exact="influenza" post="strains had no significant increase in EC 50 after"/>
   <result pre="in IC 50 [ 43, 44]. However, continued exposure of" exact="influenza" post="to CPC beyond 10 passages should be performed to"/>
   <result pre="in vivo trials in ferrets, another important animal model for" exact="influenza" post="infection, to assess the potential of CPC-based therapies to"/>
   <result pre="to assess the potential of CPC-based therapies to protect against" exact="influenza" post="disease. In conclusion, we demonstrated that CPC shows significant"/>
   <result pre="In conclusion, we demonstrated that CPC shows significant activity against" exact="influenza" post="via direct virucidal activity by disruption of the viral"/>
   <result pre="We submit that CPC has the ability to protect against" exact="influenza" post="respiratory tract infections and should be considered for further"/>
   <result pre="Esper F Cetylpyridinium chloride (CPC) exhibits potent, rapid activity against" exact="influenza" post="viruses in vitro and in vivo . Pathogens and"/>
   <result pre=", Tapper ML , Uyeki TM , Zimmerman RK Seasonal" exact="influenza" post="in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak"/>
   <result pre="Weintraub E , Bridges CB The annual impact of seasonal" exact="influenza" post="in the US: measuring disease burden and costs. Vaccine."/>
   <result pre="C, Prevention. Antiviral agents for the treatment and chemoprophylaxis of" exact="influenza" post="--- recommendations of the Advisory Committee on Immunization Practices"/>
   <result pre="R , Thompson MJ Neuraminidase inhibitors for preventing and treating" exact="influenza" post="in healthy adults and children . Cochrane Database Syst"/>
   <result pre="between adverse clinical outcome in human disease caused by novel" exact="influenza" post="A H7N9 virus and sustained viral shedding and emergence"/>
   <result pre="JA , collab: Centers for Disease C, Prevention. Surveillance of" exact="influenza" post="vaccination coverage--United States, 2007-08 through 2011-12 influenza seasons ."/>
   <result pre="Prevention. Surveillance of influenza vaccination coverage--United States, 2007-08 through 2011-12" exact="influenza" post="seasons . MMWR Surveill Summ. 2013; 62( 4): 1–"/>
   <result pre=", Rivetti A , Di Pietrantonj C Vaccines for preventing" exact="influenza" post="in healthy adults. Cochrane Database Syst Rev. 2014; 3:"/>
   <result pre="Spencer S , Fry AM Interim estimates of 2013-14 seasonal" exact="influenza" post="vaccine effectiveness - United States, february 2014 . MMWR"/>
   <result pre="Vogt T , Town M , Singleton JA Surveillance of" exact="influenza" post="vaccination coverage--United States, 2007-08 through 2011-12 influenza seasons ."/>
   <result pre="JA Surveillance of influenza vaccination coverage--United States, 2007-08 through 2011-12" exact="influenza" post="seasons . MMWR Surveill Summ. 2013; 62( 4): 1–"/>
   <result pre=", Ludwig S , Schughart K Pathogenicity of different PR8" exact="influenza" post="A virus variants in mice is determined by both"/>
   <result pre="HA Lipid composition of viral envelope of three strains of" exact="influenza" post="virus - not all viruses are created equal ."/>
   <result pre="TF , Finberg RW , Wang JP Evolution of the" exact="influenza" post="A virus genome during development of oseltamivir resistance in"/>
   <result pre="IG In vitro generation of neuraminidase inhibitor resistance in A(H5N1)" exact="influenza" post="viruses. Antimicrob Agents Chemother. 2009; 53( 10): 4433– 40."/>
   <result pre="Y , Boivin G Generation and characterization of recombinant pandemic" exact="influenza" post="A(H1N1) viruses resistant to neuraminidase inhibitors . J Infect"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC5683535/results/search/disease/results.xml">
   <result pre="10.1186/s41256-017-0034-y : Research Phylodynamic applications in 21 st century global" exact="infectious disease" post="research http://orcid.org/0000-0001-6088-4651 Rife Brittany D brittany.rife@ufl.edu 1 Mavian Carla"/>
   <result pre="the literature, we discuss the evolution of the field of" exact="infectious disease" post="epidemiology and recent accomplishments, highlighting the advancements in phylodynamics,"/>
   <result pre="are thus often inadequate to investigate the epidemiology of an" exact="infectious disease." post="Putative outbreak investigations typically ensue following case notification of"/>
   <result pre="of epidemiological surveillance and phylodynamic methods employed for control of" exact="infectious disease" post="Despite the limitations to traditional infectious disease epidemiology, major"/>
   <result pre="for control of infectious disease Despite the limitations to traditional" exact="infectious disease" post="epidemiology, major advances in study designs and methods for"/>
   <result pre="and population levels [ 14, 15]. However, many challenges for" exact="infectious disease" post="research remain salient in contemporary molecular epidemiology, such as"/>
   <result pre="[ 16– 18]. An expanded multi-disciplinary approach posits advancement in" exact="infectious disease" post="epidemiology research and control in an era of economic"/>
   <result pre="relationships, or phylodynamics [ 23], offers a unique perspective on" exact="infectious disease" post="epidemiology, enabling researchers to better understand the impact of"/>
   <result pre="enabled evolutionary biologists to gain a higher resolution view of" exact="infectious disease" post="dynamics. The 21 st century, in particular, has witnessed"/>
   <result pre="hypotheses regarding the evolution or epidemiological models used to describe" exact="infectious disease" post="behavior, but because of the intricate relationship of these"/>
   <result pre="the effective population size ( Ne), of fundamental importance to" exact="infectious disease" post="epidemiology, as it describes the level of genetic diversity"/>
   <result pre="of evolutionary datasets for Ebola, Zika, and avian and seasonal" exact="influenza" post="viruses contributed by research groups from all over the"/>
   <result pre="the drug discovery process, which is highly applicable to global" exact="infectious disease" post="research. Without a similar collaborative approach to Synodos, the"/>
   <result pre="met with more realistic models that capture the complexity of" exact="infectious disease" post="transmission. Furthermore, theoretical research in the field of infectious"/>
   <result pre="infectious disease transmission. Furthermore, theoretical research in the field of" exact="infectious disease" post="phylodynamics is still growing. Consequently, there is a need"/>
   <result pre="their application in areas within and outside the realm of" exact="infectious disease." post="For example, in the era of global health, translational"/>
   <result pre="Yersinia pestis genomes reveal the long-term persistence of an historical" exact="plague" post="focus Elife 2016 5 e12994 10.7554/eLife.12994 26795402 30. Min"/>
   <result pre="Cauchemez S et al. Pandemic potential of a strain of" exact="influenza" post="A (H1N1): early findings Science 2009 324 1557 1561"/>
   <result pre="transportation data to predict the global transmission dynamics of human" exact="influenza" post="H3N2 PLoS Pathog 2014 10 e1003932 10.1371/journal.ppat.1003932 24586153 67."/>
   <result pre="high-resolution genetic signature of demographic and spatial expansion in epizootic" exact="rabies" post="virus Proc Natl Acad Sci 2007 104 7993 7998"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC5693564/results/search/disease/results.xml">
   <result pre="most commonly reported symptoms in mild cases, but respiratory distress," exact="kidney failure" post="and septic shock have been reported in acute cases"/>
   <result pre="SD Weber DJ Transmission of SARS and MERS coronaviruses and" exact="influenza" post="virus in healthcare settings: the possible role of dry"/>
   <result pre="al. Genomic characterization of a newly discovered coronavirus associated with" exact="acute respiratory distress syndrome" post="in humans MBio 2012 3 e00473 12 23170002 54."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC5735522/results/search/disease/results.xml">
   <result pre="flaviviruses such as dengue (DENV), West Nile (WNV), and Japanese" exact="encephalitis" post="viruses (JEV) [ 14, 15]. ZIKV has a positive-sense,"/>
   <result pre="Martin, 2013 EVAg ZIKV Zika virus, DENV dengue virus, YFV" exact="yellow fever" post="virus, WNV West Nile virus, CHIKV Chikungunya virus, N/A"/>
   <result pre="in a field test carried out in Vietnam for monitoring" exact="avian influenza" post="A viruses in poultry markets. Test results using a"/>
   <result pre="a field test carried out in Vietnam for monitoring avian" exact="influenza" post="A viruses in poultry markets. Test results using a"/>
   <result pre="influenza A viruses in poultry markets. Test results using a" exact="influenza" post="A RT-iiPCR reagent set were comparable to those of"/>
   <result pre="threshold DENV Dengue virus IVT In vitro transcribed JEV Japanese" exact="encephalitis" post="virus MERS-CoV Middle East respiratory syndrome coronavirus ORF Open"/>
   <result pre="Chai HC Development of insulated isothermal PCR for rapid on-site" exact="malaria" post="detection Malar J 2016 15 134 137 10.1186/s12936-016-1183-z 26931146"/>
   <result pre="duplex real-time RT-PCR test for the detection of porcine epidemic" exact="diarrhea" post="virus and porcine deltacoronavirus J Virol Methods 2016 234"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC5765694/results/search/disease/results.xml">
   <result pre="clinical symptoms vary from upper respiratory tract infection to severe" exact="bronchiolitis" post="with respiratory insufficiency for which mechanical ventilation is needed."/>
   <result pre="young children, no antivirals, vaccines, or other targeted treatments for" exact="bronchiolitis" post="have proven to be beneficial yet, and therefore, only"/>
   <result pre="environmental factors plays a role in the pathogenesis of RSV" exact="bronchiolitis" post="[ 4– 6]. To date, it is thought that"/>
   <result pre="absence of cytotoxic CD8 cells in fatal cases of RSV" exact="bronchiolitis" post="and the presence of massive influx of neutrophils in"/>
   <result pre="of these bacterial products [ 22]. Findings from the MARC-35" exact="bronchiolitis" post="cohort by Mansbach and coworkers, a prospective study of"/>
   <result pre="in this study predominantly belongs to the species of Haemophilus" exact="influenza" post="(Additional file 2: Figure S7) . The top 10"/>
   <result pre="fraction of Haemophilus-assigned reads, could confidently be assigned to H." exact="influenza" post="(27.7% of all reads in this study). Other candidate"/>
   <result pre="to microbiota composition. Discussion Understanding why some children develop severe" exact="bronchiolitis" post="while most children experience an upper respiratory tract infection"/>
   <result pre="by Hasegawa and coworkers, our study exclusively focused on RSV-implicated" exact="bronchiolitis" post="[ 29, 30]. RSV disease severity is a multifactorial"/>
   <result pre="year) [ 31] and after administration of an intranasal live-attenuated" exact="influenza" post="vaccine in adults [ 32]. Both studies were performed"/>
   <result pre="other bacteria, such as Moraxella [ 30]. In the MARC-35" exact="bronchiolitis" post="cohort by Mansbach and coworkers, lower levels of Haemophilus/"/>
   <result pre="a few studies describing the association of Achromobacter xyloxosidans with" exact="pneumonia" post="in newborns and young infants, and chronic infection in"/>
   <result pre="pneumonia in newborns and young infants, and chronic infection in" exact="cystic fibrosis" post="patients, not much is known about this species ["/>
   <result pre="Interaction of Haemophilus with epithelial cells may lead to the" exact="suppression" post="of anti-viral immune pathways allowing increased replication. An alternative"/>
   <result pre="obtained from all parents. Because the peak incidence of (severe)" exact="bronchiolitis" post="is below the age of 6 months, and to"/>
   <result pre="admitted to the hospital for surgery, who needed an elective" exact="inguinal hernia" post="correction and had no signs of respiratory infection and"/>
   <result pre="to the hospital for surgery, who needed an elective inguinal" exact="hernia" post="correction and had no signs of respiratory infection and"/>
   <result pre="this study. Patients younger than 6 months with PCR-confirmed RSV-positive" exact="bronchiolitis" post="were selected and divided into three groups. Children without"/>
   <result pre="ill’ children required mechanical ventilation. Patients with congenital heart or" exact="lung disease," post="immunodeficiency, or glucocorticoid use were excluded. Within 24 h"/>
   <result pre="were analyzed by multiplex PCR, quantifying 15 different viral pathogens:" exact="influenza" post="virus types A and B, coronavirus 229E and OC43,"/>
   <result pre="2009 360 6 588 598 19196675 3. Meissner HC Viral" exact="bronchiolitis" post="in children N Engl J Med 2016 374 1"/>
   <result pre="lower respiratory tract illness caused by respiratory syncytial virus and" exact="influenza" post="virus is characterized by the absence of pulmonary cytotoxic"/>
   <result pre="Mansbach JM et al. Respiratory syncytial virus and rhinovirus severe" exact="bronchiolitis" post="are associated with distinct nasopharyngeal microbiota J Allergy Clin"/>
   <result pre="Hasegawa K et al. Nasal airway microbiota profile and severe" exact="bronchiolitis" post="in infants: a case-control study Pediatr Infect Dis J"/>
   <result pre="Hasegawa K et al. Association of nasopharyngeal microbiota profiles with" exact="bronchiolitis" post="severity in infants hospitalised for bronchiolitis Eur Respir J"/>
   <result pre="nasopharyngeal microbiota profiles with bronchiolitis severity in infants hospitalised for" exact="bronchiolitis" post="Eur Respir J 2016 48 5 1329 1339 27799386"/>
   <result pre="Tarabichi Y et al. The administration of intranasal live attenuated" exact="influenza" post="vaccine induces changes in the nasal microbiota and nasal"/>
   <result pre="in respiratory syncytial virus resembles profile associated with increased childhood" exact="asthma" post="risk Am J Respir Crit Care Med 2016 193"/>
   <result pre="in the lower respiratory tracts of neonates with bacterial infectious" exact="pneumonia" post="combined with ventilator-associated pneumonia Mol Med Rep 2016 14"/>
   <result pre="tracts of neonates with bacterial infectious pneumonia combined with ventilator-associated" exact="pneumonia" post="Mol Med Rep 2016 14 6 5223 5230 27779696"/>
   <result pre="Lambiase A et al. Achromobacter xylosoxidans respiratory tract infection in" exact="cystic fibrosis" post="patients Eur J Clin Microbiol Infect Dis 2011 30"/>
   <result pre="37. Rajan S Saiman L Pulmonary infections in patients with" exact="cystic fibrosis" post="Semin Respir Infect 2002 17 1 47 56 11891518"/>
   <result pre="microbiome impacts severity of lower respiratory infection and risk of" exact="asthma" post="development Cell Host Microbe 2015 17 5 704 715"/>
   <result pre="nasopharyngeal CCL5 and microbiota on disease severity among infants with" exact="bronchiolitis" post="Allergy 2017 72 11 1796 1800 28306146 45. Vissers"/>
   <result pre="method using multiplex real-time PCR for diagnosis of infections by" exact="influenza" post="a and influenza B viruses, respiratory syncytial virus, and"/>
   <result pre="real-time PCR for diagnosis of infections by influenza a and" exact="influenza" post="B viruses, respiratory syncytial virus, and parainfluenza viruses 1,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC5819479/results/search/disease/results.xml">
   <result pre="Background and Summary Infections due to RNA viruses such as" exact="influenza" post="virus, measles virus, HIV-1 and rotavirus impose a huge"/>
   <result pre="Summary Infections due to RNA viruses such as influenza virus," exact="measles" post="virus, HIV-1 and rotavirus impose a huge public health"/>
   <result pre="include subtypes known to have different levels of transmissibility, e.g." exact="influenza" post="A, the highest level is assigned. The distribution of"/>
   <result pre="epidemiology of subtypes of Influenza A virus: contrast the human" exact="influenza" post="viruses such as H1N1 and H3N2 with avian influenza"/>
   <result pre="the human influenza viruses such as H1N1 and H3N2 with" exact="avian influenza" post="viruses such as H5N1 and H7N9 that only occasionally"/>
   <result pre="human influenza viruses such as H1N1 and H3N2 with avian" exact="influenza" post="viruses such as H5N1 and H7N9 that only occasionally"/>
   <result pre="( 2013). Hay S. I. et al. Global mapping of" exact="infectious disease." post="Philos. Trans. R. Soc. B 368, 20120250 ( 2013)."/>
   <result pre="M. The global mammal parasite database: an online resource for" exact="infectious disease" post="records in wild primates . Evol. Anthropol. 14, 1–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6043914/results/search/disease/results.xml">
   <result pre="a range of viruses. For example, the viruses included were" exact="hepatitis" post="C virus and hepatitis B virus (Mike Sofia), HIV"/>
   <result pre="For example, the viruses included were hepatitis C virus and" exact="hepatitis" post="B virus (Mike Sofia), HIV and hepatitis B virus"/>
   <result pre="C virus and hepatitis B virus (Mike Sofia), HIV and" exact="hepatitis" post="B virus (David Chu), multiple antiviral projects (Maaike Everts),"/>
   <result pre="be in Porto, Portugal, 11–15 June 2018. Antiviral therapy HIV" exact="hepatitis" post="C virus rhinovirus C Zika virus Introduction This article"/>
   <result pre="spectrum of antiviral research. Gertrude Elion Memorial Award Lecture: Viral" exact="hepatitis" post="– The search for a cure Michael (Mike) J"/>
   <result pre="presented to Michael Sofia by ISAR President, José Esté. Viral" exact="hepatitis" post="is a major, worldwide clinical problem, with about 170"/>
   <result pre="worldwide clinical problem, with about 170 million chronically infected with" exact="hepatitis" post="C virus (HCV) and 350 million with hepatitis B"/>
   <result pre="infected with hepatitis C virus (HCV) and 350 million with" exact="hepatitis" post="B virus (HBV). In the USA, during the period"/>
   <result pre="USA, during the period 1999–2007, the burden of mortality with" exact="viral hepatitis" post="due to HBV had been falling steadily (from six"/>
   <result pre="during the period 1999–2007, the burden of mortality with viral" exact="hepatitis" post="due to HBV had been falling steadily (from six"/>
   <result pre="– African Americans, in cirrhotic patients, in those with decompensated" exact="liver disease" post="and in liver transplant patients. To date, there have"/>
   <result pre="two other herpesviruses, Epstein–Barr virus (EBV, glandular fever/infectious mononucleosis) and" exact="herpes simplex" post="virus type 1 (cold sores). Against these herpesviruses, l-BHDU"/>
   <result pre="important toxicity issue when BVdU and 5-FU were co-administered to" exact="cancer" post="patients. In a VZV animal model, l-BHDU (150 mg/kg)"/>
   <result pre="did not inhibit cell replication at &amp;gt;100 µM. Against woodchuck" exact="hepatitis" post="virus (WHV) in woodchucks (n = 4/group), l-FMAU (clevudine) at various"/>
   <result pre="region of E from dengue, Zika, West Nile and Japanese" exact="encephalitis" post="viruses, the compounds were tested for activity against these"/>
   <result pre="(VP-1, 2, 3 and 4). Following the outbreak of a" exact="severe acute respiratory syndrome," post="which was shown to be caused by a coronavirus"/>
   <result pre="RV-C has been shown to be the primary cause of" exact="asthma" post="exacerbations and viral pneumonia in infants. In a clinical"/>
   <result pre="shown to be the primary cause of asthma exacerbations and" exact="viral pneumonia" post="in infants. In a clinical study, RV-C was detected"/>
   <result pre="to be the primary cause of asthma exacerbations and viral" exact="pneumonia" post="in infants. In a clinical study, RV-C was detected"/>
   <result pre="clinical study, RV-C was detected in 60% of children with" exact="asthma" post="exacerbations versus 24% with either RV-A or RV-B, 14%"/>
   <result pre="CDHR3 was reported to be an important susceptibility gene for" exact="asthma" post="exacerbations, which are one of the most frequent causes"/>
   <result pre="parents (homozygous for Tyr 529), have 5–10-fold higher risk for" exact="asthma" post="exacerbations and hospitalisation than those with only Cys 529"/>
   <result pre="intermediate risk. In this study, the proportions of patients with" exact="asthma" post="were 67, 3 and 29%, respectively. The CDHR3 Tyr"/>
   <result pre="of Wisconsin-Madison. For his postdoctoral fellowship (1984), he studied persistent" exact="measles" post="infections at the Rockefeller University in New York. Currently,"/>
   <result pre="comparison, this mutation rate is faster than that for HIV," exact="influenza" post="viruses and HCV, viruses generally considered to be rapidly"/>
   <result pre="deficiency can lead to prolonged virus shedding (&amp;gt;6 months) but" exact="severe combined immunodeficiency" post="(SCID) and common variable immunodeficiency (CVID) can result in"/>
   <result pre="virus shedding (&amp;gt;6 months) but severe combined immunodeficiency (SCID) and" exact="common variable immunodeficiency" post="(CVID) can result in chronic shedding (&amp;gt;5 years). One"/>
   <result pre="antiviral therapies for flaviviruses, there are some vaccines, for example," exact="yellow fever" post="virus vaccine. This suggests that a vaccine for Zika"/>
   <result pre="study identifies CDHR3 as a susceptibility locus for early childhood" exact="asthma" post="with severe exacerbations . Nat Genet 2014; 46: 51–"/>
   <result pre="27815125 8 Vere Hodge RA Field HJ. Antiviral agents for" exact="herpes simplex" post="virus. Adv Pharmacol 2013; 67: 1– 38. 23885997"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6156540/results/search/disease/results.xml">
   <result pre="into the human population. While the occurrence of a future" exact="influenza" post="pandemic is almost certain, it is impossible to predict"/>
   <result pre="in 2009 but caused relatively mild symptoms and the 1918" exact="influenza" post="A H1N1 pandemic (&quot;Spanish flu&quot;) on the other hand,"/>
   <result pre="of around 50 million people ( 1). Currently licensed seasonal" exact="influenza" post="vaccines are specific for pre-defined viral strains and are"/>
   <result pre="Hence, new vaccine technologies able to induce broad protection against" exact="influenza" post="A viruses are urgently required. Severe acute respiratory syndrome"/>
   <result pre="in the last decades: according to the WHO, cases of" exact="dengue fever" post="have risen 30-fold in the past 50 years. Zika"/>
   <result pre="of Zika in South America, with over 4,000 cases of" exact="microcephaly" post="led to the declaration of a Public Health Emergency"/>
   <result pre="MDR organisms, such as methicillin-resistant Staphylococcus aureus (MRSA) or multidrug-resistant" exact="tuberculosis" post="(MDR-TB) are becoming a serious threat to global public"/>
   <result pre="for SARS and MERS CoV. The outbreaks caused by pandemic" exact="influenza" post="virus demonstrate the potential of a known pathogen to"/>
   <result pre="known and vaccine manufacturing technologies are established, like for pandemic" exact="influenza" post="vaccine, production capacity to meet peak demands during a"/>
   <result pre="coordinated by the WHO, the potential production capacity for pandemic" exact="influenza" post="vaccines in 2015 could in theory support the vaccination"/>
   <result pre="according to a survey made in 2015, only 5% of" exact="influenza" post="vaccine doses were distributed among Southeast Asia, Eastern Mediterranean,"/>
   <result pre="vaccines would take 5–3 months between identification of a pandemic" exact="influenza" post="and vaccine distribution, which would give a pandemic virus"/>
   <result pre="or 26; ChAd, chimpanzee adenovirus; HIV, human immunodeficiency virus; H5N1," exact="influenza" post="H5N1; H1N1 pdm09, influenza H1N1 2009 &quot;swine flu&quot;; H10N8,"/>
   <result pre="adenovirus; HIV, human immunodeficiency virus; H5N1, influenza H5N1; H1N1 pdm09," exact="influenza" post="H1N1 2009 &quot;swine flu&quot;; H10N8, influenza H10N8; DNA, deoxyribonucleic"/>
   <result pre="influenza H5N1; H1N1 pdm09, influenza H1N1 2009 &quot;swine flu&quot;; H10N8," exact="influenza" post="H10N8; DNA, deoxyribonucleic acid based vaccine, MVA, modified vaccinia"/>
   <result pre="modified vaccinia Ankara; RNA, ribonucleic acid based vaccine; VSV, vesicular" exact="stomatitis" post="virus; HPIV3, human parainfluenza virus type 3; MV, measles"/>
   <result pre="vesicular stomatitis virus; HPIV3, human parainfluenza virus type 3; MV," exact="measles" post="virus. Viral vector based vaccines Viral vector based vaccines,"/>
   <result pre="adeno-associated viruses, AAV), togaviruses (e.g., Semliki Forest virus), paramyxoviruses (e.g.," exact="measles" post="virus, Newcastle disease virus or human parainfluenza virus), rhabdoviruses"/>
   <result pre="Newcastle disease virus or human parainfluenza virus), rhabdoviruses (e.g., vesicular" exact="stomatitis" post="virus, VSV), and poxviruses (e.g., Modified vaccinia Ankara, MVA)."/>
   <result pre="will only describe some commonly used viral vectors, i.e., adenovirus," exact="measles" post="virus, and VSV in some detail, whose use in"/>
   <result pre="restrict availability of manufacturing facilities in an outbreak setting. Recombinant" exact="measles" post="viruses are able to induce high levels of both"/>
   <result pre="Dengvaxia, which is a recombinant Dengue vaccine based on the" exact="yellow fever" post="attenuated strain 17D, has been licensed for human use."/>
   <result pre="parainfluenza virus type 3 (HPIV3), recombinant cytomegalovirus (rCMV), and recombinant" exact="rabies" post="virus (RABV). Clinical trials were conducted for VSV-EBOV, ChAd3"/>
   <result pre="GP EBOV (1995) Safety: Mild adverse events, no cases of" exact="arthritis" post="Immunogenicity: - Antibody titers in all participants by day"/>
   <result pre="higher: - Arthralgia in 22% (11/51) participants of Geneva cohort;" exact="arthritis" post="confirmed in 9/ 11 cases; maculopapular rash in 27%"/>
   <result pre="of Geneva cohort; arthritis confirmed in 9/ 11 cases; maculopapular" exact="rash" post="in 27% (3/11) of these cases - Self-limiting cases"/>
   <result pre="in 27% (3/11) of these cases - Self-limiting cases of" exact="arthritis" post="in 3.4% (2/60) participants in Germany and Kenya cohort"/>
   <result pre="Unit; SUDV, Sudan virus; VNT, virus neutralization titers; VSV, vesicular" exact="stomatitis" post="virus; VP, viral particles. * Boost with MVA based"/>
   <result pre="10 7 PFU or higher were associated with the development" exact="arthritis" post="lasting a median of 8 days. In addition, some"/>
   <result pre="days. In addition, some participants experiencing arthralgia developed a maculopapular" exact="rash" post="indicative of VSV replication and dissemination. Following this, the"/>
   <result pre="participants but only mild adverse events without further cases of" exact="arthritis" post="( 73). A phase II/III clinical trial (NCT02378753) was"/>
   <result pre="against a large variety of human pathogens such as HIV," exact="influenza" post="virus, malaria, hepatitis B virus, respiratory syncytial and herpes"/>
   <result pre="variety of human pathogens such as HIV, influenza virus, malaria," exact="hepatitis" post="B virus, respiratory syncytial and herpes simplex virus. No"/>
   <result pre="HIV, influenza virus, malaria, hepatitis B virus, respiratory syncytial and" exact="herpes simplex" post="virus. No DNA based vaccine is licensed for human"/>
   <result pre="inhibition; ID, intradermal; IL-12, interleukin 12; IM, intramuscular; JEV, Japanese" exact="encephalitis" post="virus; M2, ion channel protein influenza; MARV, Marburg virus;"/>
   <result pre="assessed the ability of DNA vaccines to mediated protection against" exact="influenza" post="viruses, either alone or as part of prime boost"/>
   <result pre="tested a vaccine that targets the highly pathogenic avian H5N1" exact="influenza" post="endemic in poultry. Its ability to cross the species"/>
   <result pre="and trivalent groups, respectively. Upon emergence of a novel H1N1" exact="influenza" post="that originated in pigs and became pandemic in humans"/>
   <result pre="whose GMP production was finalized 2 months before licensed monovalent" exact="influenza" post="vaccines became available ( 101) (Table 2). However, 4"/>
   <result pre="to 72%, 4 weeks after boosting with a licensed monovalent" exact="influenza" post="vaccine. Based on results gained at this point, the"/>
   <result pre="support the use of DNA-based vaccines for controlling a potential" exact="influenza" post="pandemic by employing DNA as an initial priming agent,"/>
   <result pre="as an initial priming agent, followed by boosting with conventional" exact="influenza" post="vaccines upon availability. DNA based vaccines were among the"/>
   <result pre="regions (VRC5288) were exchanged with the corresponding sequences from Japanese" exact="encephalitis" post="virus (JEV). Both vaccine candidates are evaluated in clinical"/>
   <result pre="(ARCA) in the reaction ( 115), or subsequently, using the" exact="vaccinia virus" post="capping complex ( 116). The UTRs, which can be"/>
   <result pre="and capable of inducting protection against lethal challenge infections with" exact="influenza" post="or rabies virus in several animal models ( 124,"/>
   <result pre="of inducting protection against lethal challenge infections with influenza or" exact="rabies" post="virus in several animal models ( 124, 151). Using"/>
   <result pre="nucleoside-modified mRNA-LNP vaccines against the Zika virus, as well as" exact="influenza" post="A H10N8 and H7N9 viruses proved to be immunogenic"/>
   <result pre="163). Single IM immunization of NHPs with LNP-formulated mRNAs encoding" exact="rabies" post="or influenza antigens induced protective antibody titers, which could"/>
   <result pre="IM immunization of NHPs with LNP-formulated mRNAs encoding rabies or" exact="influenza" post="antigens induced protective antibody titers, which could be boosted"/>
   <result pre="to antibody responses elicited by a modified non-replicating mRNA encoding" exact="influenza" post="A H10 HA encapsulated in LNPs showed that, while"/>
   <result pre="ID delivery generated this response more rapidly ( 168). Circulating" exact="influenza" post="H10-specific memory B cells expanded after each of the"/>
   <result pre="shown to correlate with high avidity antibody responses after seasonal" exact="influenza" post="vaccination in humans. In addition, a non-replicating sequence optimized"/>
   <result pre="mRNA vaccine induced long-lived functional antibody responses against HA of" exact="influenza" post="A H1N1pdm in NHPs which persisted for one year"/>
   <result pre="potential ( 162, 173– 176). Self-amplifying mRNA vaccines encoding various" exact="influenza" post="antigens complexed with LNP or oil-in-water cationic nanoemulsions (CNE)"/>
   <result pre="containment of viral replication in the upper respiratory tract upon" exact="influenza" post="infection and conferred protection against homologous and heterosubtypic viral"/>
   <result pre="nanoparticle (MDNP)-based RNA replicon vaccine platform provides protection against lethal" exact="influenza" post="and Ebola virus infections and elicits antibody and CD8"/>
   <result pre="that ID administration of protamine-complexed non-replicating sequence-optimized mRNA vaccines encoding" exact="influenza" post="HA was protective in mice upon homologous challenge with"/>
   <result pre="influenza HA was protective in mice upon homologous challenge with" exact="influenza" post="H1N1, H3N2, and H5N1 and was immunogenic in ferrets"/>
   <result pre="nucleotides, that encoded for HA proteins of the potentially pandemic" exact="influenza" post="A subtypes H10N8 or H7N9 ( 159). A single"/>
   <result pre="vaccines for human use and clinical trials testing vaccines against" exact="influenza" post="and Zika have furthermore highlighted the speed of vaccine"/>
   <result pre=". Updating the accounts: global mortality of the 1918-1920 &quot;Spanish&quot;" exact="influenza" post="pandemic. Bull Hist Med. ( 2002) 76: 105– 15."/>
   <result pre="al. . Identification of a novel coronavirus in patients with" exact="severe acute respiratory syndrome." post="N Engl J Med. ( 2003) 348: 1967– 76."/>
   <result pre="Peiris JS Yuen KY Osterhaus AD Stohr K . The" exact="severe acute respiratory syndrome." post="N Engl J Med. ( 2003) 349: 2431– 41."/>
   <result pre="from a Phase 3 clinical trial of a live-attenuated chimeric" exact="yellow fever" post="tetravalent dengue vaccine . Hum Vaccin Immunother. ( 2018)"/>
   <result pre=". The 2015 global production capacity of seasonal and pandemic" exact="influenza" post="vaccine. Vaccine ( 2016) 34: 5410– 3. 10.1016/j.vaccine.2016.08.019 27531411"/>
   <result pre="Toth K . Adenovirus vectors for gene therapy, vaccination and" exact="cancer" post="gene therapy. Curr Gene Ther. ( 2013) 13: 421–"/>
   <result pre="Hangartner L Caballero M Pavlovic J et al. . Attenuated" exact="measles" post="virus as a vaccine vector. Vaccine ( 2007) 25:"/>
   <result pre="N Jacobson RM Vierkant RA Poland GA . Frequency of" exact="measles" post="virus-specific CD4+ and CD8+ T cells in subjects seronegative"/>
   <result pre="CD8+ T cells in subjects seronegative or highly seropositive for" exact="measles" post="vaccine . Clin Diagn Lab Immunol. ( 2003) 10:"/>
   <result pre="6. 10.1128/CDLI.10.3.411-416.2003 12738640 35. Muhlebach MD . Vaccine platform recombinant" exact="measles" post="virus. Virus Genes ( 2017) 53: 733– 40. 10.1007/s11262-017-1486-3"/>
   <result pre="E Tangy F Herman P . Biosafety considerations for attenuated" exact="measles" post="virus vectors used in virotherapy and vaccination . Hum"/>
   <result pre="ND Stillman EA Whitt MA Rose JK . Recombinant vesicular" exact="stomatitis" post="viruses from DNA. Proc Natl Acad Sci USA. ("/>
   <result pre="Den Pol AN Davis JN . Highly attenuated recombinant vesicular" exact="stomatitis" post="virus VSV-12'GFP displays immunogenic and oncolytic activity . J"/>
   <result pre="Draper K et al. . Neurovirulence properties of recombinant vesicular" exact="stomatitis" post="virus vectors in non-human primates . Virology ( 2007)"/>
   <result pre="et al. . Live virus vaccines based on a vesicular" exact="stomatitis" post="virus (VSV) backbone: standardized template with key considerations for"/>
   <result pre="Garg SJ Tucker SN . High titre neutralising antibodies to" exact="influenza" post="after oral tablet immunisation: a phase 1, randomised, placebo-controlled"/>
   <result pre=". Oral administration of an adenovirus vector encoding both an" exact="avian influenza" post="A hemagglutinin and a TLR3 ligand induces antigen specific"/>
   <result pre="Oral administration of an adenovirus vector encoding both an avian" exact="influenza" post="A hemagglutinin and a TLR3 ligand induces antigen specific"/>
   <result pre=". Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored" exact="malaria" post="vaccines adjuvanted with Matrix-M . Vaccine ( 2017) 35:"/>
   <result pre="P Wagner R et al. . Properties of replication-competent vesicular" exact="stomatitis" post="virus vectors expressing glycoproteins of filoviruses and arenaviruses ."/>
   <result pre="Martellaro C Kobinger G Feldmann H . Efficacy of vesicular" exact="stomatitis" post="virus-Ebola virus postexposure treatment in Rhesus Macaques infected With"/>
   <result pre="Castellano AR Hu Z et al. . A recombinant vesicular" exact="stomatitis" post="virus Ebola vaccine. N Engl J Med. ( 2017)"/>
   <result pre="Rusalov D Geall A Enas J et al. . Vaxfectin-formulated" exact="influenza" post="DNA vaccines encoding NP and M2 viral proteins protect"/>
   <result pre="protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1)" exact="influenza" post="virus . J Infect Dis. ( 2008) 197: 1643–"/>
   <result pre="Lindstrom S et al. . Emergence of a novel swine-origin" exact="influenza" post="A (H1N1) virus in humans. N Engl J Med."/>
   <result pre="of RNA triphosphatase with the RNA guanylyltransferase-RNA (guanine-7-)methyltransferase complex from" exact="vaccinia virus." post="J Biol Chem. ( 1980) 255, 903– 908. 6243301"/>
   <result pre="Protective efficacy of in vitro synthesized, specific mRNA vaccines against" exact="influenza" post="A virus infection . Nat Biotechnol. ( 2012) 30:"/>
   <result pre="et al. . An alphavirus replicon particle chimera derived from" exact="venezuelan equine encephalitis" post="and sindbis viruses is a potent gene-based vaccine delivery"/>
   <result pre=". An alphavirus replicon particle chimera derived from venezuelan equine" exact="encephalitis" post="and sindbis viruses is a potent gene-based vaccine delivery"/>
   <result pre="et al. . Self-amplifying RNA vaccines give equivalent protection against" exact="influenza" post="to mRNA vaccines but at much lower doses ."/>
   <result pre=". Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against" exact="cancer" post=". Nature ( 2017) 547: 222– 6. 10.1038/nature23003 28678784"/>
   <result pre="immune response to RNA immunization with flavivirus replicons derived from" exact="tick-borne encephalitis" post="virus . J Virol ( 2005) 79: 15107– 13."/>
   <result pre="response to RNA immunization with flavivirus replicons derived from tick-borne" exact="encephalitis" post="virus . J Virol ( 2005) 79: 15107– 13."/>
   <result pre="A Duchardt KM et al. . Highly potent mRNA based" exact="cancer" post="vaccines represent an attractive platform for combination therapies supporting"/>
   <result pre="P Kramps T et al. . An mRNA vaccine encoding" exact="rabies" post="virus glycoprotein induces protection against lethal infection in mice"/>
   <result pre="G et al. . Safety and immunogenicity of a mRNA" exact="rabies" post="vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human"/>
   <result pre="demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9" exact="influenza" post="viruses . Mol Ther. ( 2017) 25: 1316– 27."/>
   <result pre="et al. . Induction of robust B cell responses after" exact="influenza" post="mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+"/>
   <result pre="broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding" exact="influenza" post="virus hemagglutinin . J Virol. ( 2016) 90: 332–"/>
   <result pre="JB et al. . Self-amplifying mRNA vaccines expressing multiple conserved" exact="influenza" post="antigens confer protection against homologous and heterosubtypic viral challenge"/>
   <result pre="et al. . Rapidly produced SAM ® vaccine against H7N9" exact="influenza" post="is immunogenic in mice . Emerg Microbes Infect. ("/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6369834/results/search/disease/results.xml">
   <result pre="and reliable information on pathogen detection and characterization for effective" exact="infectious disease" post="treatment, prevention, alert, and control. The Regional Seminar on"/>
   <result pre="for rare and emerging diseases, such as smallpox, SARS, and" exact="yellow fever." post="For botulism, plague, poliomyelitis, rabies, tetanus, and yersiniosis the"/>
   <result pre="Treponema pallidum) TOXOPLASMOSIS, CONGENITAL ( Toxoplasma gondii) TUBERCULOSIS ( Mycobacterium" exact="tuberculosis" post="complex) TYPHOID/PARATYPHOID FEVER ( Salmonella Typhi/Paratyphi) VIRAL HAEMORRHAGIC FEVERS"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6509602/results/search/disease/results.xml">
   <result pre="approach, but implementation remains challenging. Methodologies for better decision-making during" exact="infectious disease" post="outbreaks require refinement, especially detailed scenario planning and improved"/>
   <result pre="Regulations; OIE, World Organisation of Animal Health. Animal reservoirs The" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV) outbreak in 2003 highlighted the importance of"/>
   <result pre="partnership with the Bill and Melinda Gates Foundation to tackle" exact="malaria" post="and other infectious diseases. 19 The Australian government committed"/>
   <result pre="individuals, the 48 hours presymptomatic period during which patients with" exact="influenza" post="are infectious and unrecognised colonisation with multidrug-resistant organisms. Outbreak"/>
   <result pre="national problem Focus on AMR (including growing drug resistance in" exact="tuberculosis" post="and malaria) as part of the DFAT regional Health"/>
   <result pre="George Osborne and Bill Gates to join forces to end" exact="malaria" post="[Internet]. gov.uk , 2015 Available: https://www.gov.uk/government/news/chancellor-george-osborne-and-bill-gates-to-join-forces-to-end-malaria [Accessed cited 2015"/>
   <result pre="al. Public health measures to control the spread of the" exact="severe acute respiratory syndrome" post="during the outbreak in Toronto . N Engl J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6593267/results/search/disease/results.xml">
   <result pre="significantly advantage for detection of the true etiology of a" exact="respiratory disease." post="Furthermore, knowledge of which virus is the cause of"/>
   <result pre="Furthermore, knowledge of which virus is the cause of a" exact="respiratory disease" post="is not useful from a therapeutic point of view"/>
   <result pre="is not useful from a therapeutic point of view unless" exact="influenza" post="virus or respiratory syncytial virus are the infecting agents"/>
   <result pre="are warranted. multiplex platforms PCR respiratory pathogens respiratory tract infection" exact="influenza" post="respiratory syncytial virus Funding Horizon 2020 10.13039/501100007601 fig-count: table-count:"/>
   <result pre="viruses, mainly respiratory syncytial virus (RSV) (Griffiths et al., 2017)," exact="influenza" post="virus (IV) (Antonova et al., 2012), and rhinovirus (RV)"/>
   <result pre="are the cause, Streptococcus pyogenes is a common cause of" exact="pharyngitis" post="(Paradise, 1992), and Streptococcus pneumoniae is a typical cause"/>
   <result pre="capacity to cause upper and lower RTIs and to trigger" exact="asthma" post="and chronic obstructive pulmonary disease exacerbations (Esposito et al.,"/>
   <result pre="cause upper and lower RTIs and to trigger asthma and" exact="chronic obstructive pulmonary disease" post="exacerbations (Esposito et al., 2012b; Parker et al., 2014;"/>
   <result pre="for those agents that are frequently asymptomatically carried. Although certain" exact="influenza" post="patients can shed the virus up to 8 days,"/>
   <result pre="currently available on these diagnostic platforms. Presently, only drugs against" exact="influenza" post="virus, RSV and atypical bacteria are licensed. Furthermore, it"/>
   <result pre="al., 2018) is not recommended for all the cases of" exact="influenza" post="because influenza is frequently a mild disease, and the"/>
   <result pre="is not recommended for all the cases of influenza because" exact="influenza" post="is frequently a mild disease, and the advantage of"/>
   <result pre="is a drug licensed for the treatment of cytomegalovirus (CMV)" exact="retinitis" post="in HIV-infected patients, has been used to treat ADV"/>
   <result pre="considered as a potential solution to treat mild-to-moderate cases of" exact="respiratory disease" post="in otherwise healthy children (Ganapathi et al., 2016). Can"/>
   <result pre="risk of transmission and potential nosocomial clusters of RSV and" exact="influenza" post="virus on hemato-oncological wards (Baier et al., 2018). On"/>
   <result pre="and untested children was not significant. The knowledge that a" exact="bronchiolitis" post="case was associated with the detection of RSV in"/>
   <result pre="al. ( 2003) showed that children with a positive rapid" exact="influenza" post="test were significantly less likely than those with a"/>
   <result pre="et al. ( 2018), who showed that the diagnosis of" exact="influenza" post="was followed by a 47.9% reduction in blood puncture,"/>
   <result pre="improve the judgement of clinicians. However, the diagnosis of a" exact="viral disease" post="by a laboratory test can be interpreted as a"/>
   <result pre="S. Heikkinen T. Principi N. ( 2012). Burden of paediatric" exact="influenza" post="in Western Europe: a systematic review. BMC Public Health"/>
   <result pre="P. et al. . ( 1997). Chlamydia pneumoniae in acute" exact="otitis media" post=". Pediatr. Infect. Dis. J. 16, 858– 862. 10.1097/00006454-199709000-00008"/>
   <result pre="et al. . ( 2018). Impact of bedside diagnosis of" exact="influenza" post="in the paediatric emergency ward. Clin. Microbiol. Infect. 10.1016/j.cmi.2018.11.019"/>
   <result pre="human rhinovirus isolates collected from otherwise healthy children with community-acquired" exact="pneumonia" post="during five successive years . PLoS ONE 8: e80614."/>
   <result pre="Crovari P. Principi N. ( 2003). Effect of a rapid" exact="influenza" post="diagnosis. Arch. Dis. Child. 88, 525– 526. 10.1136/adc.88.6.525 12765923"/>
   <result pre="Seegene Allplex Respiratory Panel 1 kit for the detection of" exact="influenza" post="virus and human respiratory syncytial virus . J. Clin."/>
   <result pre="C. et al. . ( 2018). Baloxavir marboxil for uncomplicated" exact="influenza" post="in adults and adolescents. N. Engl. J. Med. 379,"/>
   <result pre="2017). Viral shedding and transmission potential of asymptomatic and paucisymptomatic" exact="influenza" post="virus infections in the community . Clin. Infect. Dis."/>
   <result pre="Etiology and impact of coinfections in children hospitalized with community-acquired" exact="pneumonia" post=". J. Infect. Dis. 218, 179– 188. 10.1093/infdis/jix641 29228381"/>
   <result pre="30619180 Paradise J. L. ( 1992). Etiology and management of" exact="pharyngitis" post="and pharyngotonsillitis in children: a current review . Ann."/>
   <result pre=". ( 2015a). Bocavirus infection in otherwise healthy children with" exact="respiratory disease." post="PLoS ONE 10: e0135640. 10.1371/journal.pone.0135640 26267139 Principi N. Zampiero"/>
   <result pre="( 2013). Mycoplasma pneumoniae in children with acute and refractory" exact="asthma" post=". Ann. Allergy Asthma Immunol. 110, 328– 334. 10.1016/j.anai.2013.01.022"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6594388/results/search/disease/results.xml">
   <result pre="seasonally and less frequently (such as in the case of" exact="influenza" post="virus) as pandemic infections. Some of these viruses have"/>
   <result pre="A recent example of these events is the avian-origin H7N9" exact="influenza" post="virus outbreak currently undergoing in China. Human H7N9 influenza"/>
   <result pre="H7N9 influenza virus outbreak currently undergoing in China. Human H7N9" exact="influenza" post="viruses are resistant to amantadines and some strains are"/>
   <result pre="(RSV) may cause a lower respiratory tract infection characterized by" exact="bronchiolitis" post="and pneumonia mainly in children and the elderly. Infection"/>
   <result pre="cause a lower respiratory tract infection characterized by bronchiolitis and" exact="pneumonia" post="mainly in children and the elderly. Infection with RSV"/>
   <result pre="currently under development for the treatment of these infections. antiviral" exact="influenza" post="respiratory syncytial virus MERS-coronavirus novel therapeutic agents Funding NIAID-funded"/>
   <result pre="Among the two leading causes of respiratory virus infection are" exact="influenza" post="(A and B) viruses and the respiratory syncytial virus"/>
   <result pre="and develop severe disease ( Jorquera and Tripp, 2017). While" exact="influenza" post="viruses and RSV circulate seasonally between beginning of fall"/>
   <result pre="beginning of fall and early spring, the increased numbers of" exact="avian influenza" post="(H7N9) in China including highly pathogenic (HP) strains of"/>
   <result pre="of fall and early spring, the increased numbers of avian" exact="influenza" post="(H7N9) in China including highly pathogenic (HP) strains of"/>
   <result pre="strains of the virus, the continued outbreaks of the HP" exact="avian influenza" post="(HPAI) H5N1 viruses, novel variants of seasonal influenza viruses"/>
   <result pre="of the virus, the continued outbreaks of the HP avian" exact="influenza" post="(HPAI) H5N1 viruses, novel variants of seasonal influenza viruses"/>
   <result pre="HP avian influenza (HPAI) H5N1 viruses, novel variants of seasonal" exact="influenza" post="viruses (H3N2var), and the emergence of the Middle East"/>
   <result pre="antivirals. A diagram of the virus life cycle of (A)" exact="influenza" post="virus, (B) respiratory syncytial virus, and (C) Middle East"/>
   <result pre="the availability of successful vaccines and antivirals, infection with seasonal" exact="influenza" post="viruses is still the cause of 3–5 million cases"/>
   <result pre="2017). In the US alone, it is estimated that seasonal" exact="influenza" post="affects up to 9 million people a year resulting"/>
   <result pre="of dollars ( Putri et al., 2018). In addition, pandemic" exact="influenza" post="outbreaks emerge at unpredictable intervals causing increased morbidity, mortality,"/>
   <result pre="and Chou, 2008; Ison, 2017). These compounds are specific for" exact="influenza" post="A viruses since the M2 protein of influenza B"/>
   <result pre="specific for influenza A viruses since the M2 protein of" exact="influenza" post="B viruses is structurally different ( Wang et al.,"/>
   <result pre="reported high levels of resistance (&amp;gt;99%) to adamantanes among circulating" exact="influenza" post="A(H3N2) and influenza A(H1N1)pdm09 viruses, and the centers for"/>
   <result pre="of resistance (&amp;gt;99%) to adamantanes among circulating influenza A(H3N2) and" exact="influenza" post="A(H1N1)pdm09 viruses, and the centers for disease control and"/>
   <result pre="these compounds for antiviral treatment or chemoprophylaxis of currently circulating" exact="influenza" post="A viruses ( Centers for Disease Control and Prevention,"/>
   <result pre="oseltamivir, zanamivir, and peramivir is very low in currently circulating" exact="influenza" post="virus strains, although this can change because several clusters"/>
   <result pre="cap-dependent endonuclease, preventing the initiation of mRNA synthesis of the" exact="influenza" post="virus ( Takashita et al., 2018). This is a"/>
   <result pre="is a potent small molecule that shows activity against several" exact="influenza" post="A viruses, including oseltamivir-resistant viruses as well as B"/>
   <result pre="al., 2018). Preclinical studies demonstrated that treated mice infected with" exact="influenza" post="virus were protected from clinical signs and mortality even"/>
   <result pre="et al., 2018). In addition, studies in mice infected with" exact="avian influenza" post="viruses such as H5N1 or H7N9 also demonstrated protection"/>
   <result pre="al., 2018). In addition, studies in mice infected with avian" exact="influenza" post="viruses such as H5N1 or H7N9 also demonstrated protection"/>
   <result pre="with a placebo or oseltamivir in healthy patients infected with" exact="influenza" post="demonstrated that the drug was well tolerated and was"/>
   <result pre="combination with standard-of-care neuraminidase inhibitor in hospitalized participants with severe" exact="influenza" post="(NCT03684044). These studies are currently recruiting and expected to"/>
   <result pre="approved by the FDA for the treatment of acute, uncomplicated" exact="influenza" post="in people aged 12 years and older ( Food"/>
   <result pre="easily administered in uncomplicated as well as complicated cases of" exact="influenza" post="( Koszalka et al., 2017; Shaw, 2017). Next, we"/>
   <result pre="(mAbs) have stimulated the development of novel mAbs-based therapies for" exact="influenza" post="and other infectious diseases ( Jin et al., 2017)."/>
   <result pre="broadly neutralizing mAbs targeting the conserved stalk region of the" exact="influenza" post="virus hemagglutinin (HA) molecule are currently under development. In"/>
   <result pre="of mAbs demonstrated neutralization activity across a broad spectrum of" exact="influenza" post="A subtypes. CR6261 is protective in mice against lethal"/>
   <result pre="region of hemagglutinin. The mAb is active against group 2" exact="influenza" post="viruses and has been shown to have neutralization activity"/>
   <result pre="evaluate the protective efficacy and safety of CR8020 in an" exact="influenza" post="challenge model was completed in 2014 (NCT01938352). Unfortunately, a"/>
   <result pre="and in vivo against different group 1 and group 2" exact="influenza" post="viruses. A phase 2a clinical trial (NCT02071914) was conducted"/>
   <result pre="to evaluate the efficacy and safety of CT-P27 in an" exact="influenza" post="challenge model. The study concluded in July 2014, however"/>
   <result pre="combo in comparison to placebo in subjects with acute uncomplicated" exact="influenza" post="A infection. MEDI8852 This is a potent, broadly neutralizing"/>
   <result pre="protein. MEDI8852 has been reported to effectively neutralize all known" exact="influenza" post="A HA subtypes ( Kallewaard et al., 2016). Preclinical"/>
   <result pre="in animal models have shown efficacy in protecting against H5N1" exact="influenza" post="virus lethal challenges when used alone or in combination"/>
   <result pre="evaluate the safety of MEDI8852 in adults with acute, uncomplicated" exact="influenza" post="was recently concluded and results demonstrated an acceptable safety"/>
   <result pre="HA and is capable of neutralizing all tested seasonal human" exact="influenza" post="A strains ( Nakamura et al., 2013). Two mechanisms"/>
   <result pre="efficacy in the mouse model against a diverse group of" exact="influenza" post="viruses including group 1 and group 2 strains even"/>
   <result pre="(IV) dose of MHAA4549A in adult participants hospitalized with severe" exact="influenza" post="A in combination with oseltamivir was recently concluded and"/>
   <result pre="novel, non-nucleoside polymerase inhibitor that targets the PB2 subunit of" exact="influenza" post="A viruses. Targeting the PB2 avoids docking of the"/>
   <result pre="2015). Furthermore, it is active against a diverse group of" exact="influenza" post="A viruses including the H1N1pdm, H5N1, and H7N9 ("/>
   <result pre="days versus placebo, in adult patients with acute, uncomplicated seasonal" exact="influenza" post="A. Recently, pimodivir has received FDA Fast Track designation"/>
   <result pre="to address an unmet medical need in those who develop" exact="influenza" post="A infection complications. A phase 3 clinical trial (NCT03381196)"/>
   <result pre="T-705, this substituted pyrazinecarboxamide derivative is an inhibitor of the" exact="influenza" post="virus polymerase. As a purine nucleoside analog, favipiravir directly"/>
   <result pre="et al., 2005) and it has broad-spectrum activity against all" exact="influenza" post="subtypes including those resistant to neuraminidase and M2 inhibitors"/>
   <result pre="broad antiviral spectrum of this compound against different human and" exact="avian influenza" post="A and B viruses including avian influenza viruses H5N1"/>
   <result pre="antiviral spectrum of this compound against different human and avian" exact="influenza" post="A and B viruses including avian influenza viruses H5N1"/>
   <result pre="different human and avian influenza A and B viruses including" exact="avian influenza" post="viruses H5N1 and H7N9 ( Sidwell et al., 2007;"/>
   <result pre="human and avian influenza A and B viruses including avian" exact="influenza" post="viruses H5N1 and H7N9 ( Sidwell et al., 2007;"/>
   <result pre="loss, and survival in mice infected with a pandemic H1N1" exact="influenza" post="virus ( Tarbet et al., 2012) or with an"/>
   <result pre="influenza virus ( Tarbet et al., 2012) or with an" exact="avian influenza" post="virus H5N1 ( Smee et al., 2010). Favipiravir is"/>
   <result pre="virus ( Tarbet et al., 2012) or with an avian" exact="influenza" post="virus H5N1 ( Smee et al., 2010). Favipiravir is"/>
   <result pre="but its use is restricted to patients infected with an" exact="influenza" post="virus resistant to NAI or in the event of"/>
   <result pre="efficacy and safety of favipiravir for the treatment of uncomplicated" exact="influenza" post="infection in adults have been completed but the results"/>
   <result pre="to determine the pharmacokinetics of favipiravir in patients with severe" exact="influenza" post="is reported as active but not currently recruiting with"/>
   <result pre="et al., 2016) , in vitro escalation studies showed that" exact="influenza" post="viruses can adapt to low concentration of the compound"/>
   <result pre="concentration of the compound which highlights the potential for some" exact="influenza" post="virus strains to possibly develop resistance ( Ormond et"/>
   <result pre="acids are the primary receptors for binding and entry of" exact="influenza" post="viruses. Fludase works by removing sialic receptors from the"/>
   <result pre="broad-spectrum anti-influenza antiviral with potent antiviral activity against human and" exact="avian influenza" post="viruses with no cellular toxicity ( Triana-Baltzer et al.,"/>
   <result pre="anti-influenza antiviral with potent antiviral activity against human and avian" exact="influenza" post="viruses with no cellular toxicity ( Triana-Baltzer et al.,"/>
   <result pre="In vivo studies showed that mice can be rescued from" exact="influenza" post="infection after treatment with fludase, including after infection with"/>
   <result pre="determine the effective dose in healthy adult participants with laboratory-confirmed" exact="influenza" post="(NCT01037205), it was observed that treatment with fludase significantly"/>
   <result pre="has shown activity against a broad range of viruses including" exact="influenza" post="viruses ( Belardo et al., 2015; Tilmanis et al.,"/>
   <result pre="2017; Stachulski et al., 2018). The mechanism of action against" exact="influenza" post="virus is achieved by impairing the trafficking of the"/>
   <result pre="Preclinical studies demonstrated an antiviral activity against different strains of" exact="influenza" post="A, and B viruses in vitro including avian influenza"/>
   <result pre="strains of influenza A, and B viruses in vitro including" exact="avian influenza" post="viruses ( Sleeman et al., 2014). There are not"/>
   <result pre="of influenza A, and B viruses in vitro including avian" exact="influenza" post="viruses ( Sleeman et al., 2014). There are not"/>
   <result pre="facilitating the advancement of this drug as a treatment for" exact="influenza" post="virus infection ( Rossignol, 2009). A phase 2b/3 clinical"/>
   <result pre="and efficacy of NTZ in the treatment of acute uncomplicated" exact="influenza" post="established that treatment with 300 mg twice a day"/>
   <result pre="( Stachulski et al., 2018) in the treatment of uncomplicated" exact="influenza" post="was concluded in March 2019 but results have not"/>
   <result pre="with activity against RSV and other RNA viruses such as" exact="hepatitis" post="C and Zika viruses ( Antonini et al., 2018;"/>
   <result pre="premature infants as well as in high-risk children with chronic" exact="lung disease" post="of prematurity ( Abarca et al., 2009; O’Brien et"/>
   <result pre="of this siRNA were observed in reducing the risk of" exact="bronchiolitis" post="obliterans syndrome ( Gottlieb et al., 2016). Further evaluations"/>
   <result pre="2017). Symptoms may include respiratory illness that can lead to" exact="acute respiratory distress syndrome" post="( Assiri et al., 2013; Memish et al., 2013)"/>
   <result pre="et al., 2013) and digestive symptoms including nausea, vomiting, and" exact="diarrhea" post="( Centers for Disease Control and Prevention, 2017) with"/>
   <result pre="and their use is based on knowledge obtained during the" exact="severe acute respiratory syndrome" post="(SARS) outbreak in 2003 and the recent influenza pandemic"/>
   <result pre="acute respiratory syndrome (SARS) outbreak in 2003 and the recent" exact="influenza" post="pandemic in 2009 ( Mo and Fisher, 2016). Furthermore,"/>
   <result pre="plasma) has shown beneficial effects in outbreaks of SARS and" exact="influenza" post="virus infections ( Al-Tawfiq et al., 2017). Studies in"/>
   <result pre="review summarizes the current antivirals available for the treatment of" exact="influenza" post="and RSV along with potential new therapies for these"/>
   <result pre="1). Greater advances have been achieved in the field of" exact="influenza" post="antivirals. Currently, three groups of drugs are approved for"/>
   <result pre="therapeutics currently under development (clinical trials), for the treatment of" exact="influenza" post="virus, respiratory syncytial virus (RSV), and Middle East respiratory"/>
   <result pre="Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute" exact="influenza" post="infections . Front. Microbiol. 7: 450. 10.3389/fmicb.2016.00450 , PMID:"/>
   <result pre="MEDI8852, an anti-influenza A monoclonal antibody, in treating acute uncomplicated" exact="influenza" post=". Antimicrob. Agents Chemother. 62: e00694-18. 10.1128/AAC.00694-18 30150460 Al-Tawfiq"/>
   <result pre="( 2015). Synergistic effect of nitazoxanide with neuraminidase inhibitors against" exact="influenza" post="A viruses in vitro . Antimicrob. Agents Chemother. 59,"/>
   <result pre="DAS181, a novel sialidase fusion protein, protects mice from lethal" exact="avian influenza" post="H5N1 virus infection . J. Infect. Dis. 196, 1493–"/>
   <result pre="a novel sialidase fusion protein, protects mice from lethal avian" exact="influenza" post="H5N1 virus infection . J. Infect. Dis. 196, 1493–"/>
   <result pre="of charge on antiviral potency and kinase activity of azaindole-based" exact="influenza" post="PB2 inhibitors . Bioorg. Med. Chem. Lett. 25, 1990–"/>
   <result pre="activity of VX-787, a first-in-class, orally bioavailable inhibitor of the" exact="influenza" post="virus polymerase PB2 subunit . Antimicrob. Agents Chemother. 59,"/>
   <result pre="of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of" exact="influenza" post="PB2 . J. Med. Chem. 57, 6668– 6678. 10.1021/jm5007275"/>
   <result pre="Berlin, Heidelberg: Springer-Verlag), 3– 38. Davidson S. ( 2018). Treating" exact="influenza" post="infection, from now and into the future. Front. Immunol."/>
   <result pre="an anti-influenza A monoclonal antibody, in healthy subjects challenged with" exact="influenza" post="A virus in a phase IIa randomized trial ."/>
   <result pre="( 2011). A highly conserved neutralizing epitope on group 2" exact="influenza" post="A viruses. Science 333, 843– 850. 10.1126/science.1204839 , PMID:"/>
   <result pre="D. Ferguson S. et al. . ( 2018). A universal" exact="influenza" post="vaccine: the strategic plan for the National Institute of"/>
   <result pre="Ferkol T. Schraufnagel D. ( 2014). The global burden of" exact="respiratory disease." post="Ann. Am. Thorac. Soc. 11, 404– 406. 10.1513/AnnalsATS.201311-405PS 24673696"/>
   <result pre="marboxil and a neuraminidase inhibitor in a mouse model of" exact="influenza" post="A virus infection . J. Antimicrob. Chemother. 74, 654–"/>
   <result pre="al. . ( 2005). Mechanism of action of T-705 against" exact="influenza" post="virus. Antimicrob. Agents Chemother. 49, 981– 986. 10.1128/AAC.49.3.981-986.2005 ,"/>
   <result pre="D. et al. . ( 2016). ALN-RSV01 for prevention of" exact="bronchiolitis" post="obliterans syndrome after respiratory syncytial virus infection in lung"/>
   <result pre="C. et al. . ( 2018). Baloxavir Marboxil for uncomplicated" exact="influenza" post="in adults and adolescents. N. Engl. J. Med. 379,"/>
   <result pre="the I38T PA substitution as a resistance marker for next-generation" exact="influenza" post="virus endonuclease inhibitors . MBio 9: e00430-18. 10.1128/mBio.01868-18 ,"/>
   <result pre="2016). Structure and function analysis of an antibody recognizing all" exact="influenza" post="A subtypes. Cell 166, 596– 608. 10.1016/j.cell.2016.05.073 , PMID:"/>
   <result pre="postexposure use of human monoclonal antibody against H5N1 and H1N1" exact="influenza" post="virus in mice: viable alternative to oseltamivir . J."/>
   <result pre="2006). Sialidase fusion protein as a novel broad-spectrum inhibitor of" exact="influenza" post="virus infection. Antimicrob. Agents Chemother. 50, 1470– 1479. 10.1128/AAC.50.4.1470-1479.2006"/>
   <result pre="An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic" exact="influenza" post="A virus subtype H7N9 and protects mice from lethality"/>
   <result pre="A. Sleeman K. et al. ( 2015). Characterization of drug-resistant" exact="influenza" post="A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan"/>
   <result pre="of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human" exact="influenza" post="A virus challenge model . Antimicrob. Agents Chemother. 61:"/>
   <result pre="DAS181, a novel host directed antiviral for the treatment of" exact="influenza" post="infection . J. Infect. Dis. 206, 1844– 1851. 10.1093/infdis/jis622"/>
   <result pre="in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic" exact="influenza" post="A antibodies . Cell Host Microbe 14, 93– 103."/>
   <result pre="of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the" exact="influenza" post="virus polymerase PA subunit . Antiviral Res. 160, 109–"/>
   <result pre="( 2017). The combined effect of oseltamivir and favipiravir on" exact="influenza" post="A virus evolution. Genome Biol. Evol. 9, 1913– 1924."/>
   <result pre="determination of neuraminidase-active foci in cell monolayer cultures infected with" exact="influenza" post="or Newcastle disease virus . J. Virol. 6, 556–"/>
   <result pre="MEDI8852 prevents and controls disease and limits transmission of pandemic" exact="influenza" post="viruses . J. Infect. Dis. 216, 356– 365. 10.1093/infdis/jix292"/>
   <result pre="S. Newall A. T. ( 2018). Economic burden of seasonal" exact="influenza" post="in the United States. Vaccine 36, 3960– 3966. 10.1016/j.vaccine.2018.05.057"/>
   <result pre="2008). Structure and mechanism of the M2 proton channel of" exact="influenza" post="A virus. Nature 451, 591– 595. 10.1038/nature06531 , PMID:"/>
   <result pre="25900158 Shaw M. L. ( 2017). The next wave of" exact="influenza" post="drugs. ACS Infect. Dis. 3, 691– 694. 10.1021/acsinfecdis.7b00142 ,"/>
   <result pre=". ( 2007). Efficacy of orally administered T-705 on lethal" exact="avian influenza" post="A (H5N1) virus infections in mice . Antimicrob. Agents"/>
   <result pre="( 2007). Efficacy of orally administered T-705 on lethal avian" exact="influenza" post="A (H5N1) virus infections in mice . Antimicrob. Agents"/>
   <result pre="M. et al. . ( 2014). Antiviral susceptibility of variant" exact="influenza" post="A(H3N2)v viruses isolated in the United States from 2011"/>
   <result pre="S. M. ( 2016). Activities of JNJ63623872 and oseltamivir against" exact="influenza" post="A H1N1pdm and H3N2 virus infections in mice ."/>
   <result pre="Effects of the combination of favipiravir (T-705) and oseltamivir on" exact="influenza" post="A virus infections in mice . Antimicrob. Agents Chemother."/>
   <result pre="2018). Second-generation nitazoxanide derivatives: thiazolides are effective inhibitors of the" exact="influenza" post="A virus . Future Med. Chem. 10, 851– 862."/>
   <result pre="Furuta Y. et al. . ( 2016). Antiviral susceptibility of" exact="influenza" post="viruses isolated from patients pre- and post-administration of favipiravir"/>
   <result pre="al. . ( 2015). Characterization of a large cluster of" exact="influenza" post="A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the"/>
   <result pre="A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014" exact="influenza" post="season in Japan . Antimicrob. Agents Chemother. 59, 2607–"/>
   <result pre="Fujisaki S. Shirakura M. et al. ( 2018). Susceptibility of" exact="influenza" post="viruses to the novel cap-dependent endonuclease inhibitor Baloxavir Marboxil"/>
   <result pre="Combinations of favipiravir and peramivir for the treatment of pandemic" exact="influenza" post="A/California/04/2009 (H1N1) virus infections in mice . Antiviral Res."/>
   <result pre="Cain D. Sasisekharan V. Sasisekharan R. ( 2014). Broadly neutralizing" exact="influenza" post="hemagglutinin stem-specific antibody CR8020 targets residues that are prone"/>
   <result pre="Hurt A. C. ( 2017). The susceptibility of circulating human" exact="influenza" post="viruses to tizoxanide, the active metabolite of nitazoxanide ."/>
   <result pre="2018). Pimodivir treatment in adult volunteers experimentally inoculated with live" exact="influenza" post="virus: a phase IIa, randomized, double-blind, placebo-controlled study ."/>
   <result pre="DAS181, a sialidase fusion protein, protects human airway epithelium against" exact="influenza" post="virus infection: an in vitro pharmacodynamic analysis . J."/>
   <result pre="Belser J. A. et al. . ( 2009). Novel pandemic" exact="influenza" post="A(H1N1) viruses are potently inhibited by DAS181, a sialidase"/>
   <result pre="et al. . ( 2011). Phenotypic and genotypic characterization of" exact="influenza" post="virus mutants selected with the sialidase fusion protein DAS181"/>
   <result pre="&quot; S-033188, a small molecule inhibitor of cap-dependent endonuclease of" exact="influenza" post="A and B virus, leads to rapid and profund"/>
   <result pre="viral load reduction &quot; in Options for the control of" exact="influenza" post="IX ( Chicago, USA: ISIRV), 77. Van Heeke G."/>
   <result pre="J. ( 2009). Solution structure and functional analysis of the" exact="influenza" post="B proton channel. Nat. Struct. Mol. Biol. 16, 1267–"/>
   <result pre="antibody to RSV and other respiratory viruses for use in" exact="primary immunodeficiency disease" post="and other immune compromised populations . Expert Rev. Clin."/>
   <result pre="Yamada S. et al. . ( 2013). Characterization of H7N9" exact="influenza" post="A viruses isolated from humans. Nature 501, 551– 555."/>
   <result pre="L. Li L. J. ( 2015). Successful treatment of avian-origin" exact="influenza" post="A (H7N9) infection using convalescent plasma . Int. J."/>
   <result pre="Lee S. M. ( 2018). Advancements in host-based interventions for" exact="influenza" post="treatment. Front. Immunol. 9: 1547. 10.3389/fimmu.2018.01547 30042762 Zenilman J."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6727070/results/search/disease/results.xml">
   <result pre="pmcid: 6727070 S0140-6736(19)30721-4 doi: 10.1016/S0140-6736(19)30721-4 : Article Causes of severe" exact="pneumonia" post="requiring hospital admission in children without HIV infection from"/>
   <result pre="than 5 years. In this study, we estimated causes of" exact="pneumonia" post="in young African and Asian children, using novel analytical"/>
   <result pre="detection of respiratory syncytial virus (RSV), parainfluenza virus, human metapneumovirus," exact="influenza" post="virus, S pneumoniae, Haemophilus influenzae type b (Hib), H"/>
   <result pre="of causes, whereas bacteria accounted for 27·3% (23·3–31·6) and Mycobacterium" exact="tuberculosis" post="for 5·9% (3·9–8·3). Viruses were less common (54·5%, 95%"/>
   <result pre="more common (33·7%, 27·2–40·8 vs 22·8%, 18·3–27·6) in very severe" exact="pneumonia" post="cases than in severe cases. RSV had the greatest"/>
   <result pre="a small set of pathogens accounted for most cases of" exact="pneumonia" post="requiring hospital admission. Preventing and treating a subset of"/>
   <result pre="and treating a subset of pathogens could substantially affect childhood" exact="pneumonia" post="outcomes. Funding Bill &amp;amp; Melinda Gates Foundation. Introduction Pneumonia"/>
   <result pre="A substantial reduction in the past few decades of estimated" exact="pneumonia" post="deaths (0·9 million in 2015 vs 1·7 million deaths"/>
   <result pre="improved case management—including empirical antibiotic treatment—and effective vaccines against leading" exact="pneumonia" post="pathogens. 2, 3 Despite these advances, continued progress to"/>
   <result pre="pathogens. 2, 3 Despite these advances, continued progress to reduce" exact="pneumonia" post="mortality is constrained by the absence of vaccines against"/>
   <result pre="(PERCH) study sought to characterise the causes of severe childhood" exact="pneumonia" post="requiring hospital admission among children living in high-burden, low-resource"/>
   <result pre="and lower-middle-income settings and to address challenges faced by previous" exact="pneumonia" post="aetiology studies, such as imperfect standardisation of methods and"/>
   <result pre="a detailed review to assess the body of evidence on" exact="pneumonia" post="aetiology and the epidemiological, laboratory, and analytical methods used"/>
   <result pre="epidemiological, laboratory, and analytical methods used to quantify causes of" exact="pneumonia" post="in young children. Additionally, we established an expert panel,"/>
   <result pre="Since this review, the descriptive results of three large paediatric" exact="pneumonia" post="aetiology studies in children younger than 5 years have"/>
   <result pre="multisite study of the causes of severe and very severe" exact="pneumonia" post="with hospital admission among children aged 1–59 months in"/>
   <result pre="inclusion of diverse sites but with routine implementation of existing" exact="pneumonia" post="vaccines, the duration of enrolment to capture seasonal trends,"/>
   <result pre="ten pathogens were responsible for 79–90% of cases with severe" exact="pneumonia" post="requiring hospital admission in children younger than 5 years"/>
   <result pre="a wide range of geographical and epidemiological settings. Causes of" exact="pneumonia" post="varied by age strata and severity status and, to"/>
   <result pre="the low number of pathogens that are common causes of" exact="pneumonia" post="requiring hospital admission in children younger than 5 years"/>
   <result pre="years across all sites could allow for targeted development of" exact="pneumonia" post="interventions. Respiratory syncytial virus was the most common cause"/>
   <result pre="so that results can be compared with those of other" exact="pneumonia" post="studies. Acknowledging that aetiology cannot be inferred from these"/>
   <result pre="assessed the causes of WHO-defined 12 severe or very severe" exact="pneumonia" post="(pre-2013 definitions, originally presented in 2005) among children aged"/>
   <result pre="enrolled at the time of presentation to the hospital. Severe" exact="pneumonia" post="was defined as cough or difficulty breathing with lower"/>
   <result pre="or difficulty breathing with lower chest wall indrawing; very severe" exact="pneumonia" post="was defined as cough or difficulty breathing and at"/>
   <result pre="respiratory symptoms to provide the least biased comparison for estimating" exact="pneumonia" post="causes, but were ineligible if they met the PERCH"/>
   <result pre="and gastric aspirates from cases only. Results of bacterial and" exact="tuberculosis" post="cultures of blood, lung aspirate, and pleural fluid were"/>
   <result pre="South Africa, where two specimens were routinely collected for increased" exact="tuberculosis" post="detection, or at physicians' discretion for cases with suspected"/>
   <result pre="tuberculosis detection, or at physicians' discretion for cases with suspected" exact="tuberculosis" post="diagnosis. The first specimen alone was used to define"/>
   <result pre="alone was used to define a positive result for Mycobacterium" exact="tuberculosis" post="to ensure cross-site comparability; the lower sensitivity of a"/>
   <result pre="specimens from cases who met study defined clinical criteria for" exact="measles" post="(n=33) were tested for measles by PCR ( appendix)."/>
   <result pre="study defined clinical criteria for measles (n=33) were tested for" exact="measles" post="by PCR ( appendix). Antibiotic exposure at the time"/>
   <result pre="criteria, a minimum of 100 cases per year of severe" exact="pneumonia" post="requiring hospital admission in children aged 1–59 months. Seven"/>
   <result pre="to estimate the aetiological fraction of severe and very severe" exact="pneumonia" post="among cases with a positive chest x-ray; cases were"/>
   <result pre="aetiology analysis (blood cultures, NP-OP PCR, whole blood PCR, and" exact="tuberculosis" post="cultures for cases; NP-OP PCR and whole blood PCR"/>
   <result pre="priors ( appendix). To allow for the possibility that the" exact="pneumonia" post="event was caused by a pathogen not tested for,"/>
   <result pre="category than other cases. The PIA model assumes that a" exact="pneumonia" post="event is caused by a single pathogen. For cases"/>
   <result pre="percutaneous lung aspirate and pleural fluid specimens, and of M" exact="tuberculosis" post="cultures of induced sputum (or gastric aspirate). PCR results"/>
   <result pre="S pneumoniae 12–65% 12–65% 1–control prevalence ‡ Induced sputum Mycobacterium" exact="tuberculosis" post="10–30% 10–30% 100% Lung aspirate All pathogens by culture"/>
   <result pre="stratified by age (&amp;lt;1 year and ≥1 year) and WHO" exact="pneumonia" post="severity (severe and very severe). The all-site results were"/>
   <result pre="(73·9%) of 5723 eligible children with severe or very severe" exact="pneumonia" post="as cases and 5119 (56·9%) of 8994 eligible children"/>
   <result pre="Approximately 90% of the planned specimens (ranging from 88·8% for" exact="tuberculosis" post="cultures to 98·6% for blood cultures) were collected and"/>
   <result pre="least one test result, four cases who tested positive for" exact="measles" post="by NP-OP PCR (all without an infiltrate on their"/>
   <result pre="the aetiology analysis: blood culture, NP-OP PCR, WB PCR, or" exact="tuberculosis" post="culture for cases; and NP-OP PCR or WB PCR"/>
   <result pre="manuscripts devoted to the causes of severe and very severe" exact="pneumonia" post="in children with HIV infection. ††Data for total number"/>
   <result pre="tract illness (controls only) .. .. 1206 (23·6%) .. Positive" exact="malaria" post="smear * 91 (3·9%) 19 (1·9%) 35 (1·3%) 0·1480"/>
   <result pre="640 (45·9%) 291 (46·3%) 867 (38·8%) 0·7019 Full vaccination for" exact="measles" post="§ 1453 (86·8%) 646 (85·3%) 2459 (90·6%) 0·0135 Mid-upper"/>
   <result pre="illness (days) 3·0 (2·0–5·0) 3·0 (2·0–5·0) .. .. Very severe" exact="pneumonia" post="1279 (32·1%) 519 (29·3%) .. .. Wheeze on auscultation"/>
   <result pre="sites (p&amp;lt;0·020; appendix). The proportion of cases with very severe" exact="pneumonia" post="was lowest in Bangladesh and The Gambia and highest"/>
   <result pre="site (p&amp;lt;0·0001) and was higher in cases with very severe" exact="pneumonia" post="(13·3% of 519 very severe cases without HIV infection"/>
   <result pre="x-ray; range by site 3·7–28·2%) than in cases with severe" exact="pneumonia" post="(3·6% of 1250 severe cases without HIV infection and"/>
   <result pre=".. 45 (5·4%) .. 169 (21·9%) .. 254 (38·5%) Positive" exact="malaria" post="smear * 3 (1·2%) 7 (1·1%) 6 (2·5%) 8"/>
   <result pre="(0·0%) 0 (0·0%) 1 (1·7%) 0 (0·0%) Full vaccination for" exact="measles" post="§ 119 (91·5%) 303 (89·9%) 78 (78·0%) 326 (88·1%)"/>
   <result pre="(2–5) .. 3 (2–5) .. 3 (2–4) .. Very severe" exact="pneumonia" post="39 (13·6%) .. 96 (39·8%) .. 114 (40·4%) .."/>
   <result pre="did coverage with vaccines against pertussis, Hib, S pneumoniae, and" exact="measles" post="( appendix; p&amp;lt;0·050 for all). Enrolment of cases varied"/>
   <result pre="(57·2%, 54·2%), Bangladesh (24·6%, 21·6%), and Thailand (30·6%, 19·4%). M" exact="tuberculosis" post="was cultured from 24 (1·5%) of 1571 cases with"/>
   <result pre="positive chest x-rays who met the clinical screening definition for" exact="measles" post="testing were positive for measles ( appendix). Legionella longbeachae"/>
   <result pre="the clinical screening definition for measles testing were positive for" exact="measles" post="( appendix). Legionella longbeachae infection was identified in one"/>
   <result pre="appendix). Influenza virus was rarely detected (influenza A 62 [3·6%];" exact="influenza" post="B 18 [1·0%]; influenza C 10 [0·6%]). S pneumoniae"/>
   <result pre="rarely detected (influenza A 62 [3·6%]; influenza B 18 [1·0%];" exact="influenza" post="C 10 [0·6%]). S pneumoniae was more commonly detected"/>
   <result pre="B (6·3, 4·8–8·2) having the highest adjusted ORs, followed by" exact="influenza" post="A (3·6, 2·4–5·3) and Bordetella pertussis (3·3, 1·6–7·2); parainfluenza"/>
   <result pre="adjusted ORs, followed by influenza A (3·6, 2·4–5·3) and Bordetella" exact="pertussis" post="(3·3, 1·6–7·2); parainfluenza 1, influenza A, and B pertussis"/>
   <result pre="A (3·6, 2·4–5·3) and Bordetella pertussis (3·3, 1·6–7·2); parainfluenza 1," exact="influenza" post="A, and B pertussis were infrequently detected in cases"/>
   <result pre="Bordetella pertussis (3·3, 1·6–7·2); parainfluenza 1, influenza A, and B" exact="pertussis" post="were infrequently detected in cases ( figure 3, appendix)."/>
   <result pre="(NOS category) accounted for 1·8% (95% CrI 0·2–4·5) of the" exact="pneumonia" post="aetiology distribution. The fraction of pneumonia attributable to pathogens"/>
   <result pre="CrI 0·2–4·5) of the pneumonia aetiology distribution. The fraction of" exact="pneumonia" post="attributable to pathogens targeted by currently licensed vaccines (Hib,"/>
   <result pre="licensed vaccines (Hib, vaccine-serotype S pneumoniae, pertussis, M tuberculosis, and" exact="influenza" post="A or B) was 14·0% (11·3–17·0). Figure 4 Aetiological"/>
   <result pre="Haemophilus influenzae type b and H influenzae non-type b; and" exact="influenza" post="A, B, and C. Exact figures, including subspecies and"/>
   <result pre="in the appendix. We observed differences in aetiological fraction by" exact="pneumonia" post="severity for RSV, S aureus, S pneumoniae, parainfluenza type"/>
   <result pre="and Kenya (17·5%) than in other sites (range 32·7–37·6). M" exact="tuberculosis" post="had a larger aetiological fraction in Zambia, The Gambia,"/>
   <result pre="Haemophilus influenzae type b and H influenzae non-type b; and" exact="influenza" post="virus A, B, and C. Exact figures are given"/>
   <result pre="Haemophilus influenzae type b and H influenzae non-type b; and" exact="influenza" post="virus A, B, and C. Boca=human bocavirus. Cand sp="/>
   <result pre="and PCV, viruses, especially RSV, were the predominant cause of" exact="pneumonia" post="requiring hospital admission in children younger than 5 years"/>
   <result pre="hospital defined by WHO as having severe or very severe" exact="pneumonia" post="had an infiltrate on chest x-rays, and among these"/>
   <result pre="attribution. RSV was a common pathogen across age strata and" exact="pneumonia" post="severities, although the aetiological fraction was notably higher in"/>
   <result pre="as a prevention and therapeutic target. In the past decade," exact="pneumonia" post="aetiology studies 29, 38 in the USA and South"/>
   <result pre="vary by site. We recorded a low prevalence (&amp;lt;5%) of" exact="influenza" post="A or B in all sites and the aetiological"/>
   <result pre="or B in all sites and the aetiological contribution of" exact="influenza" post="A or B did not exceed 3% in any"/>
   <result pre="infection, the role of human rhinovirus as a cause of" exact="pneumonia" post="is uncertain. 40, 41, 42 It is possible that"/>
   <result pre="viruses, might be incorrectly attributed as the true cause of" exact="pneumonia" post="despite all methodological and analytical efforts to address this."/>
   <result pre="limitation extends beyond this study to most case-control studies for" exact="pneumonia" post="aetiology, leading to an exaggeration of the contribution of"/>
   <result pre="leading to an exaggeration of the contribution of viruses to" exact="pneumonia" post="when the primary specimen used to assess causality is"/>
   <result pre="pneumoniae was the most common isolate, consistent with other childhood" exact="pneumonia" post="aetiology studies. 29, 38 Although we attempted to improve"/>
   <result pre="we attempted to improve identification of cases with true pneumococcal" exact="pneumonia" post="using whole blood PCR, 26, 27 the specificity was"/>
   <result pre="and Bangladesh used PCV), which could have reduced the pneumococcal" exact="pneumonia" post="disease burden by approximately 70% at those sites, if"/>
   <result pre="radiographic consolidation that has been shown to be associated with" exact="bacterial pneumonia," post="46, 47, 48 which comprised only 25% of all"/>
   <result pre="to care might also have reduced hospital admissions for pneumococcal" exact="pneumonia" post="through effective early outpatient treatment. In some sites, such"/>
   <result pre="other studies. 49, 50, 51 Among other vaccine-preventable pathogens, M" exact="tuberculosis" post="burden varied by site, accounting for 6–10% of the"/>
   <result pre="South Africa, and Thailand), but less than 3% elsewhere. M" exact="tuberculosis" post="was rarely cultured from induced sputum or gastric aspirates"/>
   <result pre="one specimen increased the yield. 52 The sensitivity of M" exact="tuberculosis" post="culture is low when testing a single induced sputum"/>
   <result pre="low even when multiple samples were taken from children with" exact="pulmonary tuberculosis;" post="53 this was accounted for in the aetiology model."/>
   <result pre="the aetiology model. Perhaps owing to high vaccination rates, B" exact="pertussis" post="was rarely identified but, when present, was most often"/>
   <result pre="found in children younger than 12 months. Detection of B" exact="pertussis" post="by PCR of NP-OP specimens was highly predictive of"/>
   <result pre="missed many measles-related cases of pneumonia, highlighting the efforts of" exact="measles" post="control at the sites during the study. Hib was"/>
   <result pre="sites during the study. Hib was an uncommon cause for" exact="pneumonia" post="in our study and was less common than non-type"/>
   <result pre="vaccine; the reason for the small contribution of Hib to" exact="pneumonia" post="aetiology in Thailand is unclear, but might relate to"/>
   <result pre="to outpatient antibiotics. P jirovecii is a prominent cause of" exact="pneumonia" post="among children with HIV infection. The PERCH study has"/>
   <result pre="has shown that it is also a relevant cause of" exact="pneumonia" post="in a subset of children without HIV infection. Among"/>
   <result pre="does affirm that NOS accounts for a small fraction of" exact="pneumonia" post="causes. The contribution of NP-OP data for assessing aetiological"/>
   <result pre="a source of aetiological inference for a selected group of" exact="pneumonia" post="pathogens is supported by the finding that clear distinctions"/>
   <result pre="NP-OP specimens provide little inferential value to the cause of" exact="pneumonia" post="at the individual case level, except for a small"/>
   <result pre="needed to better understand the contribution of these pathogens to" exact="pneumonia" post="aetiology and better explore the sequence from NP-OP infection"/>
   <result pre="Despite their limitations, NP-OP specimens remain of substantial importance for" exact="pneumonia" post="aetiology studies because they are easily collected, can be"/>
   <result pre="observed to occur after discharge in a study of severe" exact="pneumonia" post="requiring hospital admission in children younger than 5 years"/>
   <result pre="a normal or uninterpretable finding; by design, the WHO clinical" exact="pneumonia" post="case definitions are highly sensitive, but non-specific. We focused"/>
   <result pre="focused on the epidemiological and laboratory characteristics of cases with" exact="pneumonia" post="with a positive x-ray to enhance the specificity of"/>
   <result pre="recognising that this might introduce bias by excluding cases with" exact="pneumonia" post="whose x-ray findings lagged behind the clinical findings or"/>
   <result pre="to miss seasonal outbreaks; however, some pathogens (eg, B pertussis," exact="influenza" post="subtypes, parainfluenza viruses, and Mycoplasma pneumoniae) have periodicities that"/>
   <result pre="The PERCH study results can be compared with other childhood" exact="pneumonia" post="aetiology studies. 29, 39, 65, 66 The multisite BOSTID"/>
   <result pre="the breadth and types of laboratory testing. The multicountry GABRIEL" exact="pneumonia" post="case-control aetiology study, 65 done in low-income settings and"/>
   <result pre="have also contributed. In the EPIC study 38 of childhood" exact="pneumonia" post="aetiology from the USA, RSV and human rhinovirus were"/>
   <result pre="PERCH). In the South African Drakenstein case-control substudy 29 of" exact="pneumonia" post="aetiology (using the same multiplex PCR assay as PERCH),"/>
   <result pre="similar to that of the PERCH study was associated with" exact="pneumonia" post="case status, but the prevalence of influenza was higher."/>
   <result pre="was associated with pneumonia case status, but the prevalence of" exact="influenza" post="was higher. Unlike the PERCH study of severe pneumonia"/>
   <result pre="of influenza was higher. Unlike the PERCH study of severe" exact="pneumonia" post="with hospital admission, the Drakenstein substudy found that cytomegalovirus,"/>
   <result pre="several limitations, particularly related to viral pathogens as confounders of" exact="pneumonia" post="aetiology, to the copathogen interpretation, and to bacterial aetiology."/>
   <result pre="aetiology. Our descriptive analysis underscored limitations inherent to nearly every" exact="pneumonia" post="aetiology study—multiple specimens, multiple tests with varying sensitivity and"/>
   <result pre="observational study to accurately define the contribution of bacteria to" exact="pneumonia" post="is uncertain. To advance this problem will require better"/>
   <result pre="two pathogens at a time. Finally, the all-site PERCH study" exact="pneumonia" post="aetiological distribution reflected estimates of the distribution of cases"/>
   <result pre="aetiological distribution reflected estimates of the distribution of cases with" exact="pneumonia" post="who were admitted to a hospital, outside of the"/>
   <result pre="study sites during the period of observation. We recognise that" exact="pneumonia" post="is an important illness in neonates. Because there was"/>
   <result pre="be extrapolated as the global aetiological distribution of severe childhood" exact="pneumonia" post="or interpreted as the aetiological distribution at the national"/>
   <result pre="the cases does not necessarily reflect the aetiological distribution among" exact="pneumonia" post="deaths, especially in children who died in the community"/>
   <result pre="designed to update the evidence base on causes of serious" exact="pneumonia" post="with use of the most advanced clinical, microbiological, and"/>
   <result pre="diverse study sites in Africa and south Asia, where the" exact="pneumonia" post="burden is greatest. Beyond comparing the clinical and microbiological"/>
   <result pre="for multiple pathogens. Our results highlight the consistency of the" exact="pneumonia" post="aetiology findings across sites, disease severity, and age strata,"/>
   <result pre="and treatment. RSV is the most common cause of serious" exact="pneumonia" post="with hospital admission in these settings and should be"/>
   <result pre="and curative treatment. The PERCH study estimated that 61% of" exact="pneumonia" post="requiring hospital admission in children younger than 5 years"/>
   <result pre="discussed above. Nevertheless, this finding strengthens the need to adjust" exact="pneumonia" post="treatment algorithms to emphasise supportive care and identify children"/>
   <result pre="be therapeutic, thereby reducing the pressure for antimicrobial resistance. Future" exact="pneumonia" post="research needs to address the conundrum of multiple pathogens"/>
   <result pre="of multiple pathogens and the sequence of their role in" exact="pneumonia" post="pathogenesis. The findings from the PERCH study should prompt"/>
   <result pre="findings from the PERCH study should prompt additional investments in" exact="pneumonia" post="prevention, testing, triage, and treatment and should encourage the"/>
   <result pre="analyses in aetiology studies, especially those that can further assess" exact="pneumonia" post="as a multipathogen disease. Correspondence to: Dr Katherine L"/>
   <result pre="Etiology Research for Child Health Project: a 21st century childhood" exact="pneumonia" post="etiology study Clin Infect Dis 54 2012 S93 S101"/>
   <result pre="YD Levine OS A literature review and survey of childhood" exact="pneumonia" post="etiology studies: 2000–2010 Clin Infect Dis 54 suppl 2"/>
   <result pre="DR O’Brien KL Scott JAG The enduring challenge of determining" exact="pneumonia" post="etiology in children: considerations for future research priorities Clin"/>
   <result pre="SL Partially latent class models for case-control studies of childhood" exact="pneumonia" post="aetiology J R Stat Soc Ser C Appl Stat"/>
   <result pre="Deloria Knoll M Fu W Shi Q Bayesian estimation of" exact="pneumonia" post="etiology: epidemiologic considerations and applications to the Pneumonia Etiology"/>
   <result pre="controls with respiratory symptoms be excluded from case-control studies of" exact="pneumonia" post="etiology? Reflections from the PERCH study Clin Infect Dis"/>
   <result pre="in PERCH, a large international case-control study of severe childhood" exact="pneumonia" post="Clin Infect Dis 64 2017 S238 S244 28575357 17"/>
   <result pre="Standardized interpretation of paediatric chest radiographs for the diagnosis of" exact="pneumonia" post="in epidemiological studies Bull World Health Organ 83 2005"/>
   <result pre="B Standardized interpretation of chest radiographs in cases of pediatric" exact="pneumonia" post="from the PERCH study Clin Infect Dis 64 2017"/>
   <result pre="N Deloria-Knoll M Baggett HC Chest radiograph findings in childhood" exact="pneumonia" post="cases from the multi-site PERCH study Clin Infect Dis"/>
   <result pre="Driscoll AJ Karron RA Bhat N Laboratory methods for determining" exact="pneumonia" post="etiology in children Clin Infect Dis 54 suppl 2"/>
   <result pre="Streptococcus pneumoniae and its role in the diagnosis of pneumococcal" exact="pneumonia" post="among children aged &amp;lt;5 years in the PERCH study"/>
   <result pre="DNA in blood by polymerase chain reaction for diagnosing pneumococcal" exact="pneumonia" post="in young children from low- and middle-income countries Clin"/>
   <result pre="blood by polymerase chain reaction for the diagnosis of pneumococcal" exact="pneumonia" post="in young children in the PERCH study Clin Infect"/>
   <result pre="volume on the detection of bacterial pathogens in children with" exact="pneumonia" post="Clin Infect Dis 64 2017 S368 S377 28575366 29"/>
   <result pre="A Gardner-Lubbe S Myer L Nicol MP Aetiology of childhood" exact="pneumonia" post="in a well vaccinated South African birth cohort: a"/>
   <result pre="analysis and quality assessment of induced sputum from children with" exact="pneumonia" post="in the PERCH study Clin Infect Dis 64 2017"/>
   <result pre="diagnostic utility of induced sputum microscopy and culture in childhood" exact="pneumonia" post="Clin Infect Dis 64 2017 S280 S288 28575362 32"/>
   <result pre="in induced sputum specimens for determining the causes of childhood" exact="pneumonia" post="in resource-poor settings: findings from the Pneumonia Etiology Research"/>
   <result pre="Technical bases for the WHO recommendations on the management of" exact="pneumonia" post="in children at first-level health facilities: programme for the"/>
   <result pre="DR Scott JAG Addressing the analytic challenges of cross-sectional pediatric" exact="pneumonia" post="etiology data Clin Infect Dis 64 2017 S197 S204"/>
   <result pre="2009 http://www.who.int/growthref/tools/en/ 38 Jain S Williams DJ Arnold SR Community-acquired" exact="pneumonia" post="requiring hospitalization among U.S. children N Engl J Med"/>
   <result pre="25714161 39 Bénet T Picot VS Awasthi S Severity of" exact="pneumonia" post="in under 5-year-old children from developing countries: a multicenter,"/>
   <result pre="the role of rhinoviruses as causative agents of pediatric community-acquired" exact="pneumonia" post="over-estimated? Eur J Pediatr 175 2016 1951 1958 27714467"/>
   <result pre="SMA Enwere G Efficacy of nine-valent pneumococcal conjugate vaccine against" exact="pneumonia" post="and invasive pneumococcal disease in The Gambia: randomised, double-blind,"/>
   <result pre="49 Piralam B Tomczyk SM Rhodes JC Incidence of pneumococcal" exact="pneumonia" post="among adults in rural Thailand, 2006–2011: Implications for pneumococcal"/>
   <result pre="induced sputum and gastric aspirate samples for the diagnosis of" exact="pulmonary tuberculosis" post="in young children with acute community-acquired pneumonia Clin Infect"/>
   <result pre="sputum and gastric aspirate samples for the diagnosis of pulmonary" exact="tuberculosis" post="in young children with acute community-acquired pneumonia Clin Infect"/>
   <result pre="diagnosis of pulmonary tuberculosis in young children with acute community-acquired" exact="pneumonia" post="Clin Infect Dis 64 2017 S309 S316 28575364 53"/>
   <result pre="21172670 54 Barger-Kamate B Deloria Knoll M Kagucia EW Pertussis-associated" exact="pneumonia" post="in infants and children from low- and middle-income countries"/>
   <result pre="Abedin J Household air quality risk factors associated with childhood" exact="pneumonia" post="in urban Dhaka, Bangladesh Am J Trop Med Hyg"/>
   <result pre="Fegan G Mwangome MK Mortality after inpatient treatment for severe" exact="pneumonia" post="in children: a cohort study Paediatr Perinat Epidemiol 31"/>
   <result pre="Elguero E Simondon F Cazelles B Large-scale comparative analysis of" exact="pertussis" post="population dynamics: periodicity, synchrony, and impact of vaccination Am"/>
   <result pre="Bénet T Sánchez Picot V Messaoudi M Microorganisms associated with" exact="pneumonia" post="in children &amp;lt;5 years of age in developing and"/>
   <result pre="years of age in developing and emerging countries: the GABRIEL" exact="pneumonia" post="multicenter, prospective, case-control study Clin Infect Dis 54 2017"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6911100/results/search/disease/results.xml">
   <result pre="diseases, as has been previously demonstrated with dengue 20 and" exact="leishmaniasis" post="18 . Additionally, since these data were collected independently"/>
   <result pre="2017; 30(9): 649–653. 167 364296 Saudi Arabia Alhogbani T. Acute" exact="myocarditis" post="associated with novel Middle east respiratory syndrome coronavirus. Ann"/>
   <result pre="Prevalence of antibodies against the Middle East Respiratory Syndrome coronavirus," exact="influenza" post="A and B viruses among blood donors, Saudi Arabia."/>
   <result pre="S, Lee K, Mok JH. Successful treatment of suspected organizing" exact="pneumonia" post="in a patient with Middle East respiratory syndrome coronavirus"/>
   <result pre="Zhen W, Yang P, Hu K. No MERS-CoV but positive" exact="influenza" post="viruses in returning Hajj pilgrims, China, 2013–2015. BMC Infect"/>
   <result pre="A, Simhairi R, Mushtaq A. Successful recovery of MERS CoV" exact="pneumonia" post="in a patient with acquired immunodeficiency syndrome: a case"/>
   <result pre="RA. Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi Arabia. N Engl J Med. 2012; 367(19):"/>
   <result pre="RAM Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi Arabia N. Engl. J. Med. 2012 367"/>
   <result pre="igshare 10.6084/m9.figshare.10009919.v3 18. Pigott DM et al. Global database of" exact="leishmaniasis" post="occurrence locations, 1960–2012 Sci. Data 2014 1 140036 10.1038/sdata.2014.36"/>
   <result pre="29166910 46. Ma X et al. No MERS-CoV but positive" exact="influenza" post="viruses in returning Hajj pilgrims, China, 2013–2015 BMC Infect."/>
   <result pre="2015 205 W267 274 10.2214/AJR.15.14445 26102309 107. Alhogbani T Acute" exact="myocarditis" post="associated with novel Middle east respiratory syndrome coronavirus Ann."/>
   <result pre="A Simhairi R Mushtaq A Successful recovery of MERS CoV" exact="pneumonia" post="in a patient with acquired immunodeficiency syndrome: a case"/>
   <result pre="Prevalence of antibodies against the Middle East Respiratory Syndrome coronavirus," exact="influenza" post="A and B viruses among blood donors, Saudi Arabia"/>
   <result pre="202. Kim I et al. Successful treatment of suspected organizing" exact="pneumonia" post="in a patient with Middle East respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6925075/results/search/disease/results.xml">
   <result pre="lethal airborne pathogen with the characteristics of the 1918 pandemic" exact="influenza" post="were to emerge today, it is estimated that nearly"/>
   <result pre="income. The cost of a severe pandemic like the 1918" exact="influenza" post="pandemic could total as much as 5% of global"/>
   <result pre="an English general practitioner, conducted the first scientific investigation on" exact="smallpox" post="prevention in 1796 [ 13]. Since then, vaccinations have"/>
   <result pre="potential adverse events of special interest (AESIs), including, for example," exact="sensorineural hearing loss" post="for the safety evaluation of Lassa vaccine candidates ["/>
   <result pre="trials, for instance when there is rapid decline of the" exact="infectious disease" post="outbreak or no ongoing outbreak. Sustainable manufacturing After the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6926486/results/search/disease/results.xml">
   <result pre="plot reveals temporal changes of epidemic spread in HIV and" exact="hepatitis" post="C virus (HCV) Proc Natl Acad Sci USA 110"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6926871/results/search/disease/results.xml">
   <result pre="Activities include visual observation of travelers for signs of the" exact="infectious disease," post="measurement of travelers’ body temperature, and completion of a"/>
   <result pre="infectious agent. Travelers who have signs or symptoms of the" exact="infectious disease," post="or have been potentially exposed to the infectious agent,"/>
   <result pre="of the review: Type of screening (entry, exit) Types of" exact="infectious disease" post="or diseases that entry and exit screening was targeting"/>
   <result pre="Entry/exit screening measures for infectious diseases (g) Influenza (h) Pandemic" exact="influenza" post="preparedness (i) International air travel and infectious diseases (j)"/>
   <result pre="International air travel and infectious diseases (j) Preparedness planning for" exact="infectious disease" post="(k) Screening measures at ground crossing (l) Sever Acute"/>
   <result pre="the (Democratic Republic Congo, DRC) in 2018 and during the" exact="plague" post="outbreak in Madagascar in 2017 [ 5]. On the"/>
   <result pre="through entry screening measures for SARS were diagnosed with atypical" exact="pneumonia" post="or chronic obstructive pulmonary disease with secondary infection or"/>
   <result pre="screening measures for SARS were diagnosed with atypical pneumonia or" exact="chronic obstructive pulmonary disease" post="with secondary infection or bronchopneumonia in Taiwan [ 35]."/>
   <result pre="pneumonia or chronic obstructive pulmonary disease with secondary infection or" exact="bronchopneumonia" post="in Taiwan [ 35]. SARS was not confirmed in"/>
   <result pre="Influenza Pandemic (H1N1) 2009 in Japan, five were diagnosed as" exact="influenza" post="type A and one as type B [ 26];"/>
   <result pre="compatible with EVD, and when further assessed, were diagnosed with" exact="influenza" post="or upper respiratory tract infection [ 31]. Entry screening"/>
   <result pre="nine individuals with compatible symptoms, who were finally diagnosed with" exact="malaria" post="(four travelers), influenza (four travelers) and other (one traveler)"/>
   <result pre="compatible symptoms, who were finally diagnosed with malaria (four travelers)," exact="influenza" post="(four travelers) and other (one traveler) [ 38]. In"/>
   <result pre="that entry screening may delay the introduction of a new" exact="influenza" post="strain for about 7–12 days [ 54]. However, it"/>
   <result pre="and concluded that it will not significantly delay arrival of" exact="influenza" post="cases by air travel, but will reduce the rate"/>
   <result pre="screening (entry, exit) Yes ☐ No ☐ b. Types of" exact="infectious disease" post="or diseases that entry and exit screening was targeting"/>
   <result pre="Extraction Type of screening: entry ☐ exit ☐ Types of" exact="infectious disease" post="or diseases that entry and exit screening was targeting"/>
   <result pre="LEITMEYER, K.C. &amp;amp; TIMEN, A. 2014. Usefulness and applicability of" exact="infectious disease" post="control measures in air travel: A review. Travel Med"/>
   <result pre="CHEN, Y. &amp;amp; XIA, N. 2018. Rapid identification of imported" exact="influenza" post="viruses at Xiamen International Airport via an active surveillance"/>
   <result pre="2010. Entry screening to delay local transmission of 2009 pandemic" exact="influenza" post="A (H1N1). BMC Infect Dis, 10, 82. FUJITA, M.,"/>
   <result pre="MCANULTY, J. 2014. Airport arrivals screening during pandemic (H1N1) 2009" exact="influenza" post="in New South Wales, Australia. Med J Aust, 200,"/>
   <result pre="HOSKINS, R. S. &amp;amp; BAKER, M. G. 2012. Screening for" exact="influenza" post="A(H1N1)pdm09, Auckland International Airport, New Zealand. Emerg Infect Dis,"/>
   <result pre="S. &amp;amp; INFLUENZA SURVEILLANCE REPORT, G. 2009. Enhanced surveillance of" exact="influenza" post="A(H1N1)v in Greece during the containment phase. Euro Surveill,"/>
   <result pre="NISHIURA, H. &amp;amp; KAMIYA, K. 2011. Fever screening during the" exact="influenza" post="(H1N1-2009) pandemic at Narita International Airport, Japan. BMC Infect"/>
   <result pre="WILSON, N. &amp;amp; BAKER, M. G. 2009. Quarantine for pandemic" exact="influenza" post="control at the borders of small island nations. BMC"/>
   <result pre="C. &amp;amp; BAKER, M. G. 2011. Thermal image scanning for" exact="influenza" post="border screening: results of an airport screening study. PLoS"/>
   <result pre="BAKER, M. G. 2013. Effectiveness of border screening for detecting" exact="influenza" post="in arriving airline travelers. Am J Public Health, 103,"/>
   <result pre="the airport of Hamburg during the early phase of pandemic" exact="influenza" post="(H1N1) 2009]. Gesundheitswesen, 74, 145–153. SHIMADA, T., GU, Y.,"/>
   <result pre="YASUI, Y., TADA, Y. &amp;amp; OKABE, N. 2009. Epidemiology of" exact="influenza" post="A(H1N1)v virus infection in Japan, May-June 2009. Euro Surveill,"/>
   <result pre="measures taken at international borders during early stages of pandemic" exact="influenza" post="A (H1N1) 2009: preliminary results. Weekly epidemiological record, 21."/>
   <result pre="cases and the effectiveness of outbreak control strategies of pandemic" exact="influenza" post="A (H1N1) in China. Asia Pac J Public Health,"/>
   <result pre="in China. Asia Pac J Public Health, 24, 932–939. Pandemic" exact="influenza" post="preparedness BELL, D., NICOLL, A., FUKUDA, K., HORBY, P.,"/>
   <result pre="Plan. HOMELAND SECURITY COUNCIL USA 2006. National strategy for pandemic" exact="influenza" post="Implementation plan. MALONE, J. D., BRIGANTIC, R., MULLER, G."/>
   <result pre="&amp;amp; BAKER, M. G. 2008. Border control measures in the" exact="influenza" post="pandemic plans of six South Pacific nations: a critical"/>
   <result pre="Health Organ, 85, 923–929. WORLD HEALTH ORGANISATION 2005. WHO global" exact="influenza" post="preparedness plan. The role of WHO and recommendations for"/>
   <result pre="Health Organisation. WORLD HEALTH ORGANISATION 2018a. A checklist for pandemic" exact="influenza" post="risk and impact management: building capacity for pandemic response,"/>
   <result pre="Hepatitis A. Scientifica (Cairo), 2016, 8258946. P reparedness planning for" exact="infectious disease" post="BERNITZ, B. K. 2008. Communicable disease policy development in"/>
   <result pre="N. J. &amp;amp; EDMUNDS, W. J. 2005. Entry screening for" exact="severe acute respiratory syndrome" post="(SARS) or influenza: policy evaluation. BMJ, 331, 1242–1243. SAMAAN,"/>
   <result pre="GOH, K. T. &amp;amp; PATON, N. I. 2003. Experience of" exact="severe acute respiratory syndrome" post="in Singapore: Importation of cases, and defense strategies at"/>
   <result pre="the effect of airport fever screening on prevention of domestic" exact="dengue fever" post="outbreaks in Taiwan, 1998–2007 Int. J. Infect. Dis. 2010"/>
   <result pre="Swaan C.M. Leitmeyer K.C. Timen A. Usefulness and applicability of" exact="infectious disease" post="control measures in air travel: A review Travel Med."/>
   <result pre="19. Nishiura H. Wilson N. Baker M.G. Quarantine for pandemic" exact="influenza" post="control at the borders of small island nations BMC"/>
   <result pre="A. McAnulty J. Airport arrivals screening during pandemic (H1N1) 2009" exact="influenza" post="in New South Wales, Australia Med. J. Aust. 2014"/>
   <result pre="2018) 23. Wilder-Smith A. Paton N.I. Goh K.T. Experience of" exact="severe acute respiratory syndrome" post="in singapore: Importation of cases, and defense strategies at"/>
   <result pre="14531977 24. Nishiura H. Kamiya K. Fever screening during the" exact="influenza" post="(H1N1-2009) pandemic at Narita International Airport, Japan BMC Infect."/>
   <result pre="Airport quarantine inspection, follow-up observation, and the prevention of pandemic" exact="influenza" post="Aviat. Space Environ. Med. 2011 82 782 789 10.3357/ASEM.3023.2011"/>
   <result pre="L. Laguna-Torres V.A. Aguilar P.V. Chowell G. Kochel T.J. Pandemic" exact="influenza" post="in a southern hemisphere setting: The experience in Peru"/>
   <result pre="cases and the effectiveness of outbreak control strategies of pandemic" exact="influenza" post="A (H1N1) in China Asia Pac. J. Public Health"/>
   <result pre="S.-F. Cheng C.-H. Yu S.-K. Lin C.-C. Shu P.-Y. Imported" exact="chikungunya" post="virus strains, Taiwan, 2006-2009 Emerg. Infect. Dis. 2009 15"/>
   <result pre="measures taken at international borders during early stages of pandemic" exact="influenza" post="A (H1N1) 2009: Preliminary results Wkly. Epidemiol. Rec. 2010"/>
   <result pre="H. Entry screening to delay local transmission of 2009 pandemic" exact="influenza" post="A (H1N1) BMC Infect. Dis. 2010 10 82 10.1186/1471-2334-10-82"/>
   <result pre="the literature review: Type of screening (entry, exit) Type of" exact="infectious disease" post="or diseases that entry or exit screening was targeting"/>
   <result pre="that refer to screening of diseases such as HIV and" exact="tuberculosis" post="that were not part of a global health emergency"/>
   <result pre="type of screening, point of entry (airports, ports, ground crossings)," exact="infectious disease" post="targeted, and country of measure implementation. Disease Country Type"/>
   <result pre="31 August 2016/16 May 2017 No IHR Emergency Committee on" exact="yellow fever" post="No Νo international travel or trade restrictions (31/8/2016 to"/>
   <result pre="by public health staff and at public health units by" exact="infectious disease" post="physician and public health unit staff Questionnaire at terminal"/>
   <result pre="hospital UK/airport/entry/Ebola virus disease/2014-2015 [ 27, 37] At airport, by" exact="infectious disease" post="physician Questionnaire Questionnaire and temperature screening Ear thermometer -"/>
   <result pre="station/entry/Ebola virus disease/2014-2015 [ 27, 37] At train station, by" exact="infectious disease" post="physician Questionnaire Questionnaire and temperature screening Ear thermometer -"/>
   <result pre="axillary thermometer Information about seeking medical assistance, entry card Rapid" exact="influenza" post="test (on board), RT-PCR Close contacts were quarantined at"/>
   <result pre="Questionnaire - Information about seeking medical assistance, entry card Rapid" exact="influenza" post="test (on board and at terminal), RT-PCR At designated"/>
   <result pre="April to 20 June 120,069 391 cases (0.33%) 5 (1.28%)" exact="influenza" post="type A 1 as influenza type B - -"/>
   <result pre="391 cases (0.33%) 5 (1.28%) influenza type A 1 as" exact="influenza" post="type B - - [ 26] Japan 28 April"/>
   <result pre="the quarantine inspection, the number of Japanese patients with novel" exact="influenza" post="reached 633 by June 18, 2009. Only 11 patients"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6935926/results/search/disease/results.xml">
   <result pre="DW, Walker AS, Matthews PC. 2020. Metagenomic Nanopore sequencing of" exact="influenza" post="virus direct from clinical respiratory samples. J Clin Microbiol"/>
   <result pre="viral sequencing offers the potential for a diagnostic test for" exact="influenza" post="virus which also provides insights on transmission, evolution, and"/>
   <result pre="viral sequencing offers the potential for a diagnostic test for" exact="influenza" post="virus which also provides insights on transmission, evolution, and"/>
   <result pre="sequencing method to metagenomic sequencing of respiratory samples. We generated" exact="influenza" post="virus reads down to a limit of detection of"/>
   <result pre="strong relationship between the viral titer and the proportion of" exact="influenza" post="virus reads ( P = 4.7 × 10 −5). Applying our methods to"/>
   <result pre="−5). Applying our methods to clinical throat swabs, we generated" exact="influenza" post="virus reads for 27/27 samples with mid-to-high viral titers"/>
   <result pre="30 to 40). No false-positive reads were generated from 10" exact="influenza" post="virus-negative samples. Thus, Nanopore sequencing operated with 83% sensitivity"/>
   <result pre="influenced by increased host and bacterial reads. However, at high" exact="influenza" post="virus titers, we were able to reconstruct &amp;gt;99% complete"/>
   <result pre="to be used in the diagnosis and genetic analysis of" exact="influenza" post="virus and other respiratory viruses. Keywords influenza Nanopore metagenomic"/>
   <result pre="genetic analysis of influenza virus and other respiratory viruses. Keywords" exact="influenza" post="Nanopore metagenomic diagnosis epidemiology sequencing DNA sequencing diagnostics metagenomics"/>
   <result pre="list of &quot;ten threats to global health&quot; ( 7). Seasonal" exact="influenza" post="causes an estimated 650,000 deaths globally each year, and"/>
   <result pre="older adults, infants, young children, pregnant women, those with underlying" exact="lung disease," post="and the immunocompromised ( 9). The burden of disease"/>
   <result pre="inhibitors (NAI) ( 9). Currently, most clinical diagnostic tests for" exact="influenza" post="virus depend on detecting viral antigen or on PCR"/>
   <result pre="nonquantitative (binary) diagnostic result, and the data routinely generated for" exact="influenza" post="diagnosis have limited capacity to inform insights into epidemiological"/>
   <result pre="application of Oxford Nanopore Technologies (ONT) sequencing to generate full-length" exact="influenza" post="virus sequences from clinical respiratory samples can address these"/>
   <result pre="( 20, 22 – 24). To date, Nanopore sequencing of" exact="influenza" post="virus has been reported using high-titer virus from an"/>
   <result pre="targeted enrichment by either hybridization of cDNA ( 26) or" exact="influenza" post="virus-specific PCR amplification ( 27). We therefore aimed to"/>
   <result pre="We therefore aimed to optimize a metagenomic protocol for detecting" exact="influenza" post="viruses directly from clinical samples using Nanopore sequencing. We"/>
   <result pre="(Illumina) sequencing, using clinical samples from hospital patients during an" exact="influenza" post="season and samples from a controlled laboratory infection in"/>
   <result pre="a PCR-based test using the GeneXpert assay (Cepheid) to detect" exact="influenza" post="A and B viruses and respiratory syncytial virus (RSV)."/>
   <result pre="were generated by the GeneXpert assay, and we used the" exact="influenza" post="virus C T value to estimate the viral titers"/>
   <result pre="to show processing protocol through clinical and research pipelines for" exact="influenza" post="diagnosis. (A) Clinical sample collection (orange), clinical diagnostic testing"/>
   <result pre="and processing of sequence data (purple). (B) Outline of pooled" exact="influenza" post="virus-positive samples into an influenza virus-negative background to generate"/>
   <result pre="(purple). (B) Outline of pooled influenza virus-positive samples into an" exact="influenza" post="virus-negative background to generate various titers of influenza virus"/>
   <result pre="into an influenza virus-negative background to generate various titers of" exact="influenza" post="virus (from 0 to 10 6 genome copies/ml), undertaken"/>
   <result pre="of Hazara virus control at 10 4 genome copies/ml. FluA," exact="influenza" post="A virus. For methodological assessment, we focused on four"/>
   <result pre="pooled 19 throat swab samples that had tested positive for" exact="influenza" post="A virus in the clinical diagnostic laboratory to provide"/>
   <result pre="pools of throat swab samples that had tested negative for" exact="influenza" post="virus (consisting of 24, 38, and 38 individual samples)"/>
   <result pre="swabs and 5 nasal swabs) that had tested positive for" exact="influenza" post="A or B virus, selected to represent the widest"/>
   <result pre="samples, we selected 10 individual throat swab samples that were" exact="influenza" post="virus negative. Quantification of viral RNA in samples. We"/>
   <result pre="We quantified viral titers in Hazara virus stocks and pooled" exact="influenza" post="A virus-positive throat swabs by quantitative reverse transcription-PCR (qRT-PCR),"/>
   <result pre="consensus sequences were subjected to a BLAST search against an" exact="influenza" post="virus sequence database that included &amp;gt;2,000 H1N1 and H3N2"/>
   <result pre="virus sequence database that included &amp;gt;2,000 H1N1 and H3N2 seasonal" exact="influenza" post="virus sequences between 2018 and 2019 and were downloaded"/>
   <result pre="( 34) and Pysam ( https://github.com/pysam-developers/pysam). The subtype of the" exact="influenza" post="A virus derived from each clinical sample was determined"/>
   <result pre="time course, from 3 days prior to first exposure with" exact="influenza" post="H1N1pdm09 virus and at days 1, 2, 3, and"/>
   <result pre="protocol is shown in Fig. 1A. We first sequenced five" exact="influenza" post="A virus-positive and five influenza virus-negative throat swabs, each"/>
   <result pre="1A. We first sequenced five influenza A virus-positive and five" exact="influenza" post="virus-negative throat swabs, each spiked with Hazara virus control"/>
   <result pre="extraction from the supernatant. We used a pooled set of" exact="influenza" post="A virus-positive samples (concentration, 10 6 genome copies/ml) to"/>
   <result pre="control spiked in at 10 4 genome copies/ml. Enrichment for" exact="influenza" post="virus and Hazara virus was similar for filtration versus"/>
   <result pre="original protocol, using triplicate extractions from the pooled set of" exact="influenza" post="A virus-positive samples demonstrated no significant loss in performance"/>
   <result pre="retrieval of Hazara virus by Nanopore sequencing. Starting with an" exact="influenza" post="A virus-positive sample pool (10 6 genome copies/ml), we"/>
   <result pre="copies/ml), we made three volumetric dilution series using three independent" exact="influenza" post="virus-negative pools ( Fig. 1B). The total quantity of"/>
   <result pre="throat swab samples. FIG 2 Characteristics of three pools of" exact="influenza" post="virus-negative throat swabs and Nanopore sequence results following spiking"/>
   <result pre="virus-negative throat swabs and Nanopore sequence results following spiking with" exact="influenza" post="A virus. (A) Total concentration of cDNA produced per"/>
   <result pre="undiluted material, represented by the black bars. Samples diluted to" exact="influenza" post="virus titers of 10 4, 10 3, and 10"/>
   <result pre="generated by Nanopore sequencing of samples with different titers of" exact="influenza" post="A virus and a consistent titer of Hazara virus"/>
   <result pre="Graphs show reads per million of total reads mapping to" exact="influenza" post="A or Hazara virus genomes, across the three individual"/>
   <result pre="from all three dilution series by Nanopore sequencing, independently of" exact="influenza" post="virus titer in the sample ( Fig. 2B). Sequencing"/>
   <result pre="nonviral RNA was introduced from this high-background pool. Limit of" exact="influenza" post="virus detection by Nanopore sequencing from pooled samples. Nanopore"/>
   <result pre="samples. Nanopore sequencing of the triplicate SISPA preparations of the" exact="influenza" post="A virus-positive pool produced mean ± standard deviation of"/>
   <result pre="of 5.3 × 10 4 ± 3.6 × 10 4 RPM mapping to the" exact="influenza" post="A virus genome ( Fig. 2B). Across the dilution"/>
   <result pre="( Fig. 2B). Across the dilution series, the proportion of" exact="influenza" post="virus reads was strongly associated with influenza virus titer"/>
   <result pre="the proportion of influenza virus reads was strongly associated with" exact="influenza" post="virus titer ( P value = 4.7 × 10 −5) but"/>
   <result pre="Hazara virus control. Sequencing the negative controls (pools with no" exact="influenza" post="virus spike) generated no reads mapping to influenza virus."/>
   <result pre="with no influenza virus spike) generated no reads mapping to" exact="influenza" post="virus. At influenza virus titers of &amp;lt;10 3 copies/ml,"/>
   <result pre="virus spike) generated no reads mapping to influenza virus. At" exact="influenza" post="virus titers of &amp;lt;10 3 copies/ml, influenza virus reads"/>
   <result pre="influenza virus. At influenza virus titers of &amp;lt;10 3 copies/ml," exact="influenza" post="virus reads were inconsistently detected across the samples ("/>
   <result pre="limit of detection is between 10 2 and 10 3" exact="influenza" post="virus copies/ml. Retrieval and reconstruction of complete influenza virus"/>
   <result pre="10 3 influenza virus copies/ml. Retrieval and reconstruction of complete" exact="influenza" post="virus genomes from pooled/spiked samples. For the Hazara virus"/>
   <result pre="samples ( Fig. 3A). At 10 4 genome copies/ml of" exact="influenza" post="virus, a mean 1× coverage per segment was 90.3%"/>
   <result pre="the high-background pool 3 to 5.7% ( Fig. 3A). At" exact="influenza" post="virus titers of &amp;lt;10 4 copies/ml, coverage was highly"/>
   <result pre="subtyping as H3N2 ( Table 1). FIG 3 Coverage of" exact="influenza" post="virus and Hazara virus genome segments achieved by Nanopore"/>
   <result pre="pooled samples (A) Data from three dilution series of pooled" exact="influenza" post="virus-positive samples, diluted with three separate negative-sample pools to"/>
   <result pre="with three separate negative-sample pools to generate different titers of" exact="influenza" post="virus. Each individual dilution was spiked with Hazara virus"/>
   <result pre="at 1× depth is shown for each of the eight" exact="influenza" post="virus genome segments (encoding PB2 [polymerase subunit 2], PB1"/>
   <result pre="of all three genome segments. (B) Representative coverage plots of" exact="influenza" post="A virus genome segments from the dilution series 1"/>
   <result pre="segments from the dilution series 1 sample at 10 4" exact="influenza" post="virus copies per ml. TABLE 1 Summary of results"/>
   <result pre="Nanopore sequencing based on pooled samples with various titers of" exact="influenza" post="A virus and a consistent titer of Hazara virus"/>
   <result pre="copies/ml) Dilution pool no. Total no. of reads No. of" exact="influenza" post="A virus reads (reads per million) Influenza A virus"/>
   <result pre="from individual clinical samples. Having demonstrated our ability to retrieve" exact="influenza" post="virus sequences from pooled influenza virus-positive material diluted with"/>
   <result pre="demonstrated our ability to retrieve influenza virus sequences from pooled" exact="influenza" post="virus-positive material diluted with negative samples, we next applied"/>
   <result pre="methods to individual anonymized clinical samples, with 40 samples testing" exact="influenza" post="virus positive and 10 samples testing influenza virus negative"/>
   <result pre="40 samples testing influenza virus positive and 10 samples testing" exact="influenza" post="virus negative in the clinical diagnostic laboratory. Data yield"/>
   <result pre="3.8 × 10 5 reads) (Table S1). Reads mapping to either the" exact="influenza" post="A or B virus genome were present in all"/>
   <result pre="reads). At a C T of &amp;gt;30, 6/13 samples generated" exact="influenza" post="virus reads (range, 6 to 92,057 reads) (difference between"/>
   <result pre="Fig. 4). The highest C T value at which any" exact="influenza" post="virus reads were detected was 36.8 (sample 37; 17"/>
   <result pre="reads were detected was 36.8 (sample 37; 17 reads of" exact="influenza" post="A virus). No reads classified as influenza virus were"/>
   <result pre="17 reads of influenza A virus). No reads classified as" exact="influenza" post="virus were obtained from sequencing the 10 GeneXpert assay-negative"/>
   <result pre="T value and both the reads per sample classified as" exact="influenza" post="virus ( R 2 = 0.60) and the number"/>
   <result pre="virus ( R 2 = 0.60) and the number of" exact="influenza" post="virus reads per million reads ( R 2 ="/>
   <result pre="generated (at 10× minimum depth) covered over 90% of the" exact="influenza" post="virus genome for 17 samples, with another two generating"/>
   <result pre="T value of a sample from which &amp;gt;90% of an" exact="influenza" post="virus genome sequence was generated was 27.5 (Fig. S4)."/>
   <result pre="was 27.5 (Fig. S4). FIG 4 Total and proportion of" exact="influenza" post="virus reads derived by Nanopore sequencing of individual samples"/>
   <result pre="Left, correlation between C T value and total number of" exact="influenza" post="virus reads generated. R 2 = 0.604, P ="/>
   <result pre="2.47e−08. Right, correlation between C T value and number of" exact="influenza" post="virus reads per million reads. R 2 = 0.623,"/>
   <result pre="no detectable Hazara virus reads, two with high numbers of" exact="influenza" post="virus reads (for sample 1, C T of 13.5"/>
   <result pre="(for sample 1, C T of 13.5 and 1.5 × 10 5" exact="influenza" post="B virus reads, and for sample 6, C T"/>
   <result pre="for sample 6, C T of 18.4 and 1.5 × 10 4" exact="influenza" post="A virus reads) acting to dilute the control signal."/>
   <result pre="the control signal. The other two samples contained no detectable" exact="influenza" post="virus reads (for sample 34, C T of 35.9,"/>
   <result pre="sample 34, C T of 35.9, and for sample 46," exact="influenza" post="virus negative). The lack of control detection therefore indicates"/>
   <result pre="platform. The proportions of reads generated that mapped to the" exact="influenza" post="virus genome were similar between the two sequencing technologies"/>
   <result pre="sequences, as expected within one geographic setting in a single" exact="influenza" post="season. FIG 5 Phylogenetic trees of consensus influenza virus"/>
   <result pre="a single influenza season. FIG 5 Phylogenetic trees of consensus" exact="influenza" post="virus HA gene derived by Nanopore and Illumina sequencing."/>
   <result pre="reads mapping to human coronavirus in addition to &amp;gt;1.5 × 10 4" exact="influenza" post="A virus reads, suggesting coinfection. We also derived &amp;gt;4.0 × 10"/>
   <result pre="also derived &amp;gt;4.0 × 10 4 reads from human metapneumovirus from an" exact="influenza" post="virus-negative sample, providing a nearly complete genome (99.8% coverage)"/>
   <result pre="reproducibility of our methods across a time course model of" exact="influenza" post="A virus infection (three ferrets swabbed preinfection [day −3]"/>
   <result pre="days 1, 2, 3, and 5 following laboratory infection with" exact="influenza" post="A virus). The proportion of viral reads present at"/>
   <result pre="same cDNA (Table S2). FIG 6 Time course experiment showing" exact="influenza" post="A virus infection in three laboratory ferrets. Infection was"/>
   <result pre="proportion of total Nanopore reads (linear scale) (B) mapping to" exact="influenza" post="A virus from metagenomic sequencing of ferret nasal washes"/>
   <result pre="metagenomic sequencing of ferret nasal washes taken before and after" exact="influenza" post="virus challenge. DISCUSSION To our knowledge, this is the"/>
   <result pre="applying metagenomic Nanopore sequencing directly to respiratory samples to detect" exact="influenza" post="virus and generate influenza virus sequences. The approach demonstrates"/>
   <result pre="directly to respiratory samples to detect influenza virus and generate" exact="influenza" post="virus sequences. The approach demonstrates excellent specificity. Sensitivity varies"/>
   <result pre="to be further optimized and validated to improve sensitivity for" exact="influenza" post="virus, identify other RNA viruses, detect drug resistance mutations,"/>
   <result pre="demonstrating the ability of metagenomics to produce sufficient data for" exact="influenza" post="virus diagnostics and genome characterization, while also detecting and"/>
   <result pre="of America (IDSA) guidelines ( 9) recommend nasal/nasopharyngeal specimens for" exact="influenza" post="diagnosis, but throat swabs are easier to collect in"/>
   <result pre="virus; however, half of these contained a high titer of" exact="influenza" post="virus, so only 4% were true sensitivity failures. This"/>
   <result pre="Nanopore reads confirms semiquantitative output. Using samples from the ferret" exact="influenza" post="virus model, collected under standardized laboratory conditions, we demonstrated"/>
   <result pre="clinical diagnostics to further assess sensitivity and specificity, and using" exact="influenza" post="virus sequence data to investigate transmission events. Identifying instances"/>
   <result pre="the method is robust for the identification of commonly circulating" exact="influenza" post="virus strains in human populations, but further investigation is"/>
   <result pre="strains. Comparison with existing/alternative approaches. The current standard assay for" exact="influenza" post="diagnosis employed within the large tertiary referral teaching hospital"/>
   <result pre="study was performed is the GeneXpert assay (Cepheid), which detects" exact="influenza" post="A and B viruses and respiratory syncytial virus (RSV)."/>
   <result pre="purchasing 48 flow cells together. The cost of the current" exact="influenza" post="A/B and RSV GeneXpert test is ∼£56, and the"/>
   <result pre="approaches to generate sequence data include amplicon-based sequencing of the" exact="influenza" post="virus genome ( 51, 52). However, this approach detects"/>
   <result pre="Illumina sequencing instead of Nanopore sequencing for metagenomic sequencing of" exact="influenza" post="virus ( 53) provides the current gold standard of"/>
   <result pre="further work is needed, our methods show promise for generating" exact="influenza" post="virus sequences directly from respiratory samples. The &quot;pathogen-agnostic&quot; metagenomic"/>
   <result pre=", Smith G 2017 The ecology and adaptive evolution of" exact="influenza" post="A interspecies transmission. Influenza Other Respir Viruses 11: 74–"/>
   <result pre="84. doi: 10.1111/irv.12412 . 27426214 3. Humphreys M 2018 The" exact="influenza" post="of 1918: evolutionary perspectives in a historical context. Evol"/>
   <result pre="2009 Origins and evolutionary genomics of the 2009 swine-origin H1N1" exact="influenza" post="A epidemic. Nature 459: 1122– 1125. doi: 10.1038/nature08182 ."/>
   <result pre="TC 2018 The pandemic threat of emerging H5 and H7" exact="avian influenza" post="viruses. Viruses 10: E461. doi: 10.3390/v10090461 . 30154345 6."/>
   <result pre="2018 The pandemic threat of emerging H5 and H7 avian" exact="influenza" post="viruses. Viruses 10: E461. doi: 10.3390/v10090461 . 30154345 6."/>
   <result pre=", Liao M , Shen Y 2018 Evolutionary dynamics of" exact="avian influenza" post="A H7N9 virus across five waves in mainland China,"/>
   <result pre="Liao M , Shen Y 2018 Evolutionary dynamics of avian" exact="influenza" post="A H7N9 virus across five waves in mainland China,"/>
   <result pre="on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal" exact="influenza" post=". Clin Infect Dis 48: 1003– 1032. doi: 10.1086/598513"/>
   <result pre=", Lässig M , McCauley JW 2018 Predictive modeling of" exact="influenza" post="shows the promise of applied evolutionary biology. Trends Microbiol"/>
   <result pre="T , Foxman B 2016 What transmission precautions best control" exact="influenza" post="spread in a hospital? Am J Epidemiol 183: 1045–"/>
   <result pre="Nordén R 2019 Molecular characterization of a nosocomial outbreak of" exact="influenza" post="B virus in an acute care hospital setting ."/>
   <result pre="S 2019 Clinical impact of rapid point-of-care polymerase chain reaction" exact="influenza" post="testing in an urgent care setting: a single center"/>
   <result pre="PCR-based point-of-care method facilitates rapid, efficient, and sensitive diagnosis of" exact="influenza" post="virus infection . Clin Microbiol Infect 25: 1032– 1037."/>
   <result pre=", Iqbal Z 2017 Same-day diagnostic and surveillance data for" exact="tuberculosis" post="via whole-genome sequencing of direct respiratory samples . J"/>
   <result pre=", Luo J-Y , Chen Z-W 2016 Dynamic quantification of" exact="avian influenza" post="H7N9(A) virus in a human infection during clinical treatment"/>
   <result pre="Luo J-Y , Chen Z-W 2016 Dynamic quantification of avian" exact="influenza" post="H7N9(A) virus in a human infection during clinical treatment"/>
   <result pre="Nanopore and Illumina sequencing for recovering whole genome sequences of" exact="chikungunya" post="and dengue viruses directly from clinical samples . Euro"/>
   <result pre="2018 Illumina and Nanopore methods for whole genome sequencing of" exact="hepatitis" post="B virus (HBV). bioRxiv https://www.biorxiv.org/content/biorxiv/suppl/2018/11/14/470633.DC1/470633-1.pdf. 25. Keller MW ,"/>
   <result pre="Barnes JR 2018 Direct RNA sequencing of the coding complete" exact="influenza" post="A virus genome. Sci Rep 8: 14408. doi: 10.1038/s41598-018-32615-8"/>
   <result pre="Wentworth DE , Barnes JR 2019 Mitigating pandemic risk with" exact="influenza" post="A virus field surveillance at a swine-human interface ."/>
   <result pre="B , Silman NJ , Carroll MW 2014 Low dose" exact="influenza" post="virus challenge in the ferret leads to increased virus"/>
   <result pre="RH 2012 Influenza research database: an integrated bioinformatics resource for" exact="influenza" post="research and surveillance . Influenza Other Respir Viruses 6:"/>
   <result pre="2015 Assessment of the utility of whole genome sequencing of" exact="measles" post="virus in the characterisation of outbreaks . PLoS One"/>
   <result pre="correlates with cross-reactive interferon-gamma-secreting lymphocytes in the ferret model of" exact="influenza" post=". Sci Rep 9: 2617. doi: 10.1038/s41598-019-38885-0 . 30796267"/>
   <result pre="Schönberger K , Sing A 2018 Whole genome sequencing identifies" exact="influenza" post="A H3N2 transmission and offers superior resolution to classical"/>
   <result pre="Holmes EC 2008 The genomic and epidemiological dynamics of human" exact="influenza" post="A virus. Nature 453: 615– 619. doi: 10.1038/nature06945 ."/>
   <result pre="2018 A naturally protective epitope of limited variability as an" exact="influenza" post="vaccine target. Nat Commun 9: 3859. doi: 10.1038/s41467-018-06228-8 ."/>
   <result pre="Maesaki S , Maeda T 2018 Whole genome sequencing of" exact="influenza" post="A and B viruses with the MinION sequencer in"/>
   <result pre="DA , Hall RJ 2015 MinION Nanopore sequencing of an" exact="influenza" post="genome. Front Microbiol 6: 766. doi: 10.3389/fmicb.2015.00766 . 26347715"/>
   <result pre="P , Chiu CY 2010 A metagenomic analysis of pandemic" exact="influenza" post="A (2009 H1N1) infection in patients from North America"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6939334/results/search/disease/results.xml">
   <result pre="market [ 3], including 30 mAbs for the treatment of" exact="cancer" post="(Table 1). Table 1 US FDA-approved monoclonal antibody on"/>
   <result pre="F. Hoffmann-La Roche Ltd./Genentech Inc. CD20 Chimeric IgG1 Hybridoma Non-Hodgkin" exact="lymphoma" post="1997 Palivizumab Synagis MedImmune/AbbVie Inc. RSV Humanized IgG1 Hybridoma"/>
   <result pre="F. Hoffmann-La Roche, Ltd./Genentech Inc. HER2 Humanized IgG1 Hybridoma Breast" exact="cancer" post="1998 Alemtuzumab Campath, Lemtrada Berlex Inc./Genzyme Corp./Millennium Pharmaceuticals Inc."/>
   <result pre="Berlex Inc./Genzyme Corp./Millennium Pharmaceuticals Inc. CD52 Humanized IgG1 Hybridoma Chronic" exact="myeloid leukemia" post="2001 Adalimumab Humira AbbVie Inc. TNFα Human IgG1 Phage"/>
   <result pre="Inc./Genzyme Corp./Millennium Pharmaceuticals Inc. CD52 Humanized IgG1 Hybridoma Chronic myeloid" exact="leukemia" post="2001 Adalimumab Humira AbbVie Inc. TNFα Human IgG1 Phage"/>
   <result pre="Adalimumab Humira AbbVie Inc. TNFα Human IgG1 Phage display Rheumatoid" exact="arthritis" post="2002 Ibritumomab tiuxetan Zevalin Biogen Inc./Schering AG/Spectrum Pharmaceuticals Inc."/>
   <result pre="Biogen Inc./Schering AG/Spectrum Pharmaceuticals Inc. CD20 Murine IgG1 Hybridoma Non-Hodgkin" exact="lymphoma" post="2002 Omalizumab Xolair Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc./Novartis"/>
   <result pre="Co. Inc./Eli Lilly/ImClone Systems Inc. EGFR Chimeric IgG1 Hybridoma Colorectal" exact="cancer" post="2004 Bevacizumab Avastin Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc."/>
   <result pre="F. Hoffmann-La Roche, Ltd./Genentech Inc. VEGF-A Humanized IgG1 Hybridoma Colorectal" exact="cancer" post="2004 Natalizumab Tysabri Biogen Inc./Elan Pharmaceuticals International, Ltd. ITGA4"/>
   <result pre="2004 Panitumumab Vectibix Amgen EGFR Human IgG2 Transgenic mice Colorectal" exact="cancer" post="2006 Ranibizumab Lucentis Roche, F. Hoffmann-La Roche Ltd./Genentech Inc./Novartis"/>
   <result pre="Soliris Alexion Pharmaceuticals Inc. C5 Humanized IgG2/4 Hybridoma Paroxysmal nocturnal" exact="hemoglobinuria" post="2007 Certolizumab pegol Cimzia Celltech, UCB. TNFα Humanized Fab,"/>
   <result pre="Inc./Janssen Biotech Inc. TNFα Human IgG1 Transgenic mice Rheumatoid and" exact="psoriatic arthritis," post="ankylosing spondylitis 2009 Ofatumumab Arzerra Genmab A/S /GlaxoSmithKline /Novartis."/>
   <result pre="Inc. TNFα Human IgG1 Transgenic mice Rheumatoid and psoriatic arthritis," exact="ankylosing spondylitis" post="2009 Ofatumumab Arzerra Genmab A/S /GlaxoSmithKline /Novartis. CD20 Human"/>
   <result pre="TNFα Human IgG1 Transgenic mice Rheumatoid and psoriatic arthritis, ankylosing" exact="spondylitis" post="2009 Ofatumumab Arzerra Genmab A/S /GlaxoSmithKline /Novartis. CD20 Human"/>
   <result pre="A/S /GlaxoSmithKline /Novartis. CD20 Human IgG1 Transgenic mice Chronic lymphocytic" exact="leukemia" post="2009 Tocilizumab RoActemra, Actemra Chugai Pharmaceutical Co., Ltd./Roche, F."/>
   <result pre="F. Hoffmann-La Roche. Ltd./Genentech Inc. IL-6R Humanized IgG1 Hybridoma Rheumatoid" exact="arthritis" post="2010 Denosumab Xgeva, Prolia Amgen RANKL Human IgG2 Transgenic"/>
   <result pre="/Human Genome Sciences Inc. BLyS Human IgG1 Phage display Systemic" exact="lupus erythematosus" post="2011 Ipilimumab Yervoy Bristol-Myers Squibb/Medarex CTLA-4 Human IgG1 Transgenic"/>
   <result pre="Chimeric IgG1; ADC Hybridoma Hodgkin lymphoma, systemic anaplastic large cell" exact="lymphoma" post="2011 Pertuzumab Perjeta Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc."/>
   <result pre="Roche Ltd./Genentech Inc./ImmunoGen Inc. HER2 Humanized IgG1; ADC Hybridoma Breast" exact="cancer" post="2012 Raxibacumab Abthrax GlaxoSmithKline /Human Genome Sciences Inc. (HGSI)"/>
   <result pre="Roche, Ltd./Genentech Inc. CD20 Humanized IgG1 Glycoengineered Hybridoma Chronic lymphocytic" exact="leukemia" post="2013 Siltuximab Sylvant Centocor Inc./Janssen Biotech Inc./Janssen-Cilag International NV"/>
   <result pre="Eli Lilly/ImClone Systems Inc. VEGFR2 Human IgG1 Phage display Gastric" exact="cancer" post="2014 Vedolizumab Entyvio Genentech Inc./Millennium Pharmaceuticals Inc./Takeda Pharmaceuticals U.S.A."/>
   <result pre="Blincyto Amgen CD19, CD3 Murine bispecific tandem scFv Hybridoma Acute" exact="lymphoblastic leukemia" post="2014 Nivolumab Opdivo Bristol-Myers Squibb/Ono Pharmaceutical Co., Ltd. PD-1"/>
   <result pre="Amgen CD19, CD3 Murine bispecific tandem scFv Hybridoma Acute lymphoblastic" exact="leukemia" post="2014 Nivolumab Opdivo Bristol-Myers Squibb/Ono Pharmaceutical Co., Ltd. PD-1"/>
   <result pre="Co., Ltd. PD-1 Human IgG4 Transgenic mice Melanoma, non-small cell" exact="lung cancer" post="2014 Pembrolizumab Keytruda Merck &amp;amp; Co. Inc. PD-1 Humanized"/>
   <result pre="Ltd. PD-1 Human IgG4 Transgenic mice Melanoma, non-small cell lung" exact="cancer" post="2014 Pembrolizumab Keytruda Merck &amp;amp; Co. Inc. PD-1 Humanized"/>
   <result pre="Lilly/ImClone Systems Inc. EGFR Human IgG1 Phage display Non-small cell" exact="lung cancer" post="2015 Dinutuximab Unituxin United Therapeutics Corporation GD2 Chimeric IgG1"/>
   <result pre="Systems Inc. EGFR Human IgG1 Phage display Non-small cell lung" exact="cancer" post="2015 Dinutuximab Unituxin United Therapeutics Corporation GD2 Chimeric IgG1"/>
   <result pre="Mepolizumab Nucala Centocor Inc./GlaxoSmithKline IL-5 Humanized IgG1 Hybridoma Severe eosinophilic" exact="asthma" post="2015 Alirocumab Praluent Regeneron Pharmaceuticals Inc./Sanofi. PCSK9 Human IgG1"/>
   <result pre="Lilly/ImClone Systems Inc. PDGFRα Human IgG1 Transgenic mice Soft tissue" exact="sarcoma" post="2016 Bezlotoxumab Zinplava Merck &amp;amp; Co. Inc. Clostridium difficile"/>
   <result pre="F. Hoffmann-La Roche, Ltd./Genentech Inc. PD-L1 Humanized IgG1 Hybridoma Bladder" exact="cancer" post="2016 Obiltoxaximab Anthim Elusys Therapeutics Inc. B. anthrasis PA"/>
   <result pre="Inc. B. anthrasis PA Chimeric IgG1 Hybridoma Prevention of inhalational" exact="anthrax" post="2016 Inotuzumab ozogamicin Besponsa Wyeth Pharmaceuticals/Pfizer. CD22 Humanized IgG4"/>
   <result pre="Inotuzumab ozogamicin Besponsa Wyeth Pharmaceuticals/Pfizer. CD22 Humanized IgG4 Hybridoma Acute" exact="lymphoblastic leukemia" post="2017 Brodalumab Siliq, Lumicef MedImmune/Amgen/Kyowa Hakko Kirin /AstraZeneca/Valeant Pharmaceuticals"/>
   <result pre="ozogamicin Besponsa Wyeth Pharmaceuticals/Pfizer. CD22 Humanized IgG4 Hybridoma Acute lymphoblastic" exact="leukemia" post="2017 Brodalumab Siliq, Lumicef MedImmune/Amgen/Kyowa Hakko Kirin /AstraZeneca/Valeant Pharmaceuticals"/>
   <result pre="/AstraZeneca/Valeant Pharmaceuticals International Inc. IL-17R Human IgG2 Transgenic mice Plaque" exact="psoriasis" post="2017 Guselkumab Tremfya MorphoSys/Janssen Biotech Inc. IL-23 p19 Human"/>
   <result pre="MorphoSys/Janssen Biotech Inc. IL-23 p19 Human IgG1 Phage display Plaque" exact="psoriasis" post="2017 Dupilumab Dupixent Regeneron Pharmaceuticals Inc./Sanofi IL-4Rα Human IgG4"/>
   <result pre="Dupixent Regeneron Pharmaceuticals Inc./Sanofi IL-4Rα Human IgG4 Transgenic mice Atopic" exact="dermatitis" post="2017 Sarilumab Kevzara Regeneron Pharmaceuticals Inc./Sanofi IL-6R Human IgG1"/>
   <result pre="Kevzara Regeneron Pharmaceuticals Inc./Sanofi IL-6R Human IgG1 Transgenic mice Rheumatoid" exact="arthritis" post="2017 Avelumab Bavencio Merck Serono International S.A./Pfizer PD-L1 Human"/>
   <result pre="Gemtuzumab ozogamicin Mylotarg Pfizer CD33 Humanized IgG4; ADC Hybridoma Acute" exact="myeloid leukemia" post="2017 Durvalumab Imfinzi MedImmune/AstraZeneca PD-L1 Human IgG1 Transgenic mice"/>
   <result pre="ozogamicin Mylotarg Pfizer CD33 Humanized IgG4; ADC Hybridoma Acute myeloid" exact="leukemia" post="2017 Durvalumab Imfinzi MedImmune/AstraZeneca PD-L1 Human IgG1 Transgenic mice"/>
   <result pre="2017 Durvalumab Imfinzi MedImmune/AstraZeneca PD-L1 Human IgG1 Transgenic mice Bladder" exact="cancer" post="2017 Burosumab Crysvita Kyowa Hakko Kirin/Ultragenyx Pharmaceutical Inc. FGF23"/>
   <result pre="Hakko Kirin/Ultragenyx Pharmaceutical Inc. FGF23 Human IgG1 Transgenic mice X-linked" exact="hypophosphatemia" post="2018 Lanadelumab Takhzyro Dyax Corp. Plasma kallikrein Human IgG1"/>
   <result pre="Takhzyro Dyax Corp. Plasma kallikrein Human IgG1 Phage display Hereditary" exact="angioedema" post="attacks 2018 Mogamulizumab Poteligeo Kyowa Hakko Kirin CCR4 Humanized"/>
   <result pre="Inc./Sun Pharmaceutical Industries, Ltd. IL-23 p19 Humanized IgG1 Hybridoma Plaque" exact="psoriasis" post="2018 Cemiplimab Libtayo Regeneron Pharmaceuticals Inc. PD-1 Human mAb"/>
   <result pre="2018 Emapalumab Gamifant NovImmmune IFNγ Human IgG1 Phage display Primary" exact="hemophagocytic lymphohistiocytosis" post="2018 Fremanezumab Ajovy Teva Pharmaceutical Industries, Ltd. CGRP Humanized"/>
   <result pre="Lumoxiti MedImmune/AstraZeneca CD22 Murine IgG1 dsFv Phage display Hairy cell" exact="leukemia" post="2018 Ravulizumab Ultomiris Alexion Pharmaceuticals Inc. C5 humanized IgG2/4"/>
   <result pre="Ultomiris Alexion Pharmaceuticals Inc. C5 humanized IgG2/4 Hybridoma Paroxysmal nocturnal" exact="hemoglobinuria" post="2018 Caplacizumab Cablivi Ablynx von Willebrand factor Humanized Nanobody"/>
   <result pre="Caplacizumab Cablivi Ablynx von Willebrand factor Humanized Nanobody Hybridoma Acquired" exact="thrombotic thrombocytopenic purpura" post="2019 Romosozumab Evenity Amgen/UCB Sclerostin Humanized IgG2 Hybridoma Osteoporosis"/>
   <result pre="Ablynx von Willebrand factor Humanized Nanobody Hybridoma Acquired thrombotic thrombocytopenic" exact="purpura" post="2019 Romosozumab Evenity Amgen/UCB Sclerostin Humanized IgG2 Hybridoma Osteoporosis"/>
   <result pre="Ingelheim Pharmaceuticals/ AbbVie Inc. IL-23 p19 Humanized IgG1 Hybridoma Plaque" exact="psoriasis" post="2019 Polatuzumab vedotin Polivy Roche, F. Hoffmann-La Roche, Ltd."/>
   <result pre="Roche, Ltd. CD79β Humanized IgG1 ADC Hybridoma Diffuse large B-cell" exact="lymphoma" post="2019 Brolucizumab Beovu Novartis Pharmaceuticals Corp. VEGF-A Humanized scFv"/>
   <result pre="2018. Ab, antibody; ALCL, systematic anaplastic large-cell lymphoma; aTTP, acquired" exact="thrombotic thrombocytopenic purpura;" post="BC, breast cancer; CD, cluster of differentiation; CGRP, calcitonin"/>
   <result pre="systematic anaplastic large-cell lymphoma; aTTP, acquired thrombotic thrombocytopenic purpura; BC," exact="breast cancer;" post="CD, cluster of differentiation; CGRP, calcitonin gene-related peptide; CGRPR,"/>
   <result pre="CGRP, calcitonin gene-related peptide; CGRPR, calcitonin gene-related peptide receptor; CRC," exact="colorectal cancer;" post="CTLA-4, cytotoxic T-lymphocyte-associated protein 4; EGFR, epidermal growth factor"/>
   <result pre="receptor; mAb, monoclonal antibody; MCC, merkel-cell carcinoma; NSCLC, non-small cell" exact="lung cancer;" post="PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand"/>
   <result pre="PD-L1, programmed death-ligand 1; TNFα, tumor necrosis factor α; RA," exact="rheumatoid arthritis;" post="RANKL, receptor activator of nuclear factor kappa-B ligand; VEGF-A,"/>
   <result pre="growth factor receptor 2; vWF, von Willebrand factor; XLH, X-linked" exact="hypophosphatemia" post="The first therapeutic mAb, muromonab-CD3 (Orthoclone OKT3), was approved"/>
   <result pre="oncologic indication, rituximab, a chimeric anti-CD20 IgG1 approved for non-Hodgkin’s" exact="lymphoma" post="in 1997 by US FDA (Fig. 1) [ 8,"/>
   <result pre="biologics directed against diseases that require long-term treatment, such as" exact="cancer" post="and autoimmune diseases [ 12]. Based on the success"/>
   <result pre="16], was approved in 2002 by the US FDA for" exact="rheumatoid arthritis" post="(Fig. 1). Until now, nine human antibody drugs generated"/>
   <result pre="was approved in 2002 by the US FDA for rheumatoid" exact="arthritis" post="(Fig. 1). Until now, nine human antibody drugs generated"/>
   <result pre="from human B cells has also yielded promising results for" exact="infectious disease" post="therapeutics. The recent development of bispecific antibodies offers attractive"/>
   <result pre="that targets CD3 and CD19 for treatment of B-cell precursor" exact="acute lymphoblastic leukemia" post="(ALL) [ 42]. Second, emicizumab is a full-size bispecific"/>
   <result pre="targets CD3 and CD19 for treatment of B-cell precursor acute" exact="lymphoblastic leukemia" post="(ALL) [ 42]. Second, emicizumab is a full-size bispecific"/>
   <result pre="CD3 and CD19 for treatment of B-cell precursor acute lymphoblastic" exact="leukemia" post="(ALL) [ 42]. Second, emicizumab is a full-size bispecific"/>
   <result pre="clinical trials, about 86% of which are under evaluation as" exact="cancer" post="therapies [ 40]. The concepts and platforms driving the"/>
   <result pre="such as cancer, asthma, arthritis, psoriasis, Crohn’s disease, transplant rejection," exact="migraine" post="headaches and infectious diseases (Table 1). Important advances in"/>
   <result pre="Approval Year) Company 2018 Revenue (USD) 1 Adalimumab (Humira) Rheumatoid" exact="arthritis" post="(2002) Psoriatic arthritis (2005) Ankylosing spondylitis (2006) Juvenile Idiopathic"/>
   <result pre="2018 Revenue (USD) 1 Adalimumab (Humira) Rheumatoid arthritis (2002) Psoriatic" exact="arthritis" post="(2005) Ankylosing spondylitis (2006) Juvenile Idiopathic Arthitis (2008) Psoriasis"/>
   <result pre="1 Adalimumab (Humira) Rheumatoid arthritis (2002) Psoriatic arthritis (2005) Ankylosing" exact="spondylitis" post="(2006) Juvenile Idiopathic Arthitis (2008) Psoriasis (2008) Crohn’s disease"/>
   <result pre="Juvenile Idiopathic Arthitis (2008) Psoriasis (2008) Crohn’s disease (2010) Ulcerative" exact="colitis" post="(2012) Hidradenitis suppurativa (2015) Uveitis (2018) AbbVie $19.9 bn"/>
   <result pre="AbbVie $19.9 bn 2 Nivolumab (Opdivo) Melanoma (2015) Non-small cell" exact="lung cancer" post="(2015) Renal cell carcinoma (2015) Head and neck squamous"/>
   <result pre="$19.9 bn 2 Nivolumab (Opdivo) Melanoma (2015) Non-small cell lung" exact="cancer" post="(2015) Renal cell carcinoma (2015) Head and neck squamous"/>
   <result pre="$7.6 bn 3 Pembrolizumab (Keytruda) Melanoma (2014) Head and neck" exact="cancer" post="(2016) Non-small cell lung caccer (2015) Lymphoma (2018) Cervical"/>
   <result pre="cancer (2016) Non-small cell lung caccer (2015) Lymphoma (2018) Cervical" exact="cancer" post="(2018) Microsatellite instability-high cancer (2018) Merck &amp;amp; Co $7.2"/>
   <result pre="lung caccer (2015) Lymphoma (2018) Cervical cancer (2018) Microsatellite instability-high" exact="cancer" post="(2018) Merck &amp;amp; Co $7.2 bn 4 Trastuzumab (Herceptin)"/>
   <result pre="(2018) Merck &amp;amp; Co $7.2 bn 4 Trastuzumab (Herceptin) Breast" exact="cancer" post="(1998) Gastric cancer (2010) Roche $7.0 bn 5 Bevacizumab"/>
   <result pre="Co $7.2 bn 4 Trastuzumab (Herceptin) Breast cancer (1998) Gastric" exact="cancer" post="(2010) Roche $7.0 bn 5 Bevacizumab (Avastin) Colorectal cancer"/>
   <result pre="Gastric cancer (2010) Roche $7.0 bn 5 Bevacizumab (Avastin) Colorectal" exact="cancer" post="(2004) Non-small cell lung caccer (2006) Breast ERB2 negative"/>
   <result pre="cancer (2004) Non-small cell lung caccer (2006) Breast ERB2 negative" exact="cancer" post="(2008) Renal cell carcinoma (2009) Glioblastoma (2011) Roche $6.8"/>
   <result pre="(2009) Glioblastoma (2011) Roche $6.8 bn 6 Rituximab, (Rituxan) Non-Hodgkin’s" exact="lymphoma" post="(1997) Chronic lymphocytic leukemia (2010) Rheumatoid arthritis (2006) Pemphigus"/>
   <result pre="$6.8 bn 6 Rituximab, (Rituxan) Non-Hodgkin’s lymphoma (1997) Chronic lymphocytic" exact="leukemia" post="(2010) Rheumatoid arthritis (2006) Pemphigus vulgaris (2018) Roche $6.8"/>
   <result pre="Rituximab, (Rituxan) Non-Hodgkin’s lymphoma (1997) Chronic lymphocytic leukemia (2010) Rheumatoid" exact="arthritis" post="(2006) Pemphigus vulgaris (2018) Roche $6.8 bn 7 Infliximab"/>
   <result pre="Roche $6.8 bn 7 Infliximab (Remicade) Crohn’s Disease (1998) Rheumatoid" exact="arthritis" post="(1999) Ankylosing spondylitis (2004) Ulcerative colitis (2005) Psoriatic arthritis"/>
   <result pre="7 Infliximab (Remicade) Crohn’s Disease (1998) Rheumatoid arthritis (1999) Ankylosing" exact="spondylitis" post="(2004) Ulcerative colitis (2005) Psoriatic arthritis (2005) Psoriasis (2006)"/>
   <result pre="Crohn’s Disease (1998) Rheumatoid arthritis (1999) Ankylosing spondylitis (2004) Ulcerative" exact="colitis" post="(2005) Psoriatic arthritis (2005) Psoriasis (2006) Johnson &amp;amp; Johnson"/>
   <result pre="Rheumatoid arthritis (1999) Ankylosing spondylitis (2004) Ulcerative colitis (2005) Psoriatic" exact="arthritis" post="(2005) Psoriasis (2006) Johnson &amp;amp; Johnson $5.9 bn 8"/>
   <result pre="&amp;amp; Johnson $5.9 bn 8 Ustekinumab (Stelara) Psoriasis (2009) Psoriatic" exact="arthritis" post="(2013) Crohn’s Disease (2016) Johnson &amp;amp; Johnson $5.2 bn"/>
   <result pre="Johnson &amp;amp; Johnson $5.2 bn 9 Eculizumab (Soliris) Paroxysmal nocturnal" exact="hemoglobinuria" post="(2007) Atypical hemolytic uremic syndrome (2011) Generalized myasthenia gravis"/>
   <result pre="Paroxysmal nocturnal hemoglobinuria (2007) Atypical hemolytic uremic syndrome (2011) Generalized" exact="myasthenia gravis" post="(2017) Neuromyelitis optica spectrum disorder (2019) Alexion $3.6 bn"/>
   <result pre="Alexion $3.6 bn 10 Omalizumab (Xolair) Asthma (2003) Chronic idiopathic" exact="urticaria" post="(2014) Roche $3.0 bn bn, billion mAbs are increasingly"/>
   <result pre="subcutaneously administered biological disease modifier used for the treatment of" exact="rheumatoid arthritis" post="and other TNFα-mediated chronic debilitating diseases. It was originally"/>
   <result pre="administered biological disease modifier used for the treatment of rheumatoid" exact="arthritis" post="and other TNFα-mediated chronic debilitating diseases. It was originally"/>
   <result pre="Adalimumab reduces the signs and symptoms of moderate to severe" exact="rheumatoid arthritis" post="in adults, and it is also used to treat"/>
   <result pre="reduces the signs and symptoms of moderate to severe rheumatoid" exact="arthritis" post="in adults, and it is also used to treat"/>
   <result pre="arthritis in adults, and it is also used to treat" exact="psoriatic arthritis," post="ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa,"/>
   <result pre="adults, and it is also used to treat psoriatic arthritis," exact="ankylosing spondylitis," post="Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and"/>
   <result pre="also used to treat psoriatic arthritis, ankylosing spondylitis, Crohn's disease," exact="ulcerative colitis," post="psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis ["/>
   <result pre="treat psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis," exact="hidradenitis suppurativa," post="uveitis, and juvenile idiopathic arthritis [ 47, 48]. It"/>
   <result pre="spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and" exact="juvenile idiopathic arthritis" post="[ 47, 48]. It may be used alone or"/>
   <result pre="disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic" exact="arthritis" post="[ 47, 48]. It may be used alone or"/>
   <result pre="the molecules underlying checkpoints have recently drawn considerable interest in" exact="cancer" post="immunotherapy [ 50]. Both nivolumab (Opdivo) and pembrolizumab (Keytruda)"/>
   <result pre="a signal that normally prevents activated T cells from attacking" exact="cancer" post="cells. The target for nivolumab is the PD-1 receptor,"/>
   <result pre="[ 51, 52]. Pembrolizumab is a humanized antibody used in" exact="cancer" post="immunotherapy to treat melanoma, lung cancer, head and neck"/>
   <result pre="a humanized antibody used in cancer immunotherapy to treat melanoma," exact="lung cancer," post="head and neck cancer, Hodgkin’s lymphoma, and stomach cancer"/>
   <result pre="antibody used in cancer immunotherapy to treat melanoma, lung cancer," exact="head and neck cancer," post="Hodgkin’s lymphoma, and stomach cancer [ 53– 55]. Pembrolizumab"/>
   <result pre="melanoma, lung cancer, head and neck cancer, Hodgkin’s lymphoma, and" exact="stomach cancer" post="[ 53– 55]. Pembrolizumab is a first-line treatment for"/>
   <result pre="lung cancer, head and neck cancer, Hodgkin’s lymphoma, and stomach" exact="cancer" post="[ 53– 55]. Pembrolizumab is a first-line treatment for"/>
   <result pre="53– 55]. Pembrolizumab is a first-line treatment for NSCLC if" exact="cancer" post="cells overexpresse PD-L1 and have no mutations in EGFR"/>
   <result pre="PD-L1 and have no mutations in EGFR or in anaplastic" exact="lymphoma" post="kinase [ 56, 57]. Large randomized clinical trials indicated"/>
   <result pre="diseases. Three antibodies (erenumab, galcanezumab, and fremaezumab) were approved for" exact="migraine" post="prevention, and one (Ibalizumab) is used for human immunodeficiency"/>
   <result pre="block the activity of calcitonin gene-related peptide (CGRP) receptor in" exact="migraine" post="etiology [ 59]. CGRP acts through a heteromeric receptor,"/>
   <result pre="the US FDA: raxibacumab and obiltoxaximab for treatment of inhalational" exact="anthrax" post="[ 63], palivizumab for prevention of respiratory syncytial virus"/>
   <result pre="Most of the mAbs in Phase I (~ 70%) are for" exact="cancer" post="treatment, and the proportions of mAbs intended to treat"/>
   <result pre="cancer treatment, and the proportions of mAbs intended to treat" exact="cancer" post="are similar for those currently in Phase II and"/>
   <result pre="were 33 novel antibody therapeutics in late-stage clinical studies for" exact="cancer" post="indications in 2018. Antibody therapeutics for solid tumors clearly"/>
   <result pre="chimeric mAb under evaluation as a treatment for patients with" exact="multiple myeloma" post="(MM). Combinations of isatuximab and different chemotherapies are being"/>
   <result pre="6 weeks thereafter in four patient cohorts: microsatellite instability high (MSI-H)" exact="endometrial cancer," post="MSI-H non-endometrial cancer, microsatellite-stable endometrial cancer, and non-small cell"/>
   <result pre="microsatellite instability high (MSI-H) endometrial cancer, MSI-H non-endometrial cancer, microsatellite-stable" exact="endometrial cancer," post="and non-small cell lung cancer. Dostarlimab is also being"/>
   <result pre="cancer, MSI-H non-endometrial cancer, microsatellite-stable endometrial cancer, and non-small cell" exact="lung cancer." post="Dostarlimab is also being evaluated in another Phase III"/>
   <result pre="as first-line treatment of Stage III or IV non-mucinous epithelial" exact="ovarian cancer" post="[ 69]. Ublituximab is a glyco-engineered anti-CD20 antibody currently"/>
   <result pre="first-line treatment of Stage III or IV non-mucinous epithelial ovarian" exact="cancer" post="[ 69]. Ublituximab is a glyco-engineered anti-CD20 antibody currently"/>
   <result pre="of ublituximab compared to teriflunomide in 440 patients with relapsing" exact="multiple sclerosis" post="[ 70]. Methodologies for developing therapeutic antibodies Human, humanized,"/>
   <result pre="patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic" exact="breast cancer" post="and gastroesophageal junction adenocarcinoma [ 57, 58]. Immunogenicity of"/>
   <result pre="with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast" exact="cancer" post="and gastroesophageal junction adenocarcinoma [ 57, 58]. Immunogenicity of"/>
   <result pre="example, ADA was detected in 0.5% of women with metastatic" exact="breast cancer," post="who were treated with Trastuzumab during their therapeutic courses"/>
   <result pre="the ADA rates were 7.1% (21/296) in the HER-2 positive" exact="breast cancer" post="patients with treatment of Trastuzumab [ 87]. The variation"/>
   <result pre="ADA rates were 7.1% (21/296) in the HER-2 positive breast" exact="cancer" post="patients with treatment of Trastuzumab [ 87]. The variation"/>
   <result pre="fully human anti-TNFα antibody, combining with methotrexate for treatment of" exact="rheumatoid arthritis" post="cause 16% of patients producing anti-drug antibodies [ 91]."/>
   <result pre="human anti-TNFα antibody, combining with methotrexate for treatment of rheumatoid" exact="arthritis" post="cause 16% of patients producing anti-drug antibodies [ 91]."/>
   <result pre="these cells are often referred as tumor initiating cells or" exact="cancer" post="stem cells (CSCs) [ 111]. Phage display technology is"/>
   <result pre="clinical use. Phage display technology has been used to probe" exact="cancer" post="tissue biopsies in order to generate antibody fragments that"/>
   <result pre="immunoliposomes have been demonstrated to provide conventional liposomal drugs with" exact="cancer" post="targeting ability, which can increase the therapeutic efficacy of"/>
   <result pre="internalizing epitopes, wherein a phage-displayed library was incubated with living" exact="cancer" post="cells at 37 °C [ 123]. This method was successfully"/>
   <result pre="identify a few antibodies with broad neutralizing activity against pandemic" exact="influenza" post="virus [ 130, 131]. Chen et al. reported the"/>
   <result pre="from the PBMCs of convalescent patients infected with a novel" exact="influenza" post="A virus H7N9, which broke out in 2013. Using"/>
   <result pre="is approved to treat inflammatory diseases, such as rheumatoid and" exact="psoriatic arthritis," post="Crohn’s disease, and psoriasis. Adalimumab is the world’s best-selling"/>
   <result pre="induces B cell proliferation and differentiation that positively correlate with" exact="systemic lupus erythematosus" post="(SLE). This anti-BLYS antibody was named belimumab and marketed"/>
   <result pre="B cell proliferation and differentiation that positively correlate with systemic" exact="lupus erythematosus" post="(SLE). This anti-BLYS antibody was named belimumab and marketed"/>
   <result pre="tumor angiogenesis, but it also expressed on the surface of" exact="cancer" post="cells. The anti-VEGFR2 human antibody, ramucirumab (Cyramza), was approved"/>
   <result pre="for the treatment of gastric cancer, metastatic NSCLC and metastatic" exact="colorectal cancer" post="[ 145, 146]. The development of ramucirumab was initiated"/>
   <result pre="the treatment of gastric cancer, metastatic NSCLC and metastatic colorectal" exact="cancer" post="[ 145, 146]. The development of ramucirumab was initiated"/>
   <result pre="have been found to express PD-L1 on the surface of" exact="cancer" post="cells, using the immune-suppressing action to evade immune attacks."/>
   <result pre="of urothelial carcinoma and Merkel-cell carcinoma, an aggressive type of" exact="skin cancer" post="[ 151]. Psoriasis is a chronic autoimmune inflammatory disorder"/>
   <result pre="urothelial carcinoma and Merkel-cell carcinoma, an aggressive type of skin" exact="cancer" post="[ 151]. Psoriasis is a chronic autoimmune inflammatory disorder"/>
   <result pre="approval by the US FDA for the treatment of plaque" exact="psoriasis" post="[ 154]. Hereditary angioedema is a rare disease that"/>
   <result pre="FDA for the treatment of plaque psoriasis [ 154]. Hereditary" exact="angioedema" post="is a rare disease that results in spontaneous, recurrent,"/>
   <result pre="in the USA and Canada for prophylaxis against attacks of" exact="hereditary angioedema" post="in patients aged ≥ 12 years [ 157]. The success of"/>
   <result pre="the USA and Canada for prophylaxis against attacks of hereditary" exact="angioedema" post="in patients aged ≥ 12 years [ 157]. The success of"/>
   <result pre="wide spectrum of target antigens, including pure recombinant proteins, glycans," exact="cancer" post="cells and virus particles [ 99, 103, 104]. Human"/>
   <result pre="market (Table 5). Eight of the drugs are used for" exact="cancer" post="treatment, while the others are for autoimmune or inflammatory"/>
   <result pre="Amgen, human IgG2/kappa), was approved to treat the EGFR-expressing metastatic" exact="colorectal cancer" post="with wild-type KRAS [ 188]. This mAb blocks the"/>
   <result pre="human IgG2/kappa), was approved to treat the EGFR-expressing metastatic colorectal" exact="cancer" post="with wild-type KRAS [ 188]. This mAb blocks the"/>
   <result pre="resulting in the inhibition of EGFR signaling and induction of" exact="cancer" post="cell apoptosis. Two antibody drugs from the XenoMouse are"/>
   <result pre="IgG1), binds to proinflammatory cytokine IL-17α to reduce inflammation in" exact="psoriasis" post="[ 189]. The other is brodalumab (Siliq, Valeant Pharmaceuticals,"/>
   <result pre="two mAb drugs were approved by the US FDA for" exact="psoriasis" post="treatment in 2015 and 2017, respectively. From the HuMabMouse,"/>
   <result pre="B7 on APCs and causing cytotoxic T lymphocytes to kill" exact="cancer" post="cells [ 190]. Nivolumab recognizes to PD-1, reducing inhibitory"/>
   <result pre="[ 191]. Notably, nivolumab was also approved for non-small cell" exact="lung cancer" post="treatment in 2018. Among the mAb drugs derived from"/>
   <result pre="191]. Notably, nivolumab was also approved for non-small cell lung" exact="cancer" post="treatment in 2018. Among the mAb drugs derived from"/>
   <result pre="to ease inflammation. This drug was approved for severe plaque" exact="psoriasis" post="[ 17] in 2009 and for Crohn’s disease ["/>
   <result pre="species. B. anthracis is a fatal pathogen that causes severe" exact="anthrax" post="disease in humans and has been used as a"/>
   <result pre="used as a biological weapon. Although antibiotics are available for" exact="anthrax" post="treatment and as post-exposure prophylaxis, anti-anthrax protective antibodies from"/>
   <result pre="B cell method can enhance phagocytosis to protect against disseminated" exact="candidiasis" post="[ 223]. The single B cell method has also"/>
   <result pre="conducted on the prevention of sexual transmission of HIV-1 and" exact="herpes simplex" post="virus by MB 66 combined with an anti-herpes simplex"/>
   <result pre="simplex virus antibody (AC8) and an anti-HIV antibody (VRC01). Different" exact="influenza" post="viruses cause epidemics ever year, and influenza vaccines are"/>
   <result pre="antibody (VRC01). Different influenza viruses cause epidemics ever year, and" exact="influenza" post="vaccines are the most useful measure to prevent seasonal"/>
   <result pre="235]. MHAA4549A, a human mAb targeting the hemagglutinin stalk of" exact="influenza" post="A virus was cloned from a single human plasmablast"/>
   <result pre="was cloned from a single human plasmablast cell from an" exact="influenza" post="virus vaccinated donor [ 236]. A Phase II clinical"/>
   <result pre="trial of MHAA4549A as a monotherapy for acute uncomplicated seasonal" exact="influenza" post="A in otherwise healthy adults was recently completed (NCT02623322)."/>
   <result pre="(sarilumab and tocilizumab) can be used for the treatment of" exact="rheumatoid arthritis." post="Anti-Factor IXa/Xa antibody (emicizumab) is a valuable treatment for"/>
   <result pre="Willebrand factor antibody (caplacizumab) is approved for the treatment of" exact="thrombotic thrombocytopenic purpura," post="and other antibodies will be approved for new indications"/>
   <result pre="different mechanisms, including mediated pathways (e.g., ADCC/CDC), direct targeting of" exact="cancer" post="cells to induce apoptosis, targeting the tumor microenvironment, or"/>
   <result pre="or targeting immune checkpoints. In mediated pathways, the antibody kills" exact="cancer" post="cells by recruiting natural killer cells or other immune"/>
   <result pre="253] or modification of glycosylation [ 254– 258] to improve" exact="cancer" post="cell killing capabilities. The direct induction apoptosis in cancer"/>
   <result pre="improve cancer cell killing capabilities. The direct induction apoptosis in" exact="cancer" post="cells has traditionally been the preferred mechanism for therapeutic"/>
   <result pre="microenvironment, antibodies can inhibit tumorigenesis by targeting factors involved in" exact="cancer" post="cell growth. For example, Avastin targets vascular endothelial growth"/>
   <result pre="tumor, shutting down the supply of nutrients required for the" exact="cancer" post="cell growth. Immune checkpoints have proven to be valuable"/>
   <result pre="growth. Immune checkpoints have proven to be valuable targets for" exact="cancer" post="treatment. In the future, studies evaluating synergistic effects of"/>
   <result pre="for disease therapy. Antibodies in this category are used for" exact="cancer" post="treatment and elicit cell death by different mechanisms, including"/>
   <result pre="cell death by different mechanisms, including ADCC/CDC, direct targeting of" exact="cancer" post="cells to induce apoptosis, targeting the tumor microenvironment, or"/>
   <result pre="gene for a chimeric T cell receptor-antibody targeting a specific" exact="cancer" post="marker into T cells, such that the engineered cells"/>
   <result pre="T cells, such that the engineered cells target and kill" exact="cancer" post="cells [ 265, 266]. In recent years, this approach"/>
   <result pre="and medical community due to its significant clinical benefits to" exact="cancer" post="patients. In many cases, patients have experienced complete remission"/>
   <result pre="have experienced complete remission or even been completely cured of" exact="cancer" post="[ 267– 271]. Although new methods have been well-established"/>
   <result pre="CDR Complementary-determining region CGRP Calcitonin gene-related peptide CLL Chronic lymphocytic" exact="leukemia" post="CoV Coronavirus CSC Cancer stem cell CTLA-4 Cytotoxic T-lymphocyte–associated"/>
   <result pre="MM Multiple myeloma MSI-H Microsatellite instability high NSCLC Non-small cell" exact="lung cancer" post="PBMC Peripheral blood mononuclear cell PCR Polymerase chain reaction"/>
   <result pre="Multiple myeloma MSI-H Microsatellite instability high NSCLC Non-small cell lung" exact="cancer" post="PBMC Peripheral blood mononuclear cell PCR Polymerase chain reaction"/>
   <result pre="transcription-polymerase chain reaction scFv Single chain fragment variable SLE Systemic" exact="lupus erythematosus" post="TNFα Tumor necrosis factor α US FDA United States"/>
   <result pre="LR Abciximab. An updated review of its use in ischaemic" exact="heart disease" post="Drugs. 1998 56 629 665 10.2165/00003495-199856040-00014 9806109 8. Maloney"/>
   <result pre="anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's" exact="lymphoma" post="Blood. 1997 90 2188 2195 10.1182/blood.V90.6.2188 9310469 9. Maloney"/>
   <result pre="a phase I multiple-dose trial in patients with relapsed non-Hodgkin's" exact="lymphoma" post="J Clin Oncol 1997 15 3266 3274 10.1200/JCO.1997.15.10.3266 9336364"/>
   <result pre="10577977 17. Bartlett BL Tyring SK Ustekinumab for chronic plaque" exact="psoriasis" post="Lancet. 2008 371 1639 1640 10.1016/S0140-6736(08)60702-3 18486724 18. Church"/>
   <result pre="golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with" exact="rheumatoid arthritis" post="J Clin Pharmacol 2007 47 383 396 10.1177/0091270006298188 17322150"/>
   <result pre="a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid" exact="arthritis" post="J Clin Pharmacol 2007 47 383 396 10.1177/0091270006298188 17322150"/>
   <result pre="a novel therapeutic human CD38 monoclonal antibody, induces killing of" exact="multiple myeloma" post="and other hematological tumors J Immunol 2011 186 1840"/>
   <result pre="interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of" exact="influenza" post="and meningococcal vaccinations in healthy subjects: results of an"/>
   <result pre="JG Kricorian G et al. Brodalumab, an anti-interleukin-17-receptor antibody for" exact="psoriasis" post="N Engl J Med 2012 366 1181 1189 10.1056/NEJMoa1109017"/>
   <result pre="S Sher L Skobieranda F et al. Dupilumab in persistent" exact="asthma" post="with elevated eosinophil levels N Engl J Med 2013"/>
   <result pre="a fully human monoclonal antibody against IL-6Ralpha in patients with" exact="rheumatoid arthritis" post="and an inadequate response to methotrexate: efficacy and safety"/>
   <result pre="fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid" exact="arthritis" post="and an inadequate response to methotrexate: efficacy and safety"/>
   <result pre="fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic" exact="colorectal cancer" post="Clin Colorectal Cancer 2006 6 29 31 10.3816/CCC.2006.n.01 16796788"/>
   <result pre="human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal" exact="cancer" post="Clin Colorectal Cancer 2006 6 29 31 10.3816/CCC.2006.n.01 16796788"/>
   <result pre="Blinatumomab for minimal residual disease in adults with B-cell precursor" exact="acute lymphoblastic leukemia" post="Blood. 2018 131 1522 1531 10.1182/blood-2017-08-798322 29358182 43. Oldenburg"/>
   <result pre="for minimal residual disease in adults with B-cell precursor acute" exact="lymphoblastic leukemia" post="Blood. 2018 131 1522 1531 10.1182/blood-2017-08-798322 29358182 43. Oldenburg"/>
   <result pre="minimal residual disease in adults with B-cell precursor acute lymphoblastic" exact="leukemia" post="Blood. 2018 131 1522 1531 10.1182/blood-2017-08-798322 29358182 43. Oldenburg"/>
   <result pre="Grignani G Aglietta M Sangiolo D Next generation immune-checkpoints for" exact="cancer" post="therapy J Thorac Dis 2018 10 S1581 SS601 10.21037/jtd.2018.02.79"/>
   <result pre="safety in 23 458 patients from global clinical trials in" exact="rheumatoid arthritis," post="juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and"/>
   <result pre="23 458 patients from global clinical trials in rheumatoid arthritis," exact="juvenile idiopathic arthritis," post="ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease Ann"/>
   <result pre="from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis," exact="ankylosing spondylitis," post="psoriatic arthritis, psoriasis and Crohn's disease Ann Rheum Dis"/>
   <result pre="clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis," exact="psoriatic arthritis," post="psoriasis and Crohn's disease Ann Rheum Dis 2013 72"/>
   <result pre="in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis," exact="psoriasis" post="and Crohn's disease Ann Rheum Dis 2013 72 517"/>
   <result pre="et al. Adalimumab regulates intracellular TNFalpha production in patients with" exact="rheumatoid arthritis" post="Arthritis Res Ther 2014 16 R153 10.1186/ar4615 25037855 50."/>
   <result pre="al. Adalimumab regulates intracellular TNFalpha production in patients with rheumatoid" exact="arthritis" post="Arthritis Res Ther 2014 16 R153 10.1186/ar4615 25037855 50."/>
   <result pre="25037855 50. Pardoll DM The blockade of immune checkpoints in" exact="cancer" post="immunotherapy Nat Rev Cancer 2012 12 252 264 10.1038/nrc3239"/>
   <result pre="al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's" exact="lymphoma" post="N Engl J Med 2015 372 311 319 10.1056/NEJMoa1411087"/>
   <result pre="M et al. Pembrolizumab for patients with melanoma or non-small-cell" exact="lung cancer" post="and untreated brain metastases: early analysis of a non-randomised,"/>
   <result pre="et al. Pembrolizumab for patients with melanoma or non-small-cell lung" exact="cancer" post="and untreated brain metastases: early analysis of a non-randomised,"/>
   <result pre="60. Paemeleire K MaassenVanDenBrink A Calcitonin-gene-related peptide pathway mAbs and" exact="migraine" post="prevention Curr Opin Neurol 2018 31 274 280 10.1097/WCO.0000000000000548"/>
   <result pre="Warfvinge K Krause DN CGRP as the target of new" exact="migraine" post="therapies - successful translation from bench to clinic Nat"/>
   <result pre="Devalaraja M et al. Raxibacumab for the treatment of inhalational" exact="anthrax" post="N Engl J Med 2009 361 135 144 10.1056/NEJMoa0810603"/>
   <result pre="FDA to review isatuximab as a potential treatment for relapsed/refractory" exact="multiple myeloma." post="Paris, 2019. 67. Richardson PG Attal M Campana F"/>
   <result pre="humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic" exact="breast cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
   <result pre="anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast" exact="cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
   <result pre="P Hall S et al. Golimumab in patients with active" exact="rheumatoid arthritis" post="despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging"/>
   <result pre="Hall S et al. Golimumab in patients with active rheumatoid" exact="arthritis" post="despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging"/>
   <result pre="VEGFR2 and for inhibiting tumor growth, tumor angiogenesis and/or inducing" exact="cancer" post="cell cytotoxicity. US patent US10,196,447. 2018 February 5. 105."/>
   <result pre="human monoclonal antibody drug and target discovery platform for B-cell" exact="chronic lymphocytic leukemia" post="based on allogeneic hematopoietic stem cell transplantation and phage"/>
   <result pre="antibody drug and target discovery platform for B-cell chronic lymphocytic" exact="leukemia" post="based on allogeneic hematopoietic stem cell transplantation and phage"/>
   <result pre="S Poulsen PC Overgaard LF et al. Selection of a" exact="breast cancer" post="subpopulation-specific antibody using phage display on tissue sections Immunol"/>
   <result pre="Poulsen PC Overgaard LF et al. Selection of a breast" exact="cancer" post="subpopulation-specific antibody using phage display on tissue sections Immunol"/>
   <result pre="JM Peer D Progress and challenges towards targeted delivery of" exact="cancer" post="therapeutics Nat Commun 2018 9 1410 10.1038/s41467-018-03705-y 29650952 122."/>
   <result pre="Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to" exact="prostate cancer" post="cells Mol Cancer Ther 2007 6 2737 2746 10.1158/1535-7163.MCT-07-0140"/>
   <result pre="single chain antibody-mediated intracellular delivery of liposomal drugs to prostate" exact="cancer" post="cells Mol Cancer Ther 2007 6 2737 2746 10.1158/1535-7163.MCT-07-0140"/>
   <result pre="W Yang Y et al. Human neutralizing Fab molecules against" exact="severe acute respiratory syndrome" post="coronavirus generated by phage display Clin Vacc Immunol: CVI"/>
   <result pre="a conserved HA1 epitope has broad neutralizing potency against H5N1" exact="influenza" post="A viruses of different clades Antiviral Research 2013 99"/>
   <result pre="al. Combinatorial antibody libraries from survivors of the Turkish H5N1" exact="avian influenza" post="outbreak reveal virus neutralization strategies Proc Natl Acad Sci"/>
   <result pre="Combinatorial antibody libraries from survivors of the Turkish H5N1 avian" exact="influenza" post="outbreak reveal virus neutralization strategies Proc Natl Acad Sci"/>
   <result pre="Human monoclonal antibodies targeting the haemagglutinin glycoprotein can neutralize H7N9" exact="influenza" post="virus. Nat Commun. 2015;6. 133. Wang J, Chen Z,"/>
   <result pre="anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of" exact="rheumatoid arthritis" post="in patients taking concomitant methotrexate: the ARMADA trial Arthritis"/>
   <result pre="necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid" exact="arthritis" post="in patients taking concomitant methotrexate: the ARMADA trial Arthritis"/>
   <result pre="A Paz-Ares L Necitumumab for the treatment of advanced non-small-cell" exact="lung cancer" post="Future Oncol 2019 15 705 716 10.2217/fon-2018-0594 30501503 145."/>
   <result pre="Paz-Ares L Necitumumab for the treatment of advanced non-small-cell lung" exact="cancer" post="Future Oncol 2019 15 705 716 10.2217/fon-2018-0594 30501503 145."/>
   <result pre="A Lopez-Mejia M Ramucirumab in the treatment of non-small cell" exact="lung cancer" post="Expert Opin Drug Saf 2017 16 637 644 10.1080/14740338.2017.1313226"/>
   <result pre="Lopez-Mejia M Ramucirumab in the treatment of non-small cell lung" exact="cancer" post="Expert Opin Drug Saf 2017 16 637 644 10.1080/14740338.2017.1313226"/>
   <result pre="Rodriguez-Vida A Bellmunt J Avelumab for the treatment of urothelial" exact="cancer" post="Expert Rev Anticancer Ther 2018 18 421 429 10.1080/14737140.2018.1448271"/>
   <result pre="Riedl M et al. Icatibant, a new bradykinin-receptor antagonist, in" exact="hereditary angioedema" post="N Engl J Med 2010 363 532 541 10.1056/NEJMoa0906393"/>
   <result pre="M et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary" exact="angioedema" post="N Engl J Med 2010 363 532 541 10.1056/NEJMoa0906393"/>
   <result pre="a fully human anti-epidermal growth factor receptor antibody, in metastatic" exact="colorectal cancer" post="Clin Colorectal Cancer 2005 5 21 23 10.1016/S1533-0028(11)70161-X 15929802"/>
   <result pre="fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal" exact="cancer" post="Clin Colorectal Cancer 2005 5 21 23 10.1016/S1533-0028(11)70161-X 15929802"/>
   <result pre="human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with" exact="rheumatoid arthritis." post="J Rheumatol. 2002;29(11):2288–98. 179. Tyagi Preeta Chu Edward Jain"/>
   <result pre="187. Kreitman, Robert J, et al. Moxetumomab pasudotox in relapsed/refractory" exact="hairy cell leukemia." post="Leukemia. 2018;32(8):1768. 188. Berardi R Onofri A Pistelli M"/>
   <result pre="the evidence for its use in the treatment of metastatic" exact="colorectal cancer" post="Core Evid 2010 5 61 76 10.2147/CE.S7035 21042543 189."/>
   <result pre="evidence for its use in the treatment of metastatic colorectal" exact="cancer" post="Core Evid 2010 5 61 76 10.2147/CE.S7035 21042543 189."/>
   <result pre="NW Clinical and economic review of secukinumab for moderate-to-severe plaque" exact="psoriasis" post="Expert Rev Pharmacoecon Outcomes Res 2016 16 153 166"/>
   <result pre="et al. Rapid cloning of high-affinity human monoclonal antibodies against" exact="influenza" post="virus Nature. 2008 453 667 671 10.1038/nature06890 18449194 216."/>
   <result pre="cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated" exact="candidiasis" post="Nat Commun 2018 9 5288 10.1038/s41467-018-07738-1 30538246 224. Cox"/>
   <result pre="in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic" exact="influenza" post="A antibodies Cell Host Microbe 2013 14 93 103"/>
   <result pre="Estevez A et al. A broadly protective therapeutic antibody against" exact="influenza" post="B virus with two mechanisms of action Nat Commun"/>
   <result pre="10.1158/2326-6066.CIR-14-0029 24795350 242. Sliwkowski MX Mellman I Antibody therapeutics in" exact="cancer" post="Science. 2013 341 1192 1198 10.1126/science.1241145 24031011 243. Makabe"/>
   <result pre="Ghassemi S Milone MC CAR T cell immunotherapy for human" exact="cancer" post="Science. 2018 359 1361 1365 10.1126/science.aar6711 29567707 267. Neelapu"/>
   <result pre="Brudno JN Kochenderfer JN Chimeric antigen receptor T-cell therapies for" exact="lymphoma" post="Nat Rev Clin Oncol 2017 15 31 10.1038/nrclinonc.2017.128 28857075"/>
   <result pre="Tung CP Tsou YL et al. High throughput discovery of" exact="influenza" post="virus neutralizing antibodies from phage-displayed synthetic antibody libraries Sci"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6941257/results/search/disease/results.xml">
   <result pre="the result of bacterial cell wall depolarization [ 36]. Mycobacterium" exact="tuberculosis" post="(MTB) , the bacterium that causes tuberculosis, is another"/>
   <result pre="an anti-biofilm agent. Aptamer has led to an early stage" exact="suppression" post="of biofilm formation. In the absence of aptamer, flagella-mediated"/>
   <result pre="bacterial pneumonias and is the major cause of meningitis, septicemia," exact="otitis media" post="and sinusitis. All wild-type strains are able to form"/>
   <result pre="Moreover, enterotoxin B (SEB) from S. aureus can cause staphylococcal" exact="toxic shock syndrome" post="(TSS), which is rarely observed with other enterotoxins types."/>
   <result pre="The virulence of B. anthracis depends on the production of" exact="anthrax" post="toxin. The anthrax toxins consist of three components. One"/>
   <result pre="B. anthracis depends on the production of anthrax toxin. The" exact="anthrax" post="toxins consist of three components. One of them is"/>
   <result pre="gp120 aptamer -LTR-362 siRNA conjugates induced TGS with a ~ 10-fold" exact="suppression" post="of viral p24 levels and also, reduced CD4 +"/>
   <result pre="serovar typhi ( S. typhi) produces a feverish disease called" exact="typhoid fever." post="IVB pili is expressed by S. typhi, which is"/>
   <result pre="is the main character in the development of epidemics of" exact="typhoid fever." post="Monocytes and macrophages are critical effector molecules that play"/>
   <result pre="by inhibiting nucleocapsid assembly that reduces extracellular DNA. Apt.No.28 against" exact="hepatitis" post="B virus (HBV) exhibited this feature [ 82]. Aptamers"/>
   <result pre="impede virus binding to host cells. As an example, the" exact="influenza" post="virus hemagglutinin binds to the sialic acid receptor of"/>
   <result pre="in initiating of viral infections. A DNA aptamer, A22, obstructed" exact="influenza" post="virus infection by blocking the virus attachment to host"/>
   <result pre="host cells [ 83]. Also, T14 and F34 aptamers prevent" exact="rabies" post="virus from entering the host cells by blocking the"/>
   <result pre="cell receptors [ 84]. Moreover, in the penetration process of" exact="herpes simplex" post="virus, the gD protein is a major determinant of"/>
   <result pre="simplex virus, the gD protein is a major determinant of" exact="herpes simplex" post="virus-1 (HSV) entry. Two aptamers were selected, which interfered"/>
   <result pre="enzyme activity of HIV tat and reverse transcriptase [ 86]," exact="hepatitis" post="C virus (HCV) NS3 protease/helicase [ 87], NS5B RNA-dependent"/>
   <result pre="helicase [ 89] Rabies virus DNA Blocking the interaction between" exact="rabies" post="virus and permissive host cell receptors -Reduced viral replication"/>
   <result pre="Bayraç AT Donmez SI Selection of DNA aptamers to Streptococcus" exact="pneumonia" post="and fabrication of graphene oxide based fluorescent assay Anal"/>
   <result pre="Ha N-R Jung I-P Schlesinger SR et al. Inhibition of" exact="anthrax" post="lethal factor by ssDNA aptamers Arch Biochem Biophys 2018"/>
   <result pre="PC The polyphosphate kinase gene ppk2 is required for Mycobacterium" exact="tuberculosis" post="inorganic polyphosphate regulation and virulence MBio 2013 4 3"/>
   <result pre="Sam L Wang Y et al. Aptamer-mediated inhibition of mycobacterium" exact="tuberculosis" post="polyphosphate kinase 2 Biochem 2011 50 15 3261 3271"/>
   <result pre="M Feng X Chen L Wu M et al. Efficient" exact="suppression" post="of biofilm formation by a nucleic acid aptamer Pathog"/>
   <result pre="Photodynamic therapy (PDT): a short review on cellular mechanisms and" exact="cancer" post="research applications for PDT J Photochem Photobiol B Biol"/>
   <result pre="10.1016/j.colsurfb.2017.07.056 28778062 74. Gagneux S Ecology and evolution of mycobacterium" exact="tuberculosis" post="Nat Rev Microbiol 2018 16 4 202 10.1038/nrmicro.2018.8 29456241"/>
   <result pre="10.1038/nrmicro.2018.8 29456241 75. Rohde KH Abramovitch RB Russell DG Mycobacterium" exact="tuberculosis" post="invasion of macrophages: linking bacterial gene expression to environmental"/>
   <result pre="X Zhou J Liu S Liu J Aptamer inhibits mycobacterium" exact="tuberculosis" post="(H37Rv) invasion of macrophage Mol Biol Rep 2012 39"/>
   <result pre="Muhammad N, Abbas MN. Interferon-gamma improves macrophages function against M." exact="tuberculosis" post="in multidrug-resistant tuberculosis patients. Chemother Res Pract. 2016:7295390. 78."/>
   <result pre="MN. Interferon-gamma improves macrophages function against M. tuberculosis in multidrug-resistant" exact="tuberculosis" post="patients. Chemother Res Pract. 2016:7295390. 78. Maeurer MJ Trinder"/>
   <result pre="Yang Q et al. Reduced Th17 response in patients with" exact="tuberculosis" post="correlates with IL-6R expression on CD4+ T cells Am"/>
   <result pre="Kayhan B Ben-Yedidia T Arnon R A DNA aptamer prevents" exact="influenza" post="infection by blocking the receptor binding region of the"/>
   <result pre="Qi YL et al. Isolation of ssDNA aptamers that inhibit" exact="rabies" post="virus Int Immunopharmacol 2012 14 3 341 347 10.1016/j.intimp.2012.06.019"/>
   <result pre="Kumar PK Aptamer that binds to the gD protein of" exact="herpes simplex" post="virus 1 and efficiently inhibits viral entry J Virol"/>
   <result pre="al. Isolation and characterization of RNA aptamers specific for the" exact="hepatitis" post="C virus nonstructural protein 3 protease Eur J Biochem"/>
   <result pre="of RNA aptamers that bind the RNA-dependent RNA polymerase of" exact="hepatitis" post="C virus: a possible role of GC-rich RNA motifs"/>
   <result pre="Jeong Y-J Kim D-E Isolation of inhibitory RNA aptamers against" exact="severe acute respiratory syndrome" post="(SARS) coronavirus NTPase/helicase Biochem Biophys Res Commun 2008 366"/>
   <result pre="Xu L Long Y Liu B et al. Inhibition of" exact="hepatitis" post="C virus infection by DNA aptamer against envelope protein"/>
   <result pre="Kawasaki K Kumar PK An efficient RNA aptamer against human" exact="influenza" post="B virus hemagglutinin J Biochem 2006 139 5 837"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6958603/results/search/disease/results.xml">
   <result pre="doi: 10.1186/s12913-019-4884-5 : Research Article An evaluation of the Zambia" exact="influenza" post="sentinel surveillance system, 2011–2017 http://orcid.org/0000-0001-5755-6163 Simusika Paul psimusika@yahoo.co.uk 1"/>
   <result pre="article, unless otherwise stated. Abstract Background Over the past decade," exact="influenza" post="surveillance has been established in several African countries including"/>
   <result pre="information on the on data quality and reliability of established" exact="influenza" post="surveillance systems in Africa are limited. Such information would"/>
   <result pre="Control and Prevention guidelines to evaluate the performance of the" exact="influenza" post="surveillance system (ISS) in Zambia during 2011–2017 using 9"/>
   <result pre="flexibility (score: 3.0) especially to monitor viral pathogens other than" exact="influenza" post="viruses, its simplicity (score: 2.8), acceptability (score: 3.0) and"/>
   <result pre="Keywords Influenza Surveillance Evaluation Zambia Funding CDC,US NU511P000828-05-02). Background Seasonal" exact="influenza" post="virus infections are responsible for an estimated 291,243–645,832 respiratory"/>
   <result pre="2008 [ 3], little was known about the contribution of" exact="influenza" post="viruses to the respiratory disease burden, rendering difficult public"/>
   <result pre="was known about the contribution of influenza viruses to the" exact="respiratory disease" post="burden, rendering difficult public health planning for the prevention"/>
   <result pre="the prevention and control of influenza-associated illness. At present, no" exact="influenza" post="treatment or immunization guidelines are available in Zambia, and"/>
   <result pre="measures for mitigating the transmission and disease burden associated with" exact="influenza" post="infection are in place. Public health surveillance is the"/>
   <result pre="of research hypotheses [ 5]. The lack of a routine" exact="influenza" post="surveillance program in Zambia placed the country at a"/>
   <result pre="with the potential to detect and confirm the etiology of" exact="respiratory disease" post="outbreaks, including seasonal and pandemic influenza viruses, and trigger"/>
   <result pre="the etiology of respiratory disease outbreaks, including seasonal and pandemic" exact="influenza" post="viruses, and trigger a response. The Ministry of Health"/>
   <result pre="The Ministry of Health (MoH) recognized a need to gather" exact="influenza" post="epidemiological and virological data from Zambia that would not"/>
   <result pre="not only help decision makers to formulate policies targeted toward" exact="influenza" post="prevention in Zambia but also to provide a more"/>
   <result pre="to provide a more comprehensive understanding of the dynamics of" exact="influenza" post="viruses worldwide and in African tropical zones in particular."/>
   <result pre="help to identify seed viruses for the production of seasonal" exact="influenza" post="vaccines that can be effectively used for the Southern"/>
   <result pre="needs, in 2008 the Zambia Ministry of Health established an" exact="influenza" post="sentinel surveillance system (ISSS) targeting outpatients with influenza-like illness"/>
   <result pre="illness (SARI). The World Health Organization (WHO) recommends that established" exact="influenza" post="surveillance systems undergo a comprehensive evaluation periodically, beginning 1–2 years"/>
   <result pre="despite recent progress in describing the epidemiology and burden of" exact="influenza" post="in sub-Saharan Africa [ 8– 16], only a few"/>
   <result pre="are not included in this review. Methods Overview of the" exact="influenza" post="sentinel surveillance system during 2011–2017 In Zambia, an ISSS"/>
   <result pre="the Zambia-ISSS were to: (i) monitor the temporal trends of" exact="influenza" post="virus circulation; (ii) monitor the circulating influenza virus types"/>
   <result pre="temporal trends of influenza virus circulation; (ii) monitor the circulating" exact="influenza" post="virus types and subtypes annually, including pandemic strains; (iii)"/>
   <result pre="patients meeting the ILI and SARI case definition attributable to" exact="influenza" post="virus infection; (iv) assess risk factors for influenza-associated severe"/>
   <result pre="(vi) obtain and share clinical samples for annual selection of" exact="influenza" post="virus strains for influenza vaccine formulation under the WHO-Global"/>
   <result pre="clinical samples for annual selection of influenza virus strains for" exact="influenza" post="vaccine formulation under the WHO-Global Influenza Surveillance and Response"/>
   <result pre="the WHO-Global Influenza Surveillance and Response Network. During 2011–2017, ILI" exact="influenza" post="sentinel surveillance was conducted in three urban outpatient clinics"/>
   <result pre="surveillance sites in Zambia, 2011–2017. A: years of implementation of" exact="influenza" post="surveillance by sentinel site (solid line: sentinel sites situated"/>
   <result pre="≥5 years included any hospitalized patient with fever (≥38 °C), cough and" exact="shortness" post="of breath or difficulty breathing [ 6]. All patients"/>
   <result pre="laboratory log book. Specimens were tested for the presence of" exact="influenza" post="viruses using the U.S. CDC real-time reverse-transcription polymerase chain"/>
   <result pre="real-time reverse-transcription polymerase chain reaction (RT-PCR) protocol for characterization of" exact="influenza" post="viruses [ 3]. During 2011–2012, all specimens from children"/>
   <result pre="risk and past medical history were captured in a customized" exact="influenza" post="sentinel surveillance MS Access® database with inbuilt data validation"/>
   <result pre="included total samples processed by sentinel site and total confirmed" exact="influenza" post="infections. Weekly influenza surveillance data and influenza-positive specimens were"/>
   <result pre="processed by sentinel site and total confirmed influenza infections. Weekly" exact="influenza" post="surveillance data and influenza-positive specimens were reported to WHO"/>
   <result pre="were reported to WHO FLUNET / FLUID. Evaluation of the" exact="influenza" post="sentinel surveillance system The evaluation of the ISSS was"/>
   <result pre="way as to be capable of detecting and monitoring seasonal" exact="influenza" post="viruses, including pandemic strains; (ii) the usefulness of the"/>
   <result pre="strains; (ii) the usefulness of the collected data to assess" exact="influenza" post="disease burden in the general population; (iii) the impact"/>
   <result pre="of the system to contribute to the annual selection of" exact="influenza" post="strains for vaccine development. The performance of the system"/>
   <result pre="we used the evaluation method and scoring system utilized for" exact="influenza" post="surveillance evaluations conducted in other African countries [ 17–"/>
   <result pre="1–3) for each attribute used for the evaluation of the" exact="influenza" post="sentinel surveillance system in Zambia, 2011-2017 a Attributes Number"/>
   <result pre="timeliness, representativeness and flexibility used for the evaluation of the" exact="influenza" post="sentinel surveillance system in Zambia, 2011-2017 a Indicator Calculation/data"/>
   <result pre="Number of WHO recommended variables. CIF and WHO guidelines for" exact="influenza" post="sentinel surveillance. 82.3% 3 Timeliness • Proportion of samples"/>
   <result pre="Representativeness • Geographical coverage Number of provinces covered by the" exact="influenza" post="sentinel surveillance network / Total number of provinces of"/>
   <result pre="inception Protocol 5 3 • Surveillance for pathogens other than" exact="influenza" post="Number of investigated pathogens other than influenza Protocol 10"/>
   <result pre="pathogens other than influenza Number of investigated pathogens other than" exact="influenza" post="Protocol 10 3 Abbreviations: ILI influenza-like-illness; SARI severe acute"/>
   <result pre="investigation form; RNP RiboNucleic Protein; WHO World Health Organization; ISS" exact="influenza" post="sentinel surveillance aEach quantitative indicator was evaluated as the"/>
   <result pre="for simplicity and acceptability used for the evaluation of the" exact="influenza" post="sentinel surveillance system in Zambia, 2011-2017 a Indicator Calculation/data"/>
   <result pre="S: 69.8% VS: 20.9% • Proportion of time allocated to" exact="influenza" post="surveillance activities per week Number of hours allocated to"/>
   <result pre="influenza surveillance activities per week Number of hours allocated to" exact="influenza" post="surveillance activities per week / Number of working hour"/>
   <result pre="4 Indicators for stability used for the evaluation of the" exact="influenza" post="sentinel surveillance system in Zambia, 2011-2017 a Indicator Calculation/data"/>
   <result pre="Number of reporting weeks Surveillance reports 71.4% 2 Abbreviations: ISS" exact="influenza" post="sentinel surveillance; MoH Ministry of Health aEach quantitative indicator"/>
   <result pre="for utility and sustainability used for the evaluation of the" exact="influenza" post="sentinel surveillance system in Zambia, 2011-2017 a Indicator Calculation/data"/>
   <result pre="during 2012 and 2014–2017 3 • Number of contributions to" exact="influenza" post="Regional/Global studies Number of publications on Regional/Global studies with"/>
   <result pre="influenza Regional/Global studies Number of publications on Regional/Global studies with" exact="influenza" post="data from Zambia PubMed 2 [8,28] 2 Domestic •"/>
   <result pre="PubMed 2 [8,28] 2 Domestic • Ability to assess important" exact="influenza" post="epidemiological features/public health outcomes • Temporal patters of influenza"/>
   <result pre="important influenza epidemiological features/public health outcomes • Temporal patters of" exact="influenza" post="virus circulation (Yes) [ 3] Publications and reports 80.0%"/>
   <result pre="[ 3] Publications and reports 80.0% b 3 • Circulating" exact="influenza" post="types/subtypes, including pandemic strains (Yes) [ 3] • Proportion"/>
   <result pre="(Yes) [ 3] • Proportion of ILI/SARI illness attributable to" exact="influenza" post="virus infection (Yes) [ 3] • Risk factors for"/>
   <result pre="and utility were obtained from various sources including the main" exact="influenza" post="sentinel surveillance database, the laboratory database, annual reports and"/>
   <result pre="completeness attribute) we divided the number of samples with available" exact="influenza" post="results by the total number of samples collected and"/>
   <result pre="collected and received by the laboratory. Subsequently, similar to other" exact="influenza" post="surveillance evaluations conducted in Africa, we used a scale"/>
   <result pre="University of Zambia Biomedical Research Ethics Committee. Results Summary of" exact="influenza" post="surveillance results during the evaluation period From January 2011"/>
   <result pre="SARI, respectively. Of the 894 influenza-positive specimens, 86 (9.6%) were" exact="influenza" post="A(H1N1)pdm09, 342 (38.2%) were influenza A(H3N2), 6 (0.7%) were"/>
   <result pre="influenza-positive specimens, 86 (9.6%) were influenza A(H1N1)pdm09, 342 (38.2%) were" exact="influenza" post="A(H3N2), 6 (0.7%) were influenza A not-subtyped and 459"/>
   <result pre="influenza A(H1N1)pdm09, 342 (38.2%) were influenza A(H3N2), 6 (0.7%) were" exact="influenza" post="A not-subtyped and 459 (51.3%) were influenza B viruses."/>
   <result pre="6 (0.7%) were influenza A not-subtyped and 459 (51.3%) were" exact="influenza" post="B viruses. The weekly number of influenza-positive specimens is"/>
   <result pre="definitions) and more than 90% of samples collected had available" exact="influenza" post="results and a positive ribonucleic protein result (an indicator"/>
   <result pre="No significant difference in the proportion of samples positive for" exact="influenza" post="was observed between the sites situated in Lusaka (9.0%"/>
   <result pre="platform to monitor the circulation of respiratory viruses other than" exact="influenza" post="(even though only for two years). The mean score"/>
   <result pre="to its objectives by (i) monitoring the temporal trends of" exact="influenza" post="virus circulation; (ii) monitoring the circulating influenza virus types"/>
   <result pre="temporal trends of influenza virus circulation; (ii) monitoring the circulating" exact="influenza" post="virus types and subtypes annually and enabling the detection"/>
   <result pre="types and subtypes annually and enabling the detection of pandemic" exact="influenza" post="A(H1N1)pdm09 in 2009 [ 3] and in subsequent years,"/>
   <result pre="and in subsequent years, (iii) assessing the contribution of seasonal" exact="influenza" post="viruses to mild (ILI) and severe (SARI) respiratory illness;"/>
   <result pre="14]; and (v) generating isolates to contribute to the annual" exact="influenza" post="vaccine formulation. Nonetheless, the ISSS was not able to"/>
   <result pre="data generated, its flexibility to monitor viral pathogens other than" exact="influenza" post="viruses [ 24], its potential expandability, its stability over"/>
   <result pre="the country could provide a better representativeness of the circulating" exact="influenza" post="viruses. However, it is unclear whether expanding the number"/>
   <result pre="surveillance sites would improve the virological and epidemiological understanding of" exact="influenza" post="in Zambia. In a study that included surveillance data"/>
   <result pre="surveillance data from 15 African countries, the detection rate of" exact="influenza" post="virus among SARI and ILI cases was similar across"/>
   <result pre="outcomes that are recommended by the WHO guidelines for global" exact="influenza" post="surveillance, but are currently not fully captured by the"/>
   <result pre="ability to investigate the viral etiology of pathogens other than" exact="influenza" post="[ 24]. While the recruitment of dedicated surveillance officers"/>
   <result pre="dedicated surveillance officers may not be justifiable for a vertical" exact="influenza" post="surveillance program it may be considered for an integrated"/>
   <result pre="studies as demonstrated in Zambia and other African countries for" exact="influenza" post="[ 10– 16]. This would be particularly relevant for"/>
   <result pre="27] and this could be implemented also in Zambia for" exact="influenza" post="and other pathogens. The stability of the system was"/>
   <result pre="contributed to the body of knowledge on the burden of" exact="influenza" post="[ 3, 14] and other respiratory viruses [ 24]"/>
   <result pre="common respiratory syndromes in Zambia and globally through sharing of" exact="influenza" post="data [ 8, 28] and virus isolates. Nonetheless, despite"/>
   <result pre="the surveillance system is stable and able to identify circulating" exact="influenza" post="strains, the data being generated is not fully utilized"/>
   <result pre="Mizuta K Oshitani H Saijo M et al. Epidemiology of" exact="influenza" post="virus infections in children with acute respiratory infections in"/>
   <result pre="McMorrow ML Frimpong JA et al. Incidence of medically attended" exact="influenza" post="among residents of Shai-Osudoku and Ningo-Prampram districts, Ghana, may"/>
   <result pre="E Cohen AL McAnerney J et al. Evaluation of two" exact="influenza" post="surveillance systems in South Africa PLoS One 2015 10"/>
   <result pre="A Randrianasolo L Tempia S et al. Evaluation of the" exact="influenza" post="sentinel surveillance system in Madagascar, 2009-2014 Bull World Health"/>
   <result pre="P, Kabamba-Tshilobo J, Wemakoy EO, et al. Evaluation of the" exact="influenza" post="sentinel surveillance system in the Democratic Republic of Congo,"/>
   <result pre="R Katz M Does the length of specimen storage affect" exact="influenza" post="testing results by real-time reverse transcription-polymerase chain reaction? An"/>
   <result pre="results by real-time reverse transcription-polymerase chain reaction? An analysis of" exact="influenza" post="surveillance specimens, 2008 to 2010 Eurosurveillance 2014 19 36"/>
   <result pre="H Rassoly MH et al. Global role and burden of" exact="influenza" post="in pediatric respiratory hospitalizations, 1982-2012: a systematic analysis PLoS"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6961264/results/search/disease/results.xml">
   <result pre="of repeated vaccination using 10-year vaccination history on protection against" exact="influenza" post="in older adults: a test-negative design study across the"/>
   <result pre="adults: a test-negative design study across the 2010/11 to 2015/16" exact="influenza" post="seasons in Ontario, Canada Kwong Jeffrey C 1 2"/>
   <result pre="licence, and indicate if changes were made. Abstract Introduction Annual" exact="influenza" post="vaccination is recommended for older adults, but evidence regarding"/>
   <result pre="been inconclusive. Aim We investigated vaccine effectiveness (VE) against laboratory-confirmed" exact="influenza" post="and the impact of repeated vaccination over 10 previous"/>
   <result pre="episodes for respiratory viruses, with 11,496 (20%) testing positive for" exact="influenza" post="and 31,004 (53%) vaccinated. Adjusted VE against laboratory-confirmed influenza"/>
   <result pre="for influenza and 31,004 (53%) vaccinated. Adjusted VE against laboratory-confirmed" exact="influenza" post="for the six seasons combined was 21% (95% confidence interval"/>
   <result pre="previous vaccinations, current season vaccination likely provides some protection against" exact="influenza" post="regardless of the number of vaccinations received over the"/>
   <result pre="of the number of vaccinations received over the previous 10" exact="influenza" post="seasons. Keywords: Influenza vaccine vaccine effectiveness repeated vaccination older"/>
   <result pre="risk of severe outcomes [ 1]. In this age group," exact="influenza" post="vaccines are 24–63% effective in preventing laboratory-confirmed influenza ["/>
   <result pre="age group, influenza vaccines are 24–63% effective in preventing laboratory-confirmed" exact="influenza" post="[ 2- 4]. Due to frequent changes in circulating"/>
   <result pre="in the 1970s at a British boarding school found higher" exact="influenza" post="incidence among students who had received multiple previous vaccines"/>
   <result pre="objectives of this study were to estimate VE against laboratory-confirmed" exact="influenza" post="infection in community-dwelling older adults for the 2010/11 to"/>
   <result pre="aged &amp;gt; 65 years in Ontario (2016 population aged ≥ 65 years: 2.3 million) who were tested for" exact="influenza" post="during inpatient or outpatient healthcare encounters between 1 September"/>
   <result pre="September 2010 and 31 August 2016. Details regarding these six" exact="influenza" post="seasons have been reported previously [ 19]. We used"/>
   <result pre="physician services, hospital care, diagnostic testing, prescription medications, and trivalent" exact="influenza" post="vaccines during the study. We estimated VE using the"/>
   <result pre="VE using the test-negative design, which compares the odds of" exact="influenza" post="vaccination among laboratory-confirmed influenza cases and test-negative controls ["/>
   <result pre="design, which compares the odds of influenza vaccination among laboratory-confirmed" exact="influenza" post="cases and test-negative controls [ 20]. Ethical statement Ethics"/>
   <result pre="of the following viruses: adenovirus, bocavirus, coronavirus, enterovirus/rhinovirus, human metapneumovirus," exact="influenza" post="A, influenza B, parainfluenza virus, and respiratory syncytial virus"/>
   <result pre="following viruses: adenovirus, bocavirus, coronavirus, enterovirus/rhinovirus, human metapneumovirus, influenza A," exact="influenza" post="B, parainfluenza virus, and respiratory syncytial virus [ 19]."/>
   <result pre="same season, we included their earliest testing episode positive for" exact="influenza" post="(or their earliest testing episode if all specimens tested"/>
   <result pre="presenting with acute respiratory illnesses (ARI) who were tested for" exact="influenza" post="varied by setting (22.1% for inpatients, 2.5% for patients"/>
   <result pre="offices) [ 19]. Since only 49% of individuals positive for" exact="influenza" post="A had their specimens subtyped, we assessed their generalisability"/>
   <result pre="by comparing the characteristics of those with subtyped and unsubtyped" exact="influenza" post="A specimens ( Supplementary Table S2). Information on lineage"/>
   <result pre="A specimens ( Supplementary Table S2). Information on lineage for" exact="influenza" post="B was not available. Healthcare encounter data We identified"/>
   <result pre="for those with provincial health insurance. Influenza vaccination We ascertained" exact="influenza" post="vaccination status using physician and (starting in 2012, when"/>
   <result pre="in 2012, when a policy change permitted pharmacists to administer" exact="influenza" post="vaccines) pharmacist billing claims, maintained in the OHIP and"/>
   <result pre="determined the presence of comorbidities that increase the risk of" exact="influenza" post="complications (anaemia, cancer, cardiovascular disease, dementia, diabetes, frailty, immunodeficiency"/>
   <result pre="comorbidities that increase the risk of influenza complications (anaemia, cancer," exact="cardiovascular disease," post="dementia, diabetes, frailty, immunodeficiency due to underlying disease and/or"/>
   <result pre="effectiveness We used logistic regression to estimate VE, against laboratory-confirmed" exact="influenza" post="infection, by comparing the odds of vaccination in the"/>
   <result pre="presence of any comorbidity, calendar time (month of test), and" exact="influenza" post="season (except when estimating VE by season). These variables"/>
   <result pre="for the province to restrict the analyses to periods when" exact="influenza" post="was circulating. We estimated VE against any influenza and"/>
   <result pre="periods when influenza was circulating. We estimated VE against any" exact="influenza" post="and each influenza type/subtype for the 2010/11 to 2015/16"/>
   <result pre="was circulating. We estimated VE against any influenza and each" exact="influenza" post="type/subtype for the 2010/11 to 2015/16 seasons combined and"/>
   <result pre="were tested by PCR. Third, since Ontario residents may receive" exact="influenza" post="vaccines in settings besides physician offices and pharmacies (leading"/>
   <result pre="publicly available macro [ 21] to correct for misclassification of" exact="influenza" post="vaccination status using previously reported parameters for sensitivity (69%)"/>
   <result pre="previously reported parameters for sensitivity (69%) and specificity (90%) of" exact="influenza" post="vaccination codes for older adults in Ontario health administrative"/>
   <result pre="impact of repeated vaccination on current season VE against any" exact="influenza" post="and each influenza type/subtype for the 2010/11 to 2015/16"/>
   <result pre="vaccination on current season VE against any influenza and each" exact="influenza" post="type/subtype for the 2010/11 to 2015/16 seasons combined. We"/>
   <result pre="longer vaccination history durations (i.e. one, five, and 10 previous" exact="influenza" post="seasons). Since influenza vaccination data in Ontario are more"/>
   <result pre="durations (i.e. one, five, and 10 previous influenza seasons). Since" exact="influenza" post="vaccination data in Ontario are more accurate among those"/>
   <result pre="tested during multiple seasons), with 11,496 (20%) testing positive for" exact="influenza" post="and 31,004 (53%) vaccinated during the season of testing"/>
   <result pre="found in Supplementary Table S4. Overall adjusted VE against any" exact="influenza" post="for the 2010/11 to 2015/16 seasons combined was 21%"/>
   <result pre="against A(H3N2), and 30% (95%CI: 24 to 36%) against B. VE against unsubtyped" exact="influenza" post="A viruses was only 11% (95%CI: 5 to 16%). We observed substantial"/>
   <result pre="by PCR ( Table 1 ). VE estimates stratified by" exact="influenza" post="subtype and season are presented in Supplementary Table S5."/>
   <result pre="vaccine effectiveness estimates for community-dwelling adults aged &amp;gt; 65 years, 2010/11 to 2015/16" exact="influenza" post="seasons in Ontario, Canada (n = 58,304) a Analysis Test-positive patients"/>
   <result pre="b 5,575/11,496 25,429/46,808 21 (18 to 24) 21 (18 to 24) 38 (35 to 42) By" exact="influenza" post="type/subtype Influenza A c A(H3N2) 1,780/3,765 25,429/46,808 25 (19 to 29)"/>
   <result pre="B 1,027/2,138 25,429/46,808 22 (15 to 29) 30 (24 to 36) 42 (37 to 49) By" exact="influenza" post="season 2010/11 488/1,204 2,561/4,980 36 (27 to 43) 33 (23 to 41) 54"/>
   <result pre="in the past year, comorbidities that increase the risk of" exact="influenza" post="complications (anaemia, cancer, cardiovascular disease, dementia, diabetes, frailty, immunodeficiency"/>
   <result pre="comorbidities that increase the risk of influenza complications (anaemia, cancer," exact="cardiovascular disease," post="dementia, diabetes, frailty, immunodeficiency due to underlying disease and/or"/>
   <result pre="well as renal disease and respiratory disease), calendar time, and" exact="influenza" post="season. b For any influenza, 2010/11 to 2015/16 influenza"/>
   <result pre="and influenza season. b For any influenza, 2010/11 to 2015/16" exact="influenza" post="seasons combined. c Only 49% of influenza A specimens"/>
   <result pre="2010/11 to 2015/16 influenza seasons combined. c Only 49% of" exact="influenza" post="A specimens were subtyped. d PCR (monoplex or multiplex)."/>
   <result pre="characteristics of community-dwelling adults aged &amp;gt; 65 years for the 2010/11 to 2015/16" exact="influenza" post="seasons, stratified by vaccination history for the previous season,"/>
   <result pre="mean ± SD 16.5 ± 9.3 NA 17.4 ± 9.1 NA 15.4 ± 9.5 NA &amp;lt; 0.001 Month of" exact="influenza" post="testing November 1,407 2.4 785 2.4 622 2.5 0.83"/>
   <result pre="49,621 85.5 28,544 85.9 21,077 85.1 0.007 Specimen positive for" exact="influenza" post="11,444 19.7 6,177 18.6 5,267 21.3 &amp;lt; 0.001 Vaccinated against"/>
   <result pre="influenza 11,444 19.7 6,177 18.6 5,267 21.3 &amp;lt; 0.001 Vaccinated against" exact="influenza" post="in current season 30,916 53.3 24,592 74.0 6,324 25.5"/>
   <result pre="applicable; SD: standard deviation. a Includes acute ischaemic stroke, arrhythmias," exact="congestive heart failure," post="ischaemic heart disease, and transient ischaemic attack. Table 3"/>
   <result pre="a Includes acute ischaemic stroke, arrhythmias, congestive heart failure, ischaemic" exact="heart disease," post="and transient ischaemic attack. Table 3 Descriptive characteristics of"/>
   <result pre="of community-dwelling adults aged ≥ 70 years for the 2010/11 to 2015/16" exact="influenza" post="seasons, stratified by influenza vaccination history over five previous"/>
   <result pre="years for the 2010/11 to 2015/16 influenza seasons, stratified by" exact="influenza" post="vaccination history over five previous seasons, Ontario, Canada (n = 49,294)"/>
   <result pre="NA 17.5 ± 8.8 NA 16.8 ± 9.2 NA 13.7 ± 9.0 NA &amp;lt; 0.001 Month of" exact="influenza" post="testing November 1,178 2.4 590 2.4 380 2.4 208"/>
   <result pre="21,487 87.1 13,767 86.4 7,398 85.1 &amp;lt; 0.001 Specimen positive for" exact="influenza" post="9,877 20.0 4,743 19.2 3,117 19.6 2,017 23.2 &amp;lt; 0.001"/>
   <result pre="20.0 4,743 19.2 3,117 19.6 2,017 23.2 &amp;lt; 0.001 Vaccinated against" exact="influenza" post="in current season 27,043 54.9 18,946 76.8 7,325 46.0"/>
   <result pre="applicable; SD: standard deviation. a Includes acute ischaemic stroke, arrhythmias," exact="congestive heart failure," post="ischaemic heart disease, and transient ischaemic attack. Table 4"/>
   <result pre="a Includes acute ischaemic stroke, arrhythmias, congestive heart failure, ischaemic" exact="heart disease," post="and transient ischaemic attack. Table 4 Descriptive characteristics of"/>
   <result pre="characteristics of community-dwelling adults aged ≥ 75 years for the 2010/11 to 2015/16" exact="influenza" post="seasons, stratified by influenza vaccination history over 10 previous"/>
   <result pre="aged ≥ 75 years for the 2010/11 to 2015/16 influenza seasons, stratified by" exact="influenza" post="vaccination history over 10 previous seasons, Ontario, Canada (n = 38,766)"/>
   <result pre="NA 16.8 ± 9.0 NA 15.4 ± 8.8 NA 13.1 ± 8.8 NA &amp;lt; 0.001 Month of" exact="influenza" post="testing November 908 2.3 286 2.2 232 2.6 161"/>
   <result pre="6,511 87.8 4,449 86.4 3,595 86.4 0.01 Specimen positive for" exact="influenza" post="8,043 20.7 2,653 20.4 1,783 19.8 1,502 20.3 1,095"/>
   <result pre="19.8 1,502 20.3 1,095 21.3 1,010 24.3 &amp;lt; 0.001 Vaccinated against" exact="influenza" post="in current season 21,645 55.8 10,297 79.0 5,847 64.9"/>
   <result pre="applicable; SD: standard deviation. a Includes acute ischaemic stroke, arrhythmias," exact="congestive heart failure," post="ischemic heart disease, and transient ischaemic attack. Figure 1"/>
   <result pre="a Includes acute ischaemic stroke, arrhythmias, congestive heart failure, ischemic" exact="heart disease," post="and transient ischaemic attack. Figure 1 Forest plots of"/>
   <result pre="plots of (A) current season vaccine effectiveness estimates against any" exact="influenza" post="for community-dwelling adults aged &amp;gt; 65 years, taking into account vaccination histories"/>
   <result pre="S1) but not against A(H1N1)pdm09 ( Supplementary Figure S2) or" exact="influenza" post="B ( Supplementary Figure S3). When correcting for misclassification"/>
   <result pre="S6). When accounting for 5-year vaccination history, significant protection against" exact="influenza" post="was observed among patients with any previous vaccination, with"/>
   <result pre="this study of older adults, we estimated VE against laboratory-confirmed" exact="influenza" post="healthcare use to be 21% (95%CI: 18 to 24%) during the 2010/11"/>
   <result pre="use to be 21% (95%CI: 18 to 24%) during the 2010/11 to 2015/16" exact="influenza" post="seasons, which increased to 38% (95%CI: 35 to 42%) after correcting for"/>
   <result pre="When we examined the impact of repeated vaccination during previous" exact="influenza" post="seasons on VE for the current season, we observed"/>
   <result pre="in VE as the number of previous vaccinations increased. Nevertheless," exact="influenza" post="vaccination during the current season was associated with some"/>
   <result pre="during the current season was associated with some protection against" exact="influenza" post="infection irrespective of the number of vaccinations over the"/>
   <result pre="correcting for misclassification of vaccination status in the current season," exact="influenza" post="vaccination was associated with some protection even for those"/>
   <result pre="seasons based on current season misclassification. Similar patterns as any" exact="influenza" post="were observed against A(H3N2) but not A(H1N1)pdm09 or influenza"/>
   <result pre="any influenza were observed against A(H3N2) but not A(H1N1)pdm09 or" exact="influenza" post="B, but interpretation of these results is challenging due"/>
   <result pre="analyses leading to less precision. The observed patterns for any" exact="influenza" post="were likely driven by A(H3N2) since that subtype comprised"/>
   <result pre="A(H3N2) since that subtype comprised 67% of specimens during the" exact="influenza" post="seasons included in this study, if one assumes the"/>
   <result pre="that vaccination in the current season provided some protection against" exact="influenza" post="regardless of the number of previous vaccinations. No study"/>
   <result pre="vaccinated for the first time if they were infected by" exact="influenza" post="in the prior season. Vaccine responses may be enhanced"/>
   <result pre="for potential vaccine interference. Future studies that longitudinally ascertain both" exact="influenza" post="vaccination and influenza infection status over multiple seasons would"/>
   <result pre="interference. Future studies that longitudinally ascertain both influenza vaccination and" exact="influenza" post="infection status over multiple seasons would be helpful to"/>
   <result pre="to underestimation of VE. Third, the VE estimate against unsubtyped" exact="influenza" post="A was outside of the range between those against"/>
   <result pre="of potential bias. Although only 49% of individuals positive for" exact="influenza" post="A had their specimens subtyped, they are fairly representative"/>
   <result pre="subtyped, they are fairly representative of all individuals positive for" exact="influenza" post="A ( Supplementary Table S1). We speculate that the"/>
   <result pre="season with known poor match) and during later months of" exact="influenza" post="season (with potentially lower VE due to intra-season waning"/>
   <result pre="VE due to intra-season waning of immunity). Fourth, receipt of" exact="influenza" post="vaccines outside of physician offices and pharmacies leads to"/>
   <result pre="in our sensitivity analyses. The low sensitivity value for the" exact="influenza" post="vaccination billing claims used in these sensitivity analyses may"/>
   <result pre="immunological interactions. Eighth, we did not have information on participants’" exact="influenza" post="infections in the previous seasons, as most infections do"/>
   <result pre="we did not have information on vaccination history for &amp;gt; 10 previous" exact="influenza" post="seasons; the impact of repeated vaccination over longer periods"/>
   <result pre="older adults in Ontario, Canada during the 2010/11 to 2015/16" exact="influenza" post="seasons. We observed declining VE associated with repeated vaccination,"/>
   <result pre="vaccination, however current season vaccination likely provides some protection against" exact="influenza" post="regardless of the number of vaccines received over the"/>
   <result pre="of the number of vaccines received over the previous 10" exact="influenza" post="seasons. Moreover, among those not vaccinated in the current"/>
   <result pre="increasing numbers of previous vaccines received. Therefore, until effective universal" exact="influenza" post="vaccines are available and eliminate the need for annual"/>
   <result pre="influenza vaccines are available and eliminate the need for annual" exact="influenza" post="vaccination, our findings support current recommendations for annual vaccination"/>
   <result pre="JP Sundaram ME Kelley NS Osterholm MT et al. Variable" exact="influenza" post="vaccine effectiveness by subtype: a systematic review and meta-analysis"/>
   <result pre="Thompson MG Levêque A Moren A Sullivan SG Effectiveness of" exact="influenza" post="vaccines in preventing severe influenza illness among adults: A"/>
   <result pre="A Sullivan SG Effectiveness of influenza vaccines in preventing severe" exact="influenza" post="illness among adults: A systematic review and meta-analysis of"/>
   <result pre="MJ Hak E van den Heuvel ER Effectiveness of seasonal" exact="influenza" post="vaccine in community-dwelling elderly people: a meta-analysis of test-negative"/>
   <result pre="A Assessment of inactivated influenza-A vaccine after three outbreaks of" exact="influenza" post="A at Christ’s Hospital. Lancet. 1979; 313( 8106): 33-"/>
   <result pre="LL Hess KR Efficacy of repeated annual immunization with inactivated" exact="influenza" post="virus vaccines over a five year period. Vaccine. 1997;"/>
   <result pre="S Ackley DH Perelson AS Variable efficacy of repeated annual" exact="influenza" post="vaccination. Proc Natl Acad Sci USA. 1999; 96( 24):"/>
   <result pre="O’Donnell J et al. Exploring the effect of previous inactivated" exact="influenza" post="vaccination on seasonal influenza vaccine effectiveness against medically attended"/>
   <result pre="Exploring the effect of previous inactivated influenza vaccination on seasonal" exact="influenza" post="vaccine effectiveness against medically attended influenza: Results of the"/>
   <result pre="The Working Group Of The Project Pi/ The effectiveness of" exact="influenza" post="vaccination in preventing hospitalisations of elderly individuals in two"/>
   <result pre="influenza vaccination in preventing hospitalisations of elderly individuals in two" exact="influenza" post="seasons: a multicentre case-control study, Spain, 2013/14 and 2014/15."/>
   <result pre="HQ Chambers C Sundaram ME De Serres G Repeated annual" exact="influenza" post="vaccination and vaccine effectiveness: review of evidence. Expert Rev"/>
   <result pre="Hylton DA Zhang YB Malhotra D et al. Does consecutive" exact="influenza" post="vaccination reduce protection against influenza: A systematic review and"/>
   <result pre="Kwong JC et al. The impact of repeated vaccination on" exact="influenza" post="vaccine effectiveness: a systematic review and meta-analysis. BMC Med."/>
   <result pre="et al. Impact of repeated vaccination on vaccine effectiveness against" exact="influenza" post="A(H3N2) and B during 8 seasons. Clin Infect Dis."/>
   <result pre="Å Brytting M Leval A Hergens MP Impact of repeated" exact="influenza" post="vaccinations in persons over 65 years of age: A large"/>
   <result pre="65 years of age: A large population-based cohort study of severe" exact="influenza" post="over six consecutive seasons, 2011/12-2016/17. Vaccine. 2018; 36( 37):"/>
   <result pre="collected laboratory and health administrative data be used to assess" exact="influenza" post="vaccine effectiveness? Assessing the validity of the Flu and"/>
   <result pre="20 Jackson ML Nelson JC The test-negative design for estimating" exact="influenza" post="vaccine effectiveness. Vaccine. 2013; 31( 17): 2165- 8. 10.1016/j.vaccine.2013.02.053"/>
   <result pre="claims from the Ontario Health Insurance Plan to determine individual" exact="influenza" post="vaccination status: an updated validation study. CMAJ Open. 2016;"/>
   <result pre="al. Serial vaccination and the antigenic distance hypothesis: Effects on" exact="influenza" post="vaccine effectiveness during A(H3N2) epidemics in Canada, 2010-2011 to"/>
   <result pre="predictor of immunity in the face of natural challenge with" exact="influenza" post="viruses. Epidemiol Infect. 1989; 102( 2): 325- 33. 10.1017/S0950268800030004"/>
   <result pre="et al. collab: Marshfield Influenza Study Group Effectiveness of inactivated" exact="influenza" post="vaccines varied substantially with antigenic match from the 2004-2005"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6969405/results/search/disease/results.xml">
   <result pre="in this article, unless otherwise stated. Abstract Background Pneumonia and" exact="stomatitis" post="represent severe and often fatal diseases in different captive"/>
   <result pre="diseases. In 2014, new viruses emerged as the cause of" exact="pneumonia" post="in pythons. In a few publications, nidoviruses have been"/>
   <result pre="a few publications, nidoviruses have been reported in association with" exact="pneumonia" post="in ball pythons and a tiger python. The viruses"/>
   <result pre="methods from the organ tissue of dead animals. Methods Severe" exact="pneumonia" post="and stomatitis resulted in a high mortality rate in"/>
   <result pre="the organ tissue of dead animals. Methods Severe pneumonia and" exact="stomatitis" post="resulted in a high mortality rate in a captive"/>
   <result pre="and for some of them pathogens were identified. Pneumonia and" exact="stomatitis" post="are common problems in captive snakes and can be"/>
   <result pre="agents. Mostly, they are linked to bacteria, but often a" exact="viral disease" post="represents the basic infection. Viruses infecting reptiles and especially"/>
   <result pre="well on ball pythons. There, 12 snakes suffering from pneumonia," exact="tracheitis" post="and esophagitis were examined and were subjected to a"/>
   <result pre="an Indian python ( Python molurus) diagnosed with severe necrotizing" exact="pneumonia" post="from a zoological garden in northern Germany. Again, unbiased"/>
   <result pre="green tree pythons ( Morelia viridis). Twelve deceased animals with" exact="pneumonia" post="were investigated and this virus shared only &amp;lt; 85% sequence"/>
   <result pre="showed a causal relationship between the novel snake nidovirus and" exact="pneumonia" post="in ball pythons by experimentally infection of three animals."/>
   <result pre="families with notable human and animal pathogens like for example" exact="severe acute respiratory syndrome" post="(SARS) coronavirus and porcine reproductive and respiratory syndrome virus"/>
   <result pre="in a collection of Green Tree pythons suffered from severe" exact="stomatitis" post="and pneumonia (up to 25 animals during several weeks)."/>
   <result pre="collection of Green Tree pythons suffered from severe stomatitis and" exact="pneumonia" post="(up to 25 animals during several weeks). Bacteriological investigations"/>
   <result pre="no parasites; parasitological investigations of feces were also negative. The" exact="stomatitis" post="was treated locally (cleansing, antibiotic ointments or fluids). For"/>
   <result pre="more were examined only pathohistologically and virologically. All snakes revealed" exact="pneumonia" post="of varying degrees. Five of the snakes also showed"/>
   <result pre="also showed a diphtheroid-necrotizing stomatitis, and four suffered from renal" exact="gout" post="(Table 1). The results of the bacteriological studies showed"/>
   <result pre="empty heart, small intestine: no pathological findings. lungs: high-grade purulent-necrotizing" exact="pneumonia" post="Ziehl-Neelsen-staining lung: acid-fast rods were not detected lung: Bordetella"/>
   <result pre="Acinetobacter pitii (+), Providencia rettgeri (++) kidney: low grade renal" exact="gout" post="kidney: Acinetobacter pitii (+) after 48 h, Providencia rettgeri (+)"/>
   <result pre="inflammation inhibitor substance test: positive BH128/14–11-14 male oral cavity: purulent" exact="stomatitis" post="Lung: dark red, filled with exudate Stomach: empty Small"/>
   <result pre="no pathological findings liver: Stenotrophomonas maltophilia (+++) lungs: purulent necrotizing" exact="pneumonia" post="lung: Stenotrophomonas maltophilia (+++) kidney: slight uric acid deposits"/>
   <result pre="with solid feces Kidneys: slightly enlarged lungs: low-grade multifocal lymphoplasmacellular" exact="pneumonia" post="with a high number of coccoid bacteria within the"/>
   <result pre="all affected animals, but instead in animals deceased from a" exact="lymphoma" post="(data not shown), which did not exhibit typical symptoms"/>
   <result pre="(data not shown), which did not exhibit typical symptoms like" exact="pneumonia" post="and stomatitis. The snake nidovirus RT-qPCR was positive for"/>
   <result pre="are able to produce respiratory symptoms. However, in many collections," exact="respiratory disease" post="with high morbidity and mortality was found which was"/>
   <result pre="years, with the discovery of snake nidoviruses the knowledge about" exact="pneumonia" post="in boid snakes improved. These viruses were detected after"/>
   <result pre="could be found in control animals showing no signs of" exact="respiratory disease" post="and it is probably an already known endogenous retrovirus"/>
   <result pre="probably an already known endogenous retrovirus without a link to" exact="pneumonia" post="[ 1, 3, 31]. The bacterial findings were not"/>
   <result pre="number BH128/14–1-6 Morelia viridis green tree python I stomatitits and" exact="pneumonia" post="lung, liver, intestine, kidney, brain, pancreas positive positive –"/>
   <result pre="– BH128/14–7-10 Morelia viridis green tree python I stomatitits and" exact="pneumonia" post="lung, liver, intestine, kidney positive positive MK182565 BH128/14–11-14 Morelia"/>
   <result pre="MK182565 BH128/14–11-14 Morelia viridis green tree python I stomatitits and" exact="pneumonia" post="lung, liver, intestine, kidney positive positive MK182566 a BH171/14–1-5"/>
   <result pre="a BH171/14–1-5 Morelia viridis green tree python I stomatitits and" exact="pneumonia" post="lung, liver, intestine, kidney, brain positive positive MK182567 BH171/14–6-10"/>
   <result pre="MK182567 BH171/14–6-10 Morelia viridis green tree python I stomatitits and" exact="pneumonia" post="lung, liver, intestine, kidney, brain positive positive MK182569 a"/>
   <result pre="a BH171/14–11-15 Morelia viridis green tree python I stomatitits and" exact="pneumonia" post="lung, liver, intestine, kidney, brain positive positive MK182568 BH171/14–16-20"/>
   <result pre="MK182568 BH171/14–16-20 Morelia viridis green tree python I stomatitits and" exact="pneumonia" post="lung, liver, intestine, kidney, brain positive positive MK182570 BH171/14–21-25"/>
   <result pre="MK182570 BH171/14–21-25 Morelia viridis green tree python I stomatitits and" exact="pneumonia" post="lung, liver, intestine, kidney, brain positive positive MK182571 BH171/14/26–29"/>
   <result pre="MK182571 BH171/14/26–29 Morelia viridis green tree python I stomatitits and" exact="pneumonia" post="lung, liver, intestine, kidney positive positive MK182572 BH021/15–1-3 Python"/>
   <result pre="negative negative – BH021/15–10-13 Morelia spilota variegata carpet python V" exact="lymphoma" post="lung, liver, intestine, kidney negative negative – BH057/17–1 Morelia"/>
   <result pre="negative – BH057/17–1 Morelia viridis green tree python stomatitits and" exact="pneumonia" post="lung positive positive MK182535 BH057/17–2 Morelia viridis green tree"/>
   <result pre="lung positive positive MK182535 BH057/17–2 Morelia viridis green tree python" exact="pneumonia" post="lung negative positive – BH057/17–3 Morelia viridis green tree"/>
   <result pre="lung negative positive – BH057/17–3 Morelia viridis green tree python" exact="pneumonia" post="swab positive positive – BH057/17–4 Morelia viridis green tree"/>
   <result pre="swab positive positive – BH057/17–4 Morelia viridis green tree python" exact="pneumonia" post="swab positive positive MK182536 BH057/17–5 Morelia viridis green tree"/>
   <result pre="swab positive positive MK182536 BH057/17–5 Morelia viridis green tree python" exact="pneumonia" post="swab positive positive MK182537 BH057/17–6 Morelia viridis green tree"/>
   <result pre="swab positive positive MK182537 BH057/17–6 Morelia viridis green tree python" exact="pneumonia" post="swab positive positive – BH057/17–7 Python regius ball python"/>
   <result pre="positive positive – BH057/17–7 Python regius ball python stomatitits and" exact="pneumonia" post="lung positive positive – BH057/17–8 Python regius ball python"/>
   <result pre="positive positive – BH057/17–8 Python regius ball python stomatitits and" exact="pneumonia" post="lung positive positive – BH057/17–9 Python regius ball python"/>
   <result pre="positive positive – BH057/17–9 Python regius ball python stomatitits and" exact="pneumonia" post="swab positive positive – BH057/17–10 Python regius ball python"/>
   <result pre="positive positive – BH057/17–10 Python regius ball python stomatitits and" exact="pneumonia" post="swab positive positive MK182538 BH057/17–11 Python regius ball python"/>
   <result pre="pneumonia swab positive positive MK182538 BH057/17–11 Python regius ball python" exact="pneumonia" post="swab positive positive MK182539 BH057/17–12 Python regius ball python"/>
   <result pre="pneumonia swab positive positive MK182539 BH057/17–12 Python regius ball python" exact="pneumonia" post="swab positive positive MK182540 BH057/17–13 Python regius ball python"/>
   <result pre="pneumonia swab positive positive MK182540 BH057/17–13 Python regius ball python" exact="pneumonia" post="swab positive positive – BH057/17–14 Python molurus indian python"/>
   <result pre="positive positive – BH057/17–14 Python molurus indian python stomatitits and" exact="pneumonia" post="lung positive positive MK182541 BH057/17–15 Python molurus indian python"/>
   <result pre="pneumonia lung positive positive MK182541 BH057/17–15 Python molurus indian python" exact="pneumonia" post="swab positive positive MK182542 BH057/17–16 Python molurus indian python"/>
   <result pre="pneumonia swab positive positive MK182542 BH057/17–16 Python molurus indian python" exact="pneumonia" post="swab positive positive MK182543 BH057/17–17 Morelia spilota spilota diamond"/>
   <result pre="positive MK182543 BH057/17–17 Morelia spilota spilota diamond python stomatitits and" exact="pneumonia" post="lung positive positive MK182544 BH057/17–18 Morelia spilota spilota diamond"/>
   <result pre="positive MK182544 BH057/17–18 Morelia spilota spilota diamond python stomatitits and" exact="pneumonia" post="lung positive positive MK182545 BH057/17–19 Morelia spilota spilota diamond"/>
   <result pre="lung positive positive MK182545 BH057/17–19 Morelia spilota spilota diamond python" exact="pneumonia" post="swab positive positive – BH057/17–20 Morelia spilota spilota diamond"/>
   <result pre="swab positive positive – BH057/17–20 Morelia spilota spilota diamond python" exact="pneumonia" post="swab positive positive MK182546 BH057/17–21 Bothrochilus albertisii white-lipped python"/>
   <result pre="status was available) nidovirus RNA positive animals 285 showed no" exact="respiratory disease" post="(Table 6). In addition to the species described in"/>
   <result pre="RNA negative samples Species Common name Total positive Stomatitis and/or" exact="respiratory disease" post="Other disease No disease (routine investi-gations) No information Total"/>
   <result pre="No disease (routine investi-gations) No information Total negative Stomatitis and/or" exact="respiratory disease" post="Other disease No disease (routine investi-gations) No information Morelia"/>
   <result pre="but only a few of them revealed clinical signs like" exact="stomatitis" post="or severe respiratory disease. Therefore, no obvious correlation between"/>
   <result pre="few of them revealed clinical signs like stomatitis or severe" exact="respiratory disease." post="Therefore, no obvious correlation between virus and clinical disease"/>
   <result pre="al. Ball python nidovirus: a candidate etiologic agent for severe" exact="respiratory disease" post="in Python regius mBio 2014 5 5 e01484 e01414"/>
   <result pre="Identification of a novel nidovirus in an outbreak of fatal" exact="respiratory disease" post="in ball pythons (Python regius) Virol J 2014 11"/>
   <result pre="M et al. Novel divergent nidovirus in a python with" exact="pneumonia" post="J Gen Virol 2014 95 Pt 11 2480 2485"/>
   <result pre="and partial genomic characterisation of a novel Nidovirus associated with" exact="respiratory disease" post="in wild shingleback lizards (Tiliqua rugosa) PLoS One 2016"/>
   <result pre="et al. Discovery of a novel nidovirus in cattle with" exact="respiratory disease" post="J Gen Virol 2015 96 8 2188 2193 10.1099/vir.0.000166"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6970282/results/search/disease/results.xml">
   <result pre="Report Tonsillar hypertrophy and prolapse in a child – is" exact="epiglottitis" post="a predisposing factor for sudden unexpected death ? Nieuwoudt"/>
   <result pre="and treated for tonsillitis. The child was diagnosed with acute" exact="tonsillitis" post="2 days prior to her collapse and was placed"/>
   <result pre="infants is a common feature of both viral and bacterial" exact="tonsillitis" post="and has been postulated as a possible risk factor"/>
   <result pre="more significant role in asphyxial unexpected deaths in cases of" exact="tonsillitis" post="with tonsillar hypertrophy than previously suspected. This focusses the"/>
   <result pre="viral or bacterial pathogens. Common viral pathogens resulting in acute" exact="pharyngitis" post="include Rhinovirus, Coronavirus, Adenovirus, Respiratory Syncytial Virus, Haemophilus influenza,"/>
   <result pre="mainly Streptococcus pyogenes, Neisseria Meningitidis, Corynebacterium diphtheria, Chlamydia and Mycoplasma" exact="pneumonia" post="[ 1]. Lethal complications involving the inflamed tonsils include"/>
   <result pre="the mechanism of death. The child was diagnosed with acute" exact="tonsillitis" post="2 days prior to her collapse and was placed"/>
   <result pre="possible cause of death. Discussion and conclusions The mortality of" exact="tonsillitis" post="is low, and usually lethal complications result from surgical"/>
   <result pre="following tonsillectomy equates to 1/1000–1/27,000 [ 2]. Complications of acute" exact="tonsillitis" post="resulting in death include airway compromise secondary to airway"/>
   <result pre="proximal laryngeal ring was indeed oedematous and exhibited signs of" exact="epiglottitis" post="on histology. Fig. 4 Formalin fixed laryngo-pharyngeal specimen with"/>
   <result pre="prior to lethal airway occlusion. Conclusions Sudden death following acute" exact="tonsillitis" post="has been reported in the literature, but limited information"/>
   <result pre="tonsillar pathology. Our case represents one of most likely viral" exact="tonsillitis" post="with significant enlargement of the palatine tonsils. We postulate"/>
   <result pre="the sudden and unexpected collapse and death of children with" exact="tonsillitis" post="and associated tonsillar hypertrophy. Abbreviations Fig Figure SUDI Sudden"/>
   <result pre="have no competing interests. References References 1. Bisno AL Acute" exact="pharyngitis" post="N Engl J Med 2001 344 3 205 211"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6979112/results/search/disease/results.xml">
   <result pre="Wesenberg Kjær 09.15‐10.00 Keynote: Induced pluriupotent stem cells for unraveling" exact="neurodegeneration" post="in man and dog P. Hyttel 10.00‐10.30 Coffee Break,"/>
   <result pre="J. Tarlton, G. Chanoit, L.‐F. Wong, N. Granger O6) Congenital" exact="myopathy" post="with phospholipid inclusions in european shorthair cats N. Meyerhoff,"/>
   <result pre="Calvo, M. Pumarola i Batlle, A. Luján Feliu‐Pascual FP4) Congenital" exact="lafora disease" post="in the chihuahua breed I. Espadas, B. Minassian, P."/>
   <result pre="Vilela FP6) Hippocampal expression of the CB1 receptor in canine" exact="epilepsy" post="D. Kostic, M. Nowakowska, J. Freundt Revilla, F. Attig,"/>
   <result pre="G. Quintana, J. Van Dijk, L. De Risio FP12) Inherited" exact="polyneuropathy" post="in Border Collie: a motor and sensory polyneuropathy? H."/>
   <result pre="Stabile, L. De Risio O9) Epileptic seizures in dogs with" exact="meningoencephalitis" post="of unknown origin: clinical features, risk factors and longterm"/>
   <result pre="Lazzerini, G. Leblond O10) Seizure‐precipitating factors in dogs with idiopathic" exact="epilepsy" post="J. Forsgård, E.‐L. Metsähonkala, A.‐M. Kiviranta, S. Cizinauskas, J."/>
   <result pre="in mitochondrial peptidase results in lethal juvenile brain disorder with" exact="status epilepticus" post="in dogs M. Hytönen, R. Sarviaho, Ch. Jackson, P."/>
   <result pre="G. Quintana O14) Nova scotia duck tolling retrievers with degenerative" exact="encephalopathy" post="are homozygous for a rare nonsynonymous rb1cc1 variant J."/>
   <result pre="Volk FP16) 6 HPA axis dysregulation associated with chronic idiopathic" exact="epilepsy" post="in dogs R. Packer, A. Davies, H. Volk, R."/>
   <result pre="rat is not primate M. Rosati, K. Matiasek FP23) Unusual" exact="lactic acidosis" post="in a 5 year old dog with glycogen storage"/>
   <result pre="acidosis in a 5 year old dog with glycogen storage" exact="myopathy" post="due to muscle phosphorylase a deficiency N. Bergknut, R."/>
   <result pre="Expression of the cystine/glutamate transporter SLC7A11 in canine tumour associated" exact="epilepsy" post="M. Rosati, A. Mazzanti, G. Gandini, K. Matiasek O22)"/>
   <result pre="the short‐term effects of medium‐chain triglycerides (MCT) supplement on canine" exact="epilepsy" post="in drug‐non responders B.‐A. Berk, T. Hong Law, A."/>
   <result pre="O24) Prognostic factors for recovery of vision in dogs with" exact="optic neuritis" post="of unknown aetiology: 21 cases (2003 ‐ 2018) Ch."/>
   <result pre="(ISSL) aberrant migration is an important cause of severe acute" exact="myelitis" post="with high morbidity in endemic countries. Tentative diagnosis is"/>
   <result pre="the N‐myc downstream regulated gene 1 ( NDRG1) may cause" exact="polyneuropathy" post="in humans, dogs and rodents. Additionally, NDRG1 is dysregulated"/>
   <result pre="phosphorylation of the protein. The pathologic similarities between this canine" exact="polyneuropathy" post="and the human Charcot‐Marie‐Tooth type 4D suggest that further"/>
   <result pre="describes the diagnostic work up of a so far unknown" exact="myopathy" post="in a family of European Shorthair cats. A female"/>
   <result pre="mother and her entire litter have been affected, an inherited" exact="myopathy" post="seems most likely. Search for associated mutations using whole"/>
   <result pre="(ES) frequency and pattern in antiepileptic‐drug (AED)‐naïve dogs with idiopathic" exact="epilepsy" post="(IE) after initiation of phenobarbital or imepitoin monotherapy. This"/>
   <result pre="ES‐diary. Exclusion criteria were: occurrence of cluster seizures (CS) or" exact="status epilepticus" post="prior to treatment initiation and concurrent disease and/or treatment."/>
   <result pre="and Economics, Faculty of Veterinary Medicine, Warsaw, Poland. Patients with" exact="meningoencephalitis" post="can experience seizures acutely, but also have an increased"/>
   <result pre="to report the prevalence of epileptic seizures in dogs with" exact="meningoencephalitis" post="of unknown origin (MUO), and to define their risk"/>
   <result pre="within 3 months of the acute episode of meningoencephalitis. Post‐encephalitic" exact="epilepsy" post="(PE) was defined as recurrent seizures following that initial"/>
   <result pre="in epileptic dogs, although they are frequently reported in human" exact="epilepsy" post="patients. In humans, common seizure‐precipitating factors include for example"/>
   <result pre="epilepsy‐related factors. Furthermore, we hypothesized that most dogs with idiopathic" exact="epilepsy" post="have protective factors for seizures. In this cross‐sectional observational"/>
   <result pre="this cross‐sectional observational study, we collected 50 dogs with idiopathic" exact="epilepsy" post="from the hospital populations of the University Veterinary Teaching"/>
   <result pre="In conclusion, seizure‐precipitating factors are common in dogs with idiopathic" exact="epilepsy" post="and the nature of these factors is consistent with"/>
   <result pre="12 weeks of age. After onset, the disease progresses rapidly to" exact="status epilepticus" post="and death. Detailed clinical investigations and necropsy were carried"/>
   <result pre="assay. We discovered a novel rapidly progressing recessive juvenile mitochondrial" exact="encephalopathy" post="resulting in lethal status epilepticus. Pathology showed a diffuse"/>
   <result pre="novel rapidly progressing recessive juvenile mitochondrial encephalopathy resulting in lethal" exact="status epilepticus." post="Pathology showed a diffuse necrotizing panpolioencephalopathy with extensive neuronal"/>
   <result pre="We have characterized a novel canine brain disorder, juvenile mitochondrial" exact="encephalopathy" post="with status epilepticus, and identified the genetic cause. The"/>
   <result pre="characterized a novel canine brain disorder, juvenile mitochondrial encephalopathy with" exact="status epilepticus," post="and identified the genetic cause. The gene codes for"/>
   <result pre="in this gene have been associated with a slowly progressing" exact="neurodegeneration" post="in humans. In contrast to the human disease, the"/>
   <result pre="the canine condition is rapidly progressing after birth leading to" exact="status epilepticus" post="and death. Further functional and pathological studies aim to"/>
   <result pre="genetic variant responsible for an autosomal recessively inherited progressive degenerative" exact="encephalopathy" post="that affects Nova Scotia Duck Tolling Retriever (NSDTR) dogs."/>
   <result pre="the receptors and downstream signaling pathways resulting in inhibition of" exact="glioma" post="invasiveness. We identified peptide binding GM‐CSF using peptide microarrays,"/>
   <result pre="peptide (G7) with most potent capacity for inhibition of human" exact="glioma" post="cell invasiveness in the presence of human and mouse"/>
   <result pre="its receptor. G7 has a potent capacity for inhibition of" exact="glioma" post="cell invasiveness induced by the presence of microglia and"/>
   <result pre="with or without mild ataxia (n=22), to tetraparesis (n=28) and" exact="tetraplegia" post="(n=11). Neither weight nor age, type of trauma, length"/>
   <result pre="= 7) on transverse cine bFFE. A high prevalence of" exact="syringomyelia" post="was identified (11/12; 92%) on T2W sequences, occurring both"/>
   <result pre="within SAD, and identify a high co‐occurrence of SAD and" exact="syringomyelia" post="in the study population. Study submitted for ethical approval"/>
   <result pre="clinical signs. All tumours were classified as high grade (anaplastic" exact="oligodendroglioma" post="grade III or grade IV glioblastoma multiforme). All of"/>
   <result pre="Germany, 2Department of Veterinary Medical Science, University of Bologna. Tumor‐associated" exact="epilepsy" post="(TAE) is a common neurological sequela in glioma patients."/>
   <result pre="Bologna. Tumor‐associated epilepsy (TAE) is a common neurological sequela in" exact="glioma" post="patients. The pathogenesis of TAE is poorly understood but"/>
   <result pre="The cystine/glutamate transporter SLC7A11 is considered a major pathway of" exact="glioma" post="glutamate release. As it can be pharmacologically targeted, we"/>
   <result pre="a population of dogs affected by neuroglial tumors. Altogether, 24" exact="glioma" post="patients with (15/24) or without TAE (9/24) were included"/>
   <result pre="traced in all brains. Intratumoural expression was clearly higher in" exact="oligodendroglioma" post="than astrocytoma but it did not correlate to seizure"/>
   <result pre="all brains. Intratumoural expression was clearly higher in oligodendroglioma than" exact="astrocytoma" post="but it did not correlate to seizure prevalence or"/>
   <result pre="and/or remote expression fraction was significantly higher than in non‐epileptic" exact="glioma" post="patients. Canine TAE brains show an increased SLC7A11 expression"/>
   <result pre="of grade III anaplastic astrocytoma, oligoastrocytoma, and grade II diffuse" exact="astrocytoma" post="and oligodendroglioma were immunostained for PD‐L1, PD‐1, CD3, and"/>
   <result pre="III anaplastic astrocytoma, oligoastrocytoma, and grade II diffuse astrocytoma and" exact="oligodendroglioma" post="were immunostained for PD‐L1, PD‐1, CD3, and CD20. All"/>
   <result pre="Medical records of dogs diagnosed with isolated ONUA or with" exact="meningoencephalitis" post="of unknown aetiology (MUA)‐associated ON were reviewed. Statistical analysis"/>
   <result pre="dogs with central nervous system disorders. In a puppy with" exact="hydrocephalus" post="ICP was monitored before and after withdrawal of cerebrospinal"/>
   <result pre="seven controls, seven dogs with structural and five with idiopathic" exact="epilepsy" post="(CB1, Abcam ab23703). Hippocampal density and intensity of CB1"/>
   <result pre="in patients with idiopathic as compared to patients with structural" exact="epilepsy" post="(p&amp;lt;0.0001) or healthy dogs (p&amp;lt;0.001). In the same region,"/>
   <result pre="receptor staining was stronger in dogs with idiopathic than structural" exact="epilepsy" post="(p&amp;lt;0.001). Statistically significant group differences with smaller area and"/>
   <result pre="area and higher intensity of CB1 receptor expression in idiopathic" exact="epilepsy" post="dogs in comparison to structural epilepsy occurred in DG,"/>
   <result pre="receptor expression in idiopathic epilepsy dogs in comparison to structural" exact="epilepsy" post="occurred in DG, CA3 and hilus. Our results give"/>
   <result pre="for a downregulation of CB1 receptor expression in idiopathic canine" exact="epilepsy" post="in sub‐regions of the hippocampus. The disease seems to"/>
   <result pre="The main reason for amputation was trauma (63%) followed by" exact="cancer" post="(29%). In 45% of the patients, pain was reported"/>
   <result pre="facial &amp;amp; vestibulocochlear nerves (1/14), T3‐L3 (1/14), L4‐S3 (1/14). Peripheral" exact="eosinophilia" post="was present in 4/14. MRI revealed ill‐defined patchy T2"/>
   <result pre="two referral veterinary clinics were searched for cats diagnosed with" exact="epilepsy" post="and treated with phenobarbitone (2007‐2017). Follow‐up information was obtained"/>
   <result pre="completed by the cats’ owners. Seventy‐seven cats, 58 with idiopathic" exact="epilepsy" post="and 19 with structural epilepsy, met the inclusion criteria."/>
   <result pre="with adverse effect occurrence. Idiosyncratic adverse effects, characterised by severe" exact="neutropenia" post="and severe granulocytic hypoplasia, were diagnosed in only one"/>
   <result pre="cohort of 6 dogs. Border Collies with clinical signs of" exact="polyneuropathy" post="of juvenile onset were retrospectively included in the study."/>
   <result pre="in 3 dogs. This study suggests phenotypical heterogeneity in sensory" exact="neuropathy" post="in Border Collie, with partial motor involvement in all"/>
   <result pre="to moderate spinal cord compression. The dog died from an" exact="aspiration pneumonia" post="shortly after the MRI and was subjected to a"/>
   <result pre="moderate spinal cord compression. The dog died from an aspiration" exact="pneumonia" post="shortly after the MRI and was subjected to a"/>
   <result pre="Hypoplasia and dysplasia of the corpus callosum with concomitant lobar" exact="holoprosencephaly" post="is the most commonly reported variant. It is currently"/>
   <result pre="acutely stressful nature of generalised seizures in dogs with idiopathic" exact="epilepsy" post="(IE). Although significant spikes in salivary cortisol are observed"/>
   <result pre="has been identified to correlate with seizure incidence in structural" exact="epilepsy" post="due to glutamate induced excitotoxicity and subsequent neuronal injury."/>
   <result pre="appear to exist essential neurobiological differences regarding hippocampal involvement in" exact="epilepsy" post="and the existence of temporal lobe epilepsy in different"/>
   <result pre="differences regarding hippocampal involvement in epilepsy and the existence of" exact="temporal lobe epilepsy" post="in different species, we investigated the immunohistochemical expression pattern"/>
   <result pre="hippocampal involvement in epilepsy and the existence of temporal lobe" exact="epilepsy" post="in different species, we investigated the immunohistochemical expression pattern"/>
   <result pre="without muscle involvement but this is the first time that" exact="glycogen storage disease" post="type V has been identified in a dog. This"/>
   <result pre="old age. Untypical for McArdle patients, the dog also suffers" exact="lactic acidosis" post="with yet unclear relation to the enzyme deficiency according"/>
   <result pre="with yet unclear relation to the enzyme deficiency according to" exact="lactic acidosis" post="type B. Thus, the outcome in this particular patient"/>
   <result pre="humans and dogs. In humans, there is some evidence that" exact="temporal lobe epilepsy" post="(TLE) is characterized by abnormalities in the hippocampus, but"/>
   <result pre="dogs. In humans, there is some evidence that temporal lobe" exact="epilepsy" post="(TLE) is characterized by abnormalities in the hippocampus, but"/>
   <result pre="temporal structures has not been performed in dogs with idiopathic" exact="epilepsy" post="(IE). Hence, the aim of the study was to"/>
   <result pre="clinical outcome in 4 cases. Four dogs with histopathologically confirmed" exact="glioma" post="previously resected with curative intent followed by adjuvant temozolamide"/>
   <result pre="T helper cells playing an important role during inflammation and" exact="autoimmune disease." post="To investigate the role of these cells in diseases"/>
   <result pre="Medical records and imaging findings of dogs with diagnosis of" exact="epilepsy" post="and brain MRI (0.2T or 1.5T) performed between January"/>
   <result pre="seizure type (focal/generalised), aetiology (idiopathic/structural/unknown origin), presence of clusters or" exact="status epilepticus" post="(SE), time between last seizure and MRI, detection of"/>
   <result pre="lower in dogs with PC. Prevalence of idiopathic and structural" exact="epilepsy" post="was similar in both affected and unaffected dogs. Results"/>
   <result pre="purpose of this case report was to report a skeletal" exact="osteosarcoma" post="with central nervous system metastasis. A 9‐year‐old, male neutered"/>
   <result pre="humeral lesion for histopathology. Osteosarcoma of the humerus and brain" exact="osteosarcoma" post="metastases were confirmed on histopathology. Metastases from primary bone"/>
   <result pre="osteosarcoma metastases were confirmed on histopathology. Metastases from primary bone" exact="osteosarcoma" post="to the brain have rarely been reported in veterinary"/>
   <result pre="the first case report describing the MR Imaging features of" exact="osteosarcoma" post="metastases in the brain. [P12] MEDICAL AND SURGICAL TREATMENT"/>
   <result pre="months earlier, a subtotal pericardiectomy had been performed for neutrophilic" exact="pericarditis" post="and focal pyogranulomatous epicarditis, from which the dog recovered"/>
   <result pre="normal limits. Clinical signs of SRMA result from a combined" exact="meningitis" post="and arteritis of leptomeningeal vessels. The arteritis has also"/>
   <result pre="In human medicine, the most common cause is sclerotic metastatic" exact="bone disease" post="(prostate, breast and lung cancer). Other differential diagnoses are"/>
   <result pre="breast and lung cancer). Other differential diagnoses are Paget's disease," exact="lymphoma" post="or osteomyelitis. To the authors’ knowledge, this is the"/>
   <result pre="pathological fracture and compression of the spinal cord with associated" exact="meningitis" post="and neuritis. In the microbiological analysis, Actinobacillus (A.) pleuropneumoniae"/>
   <result pre="pathological findings are highly variable, such as vertebral abscess, vertebral" exact="osteomyelitis" post="or spinal abscess. Osteomyelitis is relatively frequent in young"/>
   <result pre="is the first report that describes MRI findings in vertebral" exact="osteomyelitis" post="in a pig potentially caused by A. pleuropneumoniae. [P18]"/>
   <result pre="Veterinary Teaching Hospital, Universitat Autònoma de Barcelona, Bellaterra Spain. External" exact="hydrocephalus" post="in infants is a benign clinical entity in which"/>
   <result pre="surgically treated. And the only canine case reported of external" exact="hydrocephalus" post="was diagnosed with computed tomography (CT) images only. A"/>
   <result pre="report of the MRI characteristics of a suspected benign external" exact="hydrocephalus" post="in a dog. [P19] THE MISERY OF INSUFFICIENT TREATMENT"/>
   <result pre="1. 1University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. Posttraumatic" exact="epilepsy" post="(PTE) is well described in human and veterinary medicine."/>
   <result pre="dogs developed seizures, leading to death of the JRT in" exact="status epilepticus." post="The MV was treated again with AEDs (Phenobarbital, Imepitoin,"/>
   <result pre="group ( p &amp;lt; 0.001; OR =12.7, Fisher test). Suspected/confirmed idiopathic" exact="epilepsy" post="accounted for 16 patients in the control group (44%)"/>
   <result pre="four‐month‐old cat was presented due to an acute onset of" exact="paraplegia" post="after receiving an injection of cefovecine and dexamethasone in"/>
   <result pre="One day after the injection, the neurological examination revealed a" exact="paraplegia" post="without deep pain sensation and reduced segmental spinal reflexes"/>
   <result pre="is the first reported case of fibrocartilaginous embolism causing an" exact="encephalopathy" post="in a cat. While this is a rare disease,"/>
   <result pre="Veterinary Medicine, Ebetsu, Japan. Neurolymphomatosis is a rare manifestation of" exact="lymphoma" post="and is characterised by neoplastic infiltration of the peripheral"/>
   <result pre="Germany. Description of MRI features of French Bulldogs with necrotizing" exact="encephalitis" post="is restricted to case reports or scattered within studies"/>
   <result pre="characteristics of 20 French Bulldogs. Dogs were suspected to have" exact="encephalitis" post="with inflammatory CSF and one or more MRI lesions"/>
   <result pre="neoplasia than for encephalitis. Brain biopsy here showed that immune‐mediated" exact="encephalitis" post="can also present with focal lesions, without CSF changes"/>
   <result pre="seen. The latter was consistent with non‐cardiogenic toxic edema or" exact="aspiration pneumonia." post="The patient remained on the ICU for forty‐eight hours,"/>
   <result pre="weakness and a peracute onset of tetraplegia. On neurological examinations," exact="tetraplegia" post="with lower motor neuron signs was notified. Myasthenia gravis"/>
   <result pre="de Pietersberg, Oosterbeek, Netherlands. Orthostatic tremor (OT) is a rare" exact="movement disorder" post="that causes instability and psychological stress in humans. A"/>
   <result pre="cats. Lymphoma is mentioned as the second most frequent intracranial" exact="neoplasm" post="in young cats. In humans, CD is reported as"/>
   <result pre="diagnosis indicated a diffuse cerebellar lesion. Blood count analysis showed" exact="thrombocytopenia" post="and lymphopenia. Cerebrospinal fluid analysis indicated mononuclear and neutrophilic"/>
   <result pre="described case of possible paraneoplastic cerebellar abiotrophy associated with CNS" exact="lymphoma" post="in a cat. [P38] CHARACTERIZATION OF NEUROLOGICAL ABNORMALITIES IN"/>
   <result pre="correlated with the presence or absence of MRI signs of" exact="brain compression." post="The study included 97 dogs. All dogs showed at"/>
   <result pre="of dogs with a pituitary detectable mass had signs of" exact="brain compression." post="The presence of an high pituitary height/brain area and"/>
   <result pre="compression. The presence of an high pituitary height/brain area and" exact="brain compression" post="represented a risk factor for developing mental status abnormalities."/>
   <result pre="findings, treatment and outcome of a case of traumatic ischiatic" exact="neuropathy" post="in a domestic chicken. A 1 year‐old hen was"/>
   <result pre="fluids is considered to be a useful test to differentiate" exact="lymphoma" post="and inflammatory disease and for immunophenotyping lymphoma cells. In"/>
   <result pre="test to differentiate lymphoma and inflammatory disease and for immunophenotyping" exact="lymphoma" post="cells. In four dogs with progressive neurological signs, intracranial"/>
   <result pre="months. Key points from this case are that exercise induced" exact="myopathy" post="causes marked, diffuse hyperintensities on T2W and STIR images,"/>
   <result pre="ambulatory. Clinical and histopathological findings were compatible with inflammatory distal" exact="polyneuropathy" post="of the chronic progressive or relapsing motor and sensory"/>
   <result pre="polyneuropathy of the chronic progressive or relapsing motor and sensory" exact="peripheral neuropathy" post="groups. These diseases have been associated with inflammatory changes"/>
   <result pre="of the chronic progressive or relapsing motor and sensory peripheral" exact="neuropathy" post="groups. These diseases have been associated with inflammatory changes"/>
   <result pre="1Fitzpatrick Referrals, Godalming, United Kingdom. Osteopetrosis is a genetically determined" exact="bone disease" post="that develops as a result of malfunction of osteoclastic"/>
   <result pre="by the dens of the axis ventrally. Spinal MRI revealed" exact="syringomyelia" post="within the C2‐C3 and C5‐L3 segments. The maximal width"/>
   <result pre="first case report where MR findings in a patient with" exact="osteopetrosis" post="associated with Chiari‐like malformation are described in veterinary medicine."/>
   <result pre="left pleurothotonus, vestibular ataxia, left proprioceptive deficits, left eye ventrolateral" exact="strabismus" post="and left lingual hemiatrophy with ipsilateral deviation. Magnetic resonance"/>
   <result pre="investigate potential risk factors for the development of secondary cervical" exact="syringomyelia" post="(SCSM) in dogs affected by single intracranial space‐occupying lesions."/>
   <result pre="better understanding of these factors may improve our understanding of" exact="epilepsy" post="and enhance management options. We designed an online questionnaire‐based"/>
   <result pre="seizure triggers. Owners of 228 dogs with Tier I idiopathic" exact="epilepsy" post="completed the survey, with 136 (60%) reporting that they"/>
   <result pre="breed or age. In conclusion, many owners of dogs with" exact="epilepsy" post="perceive both a prodromal phase in their dogs and"/>
   <result pre="rare entities. We describe a case of canine primary intradural‐extramedullary" exact="osteosarcoma" post="of the cervical spine. An 11‐year‐old male neutered crossbreed"/>
   <result pre="Ishikawa 1, Masato Kitagawa 1. 1Nihon University, Fujisaza, Japan. Although" exact="endolymphatic hydrops" post="of the internal ear and vestibular neuritis are suspected,"/>
   <result pre="images. Nine dogs with IVD and six dogs with idiopathic" exact="epilepsy" post="were included in this study. In each dog, structures"/>
   <result pre="or spontaneous (vestibular migraine, Meniere's disease, transient ischaemic attack). Vestibulogenic/vertiginous" exact="epilepsy" post="is another under‐recognised nonlesional pharmacoresponsive condition caused by lesions"/>
   <result pre="vestibular representation in the frontal cortex. In young dogs, congenital" exact="vestibular disease" post="has been reported, however it is not episodic. A"/>
   <result pre="with the head position was reported. Physical examination revealed bilateral" exact="otitis externa" post="(treated with topical medication), whilst neurological examination was unremarkable."/>
   <result pre="compatible with right peripheral vestibular system. Despite the resolution of" exact="otitis externa," post="the episodes frequency increased up to once a week."/>
   <result pre="dog still experiences daily vestibular paroxysms. In this case, congenital" exact="vestibular disease," post="ear disease or structural encephalopathy are considered unlikely due"/>
   <result pre="experiences daily vestibular paroxysms. In this case, congenital vestibular disease," exact="ear disease" post="or structural encephalopathy are considered unlikely due to their"/>
   <result pre="In this case, congenital vestibular disease, ear disease or structural" exact="encephalopathy" post="are considered unlikely due to their permanent nature. Vestibulogenic"/>
   <result pre="Vestibulogenic seizure is unlikely due to lack of pharmacoresponsiveness. Vestibular" exact="migraine" post="and transient ischaemic attacks are of central origin, whilst"/>
   <result pre="disease (IVDD) (n=42), fracture/luxation (n=34), ischaemic myelopathy (n=22), feline infectious" exact="peritonitis" post="virus myelitis (n=18), lymphoma (n=16), vertebral canal stenosis (n=11),"/>
   <result pre="(n=42), fracture/luxation (n=34), ischaemic myelopathy (n=22), feline infectious peritonitis virus" exact="myelitis" post="(n=18), lymphoma (n=16), vertebral canal stenosis (n=11), acute non‐compressive"/>
   <result pre="(n=34), ischaemic myelopathy (n=22), feline infectious peritonitis virus myelitis (n=18)," exact="lymphoma" post="(n=16), vertebral canal stenosis (n=11), acute non‐compressive nucleus pulposus"/>
   <result pre="was presented to our hospital with a 2‐weeks history of" exact="paraplegia" post="and normal deep pain perception of the pelvic limbs."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6979267/results/search/disease/results.xml">
   <result pre="mitral valve regurgitation severity in dogs with stage B2 myxomatous" exact="mitral valve disease" post="– A pilot study 16.10‐16.25 ESVC‐O‐2 Ward Retrospective evaluation"/>
   <result pre="tolerability of pimobendan in cats with obstructive versus nonobstructive hypertrophic" exact="cardiomyopathy" post="16.25‐16.40 ESVC‐O‐3 Crosara Aorto‐septal angle, isolated basal septal hypertrophy"/>
   <result pre="of noninvasively determined pulmonary artery pressure in dogs with myxomatous" exact="mitral valve disease" post="(MMVD) 11.35‐11.50 ESVC‐O‐5 Ksiazek Left atrial tear in dogs"/>
   <result pre="11.35‐11.50 ESVC‐O‐5 Ksiazek Left atrial tear in dogs with myxomatous" exact="mitral valve disease" post="‐ clinical presentation, echocardiographic features and long‐term survival 11.50‐12.05"/>
   <result pre="systolic function before and 24 hours after percutaneous closure of" exact="patent ductus arteriosus" post="in 120 dogs 12.05‐12.20 ESVC‐O‐7 Adin Delayed Electrolyte Depletion"/>
   <result pre="wall thickness, Troponin‐I and IGF‐1 in cats with asymptomatic hypertrophic" exact="cardiomyopathy" post="14.40‐14.55 ESVC‐O‐11 Patata Biomarker discovery in cats with cardiomyopathy"/>
   <result pre="hypertrophic cardiomyopathy 14.40‐14.55 ESVC‐O‐11 Patata Biomarker discovery in cats with" exact="cardiomyopathy" post="14.55‐15.10 ESVC‐O‐12 Hanås Blood pressure measurement by High Definition"/>
   <result pre="Busato Does pleural effusion protect against arterial thromboembolism in feline" exact="congestive heart failure?" post="15.25‐15.40 ESVC‐O‐14 Ferasin Iatrogenic heart murmur: a new cause"/>
   <result pre="Supraventricular tachycardia in 23 cats; comparison with 21 cats with" exact="atrial fibrillation" post="(2004‐2014) 17.00‐17.15 ESVC‐O‐18 Perego Electrocardiographic patterns of ventricular pre‐excitation"/>
   <result pre="reoccurrence of congestive signs in dogs with ACVIM‐Stage C myxomatous" exact="mitral valve disease" post="(MMVD) SCH – Society of Comparative Hepatology Thursday 19"/>
   <result pre="dehydrogenase as a prognostic marker for nodal diffuse large B‐cell" exact="lymphoma" post="in dogs 12.20‐12.35 ESVCP‐O‐2 Prasinou The paradigm of erythrocyte"/>
   <result pre="relationship between ionised and total calcium in dogs with ionised" exact="hypercalcaemia" post="14.55‐15.10 ESVCP‐O‐6 Dewhurst The effect of boric acid on"/>
   <result pre="readings in out‐patient and in‐patient dogs 15.10‐15.25 ESVNU‐O‐4 Rossi Immune‐complex" exact="glomerulonephritis" post="in cats: a retrospective study based on clinico‐pathological data"/>
   <result pre="to an E. coli probiotic as a potential therapeutic for" exact="urinary tract infection" post="15.55‐16.10 ESVNU‐O‐7 Baumgartner Prognostic factors in dogs with common"/>
   <result pre="ESVNU‐O‐7 Baumgartner Prognostic factors in dogs with common causes of" exact="proteinuria" post="16.10‐16.25 ESVNU‐O‐8 Bijsmans The effect of dietary sodium on"/>
   <result pre="relative supersaturation (CaOx RSS) in dogs 16.25‐16.40 ESVNU‐O‐9 Caccamo Proliferative" exact="urethritis" post="in dogs: long‐term follow up and prognosis ISCAID ‐"/>
   <result pre="A retrospective multi‐centre study on treatment and outcome in disseminated" exact="aspergillosis" post="in 41 dogs 14.25‐14.40 ISCAID‐O‐7 Cervone Canine Trichuris vulpis"/>
   <result pre="fecal microbiota and unconjugated fecal bile acids in dogs with" exact="diabetes mellitus" post="10.00‐10.15 ESCG‐O‐2 Stavroulaki Impact of antibiotic administration on fecal"/>
   <result pre="Sanchez Fecal microbial metabolism is altered in dogs with chronic" exact="enteropathy" post="11.20‐11.35 ESCG‐O‐4 Swales The pug breed demonstrates a worse"/>
   <result pre="pug breed demonstrates a worse response to treatment of protein‐losing" exact="enteropathy" post="than other breeds of dog 11.35‐11.50 ESCG‐O‐5 Petrelli Is"/>
   <result pre="healthy dogs 12.20‐12.35 ESCG‐O‐8 Kaufmann Long‐term consequences of acute hemorrhagic" exact="diarrhea" post="syndrome in dogs ESVIM – European Society of Veterinary"/>
   <result pre="17.15‐17.30 ESVIM‐O‐4 Jaffey Serum 25‐hydroxyvitamin D in dogs with sinonasal" exact="aspergillosis" post="17.30‐17.45 ESVIM‐O‐5 Jaffey Plasma mRNA cathelicidin expression in hospitalized"/>
   <result pre="expression in hospitalized critically ill dogs 17.45‐18.00 ESVIM‐O‐6 Jaffey Hereditary" exact="methemoglobinemia" post="in dogs caused by cytochrome b5 reductase deficiency associated"/>
   <result pre="shedding of amyloid fibrils 17.30‐17.45 ESVIM‐O‐11 Rabozzi Treatment of non‐lactate" exact="metabolic acidosis" post="in hypovolemic and normovolemic dogs: chloride‐free iso‐osmolar solution with"/>
   <result pre="is a valuable treatment option for dogs and cats with" exact="cancer" post="after failing first line therapy 14.55‐15.10 ESVONC‐O‐3 Borgatti Impact"/>
   <result pre="Hemangiosarcoma 15.10‐15.25 ESVONC‐O‐4 Škor Humoral hypercalcemia of malignancy in canine" exact="lymphoma" post="WHO types and its impact on survival 15.25‐15.40 ESVONC‐O‐5"/>
   <result pre="(MHC) class II haplotypes associated with increased risk of canine" exact="diabetes mellitus" post="– a breed‐specific study 10.30‐10.45 ESVE‐O‐7 Copley Comparison of"/>
   <result pre="Whole Genome Sequencing to explore genetic risk factors in canine" exact="diabetes mellitus" post="12.20‐12.35 ESVE‐O‐12 Linari Evaluation of 1,2‐o‐dilauryl‐rac‐glycero glutaric acid ‐"/>
   <result pre="of follicular‐cell thyroid carcinoma: a novel canine model for translational" exact="thyroid cancer" post="research ESVCN – European Society of Veterinary Comparative Nutrition"/>
   <result pre="follicular‐cell thyroid carcinoma: a novel canine model for translational thyroid" exact="cancer" post="research ESVCN – European Society of Veterinary Comparative Nutrition"/>
   <result pre="Heart rate variability of dogs in various stages of degenerative" exact="mitral valve disease" post="ESVC‐P‐2 van Israel Comparison of serum digoxin concentrations from"/>
   <result pre="rate assessed by 2‐dimensional speckle tracking echocardiography in dogs with" exact="pulmonary hypertension" post="ESVC‐P‐4 Lee Potential renoprotective effect of angiotensin‐receptor antagonists in"/>
   <result pre="Potential renoprotective effect of angiotensin‐receptor antagonists in dogs with myxomatous" exact="mitral valve disease" post="ESVC‐P‐5 Takamura Perioperative management with peripheral arteries in dogs"/>
   <result pre="concentration, renal function and survival in 85 dogs with acute" exact="congestive heart failure" post="ESVC‐P‐7 Yilmaz Platelet proteomic profile in dogs with heart"/>
   <result pre="desmin aggregates consistent with intermediate filament dysfunction in feline hypertrophic" exact="cardiomyopathy" post="ESVC‐P‐10 Guglielmini Prevalence and risk factors for atrial fibrillation"/>
   <result pre="feline hypertrophic cardiomyopathy ESVC‐P‐10 Guglielmini Prevalence and risk factors for" exact="atrial fibrillation" post="in dogs with myxomatous mitral valve disease ESVC‐P‐11 Poissonnier"/>
   <result pre="and risk factors for atrial fibrillation in dogs with myxomatous" exact="mitral valve disease" post="ESVC‐P‐11 Poissonnier Left atrial volume assessment in 160 Cavalier"/>
   <result pre="in 160 Cavalier King Charles Spaniels with and without degenerative" exact="mitral valve disease" post="(2017‐2019) ESVC‐P‐12 Passavin Hematological abnormalities in dogs with congenital"/>
   <result pre="of torasemide as a second line diuretic in dogs with" exact="congestive heart failure" post="ESVC‐P‐15 Mazzoldi Echocardiographic predictors of first onset of atrial"/>
   <result pre="heart failure ESVC‐P‐15 Mazzoldi Echocardiographic predictors of first onset of" exact="atrial fibrillation" post="in dogs with myxomatous mitral valve disease ESVC‐P‐16 Romito"/>
   <result pre="of first onset of atrial fibrillation in dogs with myxomatous" exact="mitral valve disease" post="ESVC‐P‐16 Romito Usefulness of Holter‐derived Lorenz plots analysis to"/>
   <result pre="effect of long flightprolonged air travel on dogs with heart" exact="mitral valve disease" post="ESVC‐P‐26 Lekane Clinical, ECG and echocardiographic findings in a"/>
   <result pre="in enteropathic cats ESVCP‐P‐6 Gori C‐Reactive Protein/Albumin ratio in canine" exact="acute pancreatitis" post="ESVCP‐P‐7 Navarro Martínez Urine capillary electrophoresis reference intervals for"/>
   <result pre="enteropathic cats ESVCP‐P‐6 Gori C‐Reactive Protein/Albumin ratio in canine acute" exact="pancreatitis" post="ESVCP‐P‐7 Navarro Martínez Urine capillary electrophoresis reference intervals for"/>
   <result pre="Pierini Platelet abnormalities and platelet‐to‐lymphocyte ratio (PLR) in canine immunosuppressant‐responsive" exact="enteropathy" post="(IRE): a retrospective study on 41 patients ESVCP‐P‐10 Galizzi"/>
   <result pre="immunosorbent assay (ELISA) in healthy dogs and dogs with myxomatous" exact="mitral valve disease" post="ESVNU – European Society of Veterinary Nephrology and Urology"/>
   <result pre="dogs ESVNU‐P‐7 Gori Evaluation of symmetric dimethylarginine (SDMA) in canine" exact="acute pancreatitis" post="ESVNU‐P‐8 From Evaluation of a point‐of‐care lateral flow immunoassay"/>
   <result pre="ESVNU‐P‐7 Gori Evaluation of symmetric dimethylarginine (SDMA) in canine acute" exact="pancreatitis" post="ESVNU‐P‐8 From Evaluation of a point‐of‐care lateral flow immunoassay"/>
   <result pre="acute uraemia managed with haemodialysis ESVNU‐P‐10 Pantaleo Risk factors for" exact="urinary tract infection" post="in dogs with natural occurring leptospirosis: a retrospective cohort"/>
   <result pre="in the diagnosis of renal disease in dogs affected with" exact="leishmaniasis" post="ESVNU‐P‐14 Zambarbieri Complicated UTI in dogs: uropathogens, antimicrobial resistance"/>
   <result pre="free‐roaming cats ISCAID‐P‐11 Walker Retrospective analysis of cases tested for" exact="leptospirosis" post="at a university teaching hospital ISCAID‐P‐12 Guzmán Ramos Canine"/>
   <result pre="and histopathological lesions in relation to outcomes in canine immunosuppressant‐responsive" exact="enteropathy" post="(Ire): prospective analysis in 57 dogs ESCG‐P‐2 Tabar Prevalence"/>
   <result pre="cPL, the severity of disease and mortality in suspected canine" exact="acute pancreatitis" post="ESCG‐P‐5 Candido Gastric mucosal pathology in Belgian Shepherd dogs"/>
   <result pre="the severity of disease and mortality in suspected canine acute" exact="pancreatitis" post="ESCG‐P‐5 Candido Gastric mucosal pathology in Belgian Shepherd dogs"/>
   <result pre="ESCG‐P‐9 Benvenuti Neutrophil‐to‐lymphocyte ratio (NLR) in canine patients with immunosuppressant‐responsive" exact="enteropathy" post="(IRE) ESCG‐P‐10 Ambrosini A Novel Canine‐Specific Model System to"/>
   <result pre="ESCG‐P‐13 Crisi The erythrocyte membrane lipidome in dogs with chronic" exact="enteropathy" post="ESCG‐P‐14 Da Riz Hypercobalaminaemia and its possible association with"/>
   <result pre="Weiß Serum Vitamin A and E concentrations in dogs with" exact="pancreatitis" post="ESCG‐P‐18 Galiazzo Water immersion vs gas insufflation in canine"/>
   <result pre="in the diagnosis of acid‐base basalnce disturbances in cats with" exact="chronic kidney disease" post="(CKD) ESVIM‐P‐5 Schulz Evaluation of different cleaning methods for"/>
   <result pre="or high plasma homocysteine concentration ESVIM‐P‐12 Gianesini Association between immune‐mediated" exact="hemolytic anemia" post="(IMHA) and acute pancreatitis in dogs ESVIM‐P‐13 Easley Evaluation"/>
   <result pre="high plasma homocysteine concentration ESVIM‐P‐12 Gianesini Association between immune‐mediated hemolytic" exact="anemia" post="(IMHA) and acute pancreatitis in dogs ESVIM‐P‐13 Easley Evaluation"/>
   <result pre="concentration ESVIM‐P‐12 Gianesini Association between immune‐mediated hemolytic anemia (IMHA) and" exact="acute pancreatitis" post="in dogs ESVIM‐P‐13 Easley Evaluation of Serum Procalcitonin in"/>
   <result pre="ESVIM‐P‐12 Gianesini Association between immune‐mediated hemolytic anemia (IMHA) and acute" exact="pancreatitis" post="in dogs ESVIM‐P‐13 Easley Evaluation of Serum Procalcitonin in"/>
   <result pre="Greci A statistical analysis to predict persistence of canine sinonasal" exact="aspergillosis" post="at endoscopic follow‐up by comparing three different scoring systems:"/>
   <result pre="in healthy dogs of different breeds ESVIM‐P‐23 Peano Canine sino‐nasal" exact="aspergillosis" post="in Italy (38 cases) ESVONC – European Society of"/>
   <result pre="in the dog ESVONC‐P‐2 Thumser‐Henner Sensitivity of canine and human" exact="cancer" post="cell lines towards thermoradiotherapy ESVONC‐P‐3 Lanore Interest of the"/>
   <result pre="of hepatic infiltration in case of nodal diffuse large B‐cell" exact="lymphoma" post="(DLBLCL) ESVONC‐P‐5 Campigli Pet owner feedback on psychological support"/>
   <result pre="effects of a single dose of vincristine in dogs with" exact="lymphoma" post="ESVE – European Society of Veterinary Endocrinology ESVE‐P‐1 Codea"/>
   <result pre="state and analytical method ESVE‐P‐7 Canonne‐Guibert Survival in cats with" exact="diabetes mellitus" post="and chronic pancreatitis: a preliminary study of 36 cases"/>
   <result pre="once daily Protamine Zinc Recombinant Human Insulin (ProZinc®) in canine" exact="diabetes mellitus" post="ESVE‐P‐9 Garcia Brachycephalic morphotype and pituitary tumor size in"/>
   <result pre="inflammatory response syndrome (SIRS) ESVE‐P‐11 Nerhagen Prednisolone induced hyperglycaemia and" exact="diabetes mellitus" post="in cats ESVE‐P‐12 Malerba Accuracy and precision of insulin"/>
   <result pre="fecal microbiota and unconjugated fecal bile acids in dogs with" exact="diabetes mellitus" post="B. Ruggerone 1, A.C. Manchester 2, F. del Baldo"/>
   <result pre="bile acid (BA) concentrations have been associated with type 1" exact="diabetes mellitus" post="(DM) in people. DM in dogs resembles human type"/>
   <result pre="ESCG‐O‐3 Fecal microbial metabolism is altered in dogs with chronic" exact="enteropathy" post="S. Bermudez Sanchez 1, R. Pilla 1, A. Gramenzi"/>
   <result pre="collected from 14 healthy dogs and 20 dogs with chronic" exact="enteropathy" post="(CE). Fecal DNA was extracted using a commercial kit"/>
   <result pre="pug breed demonstrates a worse response to treatment of protein‐losing" exact="enteropathy" post="than other breeds of dog H. Swales 1, D.J."/>
   <result pre="period, was selected for comparison. PLE was defined as any" exact="gastrointestinal disease" post="resulting in serum albumin below the laboratory reference interval"/>
   <result pre="cobalamin. Traditionally, their combination has been used to differentiate intestinal" exact="malabsorption" post="from dysbiosis. Despite the fact that the diagnostic and"/>
   <result pre="subgroups of food‐ (FRE), antibiotic‐ (ARE), steroid‐responsive (SRE) or protein‐losing" exact="enteropathy" post="(PLE), no difference in SF values was observed (ANOVA,"/>
   <result pre="tachypnea (RR &amp;gt; 40), hyper or hypothermia (T &amp;gt; 39.0°C or &amp;lt; 37.5°C), leucocytosis (WBC &amp;gt; 18*10 9/L)," exact="leukopenia" post="(WBC &amp;lt; 5*10 9/L, band neutrophilia and/or hypoglycaemia [glucose &amp;lt;4 mmol/L]) were"/>
   <result pre="No disclosures to report. ESCG‐O‐8 Long‐term consequences of acute hemorrhagic" exact="diarrhea" post="syndrome in dogs E. Kaufmann 1, K. Busch 1,"/>
   <result pre="this study was to evaluate, whether dogs with acute hemorrhagic" exact="diarrhea" post="syndrome (AHDS) have a higher prevalence of chronic enteropathies"/>
   <result pre="A historical control group of 67 dogs without history of" exact="gastroenteritis" post="was included to enable risk assessment. Dog owners were"/>
   <result pre="AHDS do not have an increased risk for developing chronic" exact="gastrointestinal disease" post="later in life, which is different to the risk"/>
   <result pre="mitral valve regurgitation severity in dogs with stage B2 myxomatous" exact="mitral valve disease" post="‐ A pilot study O. Belachsen, J. Sargent, T."/>
   <result pre="T. Wagner Southern Counties Veterinary Specialists, Ringwood, United Kingdom Myxomatous" exact="mitral valve disease" post="(MMVD) is associated with failure of the mitral valve"/>
   <result pre="dogs, MV regurgitation volume was calculated by subtracting the forward" exact="stroke" post="volume (Aortic outflow velocity time integral multiplied by the"/>
   <result pre="the aortic cross‐sectional area) from the total left ventricular (LV)" exact="stroke" post="volume (End‐systolic LV volume subtracted from the end‐diastolic LV"/>
   <result pre="calculated as the percentage of regurgitation volume from the total" exact="stroke" post="volume. Paired Student t‐test and Wilcoxon Signed‐Rank Test were"/>
   <result pre="significantly lower (p &amp;lt; 0.01) compared with baseline (43.7 +/− 4.7), forward" exact="stroke" post="volume was significantly increased ( P = 0.015), while"/>
   <result pre="volume was significantly increased ( P = 0.015), while total" exact="stroke" post="volume did not change significantly. This study suggests that"/>
   <result pre="tolerability of pimobendan in cats with obstructive versus nonobstructive hypertrophic" exact="cardiomyopathy" post="J.L. Ward 1, E. Kussin 2, M.A. Tropf 1,"/>
   <result pre="Pimobendan is frequently used off‐label for treatment of cats with" exact="congestive heart failure" post="(CHF) secondary hypertrophy cardiomyopathy (HCM). Concerns exist regarding the"/>
   <result pre="treatment of cats with congestive heart failure (CHF) secondary hypertrophy" exact="cardiomyopathy" post="(HCM). Concerns exist regarding the safety of pimobendan in"/>
   <result pre="cats with HOCM were more likely to manifest CHF as" exact="pulmonary edema" post="(44/47 versus 32/47; P = 0.003) and less likely to"/>
   <result pre="this study suggest that pimobendan is well‐tolerated in cats with" exact="cardiomyopathy" post="and CHF, regardless of presence of dynamic outflow tract"/>
   <result pre="of noninvasively determined pulmonary artery pressure in dogs with myxomatous" exact="mitral valve disease" post="(MMVD) G. Menciotti 1, M. Borgarelli 1, M. Aherne"/>
   <result pre="of Veterinary Medicine, Gainesville, United States of America Development of" exact="pulmonary hypertension" post="is an independent predictor of poor outcome in dogs"/>
   <result pre="this abstract. ESVC‐O‐5 Left atrial tear in dogs with myxomatous" exact="mitral valve disease" post="‐ clinical presentation, echocardiographic features and long‐term survival A.A."/>
   <result pre="(LAT) is an acute, life‐threatening, rare complication in canine myxomatous" exact="mitral valve disease" post="(MMVD). This case‐control matched multicenter retrospective study focussed on"/>
   <result pre="LAT diagnosis (time 0, T0) and at the resolution of" exact="pericardial effusion" post="(time 1, T1). Control dogs with similarly advanced MMVD"/>
   <result pre="without LAT. In both groups, 9 dogs were in ACVIM" exact="congestive heart failure" post="stage C and 6 in B2 MMVD. Commonly observed clinical"/>
   <result pre="and systolic function before and 24 hours after percutaneous closure of" exact="patent ductus arteriosus" post="in 120 dogs M. Claretti 1, D. Piantedosi 2,"/>
   <result pre="changes on left ventricular volumes before and 24‐hours after the" exact="patent ductus arteriosus" post="(PDA) occlusion by ACDO using standard echocardiography. The animals"/>
   <result pre="America Intravenous furosemide is the mainstay of treatment for acute" exact="congestive heart failure" post="in dogs, however, the potential for delayed effects on"/>
   <result pre="of dogs presented to the R(D)SVS: healthy (n = 18)," exact="chronic kidney disease" post="(CKD; IRIS stages 2‐4; serum creatinine 257 μmol/l, IQR395; n"/>
   <result pre="marked increase in UET‐1 excretion in dogs with stage C" exact="heart disease" post="(0.69,IQR 1.61 pg/mg; n = 11) compared to healthy dogs"/>
   <result pre="= 0.02). UET‐1 excretion was also increased in stage B2" exact="heart disease" post="(0.25 pg/mg, IQR 1.70; P = 0.03; n = 19)"/>
   <result pre="chronic disease (0.02 ng/mg, IQR 0.07), and none at all in" exact="heart disease" post="stages B1‐C. Renal ET‐1 activity increases with congestive heart"/>
   <result pre="in heart disease stages B1‐C. Renal ET‐1 activity increases with" exact="congestive heart failure," post="but surprisingly, also increases in MMVD before congestion develops."/>
   <result pre="different to those in isolated CKD and the development of" exact="congestive heart failure." post="Disclosures No disclosures to report. ESVC‐O‐9 High grade AV"/>
   <result pre="Connolly Royal Veterinary College, Potters Bar, United Kingdom Third degree" exact="atrioventricular block" post="(AVB) is characterised by complete atrioventricular (AV) dissociation, causing"/>
   <result pre="ventricular hypertrophy (17), chamber dilation (12); 13 cats presented with" exact="congestive heart failure" post="(CHF). Forty‐five cats had one or more comorbidities, the"/>
   <result pre="cats had one or more comorbidities, the most common were" exact="hyperthyroidism" post="(16), diabetes mellitus (9), azotaemia (8). Fifteen cats underwent"/>
   <result pre="one or more comorbidities, the most common were hyperthyroidism (16)," exact="diabetes mellitus" post="(9), azotaemia (8). Fifteen cats underwent epicardial pacemaker implantation,"/>
   <result pre="wall thickness, Troponin‐I and IGF‐1 in cats with asymptomatic hypertrophic" exact="cardiomyopathy" post="I. van Hoek 1, H. Hodgkiss‐Geere 2, E. Bode"/>
   <result pre="and echocardiographic parameters in forty‐four client‐owned cats with asymptomatic hypertrophic" exact="cardiomyopathy" post="(aHCM). Cats with diastolic interventricular septum (IVSd) and/or left"/>
   <result pre="by Royal Canin SAS. ESVC‐O‐11 Biomarker discovery in cats with" exact="cardiomyopathy" post="V. Patata 1, L. Carangiu 2, S. Pisanu 2,"/>
   <result pre="in the last decade, assays to measure circulating biomarkers of" exact="heart disease," post="such as cardiac troponin I and N‐terminal pro‐brain natriuretic"/>
   <result pre="proteins that may improve the identification of cats affected by" exact="cardiomyopathy" post="using biomarker discovery. Client‐owned cats were prospectively enrolled. Evaluation"/>
   <result pre="on diagnosis, cats were allocated to 5 groups, namely symptomatic" exact="cardiomyopathy" post="with signs of congestive heart failure (group CM‐Sx), asymptomatic"/>
   <result pre="allocated to 5 groups, namely symptomatic cardiomyopathy with signs of" exact="congestive heart failure" post="(group CM‐Sx), asymptomatic cardiomyopathy (group CM‐aSx), respiratory diseases (group"/>
   <result pre="cardiomyopathy with signs of congestive heart failure (group CM‐Sx), asymptomatic" exact="cardiomyopathy" post="(group CM‐aSx), respiratory diseases (group Resp‐Ds), systemic diseases without"/>
   <result pre="and 27 in Healthy. In CM‐Sx, 7/9 cats had hypertrophic" exact="cardiomyopathy" post="and 2/9 restrictive cardiomyopathy; lung edema was identified in"/>
   <result pre="Healthy. In CM‐Sx, 7/9 cats had hypertrophic cardiomyopathy and 2/9" exact="restrictive cardiomyopathy;" post="lung edema was identified in 7, pleural effusion and"/>
   <result pre="ESVC‐O‐13 Does pleural effusion protect against arterial thromboembolism in feline" exact="congestive heart failure?" post="F. Busato 1, A. Zoia 1, M. Drigo 2"/>
   <result pre="pleural effusion of any type or with ascites secondary to" exact="congestive heart failure" post="(CHF) show an enhanced systemic fibrinolysis, which may decreases"/>
   <result pre="without pleural effusion. Cross‐sectional study retrospectively evaluating client‐owned cats with" exact="heart disease" post="presented between 2004 and 2018. All cats included underwent"/>
   <result pre="divided into 3 groups: without CHF (group 1), with cardiogenic" exact="pulmonary edema" post="(group 2) and with pleural effusion (group 3). Frequency"/>
   <result pre="identifying patients requiring hospitalization or at risk of decompensation. Degenerative" exact="mitral valve disease" post="(DMVD) is the most common acquired canine cardiac disease."/>
   <result pre="parameters evaluated via POCUS at different ACVIM stages of degenerative" exact="mitral valve disease" post="in dogs. Echocardiographic and CVC POCUS findings of dogs"/>
   <result pre="administration of diuretics were recorded. Dogs with significant right sided" exact="heart disease" post="or pericardial effusion were excluded. POCUS CVC Cineloops were"/>
   <result pre="were recorded. Dogs with significant right sided heart disease or" exact="pericardial effusion" post="were excluded. POCUS CVC Cineloops were obtained during the"/>
   <result pre="LV dimensions were regressed against LA:Ao in 82 dogs with" exact="mitral valve disease." post="Systolic and diastolic LV volume estimates obtained by the"/>
   <result pre="LV volume index increased with increasing LA:Ao in dogs with" exact="mitral valve disease" post="( r = 0.28). Data provided by all investigators appeared"/>
   <result pre="Supraventricular tachycardia in 23 cats; comparison with 21 cats with" exact="atrial fibrillation" post="(2004‐2014) V.F.J. Greet 1, J.M.C. Sargent 2, M. Brannick"/>
   <result pre="predisposing factors and natural course of supraventricular tachycardia (SVT) and" exact="atrial fibrillation" post="(AF) are well described in people and to a"/>
   <result pre="presence of ventricular arrhythmia, left atrial diameter, heart rate and" exact="congestive heart failure" post="status on cardiac death. Differences in survival between groups"/>
   <result pre="2/10 radiographs. Echocardiographic examination disclosed RAA in 4/10 dogs with" exact="pulmonary hypertension." post="The bodyweights of dogs with RAA were significantly lower"/>
   <result pre="are necessary to assess a possible relationship between RAA and" exact="pulmonary hypertension." post="Disclosures No disclosures to report. ESVC‐O‐21 Predictors of reoccurrence"/>
   <result pre="reoccurrence of congestive signs in dogs with ACVIM‐Stage C myxomatous" exact="mitral valve disease" post="(MMVD) A. Franchini 1, J. Abbott 1, B. Tyrrell"/>
   <result pre="Clements, M. Coyne IDEXX, Westbrook, United States of America Iatrogenic" exact="hypothyroidism" post="in cats is associated with reduced glomerular filtration rate,"/>
   <result pre="percentage of cats with subnormal TT4 attributed to overtreatment of" exact="hyperthyroidism" post="have abnormal renal biomarkers as compared to those that"/>
   <result pre="hypothyroidism. The identified association of reduced renal function with iatrogenic" exact="hypothyroidism" post="emphasizes the importance of avoiding overtreatment. Comprehensive renal monitoring"/>
   <result pre="healthy cats and 25 cats with OD (9 cats with" exact="diabetes mellitus;" post="5 with hyperthyroidism; 3 each with chronic kidney disease,"/>
   <result pre="cats with diabetes mellitus; 5 with hyperthyroidism; 3 each with" exact="chronic kidney disease," post="or gastrointestinal disease; 2 with acute kidney injury; and"/>
   <result pre="5 with hyperthyroidism; 3 each with chronic kidney disease, or" exact="gastrointestinal disease;" post="2 with acute kidney injury; and 1 each with"/>
   <result pre="(MHC) class II haplotypes associated with increased risk of canine" exact="diabetes mellitus" post="‐ a breed‐specific study A. Denyer 1, J.M. Massey"/>
   <result pre="Manchester, United Kingdom, 3Royal Veterinary College, London, United Kingdom Canine" exact="diabetes mellitus" post="(DM) can be classified as insulin resistance or insulin"/>
   <result pre="laboratory and in‐clinic immunoassays are commonly used. The pathogenesis of" exact="hypothyroidism" post="may result in endogenous T4 cross‐reacting antibodies (T4AA) in"/>
   <result pre="Glycemic variability (GV) refers to glycemic excursions with episodes of" exact="hypoglycemia" post="and hyperglycemia throughout the day or on different days"/>
   <result pre="(GV) refers to glycemic excursions with episodes of hypoglycemia and" exact="hyperglycemia" post="throughout the day or on different days with no"/>
   <result pre="to be an indicator of glycemic control. In humans with" exact="diabetes mellitus" post="(DM), adding a glucagon‐like peptide‐1 (GLP‐1) analogue to the"/>
   <result pre="is a potentially valuable tool in the monitoring of canine" exact="diabetes mellitus." post="Disclosures Disclosures to report. Federico Fracassi Financial support: Dechra,"/>
   <result pre="Whole Genome Sequencing to explore genetic risk factors in canine" exact="diabetes mellitus" post="L.J. Davison 1, M.D. Wallace 1, A. Denyer 1,"/>
   <result pre="United States of America, 7University of Oxford, United Kingdom Canine" exact="diabetes mellitus" post="(DM) is more prevalent in certain breeds, suggesting an"/>
   <result pre="in canine DM and insulinoma. Previous genetics work in canine" exact="diabetes mellitus" post="(DM) has focused on candidate genes and genome‐wide association"/>
   <result pre="HiSeqX technology. Six Samoyeds and 6 Boxers without DM or" exact="insulinoma" post="underwent WGS as controls. DNA was extracted from blood"/>
   <result pre="Boxer, and 68 of which were found exclusively in the" exact="insulinoma" post="group. Replication and functional studies are in progress to"/>
   <result pre="the most sensitive and specific test for the diagnosis of" exact="pancreatitis" post="in dogs. However, relatively high costs and long turnaround"/>
   <result pre="activity in dogs affected by naturally occurring hypercortisolism. Dogs with" exact="acute pancreatitis" post="(AP) and healthy dogs (HD) were used as controls."/>
   <result pre="in dogs affected by naturally occurring hypercortisolism. Dogs with acute" exact="pancreatitis" post="(AP) and healthy dogs (HD) were used as controls."/>
   <result pre="popularity. However, there are concerns regarding its ability to differentiate" exact="hypothyroidism" post="from non‐thyroidal illness (NTI). The aim of this study"/>
   <result pre="serum samples from 150 dogs with various NTIs in which" exact="hypothyroidism" post="was not suspected. Total T4 concentration (Immulite Canine Total"/>
   <result pre="these results, fT4a cannot be recommended to differentiate NTI from" exact="hypothyroidism" post="in dogs with a low total T4 concentration. This"/>
   <result pre="of follicular‐cell thyroid carcinoma: a novel canine model for translational" exact="thyroid cancer" post="research E. Tièche* 1, K. Hahn* 2, M. Dettwiler"/>
   <result pre="follicular‐cell thyroid carcinoma: a novel canine model for translational thyroid" exact="cancer" post="research E. Tièche* 1, K. Hahn* 2, M. Dettwiler"/>
   <result pre="in 3‐dimensional cell culture systems (organoids) has revolutionized in vitro" exact="cancer" post="research. In contrast to 2‐D cell lines, organoids can"/>
   <result pre="human medicine, organoid cultures provide a unique platform for personalized" exact="cancer" post="therapy. In this study, we aimed to culture and"/>
   <result pre="model to better understand the pathogenesis and optimize treatment of" exact="thyroid cancer" post="in dogs. The culture protocol likely requires further optimization."/>
   <result pre="to better understand the pathogenesis and optimize treatment of thyroid" exact="cancer" post="in dogs. The culture protocol likely requires further optimization."/>
   <result pre="Tierklinik Hollabrunn, Hollabrunn, Austria In humans, airway narrowing due to" exact="asthma" post="or COPD commonly results in heterogeneous deposition of aerosols"/>
   <result pre="and WHWT dogs, a breed with high susceptibility for canine" exact="idiopathic pulmonary fibrosis" post="(CIPF). Bronchoalveolar lavage fluid (BALF) was obtained under anaesthesia"/>
   <result pre="WHWT dogs, a breed with high susceptibility for canine idiopathic" exact="pulmonary fibrosis" post="(CIPF). Bronchoalveolar lavage fluid (BALF) was obtained under anaesthesia"/>
   <result pre="dysphagia, regurgitation, or vomiting. In dogs, reflux likely contributes to" exact="respiratory disease" post="pathogenesis and progression. Our study objectives were as follows:"/>
   <result pre="Fellow Program. ESVIM‐O‐4 Serum 25‐hydroxyvitamin D in dogs with sinonasal" exact="aspergillosis" post="J. Jaffey 1, C. Clercx 2, F. Billen 2,"/>
   <result pre="of illness with a variety of inhaled respiratory pathogens. Sinonasal" exact="aspergillosis" post="(SNA) is a common cause of chronic nasal disease"/>
   <result pre="lack of association. Disclosures No disclosures to report. ESVIM‐O‐6 Hereditary" exact="methemoglobinemia" post="in dogs caused by cytochrome b5 reductase deficiency associated"/>
   <result pre="(Fe 3+), which is incapable of binding O 2. Hereditary" exact="methemoglobinemia" post="in dogs is most commonly caused by cytochrome b"/>
   <result pre="dog. Scattered case reports show varied clinical consequences of hereditary" exact="methemoglobinemia" post="in dogs. Therefore, the objectives of this study were"/>
   <result pre="radiographs of the thorax revealed abnormalities in 11/51 dogs. Sternal" exact="lymphadenopathy" post="and cardiomegaly were documented in 4 dogs respectively and"/>
   <result pre="in 13, diffuse steatitis in 11, enlarged pancreas and abdominal" exact="lymphadenopathy" post="in 8 and splenomegaly in 7 dogs. Hepatomegaly and"/>
   <result pre="in one third of collected bile samples. Hepatosplenomegaly and abdominal" exact="lymphadenopathy" post="were uncommonly associated with neoplasia. Disclosures No disclosures to"/>
   <result pre="undefined. Disclosures No disclosures to report. ESVIM‐O‐11 Treatment of non‐lactate" exact="metabolic acidosis" post="in hypovolemic and normovolemic dogs: chloride‐free iso‐osmolar solution with"/>
   <result pre="Torino, Italy The use of sodium bicarbonate‐based solutions for treating" exact="metabolic acidosis" post="is currently debated. The alkalizing effect of solutions with"/>
   <result pre="(Hyper‐SID), compared to Ringer's lactate used for the treatment of" exact="metabolic acidosis." post="Hyper‐SID solution was prepared by adding 145 mEq/L of sodium,"/>
   <result pre="superior to the RL solution in the treatment of non‐lactate" exact="metabolic acidosis" post="in hospitalized dogs. In the sample of subjects belonging"/>
   <result pre="These 8 sessions were performed in 6 dogs: 4 had" exact="leptospirosis" post="and 2 poisoning (grape and ethylene glycol), 4 died."/>
   <result pre="Clinic, Bordeaux, France, 2INTHERES, Toulouse University, Toulouse, France Cats with" exact="chronic kidney disease" post="(CKD) are often presented when a superimposed acute uremic"/>
   <result pre="University of Glasgow Veterinary Fund Small Grant Scheme. ESVNU‐O‐4 Immune‐complex" exact="glomerulonephritis" post="in cats: a retrospective study based on clinico‐pathological data"/>
   <result pre="has typically a non‐immune mediated origin in cats and immune‐complex" exact="glomerulonephritis" post="(ICGN) has been scarcely described. To date, few descriptions"/>
   <result pre="Additionally, comparisons were performed with cats affected by non immune‐complex" exact="glomerulonephritis" post="(non‐ICGN). Renal biopsies of cats with ICGN and non‐ICGN"/>
   <result pre="included breed, sex, age, feline immunodeficiency virus (FIV) and feline" exact="leukemia" post="virus (FeLV) status, serum creatinine concentration, urine protein‐to‐creatinine (UPC)"/>
   <result pre="cats affected by ICGN, 18 (48.6%) had MGN, 14 (37.8%)" exact="membranoproliferative glomerulonephritis" post="(MPGN) and 5 (13.5%) mesangioproliferative glomerulonephritis. Breed, sex, age,"/>
   <result pre="affected by ICGN, 18 (48.6%) had MGN, 14 (37.8%) membranoproliferative" exact="glomerulonephritis" post="(MPGN) and 5 (13.5%) mesangioproliferative glomerulonephritis. Breed, sex, age,"/>
   <result pre="to an E. coli probiotic as a potential therapeutic for" exact="urinary tract infection" post="C. Snell 1, J. Gibson 1, C. Zumpetta 1,"/>
   <result pre="using microcidin plate analysis. Clinical signs were consistent with lower" exact="urinary tract infection" post="in all cats. Serogroup and virulence factors correlated with"/>
   <result pre="interest. ESVNU‐O‐7 Prognostic factors in dogs with common causes of" exact="proteinuria" post="F. Baumgartner, F. Boretti, B. Gerber Vetsuisse Faculty, University"/>
   <result pre="aim of this study was to assess dogs with severe" exact="proteinuria" post="(UPC at least once during the disease measured &amp;gt;2.0)"/>
   <result pre="and haematocrit. Between 2014 and 2015, 89 dogs with severe" exact="proteinuria" post="were retrospectively analysed. Among them, 46 dogs were diagnosed"/>
   <result pre="are current employees of Royal Canin, Mars Petcare. ESVNU‐O‐9 Proliferative" exact="urethritis" post="in dogs: long‐term follow up and prognosis R. Caccamo"/>
   <result pre="of Bologna, Italy, 3Endovet ‐ Professional Association, Rome, Italy Proliferative" exact="urethritis" post="(PU) is an uncommon inflammatory disease with unknown etiology."/>
   <result pre="A retrospective multi‐centre study on treatment and outcome in disseminated" exact="aspergillosis" post="in 41 dogs J.R.S. Dandrieux 1, C.S. Mansfield 1,"/>
   <result pre="Werribee, Australia, 2Asia‐Pacific Centre for Animal Health, Melbourne, Australia Disseminated" exact="aspergillosis" post="(DA) in dogs has a guarded prognosis. The aim"/>
   <result pre="systemic or digestive signs, or to biological abnormalities such as" exact="anemia" post="or hypoalbuminemia, were excluded. Clinical signs, biological abnormalities and"/>
   <result pre="age of infected dogs was 4 years. Overall, clinical signs included" exact="diarrhea" post="(49%), weight loss (38%), hematochezia (29%), inappetence (24%), vomiting"/>
   <result pre="dogs and chronic in the remaining dogs. Biological abnormalities included" exact="anemia" post="(23%), eosinophilia (30%), hypoalbuminemia (60%) and Na/K ratio &amp;lt; 24 with"/>
   <result pre="chronic in the remaining dogs. Biological abnormalities included anemia (23%)," exact="eosinophilia" post="(30%), hypoalbuminemia (60%) and Na/K ratio &amp;lt; 24 with normal ACTH‐stimulation"/>
   <result pre="leading to both acute and chronic digestive clinical signs, hypoalbuminemia," exact="anemia" post="and electrolytes disorders. Disclosures No disclosures to report. ISCAID‐O‐8"/>
   <result pre="prescriptions for respiratory and urinary tract infections (UTI) and acute" exact="diarrhea" post="from two Swiss university hospitals and 14 private practices"/>
   <result pre="Antimicrobial therapy was significantly associated with the presence of bloody" exact="diarrhea" post="( P &amp;lt; 0.001). It complied in 43.5% (120/276; JS‐1)"/>
   <result pre="Gow, M. Salavati The University of Edinburgh, Roslin, Scotland Hepatic" exact="encephalopathy" post="(HE) is a syndrome of neurologic dysfunction and an"/>
   <result pre="when compared to weeks 5 and 9. Finally, an extrapolated" exact="cirrhosis" post="dysbiosis ratio (CDR) was calculated, for which lower values"/>
   <result pre="town, South Africa, 4University of Pretoria, Pretoria, South Africa Bacterial" exact="cholecystitis" post="is a debilitating disease in dogs. The presence of"/>
   <result pre="Maltese dogs with moderately increased postprandial bile acids and no" exact="liver disease" post="based on imaging (n = 3), dogs with histologically"/>
   <result pre="portal vein hypoplasia (n = 4) or histologically confirmed chronic" exact="hepatitis" post="(n = 3). All samples were analysed in batch"/>
   <result pre="is a valuable treatment option for dogs and cats with" exact="cancer" post="after failing first line therapy M. Kleiter 1, L."/>
   <result pre="cats receiving re‐irradiation because of progressive tumor recurrence. Small animal" exact="cancer" post="patients treated with re‐irradiation between 2006‐2017 were included into"/>
   <result pre="to target receptors that are uniquely or highly expressed by" exact="cancer" post="cells, improving tumor specificity with reduced adverse events (AEs)."/>
   <result pre="target tumor cells and associated vascular and inflammatory stroma for" exact="sarcoma" post="therapy. It consists of human EGF, targeting the EGF"/>
   <result pre="species and applications. ESVONC‐O‐4 Humoral hypercalcemia of malignancy in canine" exact="lymphoma" post="WHO types and its impact on survival O.P. Skor"/>
   <result pre="of malignancy (HHM) is a common paraneoplastic syndrome in canine" exact="lymphoma" post="and has always been considered a negative prognostic factor."/>
   <result pre="factor. However, studies analyzing the role of HHM in WHO" exact="lymphoma" post="types are lacking. The aim of this study was"/>
   <result pre="study was to evaluate the incidence of HHM among different" exact="lymphoma" post="types and its prognostic impact on survival. In a"/>
   <result pre="In a retrospective study data of dogs diagnosed with untreated" exact="lymphoma" post="between 2008 and 2019 were analyzed. Inclusion criteria were"/>
   <result pre="with T‐lymphomas were affected. 9/14 (64%) suffered from peripheral T‐cell" exact="lymphoma" post="(PTLC) and 5/14 (36%) from T‐lymphoblastic lymphoma (T‐LBL). HHM"/>
   <result pre="from peripheral T‐cell lymphoma (PTLC) and 5/14 (36%) from T‐lymphoblastic" exact="lymphoma" post="(T‐LBL). HHM occurred in 43% (9/21) of PTLC and"/>
   <result pre="in progression free survival (150 vs. 60 days, P = 0.29) or" exact="lymphoma" post="specific survival (170 vs. 135 days, P = 0.42) were observed"/>
   <result pre="unfavorable prognostic factor but it is associated with aggressive T‐cell" exact="lymphoma" post="types. Prospective studies assessing the role of vitamin D3,"/>
   <result pre="during and after DOX infusion. Dogs with cytologically/histopathologically confirmed high‐grade" exact="lymphoma" post="were screened with an echocardiogram and concurrent electrocardiogram for"/>
   <result pre="remains the best anatomic staging of human diffuse large B‐cell" exact="lymphoma" post="(DLBCL). AAS divides patients into four stages based on"/>
   <result pre="free survival (PFS) (116 vs. 332 days, P = 0.001) and" exact="lymphoma" post="specific survival (LSS) (180 vs. 489 days, P = 0.001)."/>
   <result pre="larger cohort of patients with standardized staging and in other" exact="lymphoma" post="types are warranted. Disclosures No disclosures to report. ESVONC‐O‐8"/>
   <result pre="significant difference between the survival outcomes according to carcinoma or" exact="sarcoma" post="diagnoses. Historically, canine nasal tumours treated surgically achieved a"/>
   <result pre="Medicine &amp;amp; B, College Station, United States of America Alimentary" exact="lymphoma" post="is one of the most common forms of neoplasia"/>
   <result pre="low‐dose radiation therapy for feline intermediate and small cell alimentary" exact="lymphoma" post="as an alternative to chronic chemotherapy or in patient's"/>
   <result pre="helical tomotherapy for treatment of intermediate and small cell alimentary" exact="lymphoma" post="in feline patients. Exclusion criteria, disease extension beyond intestines"/>
   <result pre="if available for the patient. Ten cats diagnosed with alimentary" exact="lymphoma" post="were treated with low‐dose radiation. Seven cats diagnosed with"/>
   <result pre="treated with low‐dose radiation. Seven cats diagnosed with small cell" exact="lymphoma" post="were treated with 3 Gy total and three diagnosed with"/>
   <result pre="treated with 3 Gy total and three diagnosed with intermediate cell" exact="lymphoma" post="were treated with 4 Gy total. Acute effects associated with"/>
   <result pre="of low‐dose radiation therapy for intermediate and small cell alimentary" exact="lymphoma" post="as a salvage or an alternative to oral chemotherapy"/>
   <result pre="and histopathological lesions in relation to outcomes in canine immunosuppressant‐responsive" exact="enteropathy" post="(Ire): prospective analysis in 57 dogs E. Benvenuti 1,"/>
   <result pre="Veterinary Medical Sciences, University of Bologna, Bologna, Italy Canine immunosuppressant‐responsive" exact="enteropathy" post="(IRE) is an intestinal idiopathic inflammation, in which diet"/>
   <result pre="also determined (semi‐quantitative and/or quantitative analyses) with results consistent with" exact="pancreatitis" post="in 50%(19/38). Among patients with normal cPLI results, pancreatitis"/>
   <result pre="with pancreatitis in 50%(19/38). Among patients with normal cPLI results," exact="pancreatitis" post="was suspected in 2 based on pancreatic histology (n"/>
   <result pre="= 1) and abdominal ultrasound (n = 1), and non‐cirrhotic" exact="portal hypertension" post="(n = 1) and gastrointestinal disease (n = 16)"/>
   <result pre="= 1), and non‐cirrhotic portal hypertension (n = 1) and" exact="gastrointestinal disease" post="(n = 16) were diagnosed in the other 17"/>
   <result pre="17 patients. Gastrointestinal disease was confirmed in 11 cases [food‐responsive" exact="enteropathy" post="(5), IBD (4), gastrointestinal neoplasia (2)] and pressumptive in"/>
   <result pre="without cPLI analyses. In 30 patients underlying disease was confirmed:" exact="gastrointestinal disease" post="(15), hepatopathy (4), renal disease (3), hypoadrenocorticism (1), insulinoma"/>
   <result pre="gastrointestinal disease (15), hepatopathy (4), renal disease (3), hypoadrenocorticism (1)," exact="insulinoma" post="(1), neoplasia (2) and poliartritis (1). In the 11"/>
   <result pre="with presumptive diagnosis, the most likely underlying disease was chronic" exact="enteropathy" post="(n = 9). In the present study 76,9% (40/52)"/>
   <result pre="study 76,9% (40/52) of cases with increased TLI and without" exact="pancreatitis" post="or azotemia had confirmed or suspected underlying gastrointestinal disease,"/>
   <result pre="and without pancreatitis or azotemia had confirmed or suspected underlying" exact="gastrointestinal disease," post="coincident with previous feline and human findings. In fact"/>
   <result pre="fact TLI was performed in those cases to rule out" exact="exocrine pancreatic insufficiency." post="Although cobalamin deficiency has been linked to increased feline"/>
   <result pre="and TLI levels must be carefully interpreted in animals with" exact="gastrointestinal disease." post="Disclosures No disclosures to report. ESCG‐P‐3 Serum 25‐hydroxyvitamin D3"/>
   <result pre="Denmark Hypovitaminosis D has been linked to systemic inflammation, chronic" exact="enteropathy" post="(CE) and cancer in dogs. It is unknown if"/>
   <result pre="has been linked to systemic inflammation, chronic enteropathy (CE) and" exact="cancer" post="in dogs. It is unknown if changes in serum"/>
   <result pre="D 3 [25(OH)D 3] are seen in dogs with acute" exact="enteropathy" post="(AE). This study aimed to investigate [25(OH)D 3] in"/>
   <result pre="cPL, the severity of disease and mortality in suspected canine" exact="acute pancreatitis" post="E. Gori, A. Pierini, I. Lippi, S. Citi, T."/>
   <result pre="the severity of disease and mortality in suspected canine acute" exact="pancreatitis" post="E. Gori, A. Pierini, I. Lippi, S. Citi, T."/>
   <result pre="Mannucci, V. Marchetti University of Pisa, Pisa, Italy In canine" exact="acute pancreatitis" post="(AP) abdominal ultrasound (US) is a widely‐used non‐invasive diagnostic"/>
   <result pre="V. Marchetti University of Pisa, Pisa, Italy In canine acute" exact="pancreatitis" post="(AP) abdominal ultrasound (US) is a widely‐used non‐invasive diagnostic"/>
   <result pre="recruitment, anamnesis and laboratory minimal database were performed. Canine chronic" exact="enteropathy" post="clinical activity index (CCECAI) and signs of gastroesophageal reflux"/>
   <result pre="also revise the diagnostic criteria for atrophy. Keywords: gastric, carcinoma," exact="atrophic gastritis," post="metaplasia, dysplasia, dog. Disclosures Disclosures to report. Statement of"/>
   <result pre="deficiency is a common finding in dogs diagnosed with chronic" exact="enteropathy" post="(CE) due to low absorption and/or bacterial competition. It"/>
   <result pre="based on the response to treatment (ie, diagnosis of food‐responsive" exact="enteropathy" post="[FRE] vs. steroid−/immunosuppressant‐responsive enteropathy [IRE]). The neutrophil‐to‐lymphocyte ratio (NLR)"/>
   <result pre="to treatment (ie, diagnosis of food‐responsive enteropathy [FRE] vs. steroid−/immunosuppressant‐responsive" exact="enteropathy" post="[IRE]). The neutrophil‐to‐lymphocyte ratio (NLR) was recently shown to"/>
   <result pre="significantly higher in dogs with histologic lesions compatible with protein‐losing" exact="enteropathy" post="( P = 0.006). Hypoalbuminemia ( P &amp;lt; 0.001), but not"/>
   <result pre="in feces and serum samples from dogs with chronic inflammatory" exact="enteropathy" post="(CIE). However, intestinal mucosal calprotectin concentrations have not been"/>
   <result pre="report. ESCG‐P‐9 Neutrophil‐to‐lymphocyte ratio (NLR) in canine patients with immunosuppressant‐responsive" exact="enteropathy" post="(IRE) E. Benvenuti 1, E. Gori 1, A. Pierini"/>
   <result pre="the study was to evaluate the NLR in canine immunosuppressant‐responsive" exact="enteropathy" post="(IRE). Forty‐one dogs presented to two veterinary facilities (Veterinary"/>
   <result pre="report. ESCG‐P‐13 The erythrocyte membrane lipidome in dogs with chronic" exact="enteropathy" post="P.E. Crisi 1, P. Prasinou 1, C. ferreri 2,"/>
   <result pre="cause for persistent or recurrent gastrointestinal signs in dogs. Food‐responsive" exact="enteropathy" post="(FRE), antimicrobial‐responsive enteropathy (ARE), and immunosuppressive‐responsive enteropathy (IRE) have"/>
   <result pre="or recurrent gastrointestinal signs in dogs. Food‐responsive enteropathy (FRE), antimicrobial‐responsive" exact="enteropathy" post="(ARE), and immunosuppressive‐responsive enteropathy (IRE) have different etiologies however"/>
   <result pre="in dogs. Food‐responsive enteropathy (FRE), antimicrobial‐responsive enteropathy (ARE), and immunosuppressive‐responsive" exact="enteropathy" post="(IRE) have different etiologies however clinical signs overlap and"/>
   <result pre="could be associated with specific conditions such as neoplasia and" exact="liver disease" post="and, in addition, may be a marker of severity."/>
   <result pre="Inflammatory bowel disease (IBD) is a common cause of chronic" exact="gastrointestinal disease" post="in dogs. The current paradigm of IBD involves complex"/>
   <result pre="ESCG‐P‐17 Serum Vitamin A and E concentrations in dogs with" exact="pancreatitis" post="M. Weiβ, K. Törner, H. Aupperle‐Lellbach, E. Müller Laboklin"/>
   <result pre="GmbH und Co KG, Bad Kissingen, Germany Acute and chronic" exact="pancreatitis" post="in humans results in significantly lower levels of serum"/>
   <result pre="Vitamin A and E levels in serum of dogs with" exact="pancreatitis" post="have been performed so far. The aim of this"/>
   <result pre="and E from routine diagnostic left‐over samples in dogs with" exact="pancreatitis" post="compared to a control group of dogs with other"/>
   <result pre="control group of dogs with other diseases. 40 dogs with" exact="pancreatitis" post="were included in this study. These dogs all had"/>
   <result pre="had serum pancreatic lipase concentrations &amp;gt;600 μg/L and clinical symptoms of" exact="pancreatitis" post="like vomiting, abdominal pain or inappetence and had received"/>
   <result pre="received no medical treatment so far. Additionally, in 3 dogs" exact="pancreatitis" post="was diagnosed by histology of pancreatic tissue biopsies. The"/>
   <result pre="HPLC from cooled serum within 72 hours of sampling. Dogs with" exact="pancreatitis" post="had significantly higher ( P &amp;lt; 0.001) levels of serum"/>
   <result pre="(average: 20.4 μg/L, range: 1,9‐54.6 μg/L). This study suggests that dogs with" exact="pancreatitis" post="have a different metabolism of Vitamin A and E"/>
   <result pre="other diseases and humans with pancreatitis. In the course of" exact="pancreatitis" post="a release of Vitamin A and E into the"/>
   <result pre="and significantly increases the visualization of mucosal texture and the" exact="adenoma" post="detection rate. This study was the first in veterinary"/>
   <result pre="Heart rate variability of dogs in various stages of degenerative" exact="mitral valve disease" post="R.A. Baisan 1, V. Vulpe 1, D.G. Ohad 2"/>
   <result pre="rate assessed by 2‐dimensional speckle tracking echocardiography in dogs with" exact="pulmonary hypertension" post="D. Caivano 1, M. Rishniw 2, F. Birettoni 1,"/>
   <result pre="2‐dimensional speckle tracking echocardiography in healthy dogs and dogs with" exact="pulmonary hypertension," post="to identify dogs with pulmonary hypertension. Additionally, we examined"/>
   <result pre="dogs and dogs with pulmonary hypertension, to identify dogs with" exact="pulmonary hypertension." post="Additionally, we examined relationships of transverse strain and strain"/>
   <result pre="regurgitation (TR) velocity and left atrial size in dogs with" exact="pulmonary hypertension." post="We acquired 2D echocardiographic cineloops from the left apical"/>
   <result pre="pulmonary hypertension) using Xstrain® software. Dogs were classified as having" exact="pulmonary hypertension" post="based on the TR jet velocity (&amp;gt; 3 m/sec). We classified"/>
   <result pre="TR jet velocity (&amp;gt; 3 m/sec). We classified dogs as having moderate" exact="pulmonary hypertension" post="if TR velocity &amp;gt; 3.5 m/sec, and severe pulmonary hypertension if TR"/>
   <result pre="as having moderate pulmonary hypertension if TR velocity &amp;gt; 3.5 m/sec, and severe" exact="pulmonary hypertension" post="if TR velocity &amp;gt; 4.5 m/sec. Seven dogs (3 healthy and 4"/>
   <result pre="with heart rate, body weight or age. In dogs with" exact="pulmonary hypertension," post="strain and strain rate showed weak negative relationships with"/>
   <result pre="not strain rate) showed a negative relationship with class of" exact="pulmonary hypertension," post="it was not useful in identifying dogs with pulmonary"/>
   <result pre="pulmonary hypertension, it was not useful in identifying dogs with" exact="pulmonary hypertension." post="Transverse RV strain and strain rate using 2‐dimensional speckle"/>
   <result pre="most dogs, but does not help in identifying dogs with" exact="pulmonary hypertension." post="Disclosures No disclosures to report. ESVC‐P‐4 Potential renoprotective effect"/>
   <result pre="Potential renoprotective effect of angiotensin‐receptor antagonists in dogs with myxomatous" exact="mitral valve disease" post="J. Lee 1, W. Kim 2, H. Hwang 1,"/>
   <result pre="Blockade of renin‐angiotensin‐aldosterone system is a pivotal strategy to manage" exact="congestive heart failure" post="(CHF). Angiotensin‐receptor blockers (ARBs) are perceived to offer more"/>
   <result pre="Angiotensin‐receptor blockers (ARBs) are perceived to offer more complete neurohormonal" exact="suppression" post="in the treatment of CHF by directly occupying angiotensin"/>
   <result pre="has clinically incremental benefits, is unknown in dogs with myxomatous" exact="mitral valve disease" post="(MMVD). This retrospective cohort study was conducted with client‐owned"/>
   <result pre="concentration, renal function and survival in 85 dogs with acute" exact="congestive heart failure" post="E. Martinelli 1, A. Galizzi 1, R. Toschi Corneliani"/>
   <result pre="University of Milan, Milano, Italy Critically hill patients with acute" exact="congestive heart failure" post="(CHF) may often show haemoconcentration, dysnatremia, dyskalemia and increased"/>
   <result pre="showing extra‐range values (T0‐T1) were respectively: hyponatremia (10‐23), hypernatremia (13‐17)," exact="hypokalemia" post="(18‐30), hyperkalemia (10‐10), hypocloremia (46‐61), increased BUN (26‐34), increased"/>
   <result pre="its metabolite, 3‐epi‐25(OH)D 3 (3‐epi), are lower in cats with" exact="cardiomyopathy" post="(CM) vs. normal cats, or if associations with certain"/>
   <result pre="Iowa State (ISU) and Tufts Universities; 38 CM cats had" exact="congestive heart failure." post="Exclusion criteria included hypertension, hyperthyroidism, and clinically relevant systemic"/>
   <result pre="desmin aggregates consistent with intermediate filament dysfunction in feline hypertrophic" exact="cardiomyopathy" post="W.C. Cheng 1, M. Dobromylskyj 2, L.J. Wilkie 1,"/>
   <result pre="folding are reported in humans and rodent models with hypertrophic" exact="cardiomyopathy" post="(HCM). Incorrect folding of desmin leads to its aberrant"/>
   <result pre="No disclosures to report. ESVC‐P‐10 Prevalence and risk factors for" exact="atrial fibrillation" post="in dogs with myxomatous mitral valve disease C. Guglielmini"/>
   <result pre="and risk factors for atrial fibrillation in dogs with myxomatous" exact="mitral valve disease" post="C. Guglielmini 1, M.G. Sousa 2, M. Baron Toaldo"/>
   <result pre="and risk factors for this arrhythmia in dogs with myxomatous" exact="mitral valve disease" post="(MMVD). The aims of this study were to estimate"/>
   <result pre="in 160 Cavalier King Charles Spaniels with and without degenerative" exact="mitral valve disease" post="(2017‐2019) C. Poissonnier 1, P. Foulex 2, M.P. Alvarado"/>
   <result pre="d'Alfort, Maisons‐Alfort, France, 2Ecole Nationale Vétérinaire d'Alfort, Maisons‐Alfort, France Degenerative" exact="mitral valve disease" post="(DMVD) is the most common acquired heart disease in"/>
   <result pre="Degenerative mitral valve disease (DMVD) is the most common acquired" exact="heart disease" post="in small‐sized dogs with a high predisposition of the"/>
   <result pre="B1 and B2, respectively, 23/160 (14.3%) had past or current" exact="congestive heart failure" post="(CHF, stage C), and 1/160 (0.6%) had refractory CHF"/>
   <result pre="dogs (median proportion = 45‰ cells [IQR = 10‐226‰]), and" exact="hemolytic anemia" post="in 4 dogs with PS (hemoglobinemia &amp;lt;12.4 g/dL). No significant"/>
   <result pre="(median proportion = 45‰ cells [IQR = 10‐226‰]), and hemolytic" exact="anemia" post="in 4 dogs with PS (hemoglobinemia &amp;lt;12.4 g/dL). No significant"/>
   <result pre="above‐mentioned echocardiographic parameters. Three out of the 4 dogs with" exact="hemolytic anemia" post="had a maximal ∆ P &amp;gt; 200 mmHg (242 to 412 mmHg)."/>
   <result pre="echocardiographic parameters. Three out of the 4 dogs with hemolytic" exact="anemia" post="had a maximal ∆ P &amp;gt; 200 mmHg (242 to 412 mmHg)."/>
   <result pre="with the highest maximal ∆P also had the most severe" exact="anemia" post="and schizocytosis, and both abnormalities decreased, and then resolved,"/>
   <result pre="whose safety and efficacy have been demonstrated in dogs with" exact="congestive heart failure" post="(CHF). Torasemide is characterized by a longer duration of"/>
   <result pre="All cats presented dyspnea related to CHF (pleural effusion [4/17]," exact="pulmonary edema" post="[6/17]or both [7/17]), associated with ascites in 2/17 cats."/>
   <result pre="of torasemide as a second line diuretic in dogs with" exact="congestive heart failure" post="I. Guarnera, G. Romito, P. Castagna, M. Cipone, M."/>
   <result pre="Italy Torasemide is a loop diuretic used in dogs with" exact="congestive heart failure" post="(CHF) as an alternative to furosemide. Studies comparing furosemide"/>
   <result pre="Teaching Hospital has been reviewed searching for dogs with myxomatous" exact="mitral valve disease" post="who experienced CHF and received torasemide as a second"/>
   <result pre="= 0.230) serum levels. There was no difference in prevalence of" exact="atrial fibrillation" post="between groups ( P = 1.000). The overall number of"/>
   <result pre="second line diuretic for CHF control in dogs with myxomatous" exact="mitral valve disease," post="offering a life expectance comparable if not superior to"/>
   <result pre="disclosures to report. ESVC‐P‐15 Echocardiographic predictors of first onset of" exact="atrial fibrillation" post="in dogs with myxomatous mitral valve disease C. Mazzoldi"/>
   <result pre="of first onset of atrial fibrillation in dogs with myxomatous" exact="mitral valve disease" post="C. Mazzoldi 1, C. Guglielmini 2, G. Romito 1,"/>
   <result pre="Padova, Italy Atrial fibrillation (AF) occurs in dogs with myxomatous" exact="mitral valve disease" post="(MMVD) as a consequence of left atrial (LA) dilatation."/>
   <result pre="frequent (&amp;gt;100) premature ectopic complexes (SR + PEC), either supraventricular or ventricular;" exact="atrial fibrillation" post="(AF); and AF with frequent ventricular premature complexes (AF + VPC)."/>
   <result pre="complex supraventricular ectopy, ventricular premature complexes (VPCs), complex ventricular ectopy," exact="atrial fibrillation" post="(AF), high‐grade second degree atrioventricular block (AVB) and paced"/>
   <result pre="(VPCs), complex ventricular ectopy, atrial fibrillation (AF), high‐grade second degree" exact="atrioventricular block" post="(AVB) and paced rhythms were retrospectively evaluated and utilized"/>
   <result pre="based 95% confidence interval may help in screening dogs for" exact="heart disease," post="discriminating normal aortic annulus dimension. Disclosures No disclosures to"/>
   <result pre="Ljubljana, Slovenia Various factors can influence survival of dogs with" exact="mitral valve disease" post="(MVD) and dilated cardiomyopathy (DCM). In canine cardiovascular patients,"/>
   <result pre="survival of dogs with mitral valve disease (MVD) and dilated" exact="cardiomyopathy" post="(DCM). In canine cardiovascular patients, inflammatory and antioxidant markers"/>
   <result pre="important index in the diagnosis of occult and symptomatic dilated" exact="cardiomyopathy" post="(DCM) as recently reported in the European screening guidelines"/>
   <result pre="effect of long flightprolonged air travel on dogs with heart" exact="mitral valve disease" post="A. Takahashi, S. Takeuchi, M. Uechi JASMINE veterinary cardiovascular"/>
   <result pre="Japan The effect of long air travel on animals with" exact="heart disease" post="has not been investigated. In this study, we assessed"/>
   <result pre="we assessed the changes in physical condition of animals with" exact="mitral valve disease" post="before and after flight. Target case profile: 38 dogs"/>
   <result pre="before and after flight. Target case profile: 38 dogs with" exact="mitral valve disease" post="who underwent air travel to undergo mitral valve repair"/>
   <result pre="were evaluated. Also presence or absence of events related to" exact="heart disease" post="post‐flying and post‐operative discharge rate were studied. All cases"/>
   <result pre="(2 dogs without surgery). Two dogs developed events related to" exact="mitral valve disease" post="(1 left atrium rupture and 1 pulmonary edema, respectively)."/>
   <result pre="to mitral valve disease (1 left atrium rupture and 1" exact="pulmonary edema," post="respectively). The dog with left atrial rupture died before"/>
   <result pre="receive cardiac medications during the flight. The dog that developed" exact="pulmonary edema" post="post‐flight also missed a dose during the journey, but"/>
   <result pre="showed gastrointestinal symptoms (vomiting, diarrhea) before flight. Three patients developed" exact="diarrhea" post="after the flight. Among patients who showed respiratory symptoms"/>
   <result pre="the flight. One dog had post‐flight syncope.. Although dogs with" exact="mitral valve disease" post="may show clinical changes related to air travel, these"/>
   <result pre="clock due to time difference may be sufficient to avert" exact="mitral valve disease" post="related events with sufficient alertness. In conclusion, long distance"/>
   <result pre="alertness. In conclusion, long distance air travel of patients with" exact="mitral valve disease" post="can be safely performed by carrying out routine care"/>
   <result pre="infarction (AMI) is the most common cause of human ischemic" exact="heart disease." post="Its pathogenesis involves atherosclerosis of coronary arteries, platelet activation,"/>
   <result pre="common cause of human ischemic heart disease. Its pathogenesis involves" exact="atherosclerosis" post="of coronary arteries, platelet activation, thrombosis and vasospasms. Only"/>
   <result pre="Only anecdotal information on canine AMI exists. Postmortem descriptions of" exact="arteriosclerosis" post="with myocardial ischemic injury and congestive heart failure are"/>
   <result pre="exists. Postmortem descriptions of arteriosclerosis with myocardial ischemic injury and" exact="congestive heart failure" post="are available, but clinical data regarding ante‐mortem diagnosis of"/>
   <result pre="identified in 9 dogs (4 postoperative, 3 neoplastic, 1 immune‐mediated" exact="hemolytic anemia" post="and 1 hypothyroidism). Common clinical findings were arrhythmia (13/13),"/>
   <result pre="in 9 dogs (4 postoperative, 3 neoplastic, 1 immune‐mediated hemolytic" exact="anemia" post="and 1 hypothyroidism). Common clinical findings were arrhythmia (13/13),"/>
   <result pre="(10/10). Identified ECG abnormalities were ventricular arrhythmias (9/13), 3rd degree" exact="atrioventricular block" post="(4/13) or sinus rhythm with right axis deviation (1/13)."/>
   <result pre="diseases in hypothyroid dogs. Records of 63 dogs diagnosed with" exact="hypothyroidism" post="have been examined for the presence or absence of"/>
   <result pre="presented non‐specific clinical signs such as vomiting, anorexia and lethargy," exact="diarrhea" post="and/or fever. Thirty four dogs (53.9%) were diagnosed with"/>
   <result pre="(Consultancy) Dechra Veterinary Products (Consultancy). ESVE‐P‐7 Survival in cats with" exact="diabetes mellitus" post="and chronic pancreatitis: a preliminary study of 36 cases"/>
   <result pre="Veterinary School of Alfort, Maisons‐Alfort, France Previous studies suggest that" exact="pancreatitis" post="could be a significant comorbidity in diabetic cats, even"/>
   <result pre="absence of digestive signs. Long‐term studies of diabetic cats with" exact="pancreatitis" post="are lacking and potential survival factors in such population"/>
   <result pre="epidemiological, biological and ultrasonographic findings in cats with concurrent chronic" exact="pancreatitis" post="(CP) and diabetes mellitus (DM) and 2/to document chronology"/>
   <result pre="ultrasonographic findings in cats with concurrent chronic pancreatitis (CP) and" exact="diabetes mellitus" post="(DM) and 2/to document chronology of both diseases, survival"/>
   <result pre="episode of ketoacidosis, history of hospitalization and US features suggesting" exact="biliary tract disease" post="were evaluated. Association of each criteria and ST was"/>
   <result pre="elevation of liver enzymes (63%), hyperproteinemia (61%), hyperbilirubinemia (47%) and" exact="hypokalemia" post="(54%). Median survival time (MST) was 955 days. Mortality rate"/>
   <result pre="of cats having at least one US finding compatible with" exact="biliary tract disease" post="was significantly higher and MST was also 2,57 times"/>
   <result pre="and having at least one ultrasonographic finding compatible with a" exact="biliary tract disease" post="is shorter than cats without any biliary lesion on"/>
   <result pre="once daily Protamine Zinc Recombinant Human Insulin (ProZinc®) in canine" exact="diabetes mellitus" post="S.J.M. Niessen 1, C. Kroh 2, S. Maruyama 2,"/>
   <result pre="research among diabetic dog owners emphasizes the negative impact of" exact="diabetes mellitus" post="(DM) treatment on owner lifestyle, even leading to euthanasia."/>
   <result pre="437 ± 140 to 218 ± 84 mg/dL, and fructosamine from 566 ± 119 to 394 ± 83 μmol/L. Clinical" exact="hypoglycemia" post="was observed once in two SID treated dogs, which"/>
   <result pre="Disclosures No disclosures to report. ESVE‐P‐11 Prednisolone induced hyperglycaemia and" exact="diabetes mellitus" post="in cats S. Nerhagen, H. Moberg, B. Glanemann The"/>
   <result pre="in cats. Potential adverse effects include glucocorticoid‐induced hyperglycaemia (GIH) and" exact="diabetes mellitus" post="(GIDM) but predisposing factors for the development and the"/>
   <result pre="8 requiring insulin therapy and 1 was euthanized due to" exact="diabetic ketoacidosis." post="The remaining 5 cats (3.4%) were identified as GIH"/>
   <result pre="in the diagnosis of acid‐base basalnce disturbances in cats with" exact="chronic kidney disease" post="(CKD) P. Slawuta, A. Sikorska‐Kopylowicz, A. Kurosad, G. Sapikowski"/>
   <result pre="Environmental and Life Sciences, Wroclaw, Poland In addition to hypophosphatemia," exact="metabolic acidosis" post="is the most common complication of chronic kidney disease"/>
   <result pre="to hypophosphatemia, metabolic acidosis is the most common complication of" exact="chronic kidney disease" post="in cats. Using the standard approach, metabolic acidosis is"/>
   <result pre="of chronic kidney disease in cats. Using the standard approach," exact="metabolic acidosis" post="is diagnosed based on the concentration of HCO 3"/>
   <result pre="the chloride/sodium ratio (Cl −/Na +) in the diagnosis of" exact="metabolic acidosis." post="The study was carried out on 100 cats (both"/>
   <result pre="The analysis of the arterial blood revealed the presence of" exact="metabolic acidosis" post="in cats from group IV. In the remaining groups,"/>
   <result pre="is known about the role of exosomal miRNA in canine" exact="leishmaniasis" post="(CL); in particular, the interaction between exosomal miR‐122 and"/>
   <result pre="aim of this study was to investigate which type of" exact="anemia" post="and how are the serum iron levels in cats"/>
   <result pre="investigated by Mann‐Whitney test for iron, and Unpaired t‐test for" exact="anemia" post="parameters. Categorical data were analyzed with Fisher's exact test."/>
   <result pre="were analyzed with Fisher's exact test. Twenty‐nine cats (46%) showed" exact="anemia" post="which was more frequently mild (Hct &amp;lt; 26%; 62.1%) or moderate"/>
   <result pre="an infrequent finding (6.3%), and only two cats had microcytosis," exact="anemia" post="and hypoferremia concurrently. Hypoferremia (serum iron &amp;lt;90 mcg/dL) was"/>
   <result pre="iron &amp;lt;90 mcg/dL) was present in 34 cats and concurrent" exact="anemia" post="was observed in 15 cats (without any association between"/>
   <result pre="(without any association between these two parameters). Both hypoferremia and" exact="anemia" post="were more severe in group A (median serum iron"/>
   <result pre="B (median serum iron 90.5 mcg/dL; mean RBC 7.00 M/μL). Moreover," exact="anemia" post="was more frequently present in group A (63%; P"/>
   <result pre="P = 0.0048). The most plausible hypothesis for the origin of" exact="anemia" post="was the presence of a chronic disease. Decreased serum"/>
   <result pre="to detect comet‐tail artifacts (B lines) in animals with trauma," exact="pulmonary edema" post="or alveolar‐interstitial syndrome. The scanning protocols used in previous"/>
   <result pre="(16 with cardiac disease, 12 with cardiorespiratory comorbidities, 5 with" exact="respiratory disease," post="and 1 with non‐cardiorespiratory problem) were recruited in this"/>
   <result pre="stress. Disclosures No disclosures to report. ESVIM‐P‐12 Association between immune‐mediated" exact="hemolytic anemia" post="(IMHA) and acute pancreatitis in dogs G. Gianesini 1,"/>
   <result pre="Disclosures No disclosures to report. ESVIM‐P‐12 Association between immune‐mediated hemolytic" exact="anemia" post="(IMHA) and acute pancreatitis in dogs G. Gianesini 1,"/>
   <result pre="to report. ESVIM‐P‐12 Association between immune‐mediated hemolytic anemia (IMHA) and" exact="acute pancreatitis" post="in dogs G. Gianesini 1, M. Drigo 2, A."/>
   <result pre="report. ESVIM‐P‐12 Association between immune‐mediated hemolytic anemia (IMHA) and acute" exact="pancreatitis" post="in dogs G. Gianesini 1, M. Drigo 2, A."/>
   <result pre="Padova, Italy Evidences in humans, rats and cats suggest that" exact="acute pancreatitis" post="is a complication of hemolysis, including hemolysis from IMHA."/>
   <result pre="Italy Evidences in humans, rats and cats suggest that acute" exact="pancreatitis" post="is a complication of hemolysis, including hemolysis from IMHA."/>
   <result pre="from IMHA. This study investigates the association between IMHA and" exact="pancreatitis" post="in dogs. Case control study with nested retrospective cohort"/>
   <result pre="38.6%&quot; — 54.5%) and positive anti‐erythrocyte membrane antibodies test. Acute" exact="pancreatitis" post="was diagnosed if dogs had: amylase and lipase concentrations"/>
   <result pre="(RI, 0.01 — 0.22), and anorexia and/or vomiting. Frequency of" exact="pancreatitis" post="was compared among the 3 groups (fisher exact test)."/>
   <result pre="exact test). After admission dogs with IMHA with and without" exact="pancreatitis" post="had a 7‐day follow‐up. If some of the dogs"/>
   <result pre="7‐day follow‐up. If some of the dogs with IMHA without" exact="pancreatitis" post="developed pancreatitis, they switched to the IMHA with pancreatitis"/>
   <result pre="without pancreatitis developed pancreatitis, they switched to the IMHA with" exact="pancreatitis" post="group and were followed‐up for 7 days after the pancreatitis"/>
   <result pre="with pancreatitis group and were followed‐up for 7 days after the" exact="pancreatitis" post="event. Free plasma hemoglobin (Hb fp) for dogs with"/>
   <result pre="Free plasma hemoglobin (Hb fp) for dogs with IMHA with" exact="pancreatitis" post="(at the time of pancreatitis diagnosis) and without pancreatitis"/>
   <result pre="for dogs with IMHA with pancreatitis (at the time of" exact="pancreatitis" post="diagnosis) and without pancreatitis (at presentation) was calculated (Hb"/>
   <result pre="with pancreatitis (at the time of pancreatitis diagnosis) and without" exact="pancreatitis" post="(at presentation) was calculated (Hb fp = Hb tot ‐[RBC"/>
   <result pre="dogs with and without pancreatitis. Relative Risk (RR) of developing" exact="pancreatitis" post="in dogs with IMHA and Hb fp concentration ≥ the Youden"/>
   <result pre="calculated. Finally, 7‐day mortality between IMHA dogs with and without" exact="pancreatitis" post="was evaluated (chi square test). At presentation, frequency of"/>
   <result pre="pancreatitis was evaluated (chi square test). At presentation, frequency of" exact="pancreatitis" post="was significantly ( P = 0.0013) higher in dogs with"/>
   <result pre="further 9 dogs with IMHA developed pancreatitis. IMHA dogs with" exact="pancreatitis" post="(n = 21) had a significantly ( P = 0.0067)"/>
   <result pre="range, 0.0 — 1.55) compared to the IMHA dogs without" exact="pancreatitis" post="(n = 74; median = 0.0 g/dL, range, 0.0 —"/>
   <result pre="a Hb pf concentration ≥ 0.08 g/dL resulted in an increased risk of" exact="pancreatitis" post="(RR = 2.54, 95%CI, 1.51 — 4.29). There was"/>
   <result pre="IMHA are at increased risk of pancreatitis. Several dogs developed" exact="pancreatitis" post="after being diagnosis with IMHA, this may suggest that"/>
   <result pre="diagnosis with IMHA, this may suggest that IMHA may cause" exact="pancreatitis" post="and that Hb fp is a trigger for it."/>
   <result pre="Naples Fede, Naples, Italy In these last years, the increasing" exact="obesity" post="incidence in canine species has enshrined its relevance as"/>
   <result pre="has enshrined its relevance as an important worldwide disease. Recently," exact="obesity" post="has been associated with impaired immunity and chronic low‐grade"/>
   <result pre="obese dogs. Moreover, some evidences addressed the possible impact of" exact="obesity" post="on cardiovascular apparatus in dogs. The aim of this"/>
   <result pre="been recently shown to be particularly useful in discriminating bacterial" exact="bronchopneumonia" post="from other pulmonary diseases and promising in guiding antibiotic"/>
   <result pre="elevation was also compared with dogs diagnosed with bacterial aspiration" exact="bronchopneumonia" post="(ABP). Sixteen dogs with lower airways Bb infection and"/>
   <result pre="secondary physiologically appropriate polycythemia. However, the prevalence and severity of" exact="polycythemia" post="has not been described in detail in dogs with"/>
   <result pre="group comprised of 23 West Highland white terriers with canine" exact="idiopathic pulmonary fibrosis" post="and 21 dogs of other breeds with the following"/>
   <result pre="comprised of 23 West Highland white terriers with canine idiopathic" exact="pulmonary fibrosis" post="and 21 dogs of other breeds with the following"/>
   <result pre="following lung diseases; chronic bronchitis 13/21, eosinophilic bronchopneumopathy 2/21 and" exact="interstitial lung disease" post="2/21. In 4/21 dogs with chronic respiratory signs (cough"/>
   <result pre="lung diseases; chronic bronchitis 13/21, eosinophilic bronchopneumopathy 2/21 and interstitial" exact="lung disease" post="2/21. In 4/21 dogs with chronic respiratory signs (cough"/>
   <result pre="(mean 51.0 ± STD 5.7%, range 35‐64%, laboratory reference range 38‐57%). Marked" exact="polycythemia" post="(hematocrit ≥65%) was not noted in any of the"/>
   <result pre="Hkr r = −0.99, P = 0.521). These results indicate that" exact="polycythemia" post="is uncommonly encountered in dogs with chronic hypoxic pulmonary"/>
   <result pre="ESVIM‐P‐19 A statistical analysis to predict persistence of canine sinonasal" exact="aspergillosis" post="at endoscopic follow‐up by comparing three different scoring systems:"/>
   <result pre="of Liege, Liege, Belgium Dolichocephalic breeds are predisposed to sinonasal" exact="aspergillosis" post="while brachycephalic dogs are not affected. Since disruptions in"/>
   <result pre="sinonasal aspergillosis. Disclosures No disclosures to report. ESVIM‐P‐23 Canine sino‐nasal" exact="aspergillosis" post="in Italy (38 cases) A. Peano 1, G. Fortini"/>
   <result pre="di Scienze Veterinarie, Grugliasco, Italy, 2Endovet Freelance Group, Italy Sino‐nasal" exact="aspergillosis" post="(SNA) is an important cause of chronic nasal disease"/>
   <result pre="Ratio (UPC ratio) is currently the most frequent method for" exact="proteinuria" post="quantification. Proteinuria can be classified in physiological versus pathological"/>
   <result pre="classified in physiological versus pathological (pre‐renal, renal or post‐renal). Although" exact="chronic kidney disease" post="(CKD) is assumed to be the most common cause"/>
   <result pre="(CKD) is assumed to be the most common cause of" exact="proteinuria" post="in cats, few studies have been conducted to assess"/>
   <result pre="of this study was to determine the main causes of" exact="proteinuria" post="in cats from the region of Lisbon, Portugal. All"/>
   <result pre="and 2018 in a veterinary hospital and identified with significant" exact="proteinuria" post="(UPC ratio &amp;gt; 0.4) were included. The cause of proteinuria, International"/>
   <result pre="proteinuria, 46/61 (75%) presented renal proteinuria, 4/61 (7%) had post‐renal" exact="proteinuria" post="and 11/61 (18%) had a suspected mixed origin (renal"/>
   <result pre="origin (renal + post‐renal). In detail, the causes of renal" exact="proteinuria" post="were CKD (39/61; 64%), CKD complicated with co‐morbidities (2/61;"/>
   <result pre="and diseases capable of decreasing renal permselectivity (3/61; 5%). Post‐renal" exact="proteinuria" post="was due to urinary tract infection (UTI) (3/61; 5%)"/>
   <result pre="decreasing renal permselectivity (3/61; 5%). Post‐renal proteinuria was due to" exact="urinary tract infection" post="(UTI) (3/61; 5%) and cystitis (1/61; 2%). Mixed‐proteinuria was"/>
   <result pre="was due to urinary tract infection (UTI) (3/61; 5%) and" exact="cystitis" post="(1/61; 2%). Mixed‐proteinuria was attributed to CKD + cystitis (7/61; 11%)"/>
   <result pre="and one cat was normotensive. This study strengthens that pre‐renal" exact="proteinuria" post="is rare in cats and CKD is the most"/>
   <result pre="cats and CKD is the most frequent cause of significant" exact="proteinuria" post="in this species. Severe hypertension is a common finding,"/>
   <result pre="suggests that physiological and pre‐renal causes do not induce significant" exact="proteinuria" post="in cats. Disclosures No disclosures to report. ESVNU‐P‐3 The"/>
   <result pre="have evaluated the role of CVBD in the aetiology of" exact="proteinuria" post="in these endemic countries. According to its origin, proteinuria"/>
   <result pre="of proteinuria in these endemic countries. According to its origin," exact="proteinuria" post="can be classified in pre‐renal, renal or post‐renal and"/>
   <result pre="of this study was to assess the main causes of" exact="proteinuria" post="in dogs from the region of Lisbon in order"/>
   <result pre="hospital between January 2017 and December 2018 identified with significant" exact="proteinuria" post="(UPC ratio &amp;gt; 0.5) and with an established primary diagnosis were"/>
   <result pre="Based on the medical records, cases were classified according to" exact="proteinuria" post="origin. 106 dogs were selected. From these, 54% were"/>
   <result pre="had pre‐renal proteinuria, 76% had renal proteinuria, 17% had post‐renal" exact="proteinuria" post="and 7% had a suspected mixed origin (renal+post‐renal). Detailing"/>
   <result pre="(renal+post‐renal). Detailing renal proteinuria, 46% had a presumptive diagnosis of" exact="glomerulonephritis" post="secondary to CVBD, 27% showed chronic kidney disease, 26%"/>
   <result pre="a presumptive diagnosis of glomerulonephritis secondary to CVBD, 27% showed" exact="chronic kidney disease," post="26% had systemic diseases possibly inducing an impaired glomerular"/>
   <result pre="systemic diseases possibly inducing an impaired glomerular permselectivity (bronchopneumonia, enteropathies," exact="liver disease," post="hyperadrenocorticism, diabetes mellitus or neoplasia) and 1% had acute"/>
   <result pre="inducing an impaired glomerular permselectivity (bronchopneumonia, enteropathies, liver disease, hyperadrenocorticism," exact="diabetes mellitus" post="or neoplasia) and 1% had acute kidney injury (AKI)."/>
   <result pre="or neoplasia) and 1% had acute kidney injury (AKI). Post‐renal" exact="proteinuria" post="included dogs with pyometra and urinary tract infection (UTI)."/>
   <result pre="kidney injury (AKI). Post‐renal proteinuria included dogs with pyometra and" exact="urinary tract infection" post="(UTI). Mixed proteinuria was considered in dogs with systemic"/>
   <result pre="included dogs with pyometra and urinary tract infection (UTI). Mixed" exact="proteinuria" post="was considered in dogs with systemic diseases (CVBD, CKD,"/>
   <result pre="3% Babesia canis and 3% Anaplasma spp. Whilst pre‐renal significant" exact="proteinuria" post="was uncommon, CVBD were the main cause of renal"/>
   <result pre="proteinuria was uncommon, CVBD were the main cause of renal" exact="proteinuria" post="in these dogs. Leishmaniosis was the most frequent CVBD"/>
   <result pre="that CVBD are the most common differential diagnosis of renal" exact="proteinuria" post="in dogs from Lisbon. These results might be extrapolated"/>
   <result pre="two types holds a high diagnostic and therapeutic significance. Tubular" exact="proteinuria" post="is defined by the loss of low molecular weight"/>
   <result pre="to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS‐PAGE). Solely tubular" exact="proteinuria" post="was considered ‘tubular’, while mixed (tubular and glomerular) and"/>
   <result pre="was considered ‘tubular’, while mixed (tubular and glomerular) and glomerular" exact="proteinuria" post="were considered as ‘non‐tubular’. The median (lower and upper"/>
   <result pre="value was determined to be 0.37, below which the tubular" exact="proteinuria" post="could be identified with high confidence (sensitivity = 93.75%,"/>
   <result pre="negative predictive value = 81.81%). Using this cut‐off value, tubular" exact="proteinuria" post="was diagnosed in 10 dogs (35.71%) and non‐tubular proteinuria"/>
   <result pre="tubular proteinuria was diagnosed in 10 dogs (35.71%) and non‐tubular" exact="proteinuria" post="in 17 animals (60.71%). The uAPR results showed a"/>
   <result pre="NAG index values were found to be 33,12 ± 14,8 U/g. Prolonged" exact="anuria" post="consecutive to uretral obstruction as well as repeated obstructive"/>
   <result pre="Veterinaire Agy, Granges‐Paccot, Switzerland, 3Bessy's Kleintierklinik AG, Regensdorf, Switzerland Reflux" exact="nephropathy" post="is considered a possible cause of end‐stage kidney disease"/>
   <result pre="cause of end‐stage kidney disease in young Boxer dogs. Furthermore," exact="vesicoureteral reflux" post="was found to be associated with urinary tract infection."/>
   <result pre="dogs. Furthermore, vesicoureteral reflux was found to be associated with" exact="urinary tract infection." post="The aim of this study was to evaluate the"/>
   <result pre="in 5% of the culture negative dogs. The combination of" exact="pyuria" post="and bacteria in the sediment was seen in 42%"/>
   <result pre="Boeringer Ingelheim. ESVNU‐P‐7 Evaluation of symmetric dimethylarginine (SDMA) in canine" exact="acute pancreatitis" post="E. Gori, A. Pierini, I. Lippi, V. Meucci, F."/>
   <result pre="Ingelheim. ESVNU‐P‐7 Evaluation of symmetric dimethylarginine (SDMA) in canine acute" exact="pancreatitis" post="E. Gori, A. Pierini, I. Lippi, V. Meucci, F."/>
   <result pre="of this study was to evaluate SDMA in dogs with" exact="acute pancreatitis" post="(AP) and their association with kidney injury and severity"/>
   <result pre="this study was to evaluate SDMA in dogs with acute" exact="pancreatitis" post="(AP) and their association with kidney injury and severity"/>
   <result pre="history of renal diseases (clinical records/history, bloodwork and diagnostic imaging)," exact="urinary tract infection" post="and/or on hemodialysis treatment were excluded, along with dogs"/>
   <result pre="is of limited value as a sole discriminatory test for" exact="urinary tract infection." post="A negative test result does not rule out urinary"/>
   <result pre="tract infection. A negative test result does not rule out" exact="urinary tract infection" post="but may justify withholding of antimicrobial therapy pending the"/>
   <result pre="and its correlation with systemic inflammatory response syndrome (SIRS), and" exact="disseminated intravascular coagulation" post="(DIC). Ten uremic dogs managed with HD (HDG) and"/>
   <result pre="investigations. Disclosures No disclosures to report. ESVNU‐P‐10 Risk factors for" exact="urinary tract infection" post="in dogs with natural occurring leptospirosis: a retrospective cohort"/>
   <result pre="disease. Due to the risk of dog‐to human transmission of" exact="leptospirosis" post="and the need of monitoring urine output in dogs"/>
   <result pre="indwelling urinary catheter during hospitalization. Urinary catheterization can predispose to" exact="urinary tract infection" post="(UTI). The aim of this retrospective cohort study was"/>
   <result pre="to evaluate type and frequency of UTI in dogs with" exact="leptospirosis" post="and to identify risk factors associated with UTI in"/>
   <result pre="searched between January‐2008 and December‐2018 for dogs with diagnosis of" exact="leptospirosis" post="(n = 78). Diagnosis of leptospirosis was consistent clinicopathologic"/>
   <result pre="dogs with diagnosis of leptospirosis (n = 78). Diagnosis of" exact="leptospirosis" post="was consistent clinicopathologic signs, a positive microscopic agglutination test"/>
   <result pre="titer) and/or a positive PCR (urine and/or blood). Dogs with" exact="leptospirosis" post="to be included in the study need to met"/>
   <result pre="Veterinary Specialist, Basildon, United Kingdom Renal damage associated with canine" exact="leishmaniasis" post="induces nephritis and glomerulonephritis which cannot always be detected"/>
   <result pre="Basildon, United Kingdom Renal damage associated with canine leishmaniasis induces" exact="nephritis" post="and glomerulonephritis which cannot always be detected using classical"/>
   <result pre="Kingdom Renal damage associated with canine leishmaniasis induces nephritis and" exact="glomerulonephritis" post="which cannot always be detected using classical laboratorial biomarkers"/>
   <result pre="as early markers of renal disease in dogs affected with" exact="leishmaniasis" post="using a modified IRIS chronic kidney disease staging. A"/>
   <result pre="disease in dogs affected with leishmaniasis using a modified IRIS" exact="chronic kidney disease" post="staging. A prospective study was conducted in 5 groups"/>
   <result pre="is only consistently elevated at more advanced stages of leishmania‐associated" exact="chronic kidney disease." post="Disclosures No disclosures to report. ESVNU‐P‐13 Usefulness of urine"/>
   <result pre="in the diagnosis of renal disease in dogs affected with" exact="leishmaniasis" post="J. Duque 1, P. Charlo 1, B. Macías‐García 1,"/>
   <result pre="Cardiopulmonary Service / Southfields Veterinary Specialist, Basildon, United Kingdom Canine" exact="leishmaniasis" post="is a highly prevalent zoonotic disease in Spain. All"/>
   <result pre="to severely diseased individuals being the clinical signs, creatine and" exact="proteinuria" post="used to assess the evolution of their condition. Evaluation"/>
   <result pre="tubular damage biomarkers such as NGAL and CysC in canine" exact="chronic kidney disease." post="We aimed to evaluate the diagnostic power of urinary"/>
   <result pre="in dogs diagnosed with L. infantum using a modified IRIS" exact="chronic kidney disease" post="staging. Dogs presented to the University of Extremadura veterinary"/>
   <result pre="in 63%; facial swelling, deformation of the nasal planum, and/or" exact="exophthalmos" post="in 20%. Endoscopic examination found neoformation, which was unilateral"/>
   <result pre="No disclosures to report. ESVONC‐P‐2 Sensitivity of canine and human" exact="cancer" post="cell lines towards thermoradiotherapy P.E. Thumser‐Henner 1, K.J. Nytko"/>
   <result pre="of our study were firstly to screen human and canine" exact="cancer" post="cell lines for their sensitivity towards hyperthermia‐radiotherapy treatment, and"/>
   <result pre="treatment were determined in a panel of human and canine" exact="cancer" post="cell lines using a clonogenic survival assay. We analyzed"/>
   <result pre="the major effect of hyperthermia. Interestingly, we discovered a heat‐induced" exact="suppression" post="of BRCA2 transcription, potentially inhibiting the homologous recombination repair"/>
   <result pre="of hepatic infiltration in case of nodal diffuse large B‐cell" exact="lymphoma" post="(DLBLCL) D. Lanore 1, P. Vajdovich 2, J. Borrego"/>
   <result pre="performed for each dog. The ultrasonographic patterns characteristic for canine" exact="lymphoma" post="in liver included coarse parenchyma, ill‐defined hypoechoic areas, hypoechoic"/>
   <result pre="effects of a single dose of vincristine in dogs with" exact="lymphoma" post="A. Mosca, E. Dobson, J. Dobson University of Cambridge,"/>
   <result pre="Hospital, Cambridge, United Kingdom Lymphoma is the most common haematopoetic" exact="neoplasm" post="in the canine population. Chemotherapy protocols, such as COP,"/>
   <result pre="such as COP, CHOP and LOPP are used to treat" exact="lymphoma" post="due to its chemosensitive nature. These protocols routinely involve"/>
   <result pre="single administration. The records of dogs with previously untreated, confirmed" exact="lymphoma" post="receiving vincristine between July 2015 to March 2019 were"/>
   <result pre="was 22.9 kgs ranging from 3.4‐63kgs. Four dogs (9%) experienced" exact="neutropenia" post="(neutrophil count &amp;lt;2.0 x 10^9/L) following a single administration"/>
   <result pre="part of a chemotherapy protocol for lymphoma, developed a significant" exact="neutropenia" post="within one week of vincristine administration. Disclosures No disclosures"/>
   <result pre="in tissues has been associated with tissue damage and especially" exact="glomerulonephritis" post="and renal failure. However, little is known about the"/>
   <result pre="compared with old ones ( P = 0.0451). Young dogs showed" exact="proteinuria" post="less often than older dogs ( P = 0.0029). Dogs"/>
   <result pre="dogs seem to have significantly more tendency to develop ulcerative" exact="dermatitis" post="compared to mixed breed dogs ( P = 0.0460). This"/>
   <result pre="gibsoni and Babesia vogeli have both been identified in canine" exact="babesiosis" post="in Taiwan, where information on the epidemiology of the"/>
   <result pre="relation to the local clinical relevance and treatment of canine" exact="babesiosis" post="in Taiwan. Disclosures No disclosures to report. ISCAID‐P‐5 Risk"/>
   <result pre="parasites prevention, urine color, mucous membrane color and history of" exact="babesiosis" post="were analyzed by using of chi‐square test initially. Variables"/>
   <result pre="parasites and observation of urine color are very important in" exact="babesiosis" post="epidemic areas. Disclosures No disclosures to report. ISCAID‐P‐6 Acantocheilonema"/>
   <result pre="cell count results revealed leukocytosis (n. 16), anaemia (n. 2)," exact="thrombocytopenia" post="(n. 8), eosinophilia (n. 1). Biochemical data showed increased"/>
   <result pre="revealed leukocytosis (n. 16), anaemia (n. 2), thrombocytopenia (n. 8)," exact="eosinophilia" post="(n. 1). Biochemical data showed increased serum values of"/>
   <result pre="the existence of the disease are controversially discussed. Fever and" exact="arthritis" post="are clinical manifestations most often associated with LB; other"/>
   <result pre="four cases (14%); one dog (3%) died of a dilated" exact="cardiomyopathy" post="and one suspicious dog presented barking troubles that responded"/>
   <result pre="as the dog with cardiac presentation and 3/4 cases with" exact="kidney failure" post="died. Application of parasiticides was not always recorded; 6/29"/>
   <result pre="(CMhp) are two species of canine hemoplasma that may cause" exact="hemolytic anemia" post="and chronic disease in canine species. While understanding is"/>
   <result pre="are two species of canine hemoplasma that may cause hemolytic" exact="anemia" post="and chronic disease in canine species. While understanding is"/>
   <result pre="Infiniti Medical, LLC. ISCAID‐P‐11 Retrospective analysis of cases tested for" exact="leptospirosis" post="at a university teaching hospital H.K. Walker, N.X. Bommer,"/>
   <result pre="There is very little published data on positive cases of" exact="leptospirosis" post="seen in veterinary practice in the United Kingdom. This"/>
   <result pre="Kingdom. This study aims to analyze all cases tested for" exact="leptospirosis" post="in a UK university teaching hospital between 2011 and"/>
   <result pre="from a university database; all dogs that were screened for" exact="leptospirosis" post="via urine PCR, blood PCR, or serum MAT were"/>
   <result pre="the positive cases presented with pulmonary haemorrhage or dyspnea. Primary" exact="leptospirosis" post="was the final diagnosis for 27 of the 39"/>
   <result pre="diagnosis (neoplasia (n = 3); biliary mucocele (n = 1);" exact="necrotizing fasciitis" post="(n = 1); pericardial effusion (n = 1)). Three"/>
   <result pre="(neoplasia (n = 3); biliary mucocele (n = 1); necrotizing" exact="fasciitis" post="(n = 1); pericardial effusion (n = 1)). Three"/>
   <result pre="biliary mucocele (n = 1); necrotizing fasciitis (n = 1);" exact="pericardial effusion" post="(n = 1)). Three of the positive cases had"/>
   <result pre="non‐enhancing central scar was observed within this lesion. A hepatocellular" exact="adenoma" post="was diagnosed in two cases. The lesions were T1‐W"/>
   <result pre="centre in T2‐W images. No contrast enhancement was noted. A" exact="hepatocellular carcinoma" post="was also diagnosed in one case. This lesion was"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC6981968/results/search/disease/results.xml">
   <result pre="key to critical care response. Middle East respiratory syndrome MERS-CoV" exact="infectious disease" post="prevention information disclosure policy 1. Introduction The first case"/>
   <result pre="at local district public hospitals to treat patients with acute" exact="infectious disease" post="[ 7]. However, incompleteness has been exposed despite such"/>
   <result pre="of an appropriate management system and a prevention strategy for" exact="infectious disease" post="has been raised as additional reason for the initial"/>
   <result pre="MERS symptoms such as fever, vomit, sore throat, vomiting, and" exact="diarrhea" post="and follow the prevention and control guidance voluntarily and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC7000305/results/search/disease/results.xml">
   <result pre="(http://creativecommons.org/licenses/by-nc-nd/4.0/). Abstract Background Middle East Respiratory Syndrome (MERS) is a" exact="respiratory disease" post="caused by a novel coronavirus that was identified in"/>
   <result pre="MERS-CoV Diabetes 1 Background Middle East Respiratory Syndrome (MERS) a" exact="respiratory disease" post="caused by a novel coronavirus that was identified in"/>
   <result pre="showed that underlying immunodeficiency or immunosuppressant medications and therapies or" exact="diabetes mellitus" post="are strongly associated with increased morbidity and mortality ("/>
   <result pre="symptoms: temperature (&amp;gt;38 °C), signs of upper respiratory infection (cough," exact="shortness" post="of breath, sore throat, etc), runny nose or low"/>
   <result pre="have also collected data on existing comorbidities including diabetes, chronic" exact="heart disease" post="defined as ischemic heart disease, myocardial infarction, and acute"/>
   <result pre="existing comorbidities including diabetes, chronic heart disease defined as ischemic" exact="heart disease," post="myocardial infarction, and acute coronary syndrome. Medications at the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC7006675/results/search/disease/results.xml">
   <result pre="Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) causes a severe" exact="respiratory disease" post="in humans. The MERS-CoV spike (S) glycoprotein mediates viral"/>
   <result pre="sputum of a 60 year old man suffering from acute" exact="pneumonia" post="and renal failure in Saudi Arabia [ 1]. Since"/>
   <result pre="Table 1). We further utilized pCAGGS-based expression vectors for vesicular" exact="stomatitis" post="virus (VSV) glycoprotein (G), MERS-CoV S wildtype (WT) and"/>
   <result pre="host cell entry. For this, we made use of vesicular" exact="stomatitis" post="virus (VSV) pseudotypes (VSVpp) bearing MERS-CoV S or VSV"/>
   <result pre="host cell entry driven by MERS-CoV S, we produced vesicular" exact="stomatitis" post="virus pseudotype particles (VSVpp) harboring MERS-CoV S (left) or"/>
   <result pre="S protein and the cellular receptor DPP4. A link between" exact="obesity" post="or underlying diseases like diabetes mellitus, which both can"/>
   <result pre="receptor DPP4. A link between obesity or underlying diseases like" exact="diabetes mellitus," post="which both can affect DPP4 expression levels [ 48],"/>
   <result pre="al. Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi Arabia. N Engl J Med. 2012 Nov"/>
   <result pre="et al. Association of DPP4 gene polymorphisms with type 2" exact="diabetes mellitus" post="in Malaysian Subjects . PLoS One. 2016; 11( 4):"/>
   <result pre="associated with the risk of myocardial infarction in patients with" exact="atherosclerosis" post=". Neuropeptides. 2012 Dec; 46( 6): 367– 371. doi:"/>
   <result pre=", Lubke A , et al. The glycoprotein of vesicular" exact="stomatitis" post="virus promotes release of virus-like particles from tetherin-positive cells"/>
   <result pre="to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and" exact="influenza" post="viruses . PLoS One. 2013; 8( 8): e72942. doi:"/>
   <result pre="spike (S1) proteins: differences between infectious bronchitis virus and transmissible" exact="gastroenteritis" post="virus . Viruses. 2013 Jul 26; 5( 8): 1924–"/>
   <result pre="10.3390/v5081924 23896748 40 Rentsch MB , Zimmer G. A vesicular" exact="stomatitis" post="virus replicon-based bioassay for the rapid and sensitive determination"/>
   <result pre="its family members serve as the cellular receptors for vesicular" exact="stomatitis" post="virus . Proc Natl Acad Sci U S A."/>
   <result pre="related to body fat distribution in patients with familial partial" exact="lipodystrophy" post="type 2 . Diabetol Metab Syndr. 2017; 9( 26):"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC7017508/results/search/disease/results.xml">
   <result pre="Article Annual and seasonal patterns in etiologies of pediatric community-acquired" exact="pneumonia" post="due to respiratory viruses and Mycoplasma pneumoniae requiring hospitalization"/>
   <result pre="available in this article, unless otherwise stated. Abstract Background Community–acquired" exact="pneumonia" post="(CAP) is one of the leading worldwide causes of"/>
   <result pre="at 23 nationwide hospitals in South Korea. Mycoplasma pneumoniae (MP)" exact="pneumonia" post="was clinically classified as macrolide-sensitive MP, macrolide-less effective MP"/>
   <result pre="identified pathogens of CAP. With the two epidemics of MP" exact="pneumonia" post="(2011 and 2015), the rates of clinical MLEP and"/>
   <result pre="(2011 and 2015), the rates of clinical MLEP and MRMP" exact="pneumonia" post="showed increasing trends of 36.4% of the total MP"/>
   <result pre="pediatric morbidity, requiring hospitalization, and mortality [ 1, 2]. Childhood" exact="pneumonia" post="causes diverse long-term sequelae, such as restrictive or obstructive"/>
   <result pre="pneumonia causes diverse long-term sequelae, such as restrictive or obstructive" exact="lung disease," post="as well as bronchiectasis, particularly in a considerable proportion"/>
   <result pre="in a considerable proportion of children hospitalized due to community-acquired" exact="pneumonia" post="(CAP) [ 3]. The etiologies of CAP affect the"/>
   <result pre="was in 2015 [ 7– 9]. After 2000, macrolide-resistant MP" exact="pneumonia" post="rapidly emerged, especially in Asia [ 7]. MP infections"/>
   <result pre="children are often self-limiting, even in patients with macrolide-resistant MP" exact="pneumonia" post="[ 10]. More than 80% of patients with macrolide-sensitive"/>
   <result pre="this occurs in approximately 30% of patients with macrolide-resistant MP" exact="pneumonia" post="[ 11]. Despite its high prevalence, large-scale epidemiologic studies"/>
   <result pre="Despite its high prevalence, large-scale epidemiologic studies of macrolide-resistant MP" exact="pneumonia" post="are scarce. In the present study, we aimed to"/>
   <result pre="in pediatric CAP requiring hospitalization and the prevalence of MP" exact="pneumonia" post="according to the clinical responses to macrolides. In addition,"/>
   <result pre="pediatricians based on both physical examinations and radiologic assessments. MP" exact="pneumonia" post="was defined as meeting at least one of the"/>
   <result pre="convalescent stages [ 8, 12]. The clinical courses of MP" exact="pneumonia" post="have shown heterogeneous features, even in patients with the"/>
   <result pre="clinical, laboratory, and radiologic features between children with macrolide-resistant MP" exact="pneumonia" post="and those with MSMP pneumonia [ 7– 9]. In"/>
   <result pre="between children with macrolide-resistant MP pneumonia and those with MSMP" exact="pneumonia" post="[ 7– 9]. In the present study, MP susceptibility"/>
   <result pre="were not performed. Instead, to characterize the clinically heterogeneous MP" exact="pneumonia" post="into more homogenous clinical groups, we defined clinical MSMP,"/>
   <result pre="clinical MSMP, macrolide-refractory MP (MRMP), and macrolide less-effective MP (MLEP)" exact="pneumonia" post="according to fever duration in each pneumonia episode after"/>
   <result pre="less-effective MP (MLEP) pneumonia according to fever duration in each" exact="pneumonia" post="episode after the initiation of macrolides, regardless of the"/>
   <result pre="respiratory viruses were as follows: adenovirus (AdV), human rhinovirus (HRV)," exact="influenza" post="virus (FLU), parainfluenza virus (PIV), human metapneumovirus (HMPV), respiratory"/>
   <result pre="analyses were used to examine if the characteristics of MP" exact="pneumonia" post="groups were statistically significant with the chi-squared test. For"/>
   <result pre="August). Table 1 Demographic characteristics of hospitalized children with community-acquired" exact="pneumonia" post="Variables No. (%) or mean ± SD Number 30,994 Age (mo),"/>
   <result pre="Figure S1). Fig. 1 Number of children hospitalized with community-acquired" exact="pneumonia" post="according to etiology between 2011 and 2015 in Korea"/>
   <result pre="Korea Fig. 2 Number of children hospitalized with community acquired" exact="pneumonia" post="according to etiology The two epidemics of MP pneumonia"/>
   <result pre="acquired pneumonia according to etiology The two epidemics of MP" exact="pneumonia" post="(2011 and 2015) corresponded with the two peaks of"/>
   <result pre="with the two peaks of CAP. The incidence of MP" exact="pneumonia" post="requiring hospitalization in children peaked from October to November"/>
   <result pre="year (Fig. 1). The most common clinical phenotype of MP" exact="pneumonia" post="was MSMP, followed by MLEP and MRMP (Fig. 3a)."/>
   <result pre="During the study period, the monthly rate of MSMP/total MP" exact="pneumonia" post="was 63.6–100.0% (mean ± SD, 81.3 ± 7.7), that of MRMP/total MP pneumonia"/>
   <result pre="MP pneumonia was 63.6–100.0% (mean ± SD, 81.3 ± 7.7), that of MRMP/total MP" exact="pneumonia" post="was 0.0–11.0% (4.2 ± 4.3), and that of MLEP/total MP pneumonia"/>
   <result pre="MP pneumonia was 0.0–11.0% (4.2 ± 4.3), and that of MLEP/total MP" exact="pneumonia" post="was 0.0–30.3% (14.5 ± 14.2) (Fig. 3b). The rates of clinical"/>
   <result pre="(14.5 ± 14.2) (Fig. 3b). The rates of clinical MLEP and MRMP" exact="pneumonia" post="showed increasing trends (seasonal Mann-Kendall trend tests, P = 0.0644 and"/>
   <result pre="P = 0.0644 and P = 0.0066, respectively), whereas the rates of clinical MSMP" exact="pneumonia" post="showed a significant reduction during the study period (seasonal"/>
   <result pre="the numbers of children hospitalized due to Mycoplasma pneumoniae (MP)" exact="pneumonia" post="according to clinical macrolide sensitivity. a Number of children"/>
   <result pre="clinical macrolide sensitivity. a Number of children hospitalized with MP" exact="pneumonia" post="classified as macrolide-sensitive (MSMP), macrolide-refractory (MRMP), and macrolide less-effective"/>
   <result pre="MP pneumonia, MRMP pneumonia/total MP pneumonia, and MLEP pneumonia/total MP" exact="pneumonia" post="during the study period Causative pathogens of CAP according"/>
   <result pre="age exhibited MP infections. The rate of clinical MRMP/total MP" exact="pneumonia" post="was highest in children 5–9 years of age (244/3475, 9.8%),"/>
   <result pre="according to age groups in children hospitalized due to community-acquired" exact="pneumonia" post="Detected respiratory virus &amp;lt; 2 years, No. (%) 2–4 years, No. (%)"/>
   <result pre="Systemic corticosteroids were most commonly administered to those with MP" exact="pneumonia" post="(1645/7455, 22.1%), followed by RSV pneumonia (622/4521, 13.8%). The"/>
   <result pre="to those with MP pneumonia (1645/7455, 22.1%), followed by RSV" exact="pneumonia" post="(622/4521, 13.8%). The number of children with CAP who"/>
   <result pre="who required oxygen supplementation was greatest in children with RSV" exact="pneumonia" post="(905/4521, 20.0%); ventilator care was most commonly applied in"/>
   <result pre="ventilator care was most commonly applied in children with AdV" exact="pneumonia" post="(13/680, 1.9%), followed by those with RSV pneumonia (119/4521,"/>
   <result pre="with AdV pneumonia (13/680, 1.9%), followed by those with RSV" exact="pneumonia" post="(119/4521, 2.6%). Table 3 Comparison of clinical and laboratory"/>
   <result pre="according to respiratory pathogens in children hospitalized due to community-acquired" exact="pneumonia" post="Variables only MP 1 ( n = 7455) MP coinfected with"/>
   <result pre="2, MP co-infected with virus; group 3, adenovirus; group 4," exact="influenza" post="virus; group 5, Metapneumovirus; group 6, RSV; The inequality"/>
   <result pre="analyses were used to examine if the characteristics of MP" exact="pneumonia" post="groups were statistically significant with chi-squared test. For the"/>
   <result pre="October–November and November–December, respectively. There were two epidemics of MP" exact="pneumonia" post="(2011 and 2015) during the study period. In children"/>
   <result pre="comprising up to 36% of the total cases of MP" exact="pneumonia" post="during the study period. In children less than 2 years"/>
   <result pre="problematic in infants, who are most frequently affected by RSV" exact="pneumonia" post="[ 15]. These findings may be valuable to guide"/>
   <result pre="due to CAP. The number of children hospitalized with MP" exact="pneumonia" post="was typically highest between October and November. In the"/>
   <result pre="November. In the previous studies, the peak incidence of MP" exact="pneumonia" post="showed a similar pattern to that observed in the"/>
   <result pre="Korean epidemic, the peak rate of hospitalization due to MP" exact="pneumonia" post="in children occurred in September, whereas the peak rate"/>
   <result pre="November. In addition, the number of children hospitalized with MP" exact="pneumonia" post="in the 2015 epidemic was smaller than that in"/>
   <result pre="vitro macrolide sensitivity tests, the macrolide resistance rates of MP" exact="pneumonia" post="have recently been identified as 50–90% in Asia ["/>
   <result pre="to fever duration after the initiation of macrolides in each" exact="pneumonia" post="episode, regardless of the results of in vitro macrolide"/>
   <result pre="the ratios of clinical MLEP and MRMP of total MP" exact="pneumonia" post="showed increasing trends after adjustment for monthly time series."/>
   <result pre="for monthly time series. However, the estimated clinical MRMP/total MP" exact="pneumonia" post="ratio during the study period in the present study"/>
   <result pre="study suggest that the clinical response to macrolides in MP" exact="pneumonia" post="in the real world might not be as weak"/>
   <result pre="respect to clinical and radiologic findings between MRMP and MSMP" exact="pneumonia" post="in children [ 8, 9]. When combined with the"/>
   <result pre="8, 13], a considerable proportion of cases of macrolide-resistant MP" exact="pneumonia" post="might be recategorized as clinical MSMP or MLEP pneumonia."/>
   <result pre="MSMP or MLEP pneumonia. Therefore, the first-line treatment for MP" exact="pneumonia" post="can be initially started, even in cases of MRMP"/>
   <result pre="pneumonia. Considering the exaggerated immune response in children with MP" exact="pneumonia" post="[ 18], the application of immune-modulators, such as corticosteroids"/>
   <result pre="MP pneumonia, even in some cases of MLEP or MRMP" exact="pneumonia" post="[ 19]. When selecting the proper treatment strategy for"/>
   <result pre="some patients might have been misclassified into the &quot;no MP" exact="pneumonia" post="and no respiratory virus detection&quot; group due to a"/>
   <result pre="the introduction of the pneumococcal conjugate vaccine and the Haemophilus" exact="influenza" post="type b vaccine, the disease burden due to bacterial"/>
   <result pre="Haemophilus influenza type b vaccine, the disease burden due to" exact="bacterial pneumonia" post="has been significantly decreased [ 6, 20]. Therefore, we"/>
   <result pre="influenza type b vaccine, the disease burden due to bacterial" exact="pneumonia" post="has been significantly decreased [ 6, 20]. Therefore, we"/>
   <result pre="20]. Therefore, we clinically defined the MSMP, MRMP, and MLEP" exact="pneumonia" post="groups solely based on fever duration after initiation of"/>
   <result pre="might play more important roles in the treatment of MP" exact="pneumonia" post="in some cases, the application of clinical classifications of"/>
   <result pre="LINK Additional file 1: Figure S1. Time-dependent trends of community-acquired" exact="pneumonia" post="due to various respiratory viruses. (A) Influenza. (B) Adenovirus."/>
   <result pre="(D) Parainfluenza. Abbreviations AdV Adenovirus BoV Bocavirus CAP Community acquired" exact="pneumonia" post="FLU Influenza virus HCoV Human coronavirus HMPV Human metapneumovirus"/>
   <result pre="O'Brien KL Campbell H Black RE Global burden of childhood" exact="pneumonia" post="and diarrhoea Lancet 2013 381 9875 1405 1416 10.1016/S0140-6736(13)60222-6"/>
   <result pre="C Anderson EJ Grijalva CG Self WH et al. Community-acquired" exact="pneumonia" post="requiring hospitalization among U.S. children N Engl J Med"/>
   <result pre="J Prevalence and clinical manifestations of macrolide resistant mycoplasma pneumoniae" exact="pneumonia" post="in Korean children Korean J Pediatr 2017 60 5"/>
   <result pre="Choung JT Macrolide resistance and its impacts on M. pneumoniae" exact="pneumonia" post="in children: comparison of two recent epidemics in Korea"/>
   <result pre="findings and clinical features in hospitalized children with mycoplasma pneumoniae" exact="pneumonia" post="PLoS One 2019 14 8 e0219463 10.1371/journal.pone.0219463 31461462 13."/>
   <result pre="RE Campbell H et al. Epidemiology and etiology of childhood" exact="pneumonia" post="in 2010: estimates of incidence, severe morbidity, mortality, underlying"/>
   <result pre="Z Cytokines as the good predictors of refractory mycoplasma pneumoniae" exact="pneumonia" post="in school-aged children Sci Rep 2016 6 37037 10.1038/srep37037"/>
   <result pre="JH Effects of methylprednisolone pulse therapy on refractory mycoplasma pneumoniae" exact="pneumonia" post="in children Allergy, Asthma Immunol Res 2014 6 1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC7019290/results/search/disease/results.xml">
   <result pre="animals, such as Middle East Respiratory Syndrome [MERS] [ 8]," exact="avian influenza" post="[ 9], Rift Valley fever [ 10], and swine"/>
   <result pre="such as Middle East Respiratory Syndrome [MERS] [ 8], avian" exact="influenza" post="[ 9], Rift Valley fever [ 10], and swine"/>
   <result pre="influenza [ 9], Rift Valley fever [ 10], and swine" exact="influenza" post="[ 11, 12]. Livestock animals that live in close"/>
   <result pre="In 2003, there was an outbreak of a highly pathogenic" exact="avian influenza" post="A subtype H7N7 in humans linked to multiple commercial"/>
   <result pre="2003, there was an outbreak of a highly pathogenic avian" exact="influenza" post="A subtype H7N7 in humans linked to multiple commercial"/>
   <result pre="the Netherlands [ 15]. Two years later, another highly pathogenic" exact="avian influenza" post="A H5N1 virus emerged in Asia in 2005, probably"/>
   <result pre="Netherlands [ 15]. Two years later, another highly pathogenic avian" exact="influenza" post="A H5N1 virus emerged in Asia in 2005, probably"/>
   <result pre="have zoonotic potential were reported in available mNGS studies including" exact="hepatitis" post="E viruses in gastrointestinal samples of pigs [ 45,"/>
   <result pre="NGS has opened up more opportunities to advance understanding in" exact="infectious disease" post="diagnostics, surveillance, and transmission [ 133]. One of the"/>
   <result pre="and global spread of swine viruses such as porcine epidemic" exact="diarrhea" post="virus [ 136] and African Swine Fever virus ["/>
   <result pre="included studies [ 75, 88]. Other mNGS studies also found" exact="hepatitis" post="E viruses in pigs, known to be zoonotic. In"/>
   <result pre="camel and human stools and some MERS patients also experienced" exact="diarrhea" post="[ 150]. Nonetheless, viral mNGS studies of respiratory samples"/>
   <result pre="Niezgoda M. Rupprecht C. Bresee J. Breiman R.F. Nipah virus" exact="encephalitis" post="reemergence, Bangladesh Emerg. Infect. Dis. 2004 10 2082 2087"/>
   <result pre="Zhang Y. et al. Dissemination, divergence and establishment of H7N9" exact="influenza" post="viruses in China Nature 2015 522 102 105 10.1038/nature14348"/>
   <result pre="B.B. et al. Severe acute respiratory infection caused by swine" exact="influenza" post="virus in a child necessitating extracorporeal membrane oxygenation (ECMO),"/>
   <result pre="al. Origins and evolutionary genomics of the 2009 swine-origin H1N1" exact="influenza" post="a epidemic Nature 2009 459 1122 1125 10.1038/nature08182 19516283"/>
   <result pre="J. Fouchier R. Osterhaus A. et al. Transmission of H7N7" exact="avian influenza" post="A virus to human beings during a large outbreak"/>
   <result pre="Fouchier R. Osterhaus A. et al. Transmission of H7N7 avian" exact="influenza" post="A virus to human beings during a large outbreak"/>
   <result pre="V. Roeder P. Origin and evolution of highly pathogenic H5N1" exact="avian influenza" post="in Asia Vet. Rec. 2005 157 159 164 10.1136/vr.157.6.159"/>
   <result pre="Roeder P. Origin and evolution of highly pathogenic H5N1 avian" exact="influenza" post="in Asia Vet. Rec. 2005 157 159 164 10.1136/vr.157.6.159"/>
   <result pre="C. Palacios G. Baisre-de-Leon A. Paddock C.D. et al. Astrovirus" exact="encephalitis" post="in boy with X-linked agammaglobulinemia Emerg. Infect. Dis. 2010"/>
   <result pre="Diagnosis of neuroinvasive astrovirus infection in an immunocompromised adult with" exact="encephalitis" post="by unbiased next-generation sequencing Clin. Infect. Dis. 2015 60"/>
   <result pre="et al. Diagnosis of fatal human case of St. Louis" exact="encephalitis" post="virus infection by metagenomic sequencing, California. 2016 Emerg. Infect."/>
   <result pre="Hause B.M. Metagenomic characterization of the virome associated with bovine" exact="respiratory disease" post="in feedlot cattle identified novel viruses and suggests an"/>
   <result pre="cattle identified novel viruses and suggests an etiologic role for" exact="influenza" post="D virus J. Gen. Virol. 2016 97 1771 1784"/>
   <result pre="Steinbach F. Choudhury B. Molecular and in vitro characterisation of" exact="hepatitis" post="E virus from UK pigs Virology 2019 527 116"/>
   <result pre="B.M. Collin E.A. Anderson J. Hesse R.A. Anderson G. Bovine" exact="rhinitis" post="viruses are common in U.S. cattle with bovine respiratory"/>
   <result pre="Bovine rhinitis viruses are common in U.S. cattle with bovine" exact="respiratory disease" post="PLoS ONE 2015 10 e0121998 10.1371/journal.pone.0121998 25789939 50. Guo"/>
   <result pre="Lipkin W. Discovery of a novel nidovirus in cattle with" exact="respiratory disease" post="J. Gen. Virol. 2015 96 2188 2193 10.1099/vir.0.000166 25918239"/>
   <result pre="M. Berg M. Myrmel M. Genome sequence of a bovine" exact="rhinitis" post="B virus identified in cattle in Sweden Genome Announc."/>
   <result pre="Okabayashi T. Molecular epidemiological survey and phylogenetic analysis of bovine" exact="influenza" post="D virus in Japan Transbound. Emerg. Dis. 2018 65"/>
   <result pre="C. He B. Genomes and seroprevalence of severe fever with" exact="thrombocytopenia" post="syndrome virus and Nairobi sheep disease virus in Haemaphysalis"/>
   <result pre="Junqueira D.M. Mayer F.Q. et al. The intestinal virome of" exact="malabsorption" post="syndrome-affected and unaffected broilers through shotgun metagenomics Virus Res."/>
   <result pre="an enterovirus recombinant with a torovirus-like gene insertion during a" exact="diarrhea" post="outbreak in fattening pigs Virus Evol. 2017 3 vex024"/>
   <result pre="virome indicates high diversity in pigs infected by porcine endemic" exact="diarrhea" post="virus in the United States Virol. J. 2018 15"/>
   <result pre="C. Zhou K. Zhang B. Viral communities associated with porcine" exact="respiratory disease" post="complex in intensive commercial farms in Sichuan province, China"/>
   <result pre="of a porcine polyomavirus from nasal swabs of pigs with" exact="respiratory disease" post="Genome Announc. 2018 6 e00344-18 10.1128/genomeA.00344-18 29700160 100. Sano"/>
   <result pre="novel bovine group A rotavirus G15P[1 4] strain from epizootic" exact="diarrhea" post="of adult cows by de novo sequencing using a"/>
   <result pre="B. Höper D. Beer M. A novel astrovirus associated with" exact="encephalitis" post="and ganglionitis in domestic sheep Transbound. Emerg. Dis. 2017"/>
   <result pre="porcine astrovirus 4 from nasal swabs from pigs with acute" exact="respiratory disease" post="Arch. Virol. 2016 161 2575 2579 10.1007/s00705-016-2937-1 27329081 124."/>
   <result pre="M.R. McQuiston J. Mumford E. et al. Surveillance of zoonotic" exact="infectious disease" post="transmitted by small companion animals Emerg. Infect. Dis. 2012"/>
   <result pre="time to stability in sow herds infected with porcine epidemic" exact="diarrhea" post="virus (PEDV) Prev. Vet. Med. 2016 123 202 207"/>
   <result pre="54, 55, 56] Bovine respiratory syncytial virus [ 44] Bovine" exact="rhinitis" post="A virus [ 44, 48, 49] Bovine rhinitis B"/>
   <result pre="44] Bovine rhinitis A virus [ 44, 48, 49] Bovine" exact="rhinitis" post="B virus [ 44, 48, 49, 52, 57] Bovine"/>
   <result pre="97, 98] Porcine cytomegalovirus [ 94, 95, 99] Porcine epidemic" exact="diarrhea" post="virus [ 46, 79, 84, 88, 92, 100] Porcine"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC7028525/results/search/disease/results.xml">
   <result pre="We describe a case of severe silicone pneumonitis complicated with" exact="acute respiratory distress syndrome" post="and bilateral pneumothorax secondary to silicone gluteal augmentation. In"/>
   <result pre="silicone pneumonitis complicated with acute respiratory distress syndrome and bilateral" exact="pneumothorax" post="secondary to silicone gluteal augmentation. In this case report,"/>
   <result pre="We describe a case of severe silicone pneumonitis complicated with" exact="acute respiratory distress syndrome" post="and bilateral pneumothorax secondary to silicon gluteal augmentation. In"/>
   <result pre="silicone pneumonitis complicated with acute respiratory distress syndrome and bilateral" exact="pneumothorax" post="secondary to silicon gluteal augmentation. In this case report,"/>
   <result pre="(FiO2: 60%) of high‐flow oxygen supplement. However, she developed right‐sided" exact="pneumothorax" post="and worsened respiratory failure 12 h later. On chest radiograph,"/>
   <result pre="high‐flow oxygen supplement. However, she developed right‐sided pneumothorax and worsened" exact="respiratory failure" post="12 h later. On chest radiograph, diffuse alveolar opacities in"/>
   <result pre="lung fields. (D) Chest X‐ray with bilateral alveolar opacities and" exact="pneumothorax" post="with chest tube in‐situ. (E) Chest X‐ray improvement of"/>
   <result pre="and non‐refractile vacuole‐like structures. She received lung protective ventilation for" exact="acute respiratory distress syndrome" post="(i.e. low tidal volumes and high positive end‐expiratory pressure"/>
   <result pre="hypoxia. Unfortunately, two weeks later, she again developed another spontaneous" exact="pneumothorax" post="on the left lung and required chest tube drainage."/>
   <result pre="consequences that associated with silicone injection include acute pneumonitis 4," exact="acute respiratory distress syndrome," post="alveolar haemorrhages, and pulmonary embolism 5. The respiratory symptoms"/>
   <result pre="acute pneumonitis 4, acute respiratory distress syndrome, alveolar haemorrhages, and" exact="pulmonary embolism" post="5. The respiratory symptoms generally present within 72 h after"/>
   <result pre="membrane oxygenation (ECMO) may be considered in cases of severe" exact="acute respiratory distress syndrome" post="(ARDS) deteriorating on mechanical ventilation. Surgical extraction of the"/>
   <result pre="et al. 12 2018 Injection — 15–20 years Diffuse GGO Pneumonitis," exact="pneumothorax" post="Corticosteroids No Elizabeth et al. 13 2018 Implant Breast"/>
   <result pre="Yes Implant Breast 12 years Diffuse GGO and reticular opacities Organising" exact="pneumonia" post="Prednisone 40 mg/day with tapering down over 6 months and azathioprine"/>
   <result pre="Trochanter 1 day Interstitial infiltrates, air‐space consolidation Pneumonitis Supportive Yes ARDS," exact="acute respiratory distress syndrome;" post="ECMO, extracorporeal membrane oxygenation; GGO, ground glass opacities; LN,"/>
   <result pre="silicone injection for gluteal augmentation. The patients presented with haemoptysis," exact="shortness" post="of breath, and acute respiratory failure two days after"/>
   <result pre="The patients presented with haemoptysis, shortness of breath, and acute" exact="respiratory failure" post="two days after the silicone injections 11. Her computed"/>
   <result pre="et al. reported a rare case of silicone pneumonitis with" exact="pneumothorax" post="occurred even after 15–20 years of silicone injection 12. Bronchoscopic"/>
   <result pre="associated with mild symptoms, such as fever, cough, pharyngitis, and" exact="rhinitis" post="15. In rare cases, pneumonia can occur. In total"/>
   <result pre="as fever, cough, pharyngitis, and rhinitis 15. In rare cases," exact="pneumonia" post="can occur. In total contrast to silicon pneumonitis, lung"/>
   <result pre="contrast to silicon pneumonitis, lung biopsy histopathological features of HCoV‐NL63" exact="pneumonia" post="are chronic pulmonary inflammation, severe alveolar damage, intra‐alveolar hyaline"/>
   <result pre="reduces the inflammation of the airways that leading pneumonitis with" exact="acute respiratory distress syndrome" post="but does not have any mortality benefits 3, 14."/>
   <result pre="Lung‐protective ventilation strategies improve survival. Vigilance in the occurrence of" exact="pneumothorax" post="in cases of SES especially if complicated with ARDS"/>
   <result pre="if complicated with ARDS and requiring mechanical ventilation. Risk of" exact="pneumothorax" post="in SES and will usually resolve after chest drain"/>
   <result pre="Friend R , et al. 2012 An unusual case of" exact="pulmonary embolism." post="Respir Care 57( 8): 1345– 1347. 22348969 26 Zakhia"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC7029452/results/search/disease/results.xml">
   <result pre="identified on 7 January 2020 [ 1]. Twenty-seven patients with" exact="pneumonia" post="had initially been reported, with an epidemiological link to"/>
   <result pre="in Paris on 19 January. He developed fever, chills, fatigue," exact="conjunctivitis" post="and cough on 19 January. Case 3 was a"/>
   <result pre="that occurred after 2003 (severe acute respiratory syndrome (SARS), MERS," exact="influenza" post="A(H1N1)pdm09, Ebolavirus disease), and all involved parties were already"/>
   <result pre="epidemiological link to Wuhan, China and a severe lower acute" exact="respiratory disease." post="It is noteworthy that the first nine possible cases"/>
   <result pre="were expanded on 4 February to include any lower acute" exact="respiratory disease" post="and the epidemiological criterion was extended to the whole"/>
   <result pre="Chu H Yang J et al. A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC7029759/results/search/disease/results.xml">
   <result pre="use of recombinant ACE2 is highlighted as a treatment for" exact="acute respiratory distress syndrome" post="(ARDS), including several studies exploring its use to treat"/>
   <result pre="in patients infected with 2019-nCoV. Introduction A mysterious illness causing" exact="pneumonia" post="in December 2019 in Wuhan, China is now growing"/>
   <result pre="Wuhan, China is now growing into a potential pandemic. These" exact="pneumonia" post="cases were eventually characterized to be caused by a"/>
   <result pre="2019-nCoV infection include fever, cough, and myalgia or fatigue with" exact="pneumonia" post="demonstrated on chest CT scan imaging 6 . Within"/>
   <result pre="of which are components of human immunodeficiency virus (HIV) and" exact="hepatitis" post="C virus (HCV) antiviral regimens. Pilot clinical studies are"/>
   <result pre="are established by evolution over long periods. By analogy, the" exact="influenza" post="virus changes the mutations on its surface to escape"/>
   <result pre="agent is that ACE2 administration could also directly treat the" exact="pneumonia" post="pathophysiology. A portion of patients with SARS and 2019-nCoV"/>
   <result pre="SARS and 2019-nCoV infection develop pneumonia, which is characterized by" exact="pulmonary edema" post="and acute respiratory distress syndrome (ARDS) 1, 2 ."/>
   <result pre="infection develop pneumonia, which is characterized by pulmonary edema and" exact="acute respiratory distress syndrome" post="(ARDS) 1, 2 . The viruses may, in part,"/>
   <result pre="also reduce ARDS in respiratory syncytial virus 58 and H5N1" exact="influenza" post="59 infection models. Based on these promising preclinical studies,"/>
   <result pre="Goldsmith CS et al. : A novel coronavirus associated with" exact="severe acute respiratory syndrome." post="N Engl J Med. 2003; 348( 20): 1953– 1966."/>
   <result pre=": Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi Arabia. N Engl J Med. 2012; 367("/>
   <result pre="S Kok KH et al. : A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
   <result pre="and proactive infection control measures against the emerging Wuhan coronavirus" exact="pneumonia" post="in China. J Hosp Infect. 2020; pii: S0195-6701(20)30034-7. 10.1016/j.jhin.2020.01.010"/>
   <result pre=": Public health measures to control the spread of the" exact="severe acute respiratory syndrome" post="during the outbreak in Toronto. N Engl J Med."/>
   <result pre="Geisbert TW Daddario-Dicaprio KM Lewis MG et al. : Vesicular" exact="stomatitis" post="virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman"/>
   <result pre="High prevalence of human anti-mouse antibodies in the serum of" exact="colorectal cancer" post="patients. Anticancer Res. 2010; 30( 10): 4353– 4356. 21036763"/>
   <result pre="prevalence of human anti-mouse antibodies in the serum of colorectal" exact="cancer" post="patients. Anticancer Res. 2010; 30( 10): 4353– 4356. 21036763"/>
   <result pre="Wang HR : Repurposing host-based therapeutics to control coronavirus and" exact="influenza" post="virus. Drug Discov Today. 2019; 24( 3): 726– 736."/>
   <result pre=": Discovery of a novel coronavirus associated with the recent" exact="pneumonia" post="outbreak in humans and its potential bat origin. bioRxiv."/>
   <result pre="53 Gu J Korteweg C : Pathology and pathogenesis of" exact="severe acute respiratory syndrome." post="Am J Pathol. 2007; 170( 4): 1136– 1147. 10.2353/ajpath.2007.061088"/>
   <result pre="Li W Murakami A et al. : Potent neutralization of" exact="severe acute respiratory syndrome" post="(SARS) coronavirus by a human mAb to S1 protein"/>
   <result pre="T Li W et al. : Retroviruses pseudotyped with the" exact="severe acute respiratory syndrome" post="coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme"/>
   <result pre="Y et al. : Angiotensin-converting enzyme 2 protects from lethal" exact="avian influenza" post="A H5N1 infections. Nat Commun. 2014; 5: 3594. 10.1038/ncomms4594"/>
   <result pre="et al. : Angiotensin-converting enzyme 2 protects from lethal avian" exact="influenza" post="A H5N1 infections. Nat Commun. 2014; 5: 3594. 10.1038/ncomms4594"/>
   <result pre="pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in" exact="acute respiratory distress syndrome." post="Crit Care. 2017; 21( 1): 234. 10.1186/s13054-017-1823-x 28877748 62"/>
   <result pre=": Differential downregulation of ACE2 by the spike proteins of" exact="severe acute respiratory syndrome" post="coronavirus and human coronavirus NL63. J Virol. 2010; 84("/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC7033854/results/search/disease/results.xml">
   <result pre="response to antipyretic therapy in military personnel with adenovirus-positive community-acquired" exact="pneumonia" post="Yoo Hongseok 1 Oh Jimi 2 http://orcid.org/0000-0002-6031-009X Park Chul"/>
   <result pre="otherwise stated. Abstract Background In 2014, an outbreak of adenoviral" exact="pneumonia" post="occurred in the Korean military training center. However, there"/>
   <result pre="response to antipyretic therapy in immunocompetent adults with adenovirus-positive community-acquired" exact="pneumonia" post="(CAP). Methods The medical records of the patients who"/>
   <result pre="mortality up to 80% [ 1– 4]. Outbreaks of adenoviral" exact="pneumonia" post="have been occasionally reported in young adult women or"/>
   <result pre="camp were infected with Adv, and 90% of patients with" exact="pneumonia" post="were infected with adenovirus [ 10, 11]. In 2006,"/>
   <result pre="recruits that died in boot camp due to severe adenoviral" exact="pneumonia" post="in South Korea since 2012 [ 13, 15– 17]."/>
   <result pre="some clinical data have been reported regarding predictive factors of" exact="respiratory failure" post="associated with Adv infection [ 18, 19]. If Adv"/>
   <result pre="patients is currently unavailable. We previously observed that adenovirus-positive community-acquired" exact="pneumonia" post="(CAP) patients have a high fever and respond differently"/>
   <result pre="and clinical signs, initial laboratory and radiological findings, culture results," exact="pneumonia" post="severity index, clinical course, length of hospital stay, and"/>
   <result pre="viruses included in this test are as follows; adenovirus, rhinovirus," exact="influenza" post="virus A/B, respiratory syncytial virus A/B, metapneumovirus, bocavirus, coronavirus,"/>
   <result pre="were admitted suspicious combined to underlying disease managed to acute" exact="asthma" post="exacerbation. Consequently, 251 patients were enrolled in this study,"/>
   <result pre="n = 4). A few patients had an underlying disease, such as" exact="asthma" post="( n = 3), allergic rhinitis ( n = 3), and pneumothorax ("/>
   <result pre="patients had an underlying disease, such as asthma ( n = 3)," exact="allergic rhinitis" post="( n = 3), and pneumothorax ( n = 2). No differences in"/>
   <result pre="had an underlying disease, such as asthma ( n = 3), allergic" exact="rhinitis" post="( n = 3), and pneumothorax ( n = 2). No differences in"/>
   <result pre="such as asthma ( n = 3), allergic rhinitis ( n = 3), and" exact="pneumothorax" post="( n = 2). No differences in the duration of symptoms"/>
   <result pre="headache, and nasal congestion. At admission, initial vital signs and" exact="pneumonia" post="severity index (PSI) scores were not significantly different between"/>
   <result pre="n(%)] 0.575  Asthma 3 (4.5) 2 (1.1) 5 (2.0)  Allergic" exact="rhinitis" post="2 (3.0) 1 (0.5) 3 (1.2)  Pneumothorax 1 (1.5)"/>
   <result pre="and Non-Adv groups (Table 2). The percentage of patients having" exact="leukopenia" post="and thrombocytopenia was higher in the Adv patients P &amp;lt; "/>
   <result pre="groups (Table 2). The percentage of patients having leukopenia and" exact="thrombocytopenia" post="was higher in the Adv patients P &amp;lt;  0.001), while"/>
   <result pre="(1.1) 2 (0.8) Combined etiologies [ n(%)] &amp;lt;  0.001 S." exact="pneumonia" post="plus H.pneumoniae 7 (10.4) 14 (7.6) 21 (8.4)   Rhinovirus"/>
   <result pre="patients had coinfections with viruses, such as rhinovirus ( n = 5)," exact="influenza" post="A virus ( n = 4), respiratory syncytial virus ( n = 1),"/>
   <result pre="(%) Adv Adenovirus, mMRC Modified Medical Research Council, CAP Community-acquired" exact="pneumonia" post="acAdv defined that CAP patients with adenovirus combined other"/>
   <result pre="(5.6)  GI trouble 6 (9.0) 2 (1.1) 8 (3.2)  Skin" exact="rash" post="1 (1.5) (−) 1 (0.4)  Elevated liver enzyme 4"/>
   <result pre="our study, we described the clinical characteristics of Adv-positive community-acquired" exact="pneumonia" post="in immunocompetent adult patients. The most important findings were"/>
   <result pre="to the Non-Adv group patients. In addition, the instances of" exact="leukopenia" post="and thrombocytopenia were greater in the Adv group patients"/>
   <result pre="Non-Adv group patients. In addition, the instances of leukopenia and" exact="thrombocytopenia" post="were greater in the Adv group patients than in"/>
   <result pre="33.0% of all specimens in febrile respiratory illness (FRI) or" exact="pneumonia" post="patients. This study was of reviewed military patients with"/>
   <result pre="This study was of reviewed military patients with FRI or" exact="pneumonia" post="who were tested for respiratory viruses from October 2014"/>
   <result pre="October 2014 to May 2016. The proportion of patients with" exact="pneumonia" post="and the hospitalization rate did not differ between those"/>
   <result pre="In addition, dual-pathogen patients, such as S. pneumoniae with either" exact="influenza" post="A or B, had a higher mean body temperature,"/>
   <result pre="at admission. Abbreviations Adv Adenovirus cAdv Combined Adv CAP Community-acquired" exact="pneumonia" post="CPR C-reactive protein FRI Febrile respiratory illness HRCT High"/>
   <result pre="VV Ageeva MR Vorobyeva NS Savochkina YA et al. Adenovirus" exact="pneumonia" post="with a fatal outcome in adults Ter Arkh 2014"/>
   <result pre="7. Clark TW Fleet DH Wiselka MJ Severe community-acquired adenovirus" exact="pneumonia" post="in an immunocompetent 44-year-old woman: a case report and"/>
   <result pre="259 10.1186/1752-1947-5-259 21718493 8. Hakim FA Tleyjeh IM Severe adenovirus" exact="pneumonia" post="in immunocompetent adults: a case report and review of"/>
   <result pre="153 158 10.1007/s10096-007-0416-z 18030505 9. Hung KH Lin LH Adenovirus" exact="pneumonia" post="complicated with acute respiratory distress syndrome: a case report"/>
   <result pre="outcomes among members of the United States military hospitalized with" exact="pneumonia" post="and influenza, 2000-2012 Vaccine 2015 33 49 6970 6976"/>
   <result pre="serotype 7 from south Korean military recruits with mild acute" exact="respiratory disease" post="Eur J Clin Microbiol Infect Dis 2007 26 7"/>
   <result pre="Jung SS et al. Clinical features and courses of adenovirus" exact="pneumonia" post="in healthy young adults during an outbreak among Korean"/>
   <result pre="W et al. Incidence, risk factors, and mortality associated with" exact="acute respiratory distress syndrome" post="in combat casualty care J Trauma Acute Care Surg"/>
   <result pre="BW Kim H Yoo H Park SB Characteristics of adenovirus" exact="pneumonia" post="in Korean military personnel, 2012-2016 J Korean Med Sci"/>
   <result pre="Korean military training facility: clinical and radiological characteristics of adenovirus" exact="pneumonia" post="Jpn J Infect Dis 2013 66 5 359 365"/>
   <result pre="S et al. Clinical features and radiological findings of adenovirus" exact="pneumonia" post="associated with progression to acute respiratory distress syndrome: a"/>
   <result pre="BW Kim SJ Kim K Clinical characteristics and factors predicting" exact="respiratory failure" post="in adenovirus pneumonia Respirology 2016 21 7 1243 1250"/>
   <result pre="K Clinical characteristics and factors predicting respiratory failure in adenovirus" exact="pneumonia" post="Respirology 2016 21 7 1243 1250 10.1111/resp.12828 27301912 20."/>
   <result pre="America/American Thoracic Society consensus guidelines on the management of community-acquired" exact="pneumonia" post="in adults Clin Infect Dis 2007 44 Suppl 2"/>
   <result pre="Pai H Suh GY et al. Treatment guidelines for community-acquired" exact="pneumonia" post="in Korea: an evidence-based approach to appropriate antimicrobial therapy"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC7034298/results/search/disease/results.xml">
   <result pre="caused by viruses, bacteria, mycobacteria, and fungi. They all had" exact="hypogammaglobulinemia" post="and low absolute lymphocyte count. Their lymphocytes failed to"/>
   <result pre="Infections Disseminated BCGitis Perinatal CMV, Klebsiella pneumoniae sepsis, UTI, and" exact="pneumonia" post="Oral candidiasis and Disseminated BCGitis Klebsiella pneumoniae sepsis and"/>
   <result pre="BCGitis Perinatal CMV, Klebsiella pneumoniae sepsis, UTI, and pneumonia Oral" exact="candidiasis" post="and Disseminated BCGitis Klebsiella pneumoniae sepsis and meningitis Others"/>
   <result pre="pneumonia Oral candidiasis and Disseminated BCGitis Klebsiella pneumoniae sepsis and" exact="meningitis" post="Others Extensive Maculopapular skin rash Pancytopenia Hepatosplenomegaly Intracranial calcification"/>
   <result pre="BCGitis Klebsiella pneumoniae sepsis and meningitis Others Extensive Maculopapular skin" exact="rash" post="Pancytopenia Hepatosplenomegaly Intracranial calcification Chorioretinitis Microcephaly Axial hypotonia Hepatosplenomegaly"/>
   <result pre="Hepatosplenomegaly Intracranial calcification Chorioretinitis Microcephaly Axial hypotonia Hepatosplenomegaly Hepatosplenomegaly Maculopapular" exact="rash" post="IgG * 0.75 g/L 1.39 g/L 0.574 g/L 2.679"/>
   <result pre="NA Died/infection &amp;lt;4 months P2 ( 7) 3 months Bacteremia," exact="otitis media," post="pyelonephritis, pneumonia, tinea capitis, and oropharyngeal and perineal candidiasis."/>
   <result pre="P2 ( 7) 3 months Bacteremia, otitis media, pyelonephritis, pneumonia," exact="tinea capitis," post="and oropharyngeal and perineal candidiasis. Causative organisms: Klebsiella pneumoniae,"/>
   <result pre="months P7 ( 7) 2 months Listeria monocytogenes bacteremia and" exact="meningitis" post="and oral thrush No NA NA NA NA NA"/>
   <result pre="Died/infection 2 months P8 ( 7) 1 month Oral thrush," exact="pneumonia" post="and bacteremia. Causative organism: E. coli Yes 5 months"/>
   <result pre="disseminated BCGitis No NA NA NA NA NA Died/BCGitis and" exact="cardiac arrest" post="14 months P18 ( 4) 2 months Omphalitis, delayed"/>
   <result pre="live to their fourth decade. Although both diseases result in" exact="hypogammaglobulinemia" post="and lymphopenia, patients with IKBKB GOF mutation have lower"/>
   <result pre="Jakobsen MA Møller MB Fisker N Barington T . Infantile" exact="hemophagocytic lymphohistiocytosis" post="in a case of chediak-higashi syndrome caused by a"/>
   <result pre="the LYST/CHS1 gene presenting with delayed umbilical cord detachment and" exact="diarrhea" post=". J Pediatr Hematol Oncol. ( 2015) 37: e73–"/>
   <result pre="truncating mutation in MYD88 in a patient with BCG adenitis," exact="neutropenia" post="and delayed umbilical cord separation . Clin Immunol. ("/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC7041086/results/search/disease/results.xml">
   <result pre="lung allograft dysfunction (CLAD), usually in the form of a" exact="bronchiolitis" post="obliterans syndrome (BOS), that affects 45 to 75% of"/>
   <result pre="0.10 Abbreviations: AR Acute rejection; BIG Bacterial infection group; BOS" exact="bronchiolitis" post="obliterans syndrome; CG control group; FEV-1 forced expiratory volume"/>
   <result pre="0.10 Abbreviations: AR Acute rejection; BIC Bacterial infection group; BOS" exact="bronchiolitis" post="obliterans syndrome; CG control group; CI Confidence Interval; OR"/>
   <result pre="etiology and timing of respiratory tract infections on development of" exact="bronchiolitis" post="obliterans syndrome J Heart Lung Transplant 2009 28 163"/>
   <result pre="An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of" exact="bronchiolitis" post="obliterans syndrome Eur Respir J 2014 44 1479 1503"/>
   <result pre="1031 1049 10.1016/j.healun.2009.08.004 19782285 6. Boehler A Estenne M Post-transplant" exact="bronchiolitis" post="obliterans Eur Respir J 2003 22 1007 1018 10.1183/09031936.03.00039103"/>
   <result pre="of the allograft after lung transplantation and the risk of" exact="bronchiolitis" post="obliterans syndrome Transplantation 2008 85 771 774 10.1097/TP.0b013e31816651de 18337673"/>
   <result pre="et al. Respiratory viral infections are a distinct risk for" exact="bronchiolitis" post="obliterans syndrome and death Am J Respir Crit Care"/>
   <result pre="D et al. Clinical impact of community-acquired respiratory viruses on" exact="bronchiolitis" post="obliterans after lung transplant Am J Transplant 2005 5"/>
   <result pre="RA Fung J Kusne S The pathogenesis and management of" exact="influenza" post="virus infection in organ transplant recipients Transpl Infect Dis"/>
   <result pre="for detection of respiratory viruses in pediatric patients at a" exact="cancer" post="hospital J Clin Microbiol 2012 50 2282 2288 10.1128/JCM.06186-11"/>
   <result pre="Association of minimal rejection in lung transplant recipients with obliterative" exact="bronchiolitis" post="Am J Respir Crit Care Med 2004 170 9"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC7046816/results/search/disease/results.xml">
   <result pre="Dunn PA , Teng MN 1996 Experimental reproduction of severe" exact="hypoglycemia" post="and spiking mortality syndrome using field-derived and embryo-passaged preparations"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC7047369/results/search/disease/results.xml">
   <result pre="also increased in those with comorbidities including cardiovascular, diabetes, chronic" exact="respiratory disease," post="hypertension, and cancer. The cause of death is respiratory"/>
   <result pre="respiratory disease, hypertension, and cancer. The cause of death is" exact="respiratory failure," post="shock or multiple organ failure. How are infected people"/>
   <result pre="modelling suggests that the severity of illness is more like" exact="influenza" post="than SARS, and there is concern among the public"/>
   <result pre="1. Zhou P Yang X Wang X et al. A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="./PMC7047374/results/search/disease/results.xml">
   <result pre="coronavirus (2019-nCoV) was identified as the causative virus of Wuhan" exact="pneumonia" post="of unknown etiology by Chinese authorities on 7 January,"/>
   <result pre="authorities on 7 January, 2020. The virus was named as" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) by International Committee on Taxonomy of"/>
   <result pre="East respiratory syndrome in the Middle East countries, similar to" exact="severe acute respiratory syndrome," post="but lower than MERS in the Republic of Korea."/>
   <result pre="Organization (WHO) China Country Office was informed of cases of" exact="pneumonia" post="of unknown etiology (unknown cause) detected in Wuhan City,"/>
   <result pre="reported that a novel coronavirus (2019-nCoV), which was named as" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) by International Committee on Taxonomy of"/>
   <result pre="symptomatic infection ( κ = 0.5), which was the similar value as" exact="influenza" post="[ 22]. We assumed that the relative shedding rate"/>
   <result pre="of the transmission. Researches showed that the R 0 of" exact="severe acute respiratory syndrome" post="(SARS) was about 2.7–3.4 or 2–4 in Hong Kong,"/>
   <result pre="XG, Hu B, Zhang L, Zhang W, et al. A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="Honglin Hui Christopher Kim-Ming Yuen Kwok-Yung A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
   <result pre="R Zhang X Zhang L Investigation of key interventions for" exact="shigellosis" post="outbreak control in China PLoS One 2014 9 e95006"/>
   <result pre="Liu F Yu S et al. Transmissibility of acute haemorrhagic" exact="conjunctivitis" post="in small-scale outbreaks in Hunan Province, China Sci Rep"/>
   <result pre="Zhao J Yang K Chen T Estimating the transmissibility of" exact="hand, foot, and mouth disease" post="by a dynamic model Public Health 2019 174 42"/>
   <result pre="K Chen T Estimating the transmissibility of hand, foot, and" exact="mouth disease" post="by a dynamic model Public Health 2019 174 42"/>
   <result pre="103 106203 10.1016/j.aml.2019.106203 19. Japan MoH. Development of patients with" exact="pneumonia" post="associated with new coronavirus. Ministry of Health Japan. cited"/>
   <result pre="Ungchusak K Hanshaoworakul W Cummings DA et al. Containing pandemic" exact="influenza" post="at the source Science. 2005 309 1083 1087 10.1126/science.1115717"/>
   <result pre="Chen SL Zhao J et al. The transmissibility estimation of" exact="influenza" post="with early stage data of small-scale outbreaks in Changsha,"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
